Symphogen Clinical Trial Protocol 
Trial ID: Sym023- 01 Version 5.0  
 
Confidential   Page 2 of 173 
 
 Sponsor Declarations  
This confidential document is the property of Symphogen A/S. No unpublished information 
contained herein may be passed on, reproduced, published or used without prior written approval from Symphogen A/S. Access to this document must be restricted to relevant parties. 
The trial will be conducted in compliance with this clinical trial protocol, International Council 
for Harmonisation (ICH) of Technical Requirements for Pharmaceuticals for Human Use  
E6(R2): Guideline for Good Clinical Practice  (GCP ) (EMA/CHMP/ICH/135/1995) , the 
Declaration  of Helsinki, and applicable regulations. 
The Sponsor has appoint ed a Coordinating Investigator for the trial. This Coordinating 
Investigator will provide input to the trial design and act as overall coordinator for Investigators 
across all sites. The Coor dinating Investigator will furthermore sign off the Clinical Trial Report 
on behalf of all Investigators. 
Lists of Investigators responsible for conducting the trial, medically qualified physicians 
responsible for all site -related medical decisions (if oth er than the Investigators), monitors, 
clinical laboratories, and other medical and/or technical departments and/or institutions involved 
in the trial are provided as separate documents.  
 
 
Symphogen Clinical Trial Protocol 
Trial ID: Sym023- 01 Version 5.0  
 
Confidential   Page 3 of 173 
 
 Principal Investigator  Signature Page  
 
I, the undersigned, am responsible for the conduct of the trial at this site and agree:  
• To assume responsibility for the proper conduct of the clinical trial at this Investigational 
Site 
• Not to implement any changes to the clinical trial protocol without agreemen t from the 
Sponsor and prior review and written approval from the appropriate Health Authority (as 
indicated) and the Institutional Review Board/ Ethics Committee, except where necessary 
to eliminate an immediate hazard to the patients  
• That I am aware of, and will comply with “Good Clinical Practice” (ICH E6(R2)  GCP ) 
(EMA/CHMP /ICH/135/ 1995) , the Declaration of Helsinki, and all applicable regulatory 
requirements  
• That all site staff to which I have delegated tasks for this clinical trial, are appropriately 
selected and adequately informed about the investigational product(s) and of their trial -
related duties and functions as described in the clinical trial protocol  
 
 
________________________________  ____________________ 
Signature           Date of Signature  
 
Name: ______________________________________ 
 
Academic Degree: ____________________________ 
 
Function: ___________________________________ 
 
Institution: __________________________________ 
  
 
  
 
Symphogen Clinical Trial Protocol 
Trial ID: Sym023- 01 Version 5.0  
 
Confidential   Page 4 of 173 
 
 TABLE OF CONTENTS  
LIST OF ABBREVIATIONS AND EXPANDED TERMS  .........................................................10  
1 SYNOPSIS  .............................................................................................................................17  
2 SCIENTIFIC BACKGROUND AND RATIONALE  ...........................................................31  
2.1 Background  ........................................................................................................................31  
2.1.1  Tumor Malignancies  ........................................................................................................31  
2.1.2  Overview of the Target: TIM -3 .......................................................................................31  
2.1.3  Overview of the Product: Sym023  ..................................................................................32  
2.2 Summary of Nonclinical Studies  .......................................................................................32  
2.2.1  Nonclinical Pharmacology Studies  ..................................................................................32  
2.2.2  Nonclinical Toxicology Studies  ......................................................................................33  
2.3 Clinical Experience  ............................................................................................................34  
2.3.1  Clinical Experience with Agents Related to Sym023 .....................................................34  
2.3.1.1  Clinical Evidence of Activity in Malignant Diseases  ...................................................34  
2.3.1.2  Safety and Tolerability of anti -TIM-3 mAbs  ................................................................34  
2.3.1.3  Patient Selection for Treatment with Sym023  ..............................................................35  
2.3.1.4  Potential Pharmacodynamic Biomarkers  ......................................................................35  
2.3.2  Clinical Experience with Sym023  ...................................................................................35  
2.4 Trial Rationale  ...................................................................................................................36  
2.5 Dose Rationale  ...................................................................................................................36  
2.6 Overall Benefits/Risk  .........................................................................................................37  
3 TRIAL OBJECTIVES AND DESIGN SUMMARY ............................................................39  
3.1 Objectives: Sym023 (anti -TIM-3) Dose -Escalation  ..........................................................39  
3.1.1  Primary Objective  ................................................................................................ ............39  
3.1.2  Secondary Objectives  ......................................................................................................39  
3.1.3  Exploratory Objectives  ....................................................................................................39  
3.2 Trial Design Summary  .......................................................................................................39  
4 PATIENT NUMBER AND SELECTION CRITERIA  .........................................................45  
4.1 Number of Patients  ............................................................................................................45  
4.1.1  Investigational Sites  .........................................................................................................45  
4.1.2  Number of Patients  ..........................................................................................................45  
4.2 Criteria for Inclusion  ..........................................................................................................46  
4.3 Criteria  for Exclusion .........................................................................................................46  
4.3.1  Patients to be Excluded  ...................................................................................................47  
4.3.2  Drugs and Other Treatments to be Excluded  ..................................................................50  
5 INVESTIGATIONAL MEDICINAL PRODUCT  ................................................................53  
5.1 Sym023  ..............................................................................................................................53  
5.1.1  Formulation Excipients  ...................................................................................................53  
5.2 Storage and Handling of IMP  ............................................................................................53  
5.3 Stability of IMP ..................................................................................................................53  
5.4 Labeling of IMP  .................................................................................................................54  
5.5 Packaging of IMP  ..............................................................................................................54  
5.6 Administration of IMP  .......................................................................................................54  
5.7 Dose Calculation  ................................................................................................................54  
5.8 Dose Preparati on ................................................................................................................54  
Symphogen Clinical Trial Protocol 
Trial ID: Sym023- 01 Version 5.0  
 
Confidential   Page 5 of 173 
 
 5.9 Accountability  ....................................................................................................................55  
5.10  Disposition of Used IMP  ...................................................................................................55  
5.11  Unuse d IMP  .......................................................................................................................55  
5.12  Destruction of IMP  ............................................................................................................55  
6 EXPERIMENTAL PLAN  .....................................................................................................56  
6.1 Design Elements  ................................................................................................................56  
6.2 Projected Recr uitment Period and Duration of this Trial  ..................................................56  
6.3 Cohort Management ...........................................................................................................56  
6.3.1  Patient Screening and Dose Cohort Assignment  .............................................................56  
6.3.1.1  Screening of Potential Patients  .....................................................................................56  
6.3.1.2  Submission of Patient Enrollment Documentation  .......................................................57  
6.3.1.3  Patient Identification Code Assignment ........................................................................57  
6.3.1.4  Screen Failures  ..............................................................................................................57  
6.3.2  Cohort Closure  .................................................................................................................58  
6.4 Requirements for Patient Observation  ...............................................................................58  
6.5 Drug Treatment Regimen  ..................................................................................................58  
6.5.1  Study Start Day ................................................................................................................58  
6.5.2  Patient Availability  ..........................................................................................................58  
6.5.3  Therapy with Study Drug ................................................................................................59  
6.5.3.1  Doses to be Administered .............................................................................................59  
6.5.3.1.1  Doses to be Evaluated  .................................................................................................59  
6.5.3.1.2  Changes in Dose to be Administered ..........................................................................59  
6.5.3.2  Route of Administration  ................................................................................................60  
6.5.3.3  Diluent and Delivery  .....................................................................................................60  
6.5.3.4  Volume of Infusion  .......................................................................................................60  
6.5.3.5  Duration of Infusion  ......................................................................................................60  
6.5.3.6  Schedule  ........................................................................................................................61  
6.5.4  Premedication  ..................................................................................................................61  
6.6 Cycle 1  ...............................................................................................................................61  
6.6.1  Rules for Dose -Escalation and Cohort Expansion ..........................................................62  
6.6.2  Rules for Duration of Exposure Prior to Star t of Next Patient and Next Cohort  ............63  
6.6.3  Rules for Establishing the MTD and/or RP2D  ................................................................64  
6.6.4  Rules for Stopping the Study ...........................................................................................64  
6.7 Continued Treatment After Cycle 1  ...................................................................................64  
6.7.1  Retreatment Guidelines  ...................................................................................................65  
6.7.2  Doses and Regimens  ........................................................................................................65  
6.7.3  Evaluation Schedules  .......................................................................................................66  
6.7.4  Duration of Treatment  .....................................................................................................66  
6.7.5  Continued Treatment after Radiologic Disease Progression ...........................................66  
6.7.6  Retreatment Following an Objective Response  ..............................................................66  
6.8 Adverse Events and Dose -Limiting Toxicities  ..................................................................67  
6.8.1  Adverse Event Grading  ...................................................................................................67  
6.8.2  Management of Dose -Limiting Toxicities and Other Toxicities  ....................................67  
6.8.3  Definition of Dose -Limiting Toxicity  .............................................................................67  
6.9 Definition of Maximum Tolerated Dose ............................................................................69  
6.10  Review of Safety Data During Study.................................................................................69  
Symphogen Clinical Trial Protocol 
Trial ID: Sym023- 01 Version 5.0  
 
Confidential   Page 6 of 173 
 
 6.11  Duration of Study Follow -Up ............................................................................................70  
6.12  Concurrent Treatments and Supportive Care  .....................................................................71  
7 STUDY ASSESSMENTS  .....................................................................................................73  
7.1 Consent and Medical History.............................................................................................73  
7.1.1  Signing of Informed Consent/Assessment of Eligibility  .................................................73  
7.1.2  Demography  ....................................................................................................................74  
7.1.3  Past Medical History  .......................................................................................................74  
7.1.4  History of the Primary Malignancy  .................................................................................74  
7.2 Safety Assessments (1)  ......................................................................................................74  
7.2.1  Medication and Procedure Surveys  .................................................................................74  
7.2.2  Adverse Event Reporting ................................................................................................74  
7.2.3  Dose -Limiting Toxicity Assessment ...............................................................................75  
7.2.4  Performance Status Evaluation  ........................................................................................75  
7.2.5  Vital Signs  .......................................................................................................................76  
7.2.6  Physical Examination  ......................................................................................................76  
7.2.7  Laboratory Assessments and Pregnancy Test  .................................................................77  
7.2.7.1  Hematology Panel  .........................................................................................................77  
7.2.7.2  Bioche mistry Panel .......................................................................................................78  
7.2.7.3  Coagulation Panel  .........................................................................................................78  
7.2.7.4  Thyroid Function Tests  .................................................................................................79  
7.2.7.5  Urinalysis  ......................................................................................................................79  
7.2.7.6  Pregnancy Testing .........................................................................................................80  
7.2.8  Electrocardiogram  ................................................................................................ ...........80  
7.3 Safety Assessments (2)  ......................................................................................................81  
7.3.1  Multi- Gated Acquisition Scan or Echocardiogram  .........................................................81  
7.3.2  Ophthalmology Examination ...........................................................................................81  
7.3.3  Pulmonary Function Tests  ...............................................................................................81  
7.4 Disease Assessments  ..........................................................................................................82  
7.4.1  Tumor Marker Measurement  ...........................................................................................82  
7.4.2  Diagnostic Imaging for Assessment of Disease (and Pulmonary Status)  .......................82  
7.4.3  Response Assessment  ......................................................................................................83  
7.5 Immunogenicity Assessment  .............................................................................................83  
7.5.1  Peripheral Blood for Immunogenicity Assessment (Specialty Lab)  ...............................84  
7.6 Pharmacokinetic Assessments  ...........................................................................................84  
7.6.1  Peripheral Blood for Pharmacokinetic Assessment (Specialty Lab)  ...............................84  
7.7 Pharmacodynamic and Other Biomarker Assessments (Specialty Lab)  ............................85  
7.7.1  Pharmacodynamic Assessments  ......................................................................................85  
7.7.2  Biomarker Assessments  ...................................................................................................85  
7.7.2.1  Blood Samples for Biomarker Assessments  .................................................................86  
7.7.2.2  Tumor Sample for Biomarker Assessment (Biopsies Optional)  ...................................86  
8 MANAGEMENT OF TOXICITY  .........................................................................................87  
8.1 Grading and Recording of Toxicity ...................................................................................87  
8.2 Evaluation and Treatment of Toxicity ...............................................................................87  
8.3 Determination of DLT versus Non- DLT  ...........................................................................87  
8.4 Premedication  ....................................................................................................................88  
8.4.1  Infusion- Related Reactions  .............................................................................................88  
Symphogen Clinical Trial Protocol 
Trial ID: Sym023- 01 Version 5.0  
 
Confidential   Page 7 of 173 
 
 8.4.2  Premedication for IRRs (Prior to the First Dose)  ............................................................88  
8.4.3  Premedication for IRRs (Following an IRR)  ...................................................................89  
8.4.4  Premedication for other Study Drug- Related Toxicities  .................................................89  
8.5 Dose Modification Options  ................................................................................................90  
8.5.1  Prolongation of Infusion Duration ...................................................................................90  
8.5.1.1  Instructions for Infusion Prolongation for IRRs  ...........................................................90  
8.5.1.2  Treatment Following Infusion Prolongation  .................................................................90  
8.5.2  Dose Reduction  ...............................................................................................................90  
8.5.3  Dose Delay  ......................................................................................................................91  
8.5.4  Schedule Alterations  ........................................................................................................91  
9 DISCONTINUING PATIENTS FROM STUDY TREATMENT  ........................................92  
9.1 Criteria for Treatment Discontinuation  ..............................................................................92  
9.2 Replacements  .....................................................................................................................93  
10 ADVERSE EVENTS  .............................................................................................................94  
10.1  Definitions of Adverse Events  ...........................................................................................94  
10.1.1  Adverse Event  .................................................................................................................94  
10.1.2  Events Not to be Considered as Adverse Events  .............................................................94  
10.1.3  Adverse Events of Medical Interest  ................................................................................94  
10.1.4  Serious Adverse Events  ...................................................................................................95  
10.1.5  Events That Do Not Meet the Definition of Serious Adverse Events  .............................95  
10.2  Adverse Event Recording and Reporting ..........................................................................96  
10.2.1  Information to be Provided for each AE  .........................................................................96  
10.2.2  Required Follow -up for AEs  ...........................................................................................97  
10.3  Serious Adverse Event Recording and Reporting ................................ .............................97  
10.3.1  Timeframes for Reporting to the Sponsor  .......................................................................97  
10.3.2  Safety Reporting to Health Authorities, Institutional Review Boards/Ethics Committees, 
and Investigators  ............................................................................................................................98  
10.4  Pregnancy  ...........................................................................................................................98  
11 PRECAUTIONS WHEN DOSI NG WITH STUDY DRUG  ...............................................100  
11.1  Precautions Regarding Procreation  ..................................................................................100  
11.2  Additional Precautions  .....................................................................................................100  
12 SAFETY SURVEILLANCE DURING STUDY  ................................................................102  
12.1  Safety Review  ..................................................................................................................102  
12.2  Other Safety Surveillance Activities  ................................................................................102  
13 REGULATORY AND ETHICAL CONSIDERATIONS  ...................................................104  
13.1  Conditions of Testing  .......................................................................................................104  
13.2  Institutional Review  .........................................................................................................104  
13.3  Informed Consent .............................................................................................................104  
13.4  Conditions for Modifying or Terminating the Study .......................................................105  
13.4.1  Modification of the Study Protocol  ...............................................................................105  
13.4.2  Modification of the Informed Consent Form  ................................................................106  
13.4.3  Conditions for Termination of the Study or a Study Site  ..............................................106  
13.5  Trial Registration  .............................................................................................................106  
13.6  Insurance and Liability  ....................................................................................................107  
14 INVESTIGATOR RESPONSIBILITIES  ............................................................................108  
14.1  Medical Supervision ........................................................................................................108  
Symphogen Clinical Trial Protocol 
Trial ID: Sym023- 01 Version 5.0  
 
Confidential   Page 8 of 173 
 
 14.2  Confidentiality  .................................................................................................................108  
14.3  Use of Information  ...........................................................................................................108  
14.4  Publications  ......................................................................................................................109  
14.5  Patient Screening Log  ......................................................................................................109  
14.6  Drug Dispensing Inventory ..............................................................................................109  
14.7  Handling and Disposal of Study Drug .............................................................................110  
14.8  Recording of Data  ............................................................................................................110  
14.9  Source Do cument Requirements  ......................................................................................110  
14.10  Laboratory Reports  ..........................................................................................................111  
14.11  Record Retention  .............................................................................................................111  
14.12  Monitori ng of the Study ...................................................................................................111  
14.13  Patient Confidentiality  .....................................................................................................112  
14.14  Financing and Insurance  ..................................................................................................113  
15 HANDLING AND PROCESSING OF DATA  ...................................................................114  
15.1  Data Handling  ..................................................................................................................114  
15.2  Data Review D uring this Study  .......................................................................................114  
15.3  Data Processing  ................................................................................................................114  
15.4  Clinical Trial Report ........................................................................................................114  
15.5  Compl iance with the General Data Protection Regulation  ..............................................114  
16 STATISTICAL ANALYSIS  ...............................................................................................116  
16.1  Statistical Considerations  .................................................................................................116  
16.2  Sample Size Considerations  .............................................................................................116  
16.3  Analysis Populations  ........................................................................................................116  
16.4  Trial Endpoints .................................................................................................................116  
16.4.1  Primary Endpoints  .........................................................................................................116  
16.4.2  Secondary Endpoints  .....................................................................................................117  
16.5  Statistical Analysis  ...........................................................................................................117  
16.5.1  General Specifications  ...................................................................................................117  
16.5.2  Patient Disposition, Baseline and Treatment Characteristics  ........................................117  
16.5.3  Study Treatment  ............................................................................................................118  
16.5.4  Maximum  Tolerated Dose .............................................................................................118  
16.5.5  Adverse Events  ..............................................................................................................118  
16.5.6  Laboratory Determinations  ............................................................................................119  
16.5.7  Vital Signs, Body Weight, Physical Exam Findings  .....................................................119  
16.5.8  ECG Findings  ................................................................................................................119  
16.5.9  Other Safety Data  ..........................................................................................................119  
16.5.10  Antineoplastic Activity  ..................................................................................................119  
16.5.11  Pharmacokinetic Analysis  .............................................................................................120  
16.6  Additional Endpoints and Analyses  .................................................................................121  
16.6.1  Pharmacodynamic and other Biomarker Analyses  ........................................................121  
16.7  Modeling of Pharmacokinetic and Pharmacodynamic/Biomarker Data  .........................121  
16.8  Deviations from the Statistical Plan  .................................................................................121  
16.9  Interim Analysis  ...............................................................................................................122  
17 REFERENCES  ....................................................................................................................123  
18 APPENDICES  .....................................................................................................................125  
Appendix 1  Performance S tatus Evaluation..............................................................................125  
Symphogen Clinical Trial Protocol 
Trial ID: Sym023- 01 Version 5.0  
 
Confidential   Page 9 of 173 
 
 Appendix 2  New York Heart Association Functional Criteria  .................................................126  
Appendix 3  Clinical Adverse Events: Grading Scale  ...............................................................127  
Appendix 4  Clinical Adverse Events: Determining Relationship to Study Drug .....................128  
Appendix 5  Response Evaluation Criteria in Solid Tumors (RECIST v1.1)  ............................129  
Appendix 6  Immunotherape utics RECIST (iRECIST)  .............................................................134  
Appendix 7  Response Evaluation Criteria in Lymphoma (RECIL 2017)  ................................141  
Appendix 8  Adverse Events Observed with Antibodies to PD -1 and PD -L1 ...........................142  
Appendix 9  Grading and Management of Infusion- Related Reactions  ....................................147  
Appendix 10  Management of Immune -Mediated Toxicities  ....................................................150  
Appendix 11  Maximum Total Blood Collection Volumes  .......................................................151  
Appendix 12  Schedule of Assessments  .....................................................................................152  
19 SUMMARY OF CHANGES  ...............................................................................................156  
19.1  Protocol Amendment 1 dated 04- Apr-2018  .....................................................................156  
19.2  Protocol Amendment 2 dated 02- Aug-2018  ....................................................................166  
19.3  Protocol Amendment 3 dated 18- Mar-2019  ....................................................................169  
19.4  Protocol Amendment 4 dated 02- May-2019 ....................................................................170  
 
List of Figures  
 
Figure 1:  Dose -Escalation Schema  ...............................................................................................42  
 
List of Tables  
 
Table 1:  Overall Trial Plan  ...........................................................................................................44  
Table 2:  Schedule of Safety Blood and Urine Sampling ..............................................................77  
Table 3:  ADA and PK Sampling Timepoints  ...............................................................................84  
Table 4:  Recommended Premedication Regimen  .........................................................................89  
Table 5:  PK Endpoint, Definitions, and Derivations  ..................................................................121  
Table 6:  Protocol Amendment 1 .................................................................................................157  
Table 7:  Protocol Amendment 2 .................................................................................................166  
Table 8:  Protocol Amendment 3 .................................................................................................169  
Table 9:  Protocol Amendment 4 .................................................................................................170  
 
 
Symphogen Clinical Trial Protocol 
Trial ID: Sym023- 01 Version 5.0  
 
Confidential   Page 10 of 173 
 
 LIST OF ABBREVIATIONS AND EXPANDED TERMS   
Abbreviation  Expanded Term  
1M FUP  1-Month F ollow -up 
Ab Antibody  
ADA  Anti-Drug A ntibody  
ADCC  Antibody -Dependent Cellular Cytotoxicity  
AE Adverse Event 
ALP  Alkaline Phosphatase  
ALT  Alanine Aminotransferase  
ANC  Absolute Neutrophil Count 
aPTT  Activated Partial Thromboplastin Time  
ARDS  Acute Respiratory Distress Syndrome  
AST  Aspartate A minotransferase  
AUC  Area Under the Concentration -Time Curve 
AUC τ Area Under the Concentration -Time  Curve in a dosing interval  
AUC inf Area Under the Concentration -Time Curve from start of infusion to infinity  
AUC norm, τ  Dose -Normalized Area Under the Concentration -Time Curve in a dosing interval  
β-hCG  Beta-Human Chorionic Gonadotropin  
BM Bone Marrow  
BNP    Brain  Natriuretic Peptide  
BP Blood Pressure  
BPM  Beats Per Minute  
BUN  Blood Urea Nitrogen  
Bx Biopsy  
C Centigrade, Celsius  
C#/D# Cycle #/ Day #  
Ca Calcium  
CBC  Complete Blood Count  
CDC  Complement -Dependent Cytotoxicity  
CEACAM1  Carcinoembryonic Antigen Related Cell Adhesion Molecule 1  
CEOI Concentration at the End of Infusion  
CFR  Code of Federal Regulations  
CHF  Congestive Heart Failure  
CIOMS  Council for International Organizations of Medical Sciences  
Symphogen Clinical Trial Protocol 
Trial ID: Sym023- 01 Version 5.0  
 
Confidential   Page 11 of 173 
 
 Abbreviation  Expanded Term  
CK Creatine Kinase  
Cl Chloride  
CL Clearance  
Cmax Maximum Concentration  
CPD  Confirmed Progressive Disease  
Ctrough Trough Concentration  
CNS  Central Nervous System  
CR Complete Response  
CRF  Case Report Form  
CS Clinically Significant  
CT Computed Tomography  
CTC  Common Toxicity Criteria  
CTCAE  v5.0 Common Terminology Criteria for Adverse Events (Version 5.0) 
ctDNA  Circulating Tumor Deoxyribonucleic Acid  
CTLA -4 Cytotoxic T -Lymphocyte -Associated Protein 4 
CV Curriculum Vitae  
D, d Day 
dL Deciliter  
DL CO Diffusing Capacity of Carbon Monoxide  
DLT  Dose -Limiting Toxicity  
DMP  Data Management Plan  
DNA  Deoxyribonucleic Acid  
DRF  Dose -Range -Finding  
DSUR  Development Safety Update Report  
DVT  Deep Vein Thrombosis  
EC Ethics Committee  
ECG  Electrocardiogram  
ECHO  Echocardiogram  
ECOG  Eastern Cooperative Oncology Group  
EDC  Electronic Data Capture  
EOC # End of Cycle # 
EOI End of Infusion  
EOS  End of Study  
Symphogen Clinical Trial Protocol 
Trial ID: Sym023- 01 Version 5.0  
 
Confidential   Page 12 of 173 
 
 Abbreviation  Expanded Term  
EOT  End of Treatment  
F Fahrenheit  
FAS Full Analysis Set  
FDG  Fluorodeoxyglucose  
FEV 1 Forced Expiratory Volume in 1 Second  
FFPE  Formalin -Fixed, Paraffin -Embedded  
FRC  Functional Residual Capacity  
FSH Follicle -Stimulating Hormone  
fT3 Free Triiodothyronine  
fT4 Free Thyroxine  
FUP Follow -up 
FVC  Forced Vital Capacity  
GCP  Good Clinical Practice  
GI Gastrointestinal  
GLP  Good Laboratory Practice  
H, h  Hour  
HAVCR2  Hepatitis A Virus Cellular Receptor 2  
HBV  Hepatitis B Virus  
hCG  Human Chorionic Gonadotropin  
HCV  Hepatitis C Virus  
HIPAA  Health Insurance Portability and Accountability Act  
HIV Human Immunodeficiency Virus  
HMGB1  High Mobility Group Box 1  
HPF High Power Field  
HR Heart Rate  
HRT  Hormone Replacement Therapy  
HSCT  Hematopoietic Stem Cell Transplantation  
IB Investigator’s Brochure  
ICF Informed Consent Form  
ICH International Council for Harmonization  of Technical Requirements for 
Pharmaceuticals for Human Use  
ICMJE  International Committee of Medical Journal Editors  
Ig Immunoglobulin  
Symphogen Clinical Trial Protocol 
Trial ID: Sym023- 01 Version 5.0  
 
Confidential   Page 13 of 173 
 
 Abbreviation  Expanded Term  
IHC Immunohistochemistry  
IL-2 Interleukin -2 
ILD Interstitial Lung Disease  
IMP Investigational Medicinal Product  
IND Investigational New Drug  
INR International Normalized Ratio  
IRB Institutional Review Board   
iRECIST  Immunotherapeutics Response Evaluation Criteria in Solid Tumors  
IRR Infusion -Related Reaction  
IU International Units  
IV Intravenous  
K Potassium  
KD Dissociation Constant  
KLH  Keyhole Limpet Hemocyanin  
kg Kilogram  
LSECtin  Liver Sinusoidal Endothelial Cell Lectin  
LLN  Lower Limit of Normal  
LVEF  Left Ventricular Ejection Fraction  
M, m  Month, Molar, Meter  
mAb  Monoclonal Antibody  
MABEL  Minimal Anticipated Biological Effect Level  
MAD  Maximum Administered Dose  
MedDRA  Medical Dictionary for Regulatory Activities  
Mg Magnesium  
mg Milligram  
MHC  Major Histocompatibility Complex  
MI Myocardial Infarction  
min Minute  
mL Milliliter  
MLR  Mixed Lymphocyte Reaction  
mm Millimeter  
MRI  Magnetic Resonance Imaging  
MRSD  Maximum Recommended Starting Dose  
Symphogen Clinical Trial Protocol 
Trial ID: Sym023- 01 Version 5.0  
Confidential  Page 14 of 173 Abbreviation  Expanded Term  
msec  Millisecond  
MTD  Maximum Tolerated Dose  
MUGA  Multi -Gated Acquisition  
Na Sodium  
NaCl  Sodium Chloride  
NCS  Not Clinically Significant  
NE Not Evaluable  
NK Natural Killer (cell)  
NL New Lesion  
NLNT  New Lesion -Non-Target  
NLT  New Lesion -Target  
NOAEL  No Observed Adverse Effect Level  
NT Non-Target  
NYHA  New York Heart Association  
OR Objective Response  
PBMC  Peripheral Blood Mononuclear Cell  
PD Progressive Disease , Disease Progression  
PDF Portable Document Format  
PD-1 Programmed Cell Death Protein  1 
PD-L1 Programmed Death -Ligand 1  
PE Pulmonary Embolism  
PET Positron Emission Tomography  
PFT Pulmonary Function Test  
PK Pharmacokinetic  
PO Per Os (orally, by mouth)  
PR Partial Response  
PR Interval  ECG interval between beginning of the P -wave to beginning of the QRS complex  
PS Performance Status  
PSA Prostate Specific Antigen  
PSPD  Pseudoprogression  
PT Prothrombin Time  
PtdS  Phosphatidylserine  
PTT Partial Thromboplastin Time  
Symphogen Clinical Trial Protocol 
Trial ID: Sym023- 01 Version 5.0  
 
Confidential   Page 15 of 173 
 
 Abbreviation  Expanded Term  
Q2M  Every 2 Months  
Q2W  
QT Interval  Every 2 Weeks  
ECG interval between onset of QRS complex to end of the T -wave  
QTc Interval  Heart R ate-corrected QT interval  
RBC  Red Blood Cell  
RECIL  2017  Response Evaluation Criteria in Lymphoma  (2017)  
RECIST  v1.1 Response Evaluation Criteria in Solid Tumors  (Version 1.1)  
RNA  Ribonucleic Acid  
RNA -seq Ribonucleic Acid Sequencing  
RSI Reference Safety Information  
RP2D  Recommended Phase 2 Dose  
RV Residual Volume  
SAE  Serious Adverse Event  
SAP Statistical Analysis Plan  
SAR  Suspected Adverse Reaction  
SAS Statistical Analysis System  
SD Stable Disease  
SEB Staphylococcal Enterotoxin B  
SOC  System Organ Class  
SOI Start of Infusion  
SOM  Sum of Measurements  
SOP Standard Operating Procedure  
SSA Somatostatin Analog  
SUSAR  Suspected Unexpected Serious Adverse Reaction  
T Target  
T1/2  Terminal Elimination Half-life 
TBD  To Be Determined  
TCR  T-cell Receptor  
TDAR  T-cell Dependent Antibody Response  
TEAE  Treatment Emergent Adverse Event  
TIM-3 T-cell Immunoglobulin and Mucin -Domain  Containing -3 
TK Toxicokinetic  
TLC  Total Lung Capacity  
Symphogen Clinical Trial Protocol 
Trial ID: Sym023- 01 Version 5.0  
Confidential  Page 16 of 173 Abbreviation  Expanded Term  
Tmax Time to Maximum Concentration  
TP Timepoint  
TRAE  Treatment Related Adverse Event  
TSH  Thyroid Stimulating Hormone  
TTP Time to Progression  
ULN  Upper Limit of Normal  
µg Microgram  
µM Micromolar  
UPD  Unconfirmed Progressive Disease  
U.S. United States  
U/S Ultrasound  
UV Ultraviolet  
V, v, Vol  Volume  
Vd Volume of Distribution  
VS Vital Signs  
W, w  Week  
w/v Weight to Volume  
WBC  White Blood Cell  
WES  Whole -exome Sequencing  
WHO  World Health Organization  
WOCBP  Woman of Childbearing Potential  
Symphogen Clinical Trial Protocol 
Trial ID: Sym023- 01 Version 5.0  
Confidential  Page 17 of 173 1 SYNOPSIS  
CLINICAL TRIAL PROTOCOL  
Trial Title  A Phase 1, Open -Label, Multicenter Trial Investigating the Safety, Tolerability, and Preliminary 
Antineoplastic Activity of Sym 023 (Anti -TIM-3 ) in Patients with Advanced Solid Tumor 
Malignancies or Lymphoma s 
Trial ID  Sym023-01 
Trial Phase Phase 1 
INVESTIGATIONAL MEDICINAL PRODUCT  
Investigational 
Medicinal Product  The Investigational Medicinal Product (IMP) is Sym 023 (also referred to as study drug).   
Sym023 is a recombinant T-cell immunoglobulin and m ucin-domain containing-3 (anti-TIM-3) 
human monoclonal antibody (mAb)   
Supplies  
Labeled supplies of study drug will be provided  by the Sponsor .  Each single -use glass vial 
contains Sym 023: 
• As a liquid formulatio n for intravenous (IV) infu sion
• With a nominal fill volume of 8. 0 milliliter (mL)
• At a concentration of 20 mg/mL for a total vial content of 160 milligrams (mg)  
Formulation Excipients
Provided herein  
Storage  
Refrigerate (2ºC to 8ºC); store in an access -controlled, secure location; protect from direct sunlight  
Combination Agent  None  
TRIAL OBJECTIVES 
Sym 023 Dose -
Escalation Primary 
Evaluation of the safety, tolerability, and dose -limiting toxicities (DLTs) to establish the maximum 
tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of sequential escalating doses of 
Sym023 when administered once every 2 weeks (Q2W) by 30-minute IV infusion to patient 
cohorts with locally advanced/unresectable or metastatic solid tumor malignancies or lymphoma s 
that are refractory to available therapy  or for which no standard therapy is avai lable   
Note:   Q2W dosing; 4 weeks equals 1 dosing cycle.  Goal is identification of the MTD or determination of a 
RP2D based on clinical data, including safety, pharmacokinetic (PK), and pharmacodynamic outcomes .  
The MTD , if identified , and the RP2D may  not be the same as the RP2D may be lower .  If an MTD is 
not identified , a maximum administered dose (MAD) will be determined and will not exceed 20 mg/kg . 
Secondary  
•Evaluation of the immunogenicity of Sym 023
•Characterization of  the PK profile  of Sym023
•Evaluation of the preliminary antineoplastic effects of Sym 023, including:
o Evidence of objective response (OR) or stable disease (SD)*
o Duration of OR or SD*
o Time to progression (TTP) of disease*
*As assessed by Response Evaluation Criteria in Solid Tumors  (Version 1.1)  (RECIST v1.1),
Immunotherapeutics Response Evaluation Criteria in Solid Tumors (i RECIST ), and Response Evaluation
Criteria in  Lymphoma (2017) (RECIL 2017)
Exploratory  
• Evaluation of potential pharmacodynamic markers , e.g., receptor occupancy i n peripheral
blood mononuclear cells (PBMCs)  (peripheral blood to be collected)
• Evaluation of potential biomarkers including but not limited to assessment of:
o In peripheral blood: circulating tumor deoxyribonucleic acid (ctDNA), ribonucleic acid(RNA), relevant proteins /cytokines , and cellular biomarkers
o In tumor tissue: DNA, RNA, protein, and cellular biomarkers (biopsies optional)
Note:   Assay methodology and biomarker assessments to be determined ( TBD ). Potential analyses may
include but are not limited to : ctDNA sequencing ; RNA sequencing (RNA -seq)/whole -exome 
sequencing (WES) ; measurement of relevant proteins/cytokines in the blood ; cytometric  analysis 
of cells in blood ; and immunohistochemistry (IHC) of tumor material when collected (tumor 
sampling is optional)   
Symphogen Clinical Trial Protocol 
Trial ID: Sym023- 01 Version 5.0  
Confidential  Page 18 of 173 TRIAL DESIGN  
Design Summary  This is a Phase 1, multicenter, open -label, dose -escalation study designed to evaluate safety, 
tolerability, and DLTs to  establish the MTD or MAD, and  the RP2D of sequential escalating doses 
of Sym 023 (study drug) when administered Q2W (4 weeks equals 1 cycle) by 30 -minute IV 
infusion, to patients with advanced, refractory solid  tumor malignancies  or lymphoma s. 
Approximately 20- 48 male and female patients will be entered.  Initially a modified, accelerated -
titration, dose-escalation design will be used , with entry of single patient cohort s for up to 2 dose 
levels, based on tolerability. Thereafter, d ose-escalation will follow a standard 3+3 design, with a 
target toxicity level of 33.3% or less as determined by DLTs.  It is planned that 7 dose levels up to 
a maximum dose of 20 mg/kg will be evaluated. The number of patients treated, the number of 
cohorts evaluated, and the MTD/ MAD will depend upon the observed tolerability of Sym 023 
during Cycle 1 . 
In the absence of documented progressive disease (PD)  or unacceptable toxicity, patients may 
continue to receive additional 4 -week cycles of study drug at the same dose, infusion duration, and 
schedule established for the patient.  
PATIENT SELECTION  
Recruitment Period  Enrollment Dates  
•Anticipated date of enrollment of first patient: Q2 2018
•Anticipated date of enrollment of last patient: Q3 2019
End of Trial  (i.e., data cut -off for primary analysis)  
Will be reached 1 month (30 +7 days) after all patient ha ve discontinued trial treatment or 6  months 
after the last patient has started trial treatment, whichever occurs earlier.   
Investigational Sites  This is a multicenter trial. It is anticipated that approximately 2 -4 centers in North America may 
participate based on accrual.  
Number of Patients  Considerations for estimating the number of patients are as follows: 
Sym 023 Dose -Escalation    
Approximately 20- 48 patients in escalating dose cohorts:  
•Minimum of 1 patient  per cohort for up to 2 dose cohorts
•Minimum of 3 patients  per dose cohort  thereafter
•Assume approximately 7 cohorts to establish the MTD , and/or RP2D
•Expansion of any cohort to 6 patients  in the event of a Cycle 1 DLT in any of the initial 1 to 3
patien ts
•Minimum of 6 patients  to be treated at the MTD and/or RP2D; expansion of this cohort (or any
other) up to 12 patients may be considered to further evaluate tolerability
In addition, there is potential for entry of additional patients to:  
•Ensure sufficient evaluable patients by adding an additional patient to a cohort
•Expand a lower dose cohort(s) if an initially identified MTD and/or RP2D is subsequently
determined to be not tolerated either with single or repeated cycles of therapy
•Add and e valuate a previously unplanned intermediate dose level if indicated  (inclusion of a
dose higher than those listed would require a protocol amendment)
Note:  This action would be taken in the event of an unacceptably high frequency of toxicities observed in
patients treated at one dose level considered to be in marked contrast to the tolerability noted at the 
preceding dose level , or if after review of study data , a more gradual dose -escalation appears 
warranted.
Eligibility  Patients  to be Included  (patients must meet all the following criteria)  
1. Male or female patients, ≥ 18 years
2. Patients with a documented (histologically - or cytologically -proven) solid tumor malignancy
that is locally advanced or metastatic; patients with documented lymphoma s
3. Patients with a malignancy (solid tumor or lymphoma ) that is currently not amenable to
surgical intervention due to either medical contraindications or non-resectability of the tumor
4. Patients refractory to or intolerant of existing therapy(ies) known to provide clinical benefit .
Note:  Patients may have received and failed prior therap y with a programmed cell death protein 1 /
pr
ogrammed death-ligand 1 ( PD-1/PD -L1) inhibitor  and be considered eligible for this trial .
5. Patients with measurable or non -measurable disease according to RECIST v1.1  or standard
criteria for lymphoma  (RECIL  2017 ).
Symphogen Clinical Trial Protocol 
Trial ID: Sym023- 01 Version 5.0  
Confidential  Page 19 of 173 6. Patients with an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0
or 1, and anticipated life expectancy of  ≥ 3 months
7. Patients, both male and female, who are either not of childbearing potential or who agree to
use a highly effective method of contraception during the study beginning within 2 weeks
prior to the first dose and continuing until 6 months  after the last dose of study drug.
8. Patients with the ability to understand and give written informed consent for participation in
this trial, including all evaluations and procedures as specified by this protocol .
Patients to be Excluded  (patients must not meet any  of the  following criteria)  
1. Women who are pregnant or lactating , or intending to become pregnant before, during, or
within 6 months after  the last dose of study drug. Women of childbearing potential (WOCBP)
and fertile men with WOCBP partner(s), not using and not willing to use a highly effective
method of contraception.
2. Patients with central nervous system (CNS) malignancies; patients with known, untreated
CNS or leptomeningeal metastases, or spinal cord compression , patients with any of the above
not controlled by prior surgery or radiotherapy, or patients with symptoms suggesting CNS
involvement for which treatment is required.
Note:   Patients with treated CNS metastases will be eligible if they are asymptomatic, do not requir e
c
orticosteroids , and have confirmation of at least stable brain disease status as assessed by 2 
imaging st udies performed ≥ 4 weeks apart with the most recent performed within 4 weeks prior to 
first trial drug administration .  Prophylactic anticonvulsant medications are allowed.  
3.Patients with hematologic malignancies  other than lymphoma s
4.Patients with any of the following hematologic abnormalities at baseline *:
• Hemoglobin < 9 g/dL
• Absolute neutrophil count (ANC) < 1, 000 per mm3
• P
latelet count < 75 ,000 per mm3
*Throughout this protocol “baseline” is defined as the last available observation prior to the first 
administration of study drug on Cycle 1/Day 1  (C1/D1). 
5. Patients with any of the following serum chemistry abnormalities at baseline:  
• Total bilirubin  > 1.5 × the upper limit of normal (ULN) for the institution
• Aspartate aminotransferase ( AST ) or alanine aminotransferase ( ALT ) > 3 × the ULN for
the institution (> 5 × ULN if due to hepatic involvement by tumor)
• Serum creatinine > 1.5 × ULN for the institution
6. P atients with any of the following coagulation parameter abnormalities at baseline ( unless on
a stable dose of anticoagulant therapy for a prior thrombotic event, as determined by theInvestigator ):
• Prothrombin time ( PT) (or international normalized ratio [INR ]) > 1.5 × ULN for the
institution  (> 3× ULN for the institution if anticoagulated)
• Partial thromboplastin time ( PTT) (or activated partial thromboplastin time [ aPTT ]) > 1.5
× ULN for the institution  (> 3× ULN for the institution if anticoagulated)
7. Patients with:
• Active thrombosis, or a history of deep vein thrombosis (DVT) or pulmonary embolism(PE) within 4 weeks  prior to first administration of study drug unless adequately treated
and considered by the Investigator to be stable
• Active uncontrolled bleeding or a known bleeding diathesis
8. Patients with a clinically significant (CS) cardiovascular disease or condition, including:
• Need for antiarrhythmic medical therapy for a ventricular arrhythmia or otheruncontrolled arrhythmia (patients with controlled atrial fibrillation (heart rate [HR] < 90)for > 30 days prior to study entry are eligible)
• Severe conduction disturbance (e.g. , 3
rd degree heart block)
• HR-corrected QT interval ( QTc interval ) ≥ 480 milliseconds (msec)
• Uncontrolled hypertension (per the Investigator’s discretion)
• History of myocarditis
• Left ventricular ejection fraction (LVEF)* known to be below the lower limit of normal(LLN) for the center, or < 50% by multi -gated acquisition ( MUGA ) scan or
echocardiogram ( ECHO) if no LLN is defined by the site
• Conge stive heart failure (CHF) currently requiring therapy
• Class III or IV cardiovascular disease according to the New York Heart Association(NYHA) Functional Classification
• History of acute coronary syndromes (including myocardial infarction [MI] and unstable
angina), coronary angioplasty, stenting , or bypass  within 6 months  prior to first study
Symphogen Clinical Trial Protocol 
Trial ID: Sym023- 01 Version 5.0  
Confidential  Page 20 of 173 drug administration  
9. Patients with a significant ocular disease or condition, including history of an autoimmune or
inflammatory disorder, e.g., episcleritis, uveitis, iritis
Note:    Patients with a history of dry eye for reasons other than an autoimmune disease or condition may 
be included if adequately treated. Patients with non -significant, non -inflammatory disorders (e.g., 
cataracts, glaucoma) will be allowed.   
10. Patients with a sig nificant pulmonary disease or condition, including:
• History of interstitial lung disease (ILD), pulmonary fibrosis
• History of pulmonary inflammatory disease, interstitial or other pneumonitis *, acute
respiratory distress syndrome (ARDS)
*Patients with pri or evidence of Grade 1 pneumonitis will be eligible provided they were 
asymptomatic and did not require treatment and provided pneumonitis has resolved prior to entry to
this trial. 
11. Patients with a current or recent (within 6 months ) significant gastrointestinal (GI) disease or
condition, including:
• History of inflammatory bowel disease
• Diarrhea ≥ Grade 2 within 2 weeks  prior to first administration of study drug  
12. Patients with an active, known or suspected autoimmune disease, or a documented history of
autoimmune disease or syndrome, requiring systemic steroids or  other immunosuppressive
medications
Note:    Exceptions permitted include: type I diabetes mellitus, hypothyroidism only requiring hormone 
replacement, skin disorders suc h as vitiligo, psoriasis or alopecia not requiring systemic treatment, 
conditions not expected to recur in the absence of an external trigger . 
13. Patients with a history of organ transplantation (e.g. , stem cell or solid organ transplant)
14. Patients with a known or suspected hypersensitivity to any of the excipients of formulated
study drug
15. Patients with a history of significant toxicities associated  with previous administration  of
immune checkpoint inhibitors that necessitated permanent discontinuation of that therapy
16. Patients with unresolved > Grade 1 toxicity associated with any prior antineoplastic therapy
except for  persistent Grade 2 alopecia, peripheral neuropathy, decreased hemoglobin,
lymphopenia,  hypomagnesemia, and/or  end-organ failure being adequately managed by
hormone replacement therapy
17. Patients with inadequate recovery from any prior surgical procedure, or patients having
undergone any major surgical procedure within 4 weeks  prior to first administration of study
drug
18. Patients who are known or suspected drug or alcohol abuse rs where compliance with protocol
requirements may be a concern
19. Patients with a known history of human immunodeficiency virus (HIV) or known active
infection with hepatitis B virus (HBV) or hepatitis C virus (HCV)
20. Patients with any other serious/active/uncontrolled infection, any infection requiring
parenteral antibiotics, or unexplained fever > 38ºC within 2 weeks  prior to first administration
of study drug
21. Patients with any other serious, life -threatening, or unstable pre -existing medical condition
(aside from the underlying malignancy) including significant organ system dysfunction orfailure, or CS laboratory abnormality(ies), which, in the opinion of the Investigator, wo uld
either compromise the patient’s  safety or interfere with obtaining  informed  consent, compliance
with study procedures,
 or evaluation of the safety of study drug
22. Patients with a psychiatric disorder or altered mental status that would preclude understanding
of the informed consent process and/or completion of the necessary study-related evaluations
23. Patients with known or foreseeable inability, in the opinion of the investigator, to comply with
the protocol requirements
Drugs and Other Treatments to be Excluded  (patients must not have received any  of the 
following)  
1. Other inhibitors of TIM- 3 (e.g. , mAbs)
2. Any antineoplastic agent for the primary malignancy (standard or investigational) withoutdelayed toxicity within 4 weeks or 5 plasma half -lives, whichever is shortest, prior to first
administration of study drug and during study, except for :
•Nitrosoureas and mitomycin C within 6 weeks  prior to first administration of study drug
and during study
Note:  Patients may have received and failed prior therapy with a PD -1/PD -L1 and be considered eligible 
for this trial.  
Symphogen Clinical Trial Protocol 
Trial ID: Sym023- 01 Version 5.0  
Confidential  Page 21 of 173 3. Any other investigational treatments within  4 weeks  prior to and during study. This includes
participation in any medical device or other therapeutic intervention clinical trials.
4. Radiotherapy :
• For target lesions within 4 weeks  prior to first administration of study drug unless PD has
been documented in the lesion following treatment, and during study.
• For non-target lesions within 1 week prior to first administration of study drug,
Note:   Palliative (limited -field) radiother apy for management of pain associated with bone 
metastases  present at baseline is permitted during study . Patients with suspected new bone 
lesions requiring pain management should be treated and evaluated for potential PD  
5. Use of live vaccines against infectious diseases (e.g. , varicella) 4 weeks  prior to first
administration of study drug and during study
6. Immunosuppressive or systemic hormonal therapy (> 10 mg daily prednisone equivalent)
within 2 weeks  prior to first administration of study drug and during study.  The following
therapies are allowed:
• Hormonal therapy for appetite stimulation
• Nasal, ophthalmic, inhaled, and topical glucocorticoid preparations
• Hormone replacement therapy at standard doses for end -organ failure
• Stable hormonal therapy for prostate carcinoma
• Stable hormonal therapy for ovarian suppression, hormonal contraceptive therapy, or
post-menopausal hormone replacement therapy (HRT)
• Neuroendocrine tumor patients: stable hormonal therapy with a somatostatin analog(SSA)
• Steroid therapy for contrast reaction prophylaxis
• Intra-articular steroid injections
• Low-dose maintenance steroid therapy for other conditions (e.g. , asthma exacerbation,
stable steroid therapy [excluding tapering dos e of steroids] for brain
edema/metastases/radiation)
• Higher dose steroid therapy for treatment of an acute intercurrent illness (e.g., immune-
related AEs or other adverse conditions) in patients with SD or an ongoing response.  In
such situations , study drug treatment should be interrupted for the duration of
immunosuppressive therapy.
7. Prophylactic use of hematopoietic growth factors wit hin 1 week  prior to first administration of
study drug and during Cycle 1 of study; thereafter -prophylactic use of growth factors is
allowed as clinically indicated. Use of growth factors as treatment is permitted at any time
after initiation of study drug  as clinically indicated.  Transfusions are permitted as needed.
Questions regarding patient eligibility must  be addressed and resolved by the Investigator in 
consultation with the Sponsor prior to enrollment.  
EXPERIMENTAL PLAN  
Design Elements  • Open -label, u ncontrolled, non -randomized
• Escalating doses of study drug in sequential patient cohorts
• Enrollment staggered between first and second patient in each new higher 3- patient dose
cohort to allow for initial safety observations
Study Schedule  Screening P eriod  
•Written informed consent
•Safety screening, disease assessment, and eligibility confirmation
Treatment P eriod
•C1/D1 initial dose of study drug
•Continued dosing Q2W
•28-day cycles until confirmed PD, unacceptable toxicity, or another  discontinuation criterion is
met
•End of Treatment (EOT) visit within  approximately 10 days following treatment
discontinuation, or before initiation of a new treatment, whichever occurs  first.
•1-Month Follow -up (1M FUP) visit 30 days (+7 days) following last dose
Follow -Up P eriod
•Response follow -up ( FUP) every 2 months (Q2M) following discontinuation for reasons other
than confirmed  PD until the end of trial
Observation 
Requirements  Patients wil l be treated and followed on an outpatient basis.  
•Patients will be observed for a minimum of 2 hours  following completion of the first
Symphogen Clinical Trial Protocol 
Trial ID: Sym023- 01 Version 5.0  
Confidential  Page 22 of 173 administration of study drug  on C1/D1 and a minimum of 1 hour  following completion of 
subsequent infusions of study drug  (C1/ D15, onward).   
•At the end of each infusion the IV line must remain in place during the observation period  to
allow for administration of IV drug s, if necessary.
Infusions will take place under the close supervision of a physician or other study personnel 
experienced in administration of IV agents, and  in an environment where full resuscitation facilities 
are immediately available.  
INVESTIGATIONAL MEDICINAL PRODUCT ADMINISTRATION  
Doses to be 
Administered  Doses to be Evaluated  
Dose cohorts will be numbered and entered sequentially.  The number of cohorts evaluated will be 
based upon toxicities experienced by patients during Cycle 1 .   
Sym023 will be administered at up to 7 planned dose levels; anticipated dose level s include:  
•Dose Cohort 1:  0.03 mg/kg
•Dose Cohort 2:  0.1 mg/kg
•Dose Cohort 3:  0.3 mg/kg
•Dose Cohort 4 :  1.0 mg/kg
•Dose Cohort 5 :  3.0 mg/kg
•Dose Cohort 6 :  10.0 mg/kg
•Dose Cohort 7:  20.0 mg/kg
Changes in Dose to be Administered
Once assigned to a dose cohort , patient s will continue to be treated with study drug at that same 
dose level throughout the duration of their time on study. There will be no intra -patient dose -
escalation.  
Dose adjustments should be made in the event of noted weight change ( ± 10%; less at the si te’s discretion or if 
required by institution procedures) at visits that require weight measurement. Adjustments may be made more 
frequently at the site's discretion.    
Route of 
Administration  IV infusions via indwelling venous access catheter, utilizing a controlled infusion device  
Infusion Materials  Infusion set containing a  0.22 micron  in-line filter. 
Diluent and Delivery  Commercially available sterile 0.9% sodium chloride (NaCl) for IV infusion   
Once diluted for IV administration, study drug should  be administered within 8 hours.  
Infusion Volume  • 50 mL for doses < 1 mg/kg
• 100 mL for doses ≥ 1 mg/kg  to ≤ 3 mg/kg
• 100 mL for doses of > 3 mg/kg to ≤  10 mg/kg for patients with body weight ≤ 80 kg
• 250 mL for doses of > 3 mg/kg to ≤  10 mg/kg for patients with body weight > 80 kg
• 250 mL for doses > 10 mg/kg for patients with body weight ≤ 100 kg
• 500 mL for doses > 10 mg/kg for patients with body weight > 100 kg
Infusion Duration  • Approximately 30 minutes (+10 minute s) for infusion volumes ≤ 250 mL
• Approximately 60 minutes (+10 minutes) for infusion volumes of 500 mL
Start and sto p times of each infusion, and any interruptions in infusion will be recorded.
Schedule  Q2W ( ± 2 days) on Day 1 and Day 15 of each cycle (4 weeks [28 days] equals 1 dosing cycle)  
End of Cycle 1 (EOC1) assessments are to be performed on C1 /D28 ( ±2 days).   Subsequent cycles 
may be administered Q2W ( ± 2 days), unless further delay is required to allow for amelioration of 
toxicities (or in the event of scheduling difficulties associated with weekends, holidays, etc.).  
Premedication  Premedication for Infusion -Related Reactions  
Since the mechanism of action of the  study drug is to stimulate the immune system premedication 
with agents such as glucocorticoids which are immunosuppressive  is to be avoided. As a result, n o 
premedication is required to be administered prior to patients receiving the first dose of study drug. 
In patients with a history of infusion-related reactions ( IRRs) to mAbs or similar products , it is 
recommended that premedication be administered . In such cases, patients should be premedicated 
with a regimen that includes acetaminophen as well as an H1 (e.g. , diphenhydramine/hydroxyzine) 
and possibly an H2-antagonist (e.g. , ranitidine/famotidine).   
In the event of an IRR during study:  
• For Grade 1 or Grade 2 reactions, premedication prior to subsequent infusions should be
considered.  Thereafter, if a patient is without recurrence of an IRR, the Investigator may
Symphogen Clinical Trial Protocol 
Trial ID: Sym023- 01 Version 5.0  
Confidential  Page 23 of 173 choose to withdraw premedication to determine whether such continued therapy is necessary 
for that patient.  
• For Grade 3  reactions,  not applicable as this is considered a DLT ; therefore, no further
treatment with study drug is allowed .
Premedication for Other Toxicities  
In the event of other study-drug related toxicities (e.g. , nausea, vomiting, diarrhea, etc.), patients 
may be premedicated with standard therapies to reduce the potential for such reactions in the 
future. Based on ongoing review of patient safety data, the Sponsor may implement mandatory premedication for all pat ients should a pattern begin to emerge of mild-to -moderate study drug -
related reactions that are amenable to prophylaxis with standard agents.  
DOSE -ESCALATION DECISION POINTS  
Dose -Escalation  Cycle 1  
A minimum of 1 cycle of study drug will be administered, if tolerated. Determinations regarding 
dose-escalation and MTD will be based on tolerability during these initial 4 weeks (Cycle 1) of 
treatment, and the occurrence of DLTs thought to be related  (i.e., possibly -related,  probably-
related, or related) to study drug.   
• Patients completing Cycle 1, and receiving their full planned doses of study drug in theabsence of a DLT, will be considered to have tolerated the dose level they were assigned toreceive.
• Patients will be  replaced if they have received < 2 full doses of study drug plus follow -up
through EOC1 (C1 /D28 ± 2 days) for any reason other than a DLT to ensure MTD
determination rules can be followed with an adequate number of evaluable patients in anydose cohort.
Dose Escalation and Cohort Expansion Decision Rules  
Initially a modified, accelerated -titration, dose-escalation design will be used with entry of single 
patient cohorts for up to 2 dose levels, based on tolerability. T hereafter, a standard 3+3 dose-
escalation design will be used , with a target toxicity level of 33.3% or less as determined by DLTs.  
The decision rules for dose -escalation are as follows:  
1.A minimum of 1 patient will be entered into dose Cohort 1 and 2 ONLY
•If during the initial 2 weeks of Cycle 1 no ≥  Grade 2 toxicity considered possibly-,
probably- , or related to study drug is encountered in the patient, dose -escalation may
continue to the next level when the patient has been followed for safety until C1 /D15
•If at any time during Cycle 1, a patient experiences a ≥  Grade 2 toxicity considered
possibly-, probably-, or related to study drug, the cohort will be expanded to 3 patients
•If during Cycle 1 a patient experiences a DLT considered possibly- , probably-, or related
to study drug, the cohort will be expanded to 6 patients
2.Beginning with Cohort 3, or earlier if required by observed toxicity, a m inimum of 3 patients
will be entered to each cohort.
•If during Cycle 1 no DLTs are encountered in any of the first 3 patients, dose -escalation
may continue to the next level when all patients have completed Cycle 1
•If during Cycle 1, any 1 patient experiences a DLT considered possibly-, probably-, or
related to  study drug, the cohort will be expanded to 6 patients .  If no DLTs are
encountered in the additional 3 patients, dose -escalation may continue to the next level
when all patients have completed and tolerated Cycle 1.
•If during Cycle 1, > 1 patient experiences a DLT, dose-escalation will STOP.  This willindicate that the MTD has been exceeded .
3.If it is determined that a dose level is not tolerated:
•The previous lower dose cohort will be expanded to 6 patients (if this has not already been
accomplished) as a total of 6 patients must be treated before establishing a dose as the
MTD.
•There is also the potential to evaluate and expand a previously unplanned intermediate dose
level between 2 established dose levels to 6 patients to more fully characterize tolerability.
4.The MTD will be the highest dose level of study drug at which no more than 1 of 6 evaluable
patients has had a DLT.
5.Once the MTD (or maximum dose to be studied) is achieved and/or the RP2D is identified, that
cohort may be expanded up to 12 patients  to more fully evaluate safety and tolerability at that
dose level, at the Sponsor’s discretion. Should the DLT rate equal or exceed 33.3% in an
expanded cohort, it will be determined that the dose is not tolerated.  If this occurs, the
Symphogen Clinical Trial Protocol 
Trial ID: Sym023- 01 Version 5.0  
 
Confidential   Page 24 of 173 
 
 previous lower dose cohort or an i ntermediate dose level may be expanded as above.  
Therefore:  
• There is potential for expansion of lower dose cohort(s) if an initially identified MTD 
and/or RP2D is subsequently determined to be not tolerated (either with single or repeat 
cycles of therapy), and  
• There is potential to evaluate and expand a previously unplanned intermediate dose level(s) 
between 2 established dose levels to more fully characterize tolerability  
The RP2D may be equal to or lower than the MTD  or the MAD . The RP2D will be selected based 
on safety data, as well as available PK , pharmacodynamic/biomarker results , and other data , as 
applicable.  
Duration of Exposure Prior to Start of Next Patient and Start of Next Cohort  
Single patient cohorts :  Dose -escalation and accrual to the next cohort will occur only after the 
patient has completed and tolerated the first dose of Cycle 1 , includ ing follow -up until C1/D1 5 to 
allow for review of clinical and laboratory assessments, and consultation with the Study Safety 
Team .  The DLT evaluation period for single patient cohorts will continue through to the 
EOC1 . 
The following rules apply to single  patient cohorts:  
• Should a patient experience an AE of concern  in the latter half of Cycle 1 that would, per 
protocol, result in cohort expansion, protocol rules as outlined herein will be followed.  
• Additional patients entered to an expanded single patient cohort will follow rules as 
outlined below for 3+3 patient co horts.  
• If a patient has been entered to receive the next higher dose level, that patient will be 
allowed to continue provided adequate tolerability is being demonstrated; however, 
further enrollment to the higher dose level cohort will be halted.  
3+3 patient cohorts :  Enrollment will be staggered by 2 week s between the first and second patient 
in each new higher 3+3 dose level cohort tested.  The first patient within a cohort must complete 
and tolerate the first dose of Cycle 1, including follow -up unt il C1/D15 to allow for review of 
clinical and laboratory assessments. Thereafter patients within a cohort may be added concurrently.  
All cohorts :  Dose -escalation and accrual to the next cohort will occur only after the minimum  
number of patients required for tolerability assessment in the current cohort have completed  until 
C1/D15 in a single patient cohort, or completed Cycle 1  in a 3+3 patient cohort, , and only after 
acceptable tolerance has been demonstrated in at least 1 of 1, 3 of 3 or 5 of 6 patients treated in the 
current cohort (depending on cohort size), and after consultation with the Study Safety Team.   
For all patients, EOC1 assessments are t o be performed on C1/ D28 ( ± 2 days).  
Establishment of the MTD and/or RP2D  
The MTD will be the highest dose level of study drug at which no more than 1 of 6 evaluable 
patients has had a DLT.  
The MAD, MTD , or a dose lower than the MAD or MTD , will be identified as the RP2D, provided 
a minimum of 6 evaluable patients have been treated at that dose, and provided acceptable 
tolerance has been demonstrated  in at least 5 of 6 patients treated.  
The RP2D will be based on the MTD evaluation as well as  other toxicities observed in the study, 
including observations in later cycles of administration of study drug, as well as on PK, 
pharmacodynamic/ biomarkers, and/or other data.  
Rules for Stopping the Study  
The study will be stopped if the MTD is exceeded at the lowest dose level.  
CONTINUED TREATMENT  
Continued Treatment 
after Cycle 1  
 
 Upon completion of Cycle 1, in the absence of unacceptable toxicity or documented disease 
progression, patients may continue to receive additional cycles of study drug unless further delay is required to allow for amelioration of ongoing AEs .   
Administration will be at the same dose level and infusion duration established for the patient, and on the same Q2W schedule provided retreatment guidelines are met.  If a delay is required, additional cycles should be initiated within approximately 2 weeks  of the c ompletion of the 
previous cycle, if feasible.  
Retreatment Guidelines :  To  start any new cycle,  a patient must meet the following criteria: 
• ANC ≥ 1,000 per mm3 
Symphogen Clinical Trial Protocol 
Trial ID: Sym023- 01 Version 5.0  
Confidential  Page 25 of 173 •Platelets ≥ 75,000 per mm3
•Ongoing study drug-related  AEs should NOT meet the criteria for DLT
•Ongoing study drug-related  AEs should have either ameliorated to ≤ Grade 1  severity, returned
to baseline status, or resolved, with the exceptions of :
o Grade 2 alopecia,
o Grade 2 clinical events that are being adequately controlled with best supportive care
(e.g., fatigue, nausea, vomiting, diarrhea), and
o Grade 2 asymptomatic laboratory abnormalities that are considered clinicallyinsignificant and clinically uncomplicated , and/or that are resolving spontaneously or
with conventional medical interventions
•Dosing must be delayed in patients with evidence of Grade 2 immune -mediated toxicities,
including:o Pneumonitis, myocarditis, adrenal insufficiency, encephalitis, nephritis /renal dysfunction
(serum creatinine elevation ), episcleritis /uveitis /iritis
o Colitis, hypophysitis, hyperglycemia, inflammatory arthritis, myositis, rash 
o Hepatitis (transaminitis, total bilirubin elevation)
Retreatment cycles may continue up to 12 months  at which time plans for continued therapy will 
be discussed by the Medical Monitor(s) and Investigator. Patients who stop therapy with an ongoing OR or prolonged SD may be retreated in the event of relapse , if the trial is still open .   
Continued Treatment 
after Radiologic 
Disease Progression  Immunotherapeutic agents may produce antitumor effects that can manifest as response after initial 
evidence of PD, a phenomenon referred to as “pseudoprogression”  (PSPD) . 
Patients will be permitted to continue treatment beyond initial RECIST v1.1 (or RECIL  2017) 
defined PD while waiting for confirmation of PD, provided they are clinically stable as defined by 
the following criteria (per iRECIST): 
•Investigator -assessed clinical benefit and absence of rapid disease progression
•Tolerating study drug
•Stable PS
•Absence of progressive tumor at critical anatomical sites (e.g. , cord compression) requiring
urgent alternative medical intervention.
Retreatment 
Following an 
Objective Response Treatment with study drug may be restarted in a patient who previously achieved a documented OR 
or prolonged SD (> 16 weeks) in this study, stopped treatmen t, and subsequently progresses.  Such 
action may be taken  at the Investigator’s discretion, following discussion with the Medical 
Monitor(s), provided retreatment criteria are met, no anti -cancer treatment was administered since 
the last dose of study drug, and the trial is still open.  
This option for retreatme nt does not  apply to patients who previously experienced a DLT  that 
required permanent discontinuation from study drug (see DLT and Treatment Discontinuation 
Criteria ).  
ADVERSE EVENTS AND DOSE -LIMITING TOXICITIES  
Adverse Event 
Grading  For reported adverse events (AEs), the Common Terminology Criteria for Adverse Events (Version 
5.0) (CTCAE v 5.0), will be used to grade the severity of the AE.  
Management of D ose-
Limiting Toxicitie s 
and Other Toxicities  Management of Dose -Limiting Toxicities  
AEs that meet the protocol definition of DLT will  require discontinuation from study treatment, 
without exception .   
Management of Other Toxicities  
AEs that do not meet the protocol definition of DLT, but nevertheless warrant dose modification may be managed by delay  of study drug to allow for amelioration of the toxicity.  
Symphogen Clinical Trial Protocol 
Trial ID: Sym023- 01 Version 5.0  
Confidential  Page 26 of 173 Dose-Limiting 
Toxicities  Definition Any of the following toxicities  occurring during Cycle 1 , if judged to be related to study drug  (i.e., 
possibly-related, probably -related, or related), will be considered a DLT for the purposes of 
tolerability assessment during this trial.  
1. ≥ Grade 3  evidence of any of the following immune -mediated toxicities:
•Pneumonitis
•Myocarditis
•Adrenal insufficiency
•Encephalitis
•Nephritis, renal dysfunction (serum creatinine elevation)
•Episcleritis, uveitis, or iritis
2. ≥ Grade 3  evidence of any of the following immune-mediated toxicities:
•Colitis
•Hypophysitis, hyperglycemia
•Inflammatory arthritis
•Myositis
•Rash
3. ≥ Grade 2:
• Uveitis, eye pain or blurred vision that does not resolve with topical therapy within 2
weeks
• AEs that are prolonged excessively based upon the medical judgment of the investigator,and/or lead to permanent discontinuation of the investigational agent due to poortolerance
• Immune-mediated toxicity that requires use of glucocorticoids at a dose of ≥ 1 mg/kg/dayof prednisone equivalents for tre atment of the toxicity
4. Any confirmed reduction in visual acuity, regardless of grade or duration
5. Hepatic-related findings consistent with Hy’s Law criteria :
• AST and/or ALT elevation > 3 × ULN (or > 3 × baseline if elevated at study entry due tohepatic involvement by tumor ), with
• total bilirubin ≥  2 × ULN without initial findings of cholestasis (i.e. , serum alkaline
phosphatase [ALP]  < 2 × ULN ), and
• No explanation for the above findings such as viral hepatic injury, preexisting or acuteliver disease, or another drug or condition capable of causing the observed liver injury
6. Any other  ≥ Grade 3 or 4  non-hematologic toxicity regardless of duration with the exce ptions
of:
•Grade 3 fatigue
•Grade 3 nausea, vomiting, or diarrhea lasting ≤ 2 days with best supportive care
•Grade 3  asymptomatic electrolyte abnormalities lasting ≤ 3 days  that are not clinically
complicated, and resolve spontaneously or respond to conventional medical interventions
•Other Grade 3 asymptomatic laboratory abnormalities that are clinically non -significant
in the investigator’s opinion, and that resolve spontaneously or with conventional medical
interventions
7. Any Grade 4 non- hematologic laboratory toxicity regardless of duration
8. Neutropenia that is:
• Grade 3 meeting the CTCAE v5.0 criteria for febrile neutropenia (ANC < 1000 per mm3
an
d a single temperature > 38.3º C [10 1º F] or sustained temperature ≥  38º C [100.4º  F]
for > 1h)
• Grade 4
9. Thrombocytopenia that is:• Grade 3 with CS hemorrhage or requirement for transfusion
• Grade 4 (platelets < 25,000 per mm
3)
10. Anemia that is Grade 4 and not explained by underlying disease
11. Any other Grade 4 hematologic toxicity (other than those specifically excluded) lasting > 5
days
12. Any death where a relationship to study drug cannot be ruled out
13. Inability to complete Cycle 1  at the assigned dose (i. e., receipt of < 2 full planned doses of
study drug plus 2 weeks  of follow -up) due to any toxicity
14. Treatment delays > 2 weeks  from the scheduled next dose during Cycle 1 due to any  toxicity
Other toxicities may be considered a DLT as determined by the Inv estigator in conjunction with
Symphogen Clinical Trial Protocol 
Trial ID: Sym023- 01 Version 5.0  
Confidential  Page 27 of 173 the Study Safety Team . 
The above criteria will be used to make individual patient determinations regarding dose delays  
or discontinuation throughout the course of the trial, however,  only those DLTs occurring 
during Cycle 1  will be used to make decisions regarding cohort dose -escalation and 
tolerability.  
Events occurring after Cycle 1 will also be evaluated by the Study S afety Team and taken into 
consideration when deciding upon further dose levels to be assessed as well as establishment of the 
RP2D.  
TOXICITY SAFETY MANAGEMENT AND SAFETY MONITORING  
Infusion -Related 
Reaction  Management  In addition to premedication as management f or IRRs , the following infusion prolongation 
instructions are provided:  
• For Grade 1 reactions , the infusion may be slowed to 50%  of the prior rate such that the
remaining dose to be delivered is  administered in 2× the amount of time as was initially
scheduled.
•For Grade 2 reactions , the infusion should be interrupted for a minimum of 30 minutes, and at
least until there is either amelioration to ≤ Grade 1 severity or return to baseline status.
Supportive care should be provided. The infusion should then be restarted and slowed to 50%of the prior rate, as described. Subsequent infusions should be administered at the prolonged
rate.
•For Grade 3 reactions , the infusion will be STOPPED  and s upportive care will be provided.
The occurrence will be considered a DLT and the patient will be discontinued from treatment.
•For Grade 4 reactions , the infusion will be STOPPED and supportive care will be provided.
The occurrence will be considered a DLT and the patient will be discontinued from treatment.
In all cases the Investigator should use best clinical judgment in managing such reactions. For 
Grade 1 and Grade 2 IRRs, rechal lenge with a shorter duration of infusion (no less than the 
duration designated by the patient’s dose assignment and weight ) may be attempted at the 
Investigator ’s discretion, after a minimum of 2 doses  with no evidence of infusion-related toxicity  
at the prolonged rate .  
Dose Delays  Toxicities may be managed by delay  in dosing, provided they do not meet the criteria for study 
discontinuation.  
For toxicities that are to be managed by dose delay , dosing may be restarted at the same dose, once 
study retreatment criteria have been met .   
Safety Monitoring  Clinical and la boratory safety data will be reviewed on an ongoing basis throughout the study by 
the Investigators and Sponsor’s Medical Representative(s) so that decisions regarding the 
advisability of continuing accrual to a dose cohort, and/or escalating the dose and allowing accrual to a higher dose cohort may be made. In addition, patients will be carefully evaluated for evidence of potential cumulative and/or delayed toxicities throughout the duration of their time on study.   
To do so, Serious Adverse Events (SAEs), immune-related AEs of significance, AEs resulting in 
permanent discontinuation from study (regardless of seriousness or relationship to study drug), DLTs, IRRs, and dose delays  will be promptly reported to the Sponsor  (or designee).  
A Study Safety Team will be established and will be comprised of the Investigat ors(s) and the 
Sponsor’s Medical Representative(s).  Biweekly Study Safety Team  teleconferences will be held to 
discuss ongoing patient status and any emerging s afety concerns; the frequency of teleconferences 
may fluctuate based on accrual and study activity, as indicated.  
STUDY ASSESSMENTS  
Screening 
(within 14 days prior to 1st 
dose unless otherwise 
stipulated)  • Informed consent
• Eligibility assessment
• Demography
• Past medical history
• History of the primary malignancy (including data on the extent, duration, and best response
to prior therapy, if available)
Symphogen Clinical Trial Protocol 
Trial ID: Sym023- 01 Version 5.0  
 
Confidential   Page 28 of 173 
 
 Safety Assessments  Patients to be monitored throughout the treatment and follow -up peri od for occurrence of AEs 
(acute, delayed, and/or cumulative), as well as for changes in clinical status, vital signs (VS), and 
laboratory data.   
Safety Assessments (1)  (within 14 days prior to 1st dose unless otherwise stipulated)  
• Concomitant Medication/Procedure surveys  
• AE reporting (collection of data from signing of informed consent to 30 days after final dose, with long -term follow -up to surveil for [up to 6 months]and follow [up to 2 years] im mune -
mediated toxicities)  
• DLT assessment (Cycle 1)  
• PS evaluation (ECOG)  
• VS assessment (including temperature, pulse, respiratory rate, blood pressure [BP], and 
oxygen saturation by pulse oximetry at rest and exertion)  
• Physical examination (with weight, and  pulmonary/cardiac assessment at each visit)  
• Hematology panel  
• Biochemistry panel (to include creatine kinase [CK] for cardiac assessment)  
• Coagulation panel  
• Thyroid function studies (to include measurement of thyroid stimulating hormone [TSH], free triiodo thyronine [fT3] and free thyroxine [fT4])  
• Urinalysis (by multi -panel chemical test strip analysis; include microscopic examination of 
sediment if clinically indicated ) 
• Pregnancy testing (if applicable)  (serum test within 14 days, urine test repeated within 2 
working days prior to 1
st dose)  
• Electrocardiogram (ECG), 12 -lead  
Safety Assessments (2)  (results from assessments previously performed as standard of care  within 
28 days [+2 days] prior to 1st dose may be utilized , provided no antineoplastic therapy has been 
delivered between assessment and 1st dose; otherwise within 14 days prior to 1st dose) 
• Ophthalmology examination  
• MUGA scan or ECHO (To be performed ONLY in patients with a history of CHF)  
• Pulmonary function tests (PFTs) (to include spirometry and assessment of diffusing capacity 
of carbon monoxide [DL CO]) 
Disease Assessments  
 Disease Status  (within 28 days [+2 days] prior to 1st dose)  
• Tumor marker measurement (as indicated by tumor type)  
• Diagnostic imaging for assessment of disease (computed tomography [CT]/magnetic resonance imaging [MRI]) (The same method and technique should be used throughout the 
study.) For safety, imaging of the chest required at each evaluation to assess pulmo nary status  
• Response assessment (per RECIST v1.1, RECIL 2017 , and iRECIST). Data on evidence of 
and duration of any OR (CR or PR) or SD, as well as disease progression  to be collected.  
Other Assessments  
(Specialty Lab)  
  Immunogenicity  
Serum sampling to assess the potential for anti -drug antibody (ADA) formation  
Pharmacokinetics  
Serum sampling to assess the PK profile of the study drug  
Pharmacodynamic and other Biomarker Studies  
Peripheral blood sampling (pre - and post -dosing)  
• Pharmacodynamic evaluation (e.g., receptor occupancy ) 
• Evaluation of DNA, RNA, proteins/cytokines , and cellular biomarkers  
Tumor tissue sampling  (pre- and post -dosing) (biopsies o ptional ) 
• Evaluation of DNA, RNA, protein, and cellular biomarkers  
DISCONTINUATION AND FOLLOW -UP 
Key Treatment 
Discontinuation Criteria  Patients are to be discontinued from treatment in the event of any of the following:  
1. Adverse Events, including : 
• Any AE or SAE that meets the study DLT criteria at any time during the study   
• Another AE or SAE considered by the Investigator to require treatment discontinuation  
2. Progressive Diseas e: Confirmed radiologically  
3. Clinical Progression: Treatment failure not meeting the criteria for PD, but considered by the 
Investigator to require treatment discontinuation   
4. Physician Decision, including:  
• Use of or requirement for a non -permitted concomitant medication  
Symphogen Clinical Trial Protocol 
Trial ID: Sym023- 01 Version 5.0  
 
Confidential   Page 29 of 173 
 
 • Requirement for a significant surg ical procedure  
• Intercurrent illness that would prevent completion of study-related evaluations  
• Any other reason in the opinion of the Investigator that would justify treatment 
discontinuation   
5. Withdrawal by Patient: Withdrawal of consent and election to discontinue treatment  
Replacements  Should a patient discontinue treatment with study drug for reasons other than the occurrence of a 
DLT prior to completing Cycle 1, a replacement patient will be obtained using the original eligibility criteria.   
Follow -up All follow -up visits and assessments, as described, should be conducted to the extent possible.  
• End of Treatment  (EOT) evaluations to be conducted within approximately 10 days  following 
treatment discontinu ation , or before initiation of a new treatment, whichever occurs first    
• 1-Month Follow -up (1M FUP) evaluations to be conducted approximately 30 days  (+7 days) 
following the last dose of study drug.   
• Long -Term FUP for Safety : If an observed toxicity (non-immune-mediated) thought to be 
related to study drug has not resolved by t he 1M FUP  evaluation, an additional FUP AE 
assessment will be conducted approximately 2 months  (may be repeated at 4 months if needed) 
following the last dose of study drug, if feasible, to confirm that the event has either resolved, returned to baseline s tatus, or been adequately explained  and assessed by the Investigator as 
chronic and/or stable, and that no long-term deleterious effects have become evident   
Since late-occurring immune-mediated toxicities have been reported to occur several weeks to months after treatment with other immune checkpoint inhibitors, long-term surveillance for such toxicities will be conducted in this study. Patients will be followed at approximately 2 -
month intervals following the last dose of study drug for up to 6 months to assess for the onset 
of any post -therapy immune-mediated event thought to be related to study drug.  
Any patient who develops an immune -mediated toxicit y during study, or during the 6-month 
post-therapy FUP period, will be followed at approximately 2-month intervals following the 
last dose of study drug for up to 2 years to assess the course of the condition and evaluate potential reversibility of the finding.  
• Long -Term FUP for Response: In the event of an ongoing OR or SD at the EOT, response 
assessments  based on imaging studies will continue to be performed every 2 months  following 
the last dose of study drug, until confirmed PD or another therapeutic intervention is initiated , 
until the end of trial , so that data may be collected on the duration of S D or OR, as well as 
disease progression  
ANALYSIS PLAN 
Endpoints  Primary Endpoint  
DLTs to establish MTD and/or recommended RP2D  
 
Secondary Endpoints  
• Safety profile  
• Incidence and characterization of immunogenicity (ADA)  
• PK profile  
• Preliminary antineoplastic activity, to include occurrence/duration of OR or SD, and TTP  
Pharmacokinetic 
Parameters  Evaluations to delineate dose -response and PK parameter -response relationships will be 
undertaken.  Based on the concentrations determined, the followi ng PK parameters for the study 
drug will be calculated for each subject: area under the concentration -time curve (AUC) from start 
of first infusion (SOI) to 336 hours (AUC τ), from SOI to infinity (AUC inf), terminal elimination 
half-life (T 1/2), clearance ( CL), volume of distribution (V d), maximum concentration (C max), 
concentration at end of infusion (C EOI), trough concentration (C trough), and time to reach C max (Tmax) 
Exploratory 
Pharmacodynamic 
and Biomarker 
Parameters  A summary of the changes in potential pharmacodynamic and other biomarker(s) will be presented.   
Statistical Methods 
and Sample Size Calculation  The primary endpoint of Sym 023 dose-escalation is the occurrence of DLTs during Cycle 1 for 
each dosing regim en. The number of enrolled patients will depend on the extent of observed DLTs 
independently in each cohort. Based on the dose -escalation design, it is planned to enroll 
approximately ( 20-48) patients during this part of the trial.  
Symphogen Clinical Trial Protocol 
Trial ID: Sym023- 01 Version 5.0  
 
Confidential   Page 30 of 173 
 
 All DLT events will be listed by dose cohort and patient. A summary table of DLTs across dose 
cohorts by System Organ Class (SOC) and preferred term will be presented, if applicable. The 
summaries will include number of DLTs and number and percentages of patients experiencing a 
DLT. 
Safety evaluation will be based on reported AEs and safety laboratory test results, immunogenicity, 
and other safety data. Unless otherwise specified, all summaries will be descriptive.  
Interim Analysis  Safety evaluation will be performed prior to ea ch dose -escalation. No other interim analyses are 
planned.  
TRIAL REPORTING  
Final Clinical Trial 
Report  Final integrated clinical/statistical trial report to be prepared at the end of trial  
 
Symphogen Clinical Trial Protocol 
Trial ID: Sym023- 01 Version 5.0  
 
Confidential   Page 31 of 173 
 
 2 SCIENTIFIC BACKGROUND AND RATIONALE  
2.1 Background  
2.1.1 Tumor Malignancies  
Cancers are malignant tumors formed by an abnormal growth of cells and tissue leading to organ 
failure. They fall into two categories: solid and hematological cancers. Solid tumors are formed 
by an abnormal growth of body tissue cells other than blood, bone marrow  (BM),  or lymphatic 
cells. A solid tumor consists of an abnormal mass of cells, which may stem from different tissue 
types such as lung, breast, colon, prostate, stomach , and liver, and which initially grows in the 
organ of its cellula r origin.  In advanced stages of the disease, solid tumors may spread to other 
organs through metastatic tumor growth.   
Cancer is the second -leading cause of death and disability in the world, only surpassed by heart 
disease. In 2012, 14.1 million people w ere diagnosed with cancer worldwide. An estimated 8.2 
million people died from the disease. The World Health Organization (WHO) projected that by 
2035, these figures could increase to 24 million new cases and 14.6 million cancer deaths worldwide. Lung, bre ast, colorectal, prostate, and stomach cancer are the most common 
malignancies ( 1). 
2.1.2 Overview of the Target: TIM -3 
TIM-3 (T-cell immunoglobulin and mucin- domain containing- 3), also known as HAVCR2 
(hepatitis A virus cellular receptor 2) or CD366, is an immune checkpoint rec eptor expressed by 
a range of different immune cells, including T -cells, dendritic cells, macrophages, and natural 
killer (NK) cells . On naïve T -cells, TIM -3 expression is low, but becomes upregulated upon T -
cell activation.  In contrast to T -cells, dendri tic cells, NK cells and monocytes have high basal 
TIM-3 expression.TIM -3 has been associated with several, mostly promiscuous, ligands, 
including galectin- 9, phosphatidylserine (PtdS), carcinoembryonic antigen related cell adhesion 
molecule 1 ( CEACAM1 ) and high mobility group box 1 ( HMGB1 ) protein . The exact roles of 
these ligands are currently not well understood and most likely are context dependent ( 2-4).  
The role of TIM -3 in regulating immune cell function is complex and appears context -
dependent; both activating and inhibiting functions have been described ( 3, 4). TIM -3 
engagement on myeloid cells, such as dendritic cells and macrophages, has been reported to 
increase their state of activation. TIM -3 on T -cells, on the other hand, has been described to 
correlate with an “exhausted” phenotype. Most of the functional data related to TIM -3 and its 
role in tumor immunology come from studies in mice using various antibodies ( 5, 6).  
Antibody- mediated engagement of TIM -3 has been shown to induce increased proliferation and 
cytokine production by T -cells activated in vitro , as well as tumor growth inhibition in tumor 
xenograft models, especially in combination with Programmed Cell Death Protein 1 (PD -1) 
blockade ( 5, 6). In most of these studies, due to poor antibody validation, it is not clear whether 
the effects of the TIM -3 antibodies are mediated by inhibition of ligand binding, by antibody 
mediated target engagement, or both. Furthermore, due to the expression of TIM -3 in both 
myeloid cells and lymphocytes , the exact cellular mechanisms underlying the in vivo  antitumor 
activity of anti -TIM-3 antibodies are still not understood.  
Symphogen Clinical Trial Protocol 
Trial ID: Sym023- 01 Version 5.0  
 
Confidential   Page 32 of 173 
 
 Three anti -TIM-3 antibodies, MGB453 (Novartis), TSR -022 (Tesaro) and LY3321367 (Lilly) are 
in early clinical development for use as cancer immunotherapy in solid and hematologic 
malignancies. All three antibodi es are to be tested alone (i.e. , as monotherapy) and in 
combination with anti -PD-1 antibodies. Additional TIM -3 antibodies and small -molecul e 
inhibitors are in pre -clinical development. TSR -022, a humanized IgG4 monoclonal anti -TIM-3 
antibody that enhances T -cell activation, is the only antibody drug candidate for which any 
clinical results have been published to date ( 7). The results indicate that TSR -022 monotherapy 
is well tolerated across multiple dose levels and that adverse events  (AEs)  are manageable and 
consistent with the safety profiles of other checkpoint inhibitors. Clinical activity in the form of disease stabilization and one case of partial response has been observed in patients with various 
cancer types, including rectal, thyroid, neuroendocrine, head and  neck cancer, and soft -tissue 
sarcoma ( 7, 8). TSR -022 is currently  being evaluated in the clinic in combination with an anti -
PD-1 antibody. 
2.1.3 Overview of the Product: Sym023 
The investigational medicinal product (IMP) tested in this trial is Sym023. Sym023 is a 
recombinant, fully human, IgG2 antibody that binds human TIM -3 with nanomolar affinity and 
cynomolgus TIM -3 with 100- fold reduced affinity. Sym023 does not cross -react with mouse or 
rat TIM -3. Sym023 blocks PtdS  binding to TIM -3 and induces cytokine secretion and activation 
of immune cells in v itro. 
2.2 Summary of Nonclinical Studies  
2.2.1 Nonclinical Pharmacology Studies  
The pharmacologic characterization of Sym023 includes in vitro  functional evaluation in various 
relevant cell -based assays and in vivo testing in mouse models of human cancer. Sym023 
stimulates T -cell and dendritic cell activation and cytokine production in vitro . 
Sym023 enhances cytokine production and T -cell proliferation in one -way and two- way mixed 
lymphocyte reaction (MLR) assays and shows comparable activity in the 2- way MLR assay with 
human and cynomolgus cells. Sym023 has a direct effect on dendritic cells leading to increased expression of activation markers and secretion of cytokines. The functional activity of Sym023 is 
dependent on interaction with Fcγ receptors;  however, Sym023 does not induce secondary 
effector functions, such as antibody- dependent cellular cytotoxicity (ADCC) and complement -
dependent cytotoxicity (CDC) in vitro . 
The ability of Sym023 to stimulate immune cells  in vitro  translates into tumor growth 
suppression in vivo . Sym023 induced activation of immune cells and reduced tumor growth in 
humanized mouse models engrafted with human cell -line derived or patient -derived tumor 
xenografts. In a human xenograft tumor model in mice reconstituted with human peripheral 
blood mononuclear cells (PBMCs), the combination of Sym023 and an anti -PD-1 antibody 
enhanced the tumor growth inhibition compared to the limited effect of single antibody treatment. These in vivo  studies demonstrate that administration of Sym023 induces a tumor -
specific immune response . 
Symphogen Clinical Trial Protocol 
Trial ID: Sym023- 01 Version 5.0  
 
Confidential   Page 33 of 173 
 
 2.2.2 Nonclinical Toxicology Studie s 
The relevance of the cynomolgus monkey as the only species for prediction of potential human 
toxicity of Sym023 was demonstrated by amino acid sequence homology, target binding affinity 
and avidity, and functional activity. 
The non- clinical development program in the cynomolgus monkey consisted of two non- Good 
Laboratory Practice ( GLP ) studies as well as a GLP -compliant 4 -week study . No adverse 
findings were observed in the 4- week dose -range -finding (DRF) study in cynomolgus monkeys, 
where Sym023 was administered at 10 and 40 mg/kg/week by four weekly intravenous ( IV) 
injections. In the  non-GLP pharmacokinetic ( PK) study, single IV infusions of Sym023 at 1 or 
10 mg/kg were well tolerated by cynomolgus monkeys. No test article related effects on in- life 
parameters were noted .  
In a subsequent pivotal 4 -week GLP -compliant toxicology study, Sym023 was administered 
once weekly IV at 0  (control), 10, or 100 mg/kg to the cynomolgus monkey for 4 weeks (a total 
of five doses). An assessment of delayed onset toxicity and/or reversibility of toxicity was made 
during a 12- week recovery period for th e animals administered 10 mg/kg. The purpose of this 
study was to support a safe starting dose in first -in-human studies. Standard toxicology 
evaluations as well as specific immunotoxicology endpoints were included in this pivotal study.  
There were no decedents during the study. Weekly IV infusion of 10 or 100 mg/kg/week 
Sym023 was generally well tolerated, with no adverse findings noted.  
All animals were anti-drug antibody ( ADA) -negative on Day 1 and Day 29, and the animals 
were adequately exposed to Sym023 throughout the study.  
No immunotoxicity was observed in this study. The results indicated that repeated IV 
administration of Sym023 did not result in any adverse test article -related changes to immune 
function as determined by cytokine levels in blood, ex vivo  stimulation with s taphylococcal 
enterotoxin B  (SEB), immunophenotyping of blood and spleen, T -cell dependent antibody 
response (TDAR) to keyhole l impet hemocyanin ( KLH) , or ex vivo  recall stimulation with KLH.  
No test article -related effects on body weight, food consumption, clinical observations, dosing 
observations, dose site observations, ophthalmic observations, blood pressures, functional 
observation battery, electro cardiogram ( ECG ), respiration, or rectal temperatures were recorded 
during the dosing phase. Likewise, there were no changes considered related to administration of Sym023 for hematology, coagulation, clinical chemistry, thyroid stimulating hormone  (TSH), 
urinalysis, organ weights, and macroscopic or microscopic pathology. Based on the data from this study, the no- observed- adverse -effect level (NOAEL) for Sym023 is ≥100 mg/kg/week. 
In vitro  safety pharmacology was addressed by assessing cytokine release, complement 
activation, as well as platelet  counts, and white blood cell counts in human whole blood from 6 
healthy donors , and by assessing mast cell degranulation in human mast cells cultured from 
peripheral blood CD133+ stem cells. Sym023 responses in the human whole blood assay were overall comparable to vehicle for cytokine levels (IFN -γ, IL -2, IL -6, and TNF -α), complement 
activation, platelet count, and white blood cell count. Sym023 did not affect the immediate degranulatory response of mast cells in the human mast cell assay. Therefore, the likelihood of acute cytokine release syndrome or mast cell degranulation associated with administration of Sym023 to humans is considered to be low .  
Symphogen Clinical Trial Protocol 
Trial ID: Sym023- 01 Version 5.0  
 
Confidential   Page 34 of 173 
 
 The half -life in cynomolgus monkeys was  approximately  7 days and the half -life of Sym023 in 
humans is anticipated to be approximately 12 days. The planned dosing, every 2 weeks, is 
predicted to ensure sustained exposure to Sym023 during repeated dosing with little or no accumulation. No PK or pharmacodynamic  properties have been identified which precludes 
administering Sym023 to humans. 
2.3 Clinical Experience 
2.3.1 Clinical Experience with Agents Related to S ym023 
2.3.1.1 Clinical Evidence of Activity in Malignant Diseases  
As noted, anti -PD-1 and anti -programmed d eath-ligand 1 ( PD-L1) monoclonal  antibodies 
(mAbs ) have been approved (accelerated and full approvals) for the treatment of various human 
cancers . These  include : (a) solid tumors (non- small cell lung carcinoma, renal cell carcinoma, 
malignant melanoma, squamous cell c arcinoma of the head and neck, urothelial carcinoma, 
Merkel cell carcinoma; (b) hematological malignancies ( classical H odgkin Lymphoma ); as well 
as (c) a number of tumors in adults or children characterized by high microsatellite instability 
without other available therapies ( 9-13). Additional agents targeting PD -1 are in development.   
These agents continue to be studied alone and in combination with other modalities including other agents with immune system targets . For example, the combination of anti -PD-1 mAbs and 
an antibody targeting Cytotoxic T -Lymphocyte -Associated Protein 4 ( CTLA -4) (ipilimumab) 
has been approved in patients with melanoma. These agents are also being studied with standard therapeutics such as ch emotherapy, radiotherapy,  and various targeted agents , all in efforts to 
both improve  the initial efficacy of immune checkpoint blockers and/ or to circumvent the 
refractoriness that emerges during or after treatment with these agents.   
Anti-PD-L1 mAbs have also been approved and are being developed alone and in combination 
with other agents.  
2.3.1.2 Safety and Tolerability of anti -TIM -3 mAbs  
Data are available from a single Phase 1 study of TSR -022, a human monoclonal IgG4 antibody 
to TIM -3. As of October 2017, 38 pts had been treated with TSR -022 monotherapy: 3 pts at 0.03 
mg/kg, 3 pts at 0.1 mg/kg, 3 pts at 0.3 mg/kg, 9 pts at 1 mg/kg, 8 pts at 3 mg/kg, and 12 pts at 10 
mg/kg ( 7). TSR‐022 monotherapy was well tolerated across multiple dose levels. AEs  that 
occurred in >15% of patients were fatigue (8 pts, 26%) ; abdominal pain (7 pts, 23%) ; nausea (6 
pts, 19%); elevated alanine aminotransferase ( ALT ); elevated aspartate aminotransferase ( AST ); 
back pain, constipation, and vomiting was each reported in 5 pts (16%). One dose -limiting 
toxicity (DLT) event occurred with TSR -022 monotherapy (immune -related Grade 3 lipase 
elevation), which did not require treatment modification. No treatment -related serious adverse 
events (SAEs) were observed. These data were updated in a presentation at the SITC meeting in 
November 2017. There were no G rade 4 or 5 AE s reported and additional AEs included: 
decreased neutrophil and lymphocyte counts; chills; dyspnea; decreased appetite; pain and 
peripheral sensory neuropathy. TSR -022 exposure and peripheral receptor occupancy increased 
in a dose proportional manner from 0.3 to 10 mg/kg ( 7, 8). 
The authors concluded that the AEs  seen in patients receiving TSR -022 monotherapy were 
manageable and consistent with the safety profiles of other checkpoint inhibitors ( 7). 
Symphogen Clinical Trial Protocol 
Trial ID: Sym023- 01 Version 5.0  
Confidential  Page 35 of 173 Although the mechanism of action is distinct, inhibitors of TIM -3 have many similarities to 
blockers of other immune checkpoint pathways. Preclinical data have documented that inhibition 
of the PD -1/PD- L1 pathway results in immune stimulation that may lead to antitumor effects, 
autoimmunity, effects on immune responses to viral infections, and alloimmunity following 
hematopoie tic stem cell transplantation  (HSCT). Because of these s imilarities, data on the 
potential AEs  seen after treatment with antibodies to PD -1 and PD-L1 are being included in this 
clinical trial protocol (CTP) since there are limited available data on toxicities associated with 
administration of antibodies to TIM -3 alone ( 7).  
AEs associated with immune checkpoint blockers targeting PD-1 or PD-L1 have been well described in publications of clinical trials of these agents, in prescribing information from 
approved products ( 8-12), as well as in literature reviews ( 14-17). Unlike AEs observed after 
standard cancer therapy, many of the toxicities of these agents are only observed after several 
weeks to months and may not be clearly dose-related. The wide variety of potential AEs  as well 
as their variable time s of onset have complicated development , although the safety profiles of 
these agents have become clearer over time as additional agents targeting these pathways  have 
been evaluated.   
The warnings and precautions variably associated with checkpoint inhibitors, specifically those 
directed to PD -1/PD- L1, have included  risk of developing: immune-mediated pneumonitis, 
immune -mediated colitis, immune -mediated hepatitis, immune -mediated endocrinopathies, 
immune -mediated nephritis and renal dysfunction, immune-mediated skin adverse reactions, and 
immune -mediated encephalitis/meningoencephalitis, immune -mediated myasthenic syndrome, 
myasthenia gravis, or Guillain -Barre, immune- mediated ocular inflammatory toxicity,  and 
immune -mediated pancreatitis . Increased infection  risk, embryo- fetal toxicity, as well as 
increased complications associated with allogeneic HSCT  have also been noted. Other immune-
mediated and non- immune -mediated AEs  have been reported in the archival literature and/or 
prescribing information for PD -1/PD- L1 pathway inhibitors and are listed in Appendix 8 ( 8-12). 
2.3.1.3 Patient Selection for Treatment with Sym 023 
Preliminary studies have been undertaken to evaluate biomarkers that allow for selection of 
patients who may have an increased likelihood of responding to anti- TIM-3 mAbs, but there are 
no definitive data available at this time .   
2.3.1.4 Potential Pharmacodynamic Biomarkers 
Limited information is available on potential pharmacodynamic biomarkers measuring responses to therapy with anti- TIM-3 mAbs. Assessment of antitumor effect in this study will be performed 
using standard response criteria as well as a modification of the Response Evaluation Criteria in Solid Tumors (Version 1.1) (RECIST v1.1) referred to as Immunotherapeutics Response Evaluation Criteria in Solid Tumors (iRECIST ) (18 , 19).  
2.3.2 Clinical Experience with Sym023 
The study described in this clinical trial protocol is ongoing.  Sym023 is also being studied in a Phase 1 study in combination with Sym021 (anti- PD-1 monoclonal antibody; C linicalT rials.gov 
number [STUDY_ID_REMOVED]).  
Symphogen Clinical Trial Protocol 
Trial ID: Sym023- 01 Version 5.0  
 
Confidential   Page 36 of 173 
 
 2.4 Trial Rationale  
Data from the literature a s well as nonclinical pharmacology, toxicology, PK and the in vitro  
safety study in human whole blood indicate that Sym 023 can be safely evaluated  in human 
cancer patients  at an appropriate starting dose. Data on both Sym 023 as well as other anti -TIM-3 
mAb s have been considered in developing this clinical trial. Sym 023 is being evaluated as a 
single agent in preparation for subsequent studies in combination with other mAbs designed to 
improve antitumor responses by further interactions with other immune sys tem targets. 
Combinations of immune checkpoint inhibitors and other agents that either increase immune 
function directly or interrupt immune suppressive pathways are under active development with 
an aim of improving the efficacy of currently available ther apies . 
2.5 Dose  Rationale  
The starting dose and dose -escalation steps are based on a combination of the toxicity studies in 
cynomolgus monkeys ( using the NOAEL  as one criterion ), in vitro  safety pharmacology, 
observations in in vitro  cell studies, and the Minimal Anticipated Biological Effect L evel 
(MABEL) for Sym023 based on pre -clinical in vitro  and in vivo  pharmacology data.  
Based on a combined evaluation of the data, a cautious approa ch was used and a starting dose of 
0.03 mg/kg every 2 weeks ( Q2W ) equal to the MABEL was selected. The evaluation takes into 
account the uncertainties for predicting the effects of Sym023 in humans while recognizing the 
lack of toxicity in cynomolgus monke ys at exposure levels well above the predicted serum 
concentration for the first dose in humans. All relevant in vitro  and in vivo  PK and 
pharmacodynamic data were considered for Sym023. In the pivotal toxicity study in cynomolgus 
monkeys, Sym023 was dosed at 10 and 100 mg/kg/week for 4 weeks. The 100 mg/kg weekly 
dose for 4 weeks (5 dosing occasions) in this study was determined to be the NOAEL. The 
Maximum Recommended Starting Dose (MRSD) was determined to be 0.1 mg/kg Q2W after 
applying a standard safety factor (10) and adjusting for differences in affinity of Sym023 to 
human and cynomolgus TIM -3 (100).  
A starting dose of 0.03 mg/kg Q2W using the MABEL approach was selected based on evaluation of all available data for predicting the Sym023 effects in humans:  
• The potentially unique mechanism of action of Sym023 compared to other anti -TIM-3 
antibodies in early clinical development, yet the absence of safety signals and lack of 
cytokine release detected in the in vitro safety pharmacology studies using human whole 
blood. 
• The lack of toxicity in cynomolgus monkeys at exposure levels well above the predicted 
serum concentration for the first dose in humans, even when corrected for differences in 
affinity for Sym023 against human TIM -3 (KD 3.3 µg/mL) and cynomolgus TIM -3 
(dissociation constant [ KD] 330 µg/mL). 
• The NOAEL of 100 mg/kg in the toxicity studies and a resulting affinity- corrected 
MRSD of 0.1 mg/kg Q2W, which is 3- fold higher than the proposed starting dose using 
the MABEL . 
• The MABEL of 0.03 mg/kg Q2W represents an average Sym023 serum concentration, which could elicit 20% of the maximal response in the in vitro 1- way MLR 
Symphogen Clinical Trial Protocol 
Trial ID: Sym023- 01 Version 5.0  
 
Confidential   Page 37 of 173 
 
 pharmacology assay using dendritic cells and T -cells derived from two donors. Thus, as 
the MABEL is based on a low level of e ffect in an in vitro assay with isolated blood cells, 
it represents a cautiously selected benchmark for potential initial pharmacological activity 
and aims to mitigate the risk of potential acute effects.  
The starting dose (0.03 mg/kg, Q2W) and the subsequent dose level (0.1 mg/kg, Q2W) is intended to be administered to a limited number of patients to investigate the potential acute AEs 
while exposing as few patients as possible to potentially sub- therapeutic dose levels. The 
therapeutic effect is predicted  to occur at higher dose levels; thus 10- 20 mg/kg Q2W may be 
needed to ensure full saturation  in vivo . The subsequent dose levels (from 0.1 mg/kg, Q2W) are 
to be administered to more patients per cohort  as described in the study protocol. Dose levels are 
planned with 3- fold increase at all dose -escalations , except for the last one from 10 to 20 mg/kg. 
The 3 -fold increase was based on a combined evaluation of the steepness of concentration-
response and non -clinical studies. The concentration -response curve b ased on the 1- way MLR 
assay did not indicate a steep concentration- response, which would have called for smaller 
escalation increases . The maximum proposed dose of 20 mg/kg is predicted to ensure full 
saturation of the target and full effect as assessed by  the 1 -way MLR assay (>95%) in humans. 
The maximum dose also takes in to account that the local concentration in tissue is typically less than 10% of the serum concentration for antibodies  (20).  
In conclusion, the proposed starting dose is 0.03 mg/kg administered Q2W. The maximum dose to be administrated in this trial is not to exceed 20 mg/kg administered Q2W . 
2.6 Overall Benefits/Risk  
No clinical information is available for patients treated with Sym023;  therefore , the benefits and 
the safety profile of Sym 023 ha ve not been fully established. However, responses have been 
reported in a single Phase 1 trial of the anti -TIM-3 mAb TSR -022 in patients with rectal, thyroid, 
neuroendocrine, head and  neck cancer, and soft -tissue sarcoma ( 7, 8).  Results from preclinical 
studies indicate that Sym023 has antitumor activity in different cancer models. Sym023 has also 
been shown to be efficacious in preclinical models at dose levels that are well tolerated in 
cynomolgus monkeys . 
During this trial, there will be an ongoing assessment of the risks with periodic evaluation of 
safety data.  The trial will be discontinued in the event of any new finding indicating a risk that 
would render continuation of  the trial unjustifiable.  A Study Safety Team  will review clinical 
and laboratory safety data on an ongoing basis and make decisions regarding the advisability of 
continuing accrual and/or dose -escalation.  
To mitigate potential risks, the trial is designed  to detect DLTs, if any, and to define a  maximum 
tolerate dose ( MTD ) in accordance with the dose -escalation scheme planned for the trial.   
Enrollment will be staggered by 2 week s between the first and second patient in each new dose 
level tested to evaluat e safety before allowing concurrent enrollment of further patients at the 
given dose level. If the dose administered in a cohort is well tolerated, dose -escalation may 
proceed , and enrollment of subsequent cohorts may occur to  establish a recommended P hase 2 
dose (RP2D). The options to slow infusions, interrupt dosing, and discontinue administration of study drug in the event of specific AEs are outlined in this CTP  (Section 8.5 ).   
Symphogen Clinical Trial Protocol 
Trial ID: Sym023- 01 Version 5.0  
 
Confidential   Page 38 of 173 
 
 Information on AEs  observed with an agent targeting the TIM -3 pathway is included ( Section 
2.3.1.2, Section 11.2). Inform ation on AEs observed with agents targeting the PD -1/PD -L1 
pathways is also included ( Section 11.2, Appendix 8) , along with recommendations for the 
management of infusion- related react ions ( IRRs) (Appendix 9)  and immune -mediated toxicities  
(Appendix 10 ). 
Patients participating in Sym023 studies will be closely monitored for anticipated adverse 
reactions as well any unanticipated safety findings. Because the risks associated with immune 
checkpoint  inhibitors can occur several weeks to months after treatment, patients will be 
monitored for up to 6 months  following the last dose to assess for the onset of any post -therapy 
immune -mediated event thought to be related to study drug. Any patient who develops an 
immune -mediated toxicity during study, or during the 6- month post -therapy follow -up period, 
will be followed for up to 2 years  after the end of treatment to assess the course of the condition 
and evaluate potential reversibility of the finding. 
FOR ADDITIONAL INFORMATION, PLEASE REFER TO THE INVESTIGATOR’S 
BROCHURE  (IB)  
Symphogen Clinical Trial Protocol 
Trial ID: Sym023- 01 Version 5.0  
 
Confidential   Page 39 of 173 
 
 3 TRIAL OBJECTIVES AND DESIGN  SUMMARY 
3.1 Objectives : Sym 023 (anti -TIM -3) Dose -Escalation  
3.1.1 Primary  Objective  
Evaluation of the safety , tolerability, and DLTs  to establish the MTD and/or RP2D of sequential 
escalating doses of Sym 023 (anti -TIM-3) when administered Q2W by 30- minute IV infusion to 
patient cohorts with locally advanced/unresectable or metastatic solid tumor malignancies  or 
lymphoma s that are refractory to available therapy  or for which no standard therapy is available   
Note:  Q2W dosing; 4 weeks equals 1 dosing cycle.  Goal is the identification of the MTD or determination of a 
RP2D dose based on clinical data , including safety, PK, and pharmacodynamic  (e.g., receptor occupancy  in 
peripheral blood)  outcomes . The MTD , if identified , and the RP2D dose may not be the same  as the RP2D 
may be lower . If an MTD is not identified a maximum administered dose (MAD) will be determined and will 
not exceed 2 0 mg/kg .    
3.1.2 Secondary Objectives   
• Evaluation of the immunogenicity of Sym 023  
• Characterization of the PK profile of Sym 023 
• Evaluation of the preliminary a ntineoplastic effect s of S ym023, including:  
o Evidence of objective response (OR) or stabl e disease (SD) *   
o Duration of OR  or SD *  
o Time to progression (TTP) of disease *  
* As assessed by RECIST v1.1  (Appendix 5), iRECIST  (Appendix 6), and Respo nse Evaluation Criteria 
in Lymphoma  (RECIL  2017; Appendix 7) 
3.1.3 Exploratory Objective s  
• Evaluation of potential pharmacodynamic markers , e.g., receptor occupancy i n peripheral 
blood mononuclear cells (PBMCs)  (peripheral blood to be collected)  
• Evaluation of potential biomarkers, including but not limited to  assessment of :  
o In peripheral blood: c irculating tumor deoxyribonucleic acid ( ctDNA ), 
ribonucleic acid ( RNA) , relevant proteins/cytokines , and cellular biomarkers  
o In tumor tissue: DNA, RNA, protein, and cellular biomarkers (biopsies optional)  
Note:  Assay methodology and biomarker assessments to be determined (TBD).  Potential analyses may 
include but are not limited to: ctDNA sequencing; RNA  sequencing (RNA -seq)/whole-exome 
sequencing (WES);  measurement of relevant proteins/cytokines in the blood; cytometr ic analysis of 
cells in blood ; and immunohistochemistry (IHC) of tumor material when collected (tumor sampling 
is optional) .  
3.2 Trial Design  Summary   
Patient Population and Obj ectives  
Symphogen Clinical Trial Protocol 
Trial ID: Sym023- 01 Version 5.0  
 
Confidential   Page 40 of 173 
 
 Approximately 20- 48 m ale and female p atients with documented either solid tumor malignancies 
that are locally advanced /unresectable or  metastatic , or lymphoma s, and with disease that is 
either refractory to standard therapy or for whom  no standard therapy is available, will be entered 
into this P hase 1, multic enter, open- label, dose -escalation , cohort study. The trial is designed to 
evaluate the safety, tolerability, and DLTs to  establish the MAD or MTD and  the RP2D  of 
sequential escalating doses  of S ym023 (study drug) , an anti -TIM-3 mAb.    
Secondary objectives include evaluation of immunogenicity, characterization of the PK profile, 
and preliminary assessment of the antineoplastic effects  of Sym 023 in this patient population. 
Exploratory evaluation of the utility of potential pharmacodynamic and other biomarkers of 
Sym023 will also be undertaken in pre - and post -dosing peripheral blood samples  and tumor 
tissue (tumor biopsies optional) . Patients will be treated and followed on an outpatient basis 
throughout the trial, unless hospitalization is required for other reasons, or to ensure patient safety.   
Dosing Schedule and Treatment Duration  
• No premedication is required prior to receiving the first dos e of study drug, except in 
patient s with a history of IRR s to mAbs  or similar products ; in these patients , it is 
recommended that premedication be administered . Thereafter, p remedication of 
individuals is at the Investigator’s discretion. Mandatory premedication will be implemented for all patients should a pattern begin to emerge of mild- to-moderate study 
drug- related reactions that are amenable to prophylaxis with standard agents .   
• On Day 1 of study, patients will receive study drug admi nistered by 30- minute  (+10 min)  
or by 60- minute (+ 10 min)  IV infusion (depending on dose and body weight)  in a fixed  
50 m L, 100 mL, 250 mL, or 500 mL volume depending on dose and body weight . 
Sym023 will be administered Q 2W with administration on Day 1 an d Day 15, with each 
dose followed by a 2 -week recovery period. This 4- week (2 8 day) period will be 
considered Cycle 1.  Determinations regarding cohort escalation, DLTs, and MTD will be 
based on the toxicities observed during this initial cycle. Patients must receive their full planned dose s of study drug, plus complete the designated 2- week follow -up period, to  be 
considere d evaluable for tolerability, unless dose delay  or discontinuation was the result 
of a DLT.  End of Cycle 1 (EOC 1) assessments are to be performed no sooner than Cycle 
1/Day 28 ( C1/D28) (± 2 days ).   
   
• In all patients entered, a minimum of at least Cycle 1 of study drug will be completed, if 
tolerated, after which in the absence of confirmed progressive disease (PD)  or 
unacceptable toxicity a patient may continue to receive additional 4- week cycles  of study 
drug at the same dose and infusion duration established for the patient , and on the same 
Q2W schedule , at the Investigator’s discretion and provided specified retreatment criteria 
have been met . Retreatment cycles may continue for up to 12 months  at which time plans 
for continued therapy will be discussed by the Medica l Monitor(s) and Investigator. 
Patients who stop therapy with an ongoing OR or prolonged SD may be retreated in the 
event of relapse, if the trial is still open . Confirmed  PD as defined by response criteria 
(RECIS T v1.1, iRECIST, RECIL  2017) at any point in the study will necessitate 
withdrawal of the patient from further participation so that alternative management of their malignancy may be considered.   
Symphogen Clinical Trial Protocol 
Trial ID: Sym023- 01 Version 5.0  
 
Confidential   Page 41 of 173 
 
 Doses to be Evaluated  
At study entry, patients will be sequentially assigned to fill escalating dose  cohorts of S ym023 
beginning at the dose of 0.03 mg/ kg, with potential doses 0.1 mg/kg, 0.3 mg/kg, 1.0 mg/kg, 3.0 
mg/kg, 10 mg/kg, and 20.0 mg/kg to follow. These doses will be evaluated until the MTD is 
identified, a MAD is reached, or until a RP2D is determined based on clinical data , including 
safety, PK, and pharmacodynamic ( e.g., receptor occupancy  in peripheral blood)  outcomes . The 
MAD, MTD if identified , and the RP2D may not be the same , as the RP2D may be lower.     
Initially , a modified, accelerated -titration, dose -escalation design will be used with entry of 
single patient cohorts for up to 2 dose levels, based on tolerability. Thereafter, a  standard 3+3 
dose-escalation design will be used with a target toxicity level of 33 .3% or less as determined by 
DLTs. The number of cohorts evaluated and the MAD will depend upon the observed tolerability 
of Sym023 during Cycle 1  of patient treatment; howe ver, the maximum dose to be administered 
in this trial is not to exceed 20 mg /kg. Dose -escalation is  shown in  Figure 1.   
The Investigator(s) and Sponsor ’s Medical Representative(s) as members of a Study Safety 
Team  will review clinical and laboratory safety data on an ongoing basis throughout the study 
and m ake decisions regarding the advisability of continuing accrual to a dose cohort, and/or 
escalating the dose and allowing accrual to a higher dose cohort. Patients will also be monitored 
for evidence of cumulative or delayed toxicities , including the occurr ence of delayed immune -
mediated toxicities .  
Symphogen Clinical Trial Protocol 
Trial ID: Sym023- 01 Version 5.0  
 
Confidential   Page 42 of 173 
 
 Figure 1:  Dose -Escalation Schema  
 
Abbreviations (in alphabetical  order): AE, adverse event; DLT, dose -limiting toxicity; kg, kilogram; MAD, maximum administered dose; MTD, 
maximum tolerated dose; mg, milligram; N, number; Q2W, dosing every 2 weeks; RP2D, recommended phase 2 dose; SAE, serious adverse 
event .  
Note: 20-48 patients anticipated for dose -escalation . Minimum of 6 patients  to be treated at the MAD, MTD and/or RP2D dose; expansion of this 
cohort (or any other) up to 12 patients may  be considered to further evaluate tolerability ; therefore approximately 20 -48 patients to be entered.  
Filling  of Cohorts  
In single patie nt cohorts, dose -escalation and accrual to the next cohort will occur only after the 
patient has completed and tolerated the first dose of Cycle 1 , including follow -up until C1/D15 to 
allow for review of clinical and laboratory assessments, and consultation with the Study Safety 
Team .  The DLT evaluation period for single patient cohorts will continue through to the 
EOC1.  Should a patient experience an AE of concern in the latter half of Cycle 1 that would, per protocol, result in cohort expansion, protocol rules as outlined herein will be followed. Additional patients entered to an expanded single patient cohort will follow rules as outlined below for 3+3 patient cohorts. If in the meantime a patient has been entered to receive the next higher dose level, that patient will be allowed to continue provided adequate tolerability is being demonstrated; however, further enrollment to the higher dose level cohort will be halted. 
In 3+3 patient cohorts, t he first patient within a cohort must complete and tolerate the first dose 
of Cycle 1 , including follow -up until C1/ D15 before entry of the next patient to a cohort  (i.e., 2-
week  stagger) ; thereafter patients within a coh ort may be added concurrently. Dose -escalation 
and accrual to the next cohort will occur after the minimum number of  patients required for 
tolerability assessment in the current cohort  have completed until C1 /D15 in a single patient 

Symphogen Clinical Trial Protocol 
Trial ID: Sym023- 01 Version 5.0  
 
Confidential   Page 43 of 173 
 
 cohort, or completed Cycle 1  in a 3+3 patient cohort , and only after acceptable tolerance has 
been demonstrated in at least 1 of 1, 3 of 3, or  5 of 6 patients treated in the current cohort 
(depending on cohort size), and review of the data with the Study Safety Team .   
Should the DLT rate equal or exceed 33.3% in any cohort, the previous lower dose cohort will be 
expanded to 6 patients (if not already accomplished) .  Thus, there is potential for expansion of a 
lower dose if an initially identified MTD and/or RP2D is found to exceed tolerability , as well as 
potential to evaluate a nd expand a  previously unplanned intermediate dose between 2 established 
dose levels, if indicated, to  more fully characterize safety and tolerability. Once the MTD (or  
maximum dose to be studied) is achieved and/or the RP2D is ident ified, that cohort may  be 
expanded up to 12 patients  to more fully evaluate safety and tolerability at that dose level, at the 
Sponsor’s discretion. Should the DLT rate equal or exceed 33.3% in an expanded cohort, it will 
be determined that the dose is not  tolerated  and exceeds the MTD . If this occurs, the previous 
lower dose cohort or an intermediate dose level may  be expanded as above. There will be no 
intrapatient dose -escalation in this trial.   
Study Assessments  
For safety, patients will be monitored th roughout the treatment and 1 -month follow -up (1M 
FUP) period for evidence of AEs , including changes in clinical status, laboratory data, 
electrocardiogram ( ECG ) findings , and either multi- gated acquisition ( MUGA)  scans or 
echocardiograms  (ECHO) in patients with a history of congestive heart failure ( CHF ). Patients 
will be evaluated for evidence of immune -mediated toxicities . Patients will also be evaluated for 
evidence of antibody formation to study drug. Patients  experiencing a DLT regarded as possibly-
, probably- , or related to  study drug at any point during treatment will be discontinued from 
study treatment , without exception. Patients may not  be retreated following the occurrence of a 
DLT. Only DLTs occurring during Cycle 1 will be used to make determinations regarding dose -
escalation and tolerability.    
 
The overall trial plan is introduced in Table 1.     
Symphogen Clinical Trial Protocol 
Trial ID: Sym023- 01 Version 5.0  
 
Confidential   Page 44 of 173 
 
 Table 1:  Overall Trial Plan  
Screening Period  
Screening  • Written informed consent  
• Disease assessment and eligibility confirmation (within 28 days  [+2 days] prior to 1st dose) 
• Safety screening and eligibility confirmation ( within 14 days prior to 1st dose unless otherwise 
stipulated ) 
• Allocated dose of study drug dependent upon cohort ass ignment; to be confirmed on Screening and 
Allocation Form  
Treatment Period  
Treatment  • C1/D1 initial dose of study drug  
• Continued dosing once Q2W  
• 28-day cycles until confirmed PD, unacceptable toxicity, or other discontinuation criterion is met  
for up to 12 months  at which time plans for continued therapy to be discussed by the Medical 
Monitor(s) and Investigator.  Patients who stop therapy with an ongoing OR or prolonged SD may 
be retreated in the event of relapse, if the trial is still open . 
• EOT visit within approximately 7-10 days following treatment discontinuation , or before initiation  
of a new treatment, whichever occur s first  
• 1M FUP visit 30 days (+7 days) following last dose *   
*Completion of the 1M FUP visit will be considered the end of the treatment period    
Follow -up Period  
Post-Treatment 
Follow -up  • Safety FUP if an observed non-immune -mediated toxicity thought to be related to study drug has 
not resolved by the 1M FUP evaluation (2 and 4 months following last study drug dose)  
• Safety FUP surveillance to assess for delayed onset immune-mediated  toxicity  (Q2M for up to 6 
months following last study drug dose)  
• Safety FUP for ongoing at the 1M FUP, and for delayed onset , immune-mediated toxicit y (Q2M 
for up to 2 years following last study drug dose)   
• Response FUP following discontinuation for reasons other than  confirmed PD until the end of trial 
(Q2M until PD or initiation of another therapy)  
*Completion of all  indicated  follow-up will be considered the EOS  
Abbreviations (in alphabetical order): 1M FUP, 1-month follow -up; C1/D1, Cycle1/Day1; EOS, end of study; EOT, end of treatment ; FUP, 
follow -up; PD, progressive disease; Q2M, every 2 months ; Q2W, every 2 weeks  
 
Symphogen Clinical Trial Protocol 
Trial ID: Sym023- 01 Version 5.0  
 
Confidential   Page 45 of 173 
 
 4 PATIENT NUMBER AND SELECTION  CRITERIA 
4.1 Number of Patients  
4.1.1 Investigational Sites  
This is a multicenter  trial. It is anticipated that approximately 2 -4 investigational sites in North 
America may participate based on accrual.  
4.1.2 Number of Patients  
Considerations for estimating the number of patients to be entered are as follows:  
• Approximately 20- 48 patients in escalating dose cohorts  
o Minimum of 1 patient per cohort for up to 2 dose cohorts  
o Minimum of 3 patients  per dose cohort  thereafter  
o Assume  appr oximately 7 dose cohorts to be evaluated  to establish the MTD  
and/or RP2D  dose  
o Expansion of any cohort to 6 patients  in the event of a Cycle 1 DLT in any of the 
initial 1 to 3 patients   
o Minimum of 6 patients  to be treated at the MTD  and/or RP2D dose ; expan sion of 
this cohort (or any other) up to 12 patients may  be considered to further evaluate 
tolerability   
In addition, t here is potential for entry of additional patients to : 
• Ensure sufficient evaluable patients by adding an additional patient to a cohort  (e.g., 
increase a 1- patient cohort to 2 patients, a 3- patient cohort to 4 patients , or a 6- patient 
cohort  to 7 patients )   
Note:   Should this action be taken, cohort tolerability assessment  and subsequent dose-escalation  will 
occur when the minimum number of patients required to evaluate tolerability have completed 
Cycle 1 . However , if any additional patient experiences an event that would, per protocol, result in 
either cohort expansion or the halting of dose -escalation, protocol rules as outlined herein will be 
followed ( Section  6.6.1 ). 
• Expand a lower dose cohort(s) if an initially identified MTD and/or RP2D is 
subsequently determined to be not tolerated either with single or repeated cycles of 
therapy   
• Add and e valuate a previously unplanned intermediate dose level(s) to further 
characterize safety and tolerabi lity, if indicated  (inclusion of a dose higher than those 
listed would require a protocol amendment)  
Note: This action would be taken in the event of an unacceptably high frequency of toxicities observed 
in patients treated at one dose considered to be in marked contrast to the tolerability noted at the 
preceding dose level , or if after review of study data , a more gradual dose -escalation appears 
warranted.  
Expanded accrual in any cohort will take place at the Sponsor ’s discretion, after discussion with 
the Investigator(s).  
Symphogen Clinical Trial Protocol 
Trial ID: Sym023- 01 Version 5.0  
 
Confidential   Page 46 of 173 
 
 4.2 Criteria for Inclus ion 
Patients must meet all  the following criteria to be eligible  for participation in the trial:  
1. Male or female patients, ≥ 18 years of age  at the time of obtaining informed consent  
2. Patients with a documented (histologically - or cytologically- proven) solid tumor 
malignancy  that is locally advanced  or metastatic ; patients with documented lymphoma s   
3. Patients with a malignancy (solid tumor or lymphoma) that is currently not amenable to 
surgical intervention due to either medical contraindications or non- resectability of the 
tumor  
4. Patients refractory to or intolerant of existing therapy(ies) known to provide clinical 
benefit .   
Note:  Patients may have received and failed prior therapy w ith a PD -1/PD -L1 inhibitor  and be considered 
eligible for this trial.  
5. Patients with measurable or non- measurable disease  according to RECIST  v1.1 or RECIL  
2017 ( Appendix 5 and  Appendix 7, respectively )   
6. Patients with a n Eastern Cooperative Oncology Group (ECOG) performance status (PS) 
of 0 or 1 ( or equivalent Karnofsky PS; Appendix 1), and anticipate d life expectancy of ≥ 
3 months  
7. Patients, both male and female, who are either not of childbearing potential or who agree to use a highly effective method of contraception during the study beginning within 2 
weeks  prior to the first dose and continuing until 6 months  after  the last dose of study 
drug.   
Note: Women are considered of childbearing potential unless they have undergone hysterectomy and/or 
bilateral tubal ligation or oophorectomy, or have been postmenopausal for at least one year.  
Postmenopausal status in non-surgerized females under 55 years of age  should be confirmed with 
a serum follicle -stimulating hormone (FSH) level within laboratory reference range for 
postmenopausal women.   
A highly effective method of contraception is defined as non -hormonal contraception equivalent to 
a double -barrier metho d (includes a  single -barrier method in combination with a spermicide ) or 
intrauterine device  (Section 11.1).  
Women of childbearing potential (WOCBP) must have a negative pregnancy test , serum at 
screening, serum or urine thereafter; negative test must be confirmed within  ≤ 2 working days  
prior to a dministration of the first dose of study drug.    
8. Patients with the ability to understand and give written informed consent for participation in this trial, including all evaluations and procedures as specified by this protocol  
Note: Informed cons ent must be obtained prior to patient screening, and before any evaluations or 
procedures specifically related to this study are performed.  
4.3 Criteria for Exclusion  
Patients meeting any  of the following criteria are ineligible  for participation in the trial.  
Symphogen Clinical Trial Protocol 
Trial ID: Sym023- 01 Version 5.0  
 
Confidential   Page 47 of 173 
 
 4.3.1 Patients to be Excluded  
1. Women who are pregnant or lactating or intending to become pregnant before, during, or 
within 6 months  after the last dose of study drug. WOCBP, and fertile men with 
WOCBP -partner (s) not using and not willing to use a highly effective method of 
contraception.  
Note:  WOCBP includes any female who has experienced menarche and who has not undergone surgical 
sterilization (hysterectomy, bilateral tubal ligation, or bilateral oophorectomy), or is not 
postmenopausal.  Post -menopause is defined as: 1) amenorrhea for > 12 months with no other 
cause, or 2) irregular menstrual periods, on hormone replacement therapy (HRT), with a documented FSH level > 35 mIU/mL.  
WOCBP and fertile men will be informed as to the potential risk of procreation while participating 
in this trial. A pregnancy test will be performed, and the results reviewed, on each premenopausal 
WOCBP  prior to fi rst study drug administration. A negative pregnancy test performed within <  2 
working days  prior to first study drug administration must be document ed in the patient’s case 
report form (CRF) (Section 11.1).  
2. Patients with central nervous system (CNS) malignancies; patients with known, untreated  
CNS or leptomeningeal  metastases , or spinal cord compression, patients with any of the 
above  not controlled by prior surgery or radiotherapy, or patients with symptoms 
suggesting CNS involvement for which treatment is required  
Note: Patients with treated CNS metastases will be eligible if they are asymptomatic, do not require 
corticosteroids, and  have confirmation of at least stable brain disease status as assessed by 2 
imaging studies performed ≥  4 weeks apart with the most recent performed within 4 weeks prior to 
first trial drug administration.  Prophylactic anticonvulsant medications are allowe d.   
Patients with newly identified CNS disease during study treatment will be considered to have 
disease progression and will be discontinued from study to allow for appropriate management.  
3. Patients with hematologic malignancies  other than lymphoma s   
4. Patients with any of the following hematologic abnormalities at baseline *:   
• Hemoglobin < 9.0 g/dL  
• Absolute neutrophil count (ANC) < 1,000 per mm3 
• Platelet count < 75,000 per mm3 
Note: Patients may have received  a blood/blood product  transfusion prior to study, if clinically 
warranted .   
*Throughout this protocol “baseline” is defined as the last available observation prior to the first administration of study drug on C1/D1 . 
5. Patients with any of the following serum chemistry abnormali ties at baseline:  
• Total bilirubin > 1.5 × the upper limit of normal ( ULN)  for the institution *  
• Aspartate aminotransferase ( AST ) or alanine aminotransferase ( ALT ) > 3 × the 
ULN for the institution (> 5 × ULN if due to hepatic involvement by tumor)  
• Serum creatinine > 1.5 × ULN for the institution  
Symphogen Clinical Trial Protocol 
Trial ID: Sym023- 01 Version 5.0  
 
Confidential   Page 48 of 173 
 
 *Patients with evidence of Gilbert’s Syndrome as the etiology of elevated total bilirubin will be eligible, 
provided all other eligibility criteria are met.  
6. Patients  with  any of  the following coagulation parameter abnormalities at baseline  
(unless on a stable dose of anticoagulant thera py for a prior thrombotic event , as 
determined by the Investigator ): 
• Prothrombin time ( PT) (or international normalized ratio [ INR]) > 1.5 × ULN for 
the institution  (> 3× ULN for the institution if anticoagulated)  
• Partial thromboplastin time ( PTT)  (or activated partial thromboplastin time 
[aPTT ]) > 1.5 × ULN for the institution (> 3× ULN for the institution if 
anticoagulated)  
7. Patients with:  
• Active thrombosis, or a history of deep vein thrombosis (DVT) or pulmonary 
embolism (PE), within 4 weeks  prior to first study drug administration, unless 
adequately treated and considered by the Investigator to be stable  
• Active uncontrolled bleeding or a known bleeding diathesis   
8. Patients with a clinically  significant  (CS) cardiovascular disease or condition, including:  
• Need for antiarrhythmic medical therapy for a ventricular ar rhythmia  or other 
uncontrolled arrhythmia (patients with controlled atrial fibrillation (heart rate 
[HR] < 90) for > 30 days prior to study entry are eligible)  
• Severe conduction disturbance  (e.g., 3rd degree heart block)  
• HR-corrected QT interval ( QTc inter val) ≥ 480 milliseconds (msec)  
• Uncontrolled hypertension (per the Investigator’s discretion)  
• History of myocarditis  
• Left ventricular ejection fraction (LVEF) * known to be below the lower limit of 
normal ( LLN ) for the center, or < 50% by MUGA scan or ECHO if no LLN is 
defined by the site  
• CHF currently requiring therapy  
• Class III or IV cardiovascular disease according to the New York Heart Association (NYHA) Functional Classification ( Appendix 2)  
• History of acute coronary syndromes (including myocardial infarction [MI] and unstable angina), coronary angioplasty, stenting, or bypass  within 6 months  prior to 
first study drug administration 
*Assessment  of LVEF will not be performed routinely in all patients.  Patients with a history of CHF 
will have either a MUGA scan or ECHO at Screening. If LLN is not defined for a given institution, 
then LVEF  must be ≥ 50% . 
Symphogen Clinical Trial Protocol 
Trial ID: Sym023- 01 Version 5.0  
 
Confidential   Page 49 of 173 
 
 9. Patients with a significant ocular disease or condition, including history of an 
autoimmune or inflammatory disorder, e.g., episcleritis, uveitis, iritis  
Note:   Patients with a histo ry of dry eye for reasons other than  an autoimmune disease or condition may be 
included if adequately treated . Patients with non -significant, non- inflammatory disorders (e.g., 
cataracts, glaucoma) will be allowed.   
10. Patients with a significant pulmonary di sease or condition, including:  
• History of interstitial lung disease (ILD), pulmonary fibrosis  
• History of pulmonary inflammatory disease , interstitial or other pneumonitis *, 
acute respiratory distress syndrome (ARDS)  
*Patients with prior evidence of Grade 1 pneumonitis will be eligible provided they were 
asymptomatic and did not require treatment  and provided pneumonitis has resolved prior to entry 
to this trial.  
11. Patients with a current or recent (within 6 months ) significant gastrointestinal (GI) 
disease or condition, including:  
• History of inflammatory bowel disease  
• Diarrhea ≥ Grade 2 within 2 weeks  prior to first study drug administration 
Note:  Patients with recent Grade 2 diarrhea secondary to administration of oral  contrast are allowed , 
provided symptoms have resolved prior to first study drug administration 
12. Patients with an active, known or suspected autoimmune disease, or a documented 
history of autoimmune disease or syndrome, requiring systemic steroids or other 
immunosuppressive medications  
Note:     Exceptions permitted include: type I diabetes mellitus, hypothyroidism only requiring hormone 
replacement, skin disorders such as vitiligo, psoriasis or alopecia not requiring systemic treatment, 
conditions not expected to recur in the absence of an external trigger.  
13. Patients with a history of organ transplantation (e.g., stem cell or solid organ transplant)  
14. Patients with a known or suspected hypersensitivity to any of the excipients of 
formulated study drug  
15. Patient s with a history of significant  toxicities associated with previous administration of 
immune checkpoint inhibitors that necessitated per manent discontinuation of that therapy     
16. Patients with unresolved > Grade 1 toxicity* associated with any prior antineoplastic therapy except for  persistent Grade 2 alopecia, peripheral neuropathy, decreased 
hemoglobin, lymphopenia, hypomagnesemia , and/or end- organ failure being adequately 
managed by hormone replacement therapy  
*Toxicity assess ments based on Common Terminology Criteria for Adverse Events  (Version 5.0) (CTCAE 
v5.0) 
Symphogen Clinical Trial Protocol 
Trial ID: Sym023- 01 Version 5.0  
 
Confidential   Page 50 of 173 
 
 17. Patients with inadequate recovery from any prior surgical procedure, or patients having 
undergone any major surgical procedure within 4 weeks  prior to first study drug 
administration   
Note:  Patients having undergone recent placement of a central venous access device will be considered 
eligible for enrollment.  
18. Patients who are known or suspected drug or alcohol abuse rs where compliance with 
protocol requirements may be a concern   
19. Patients with a known history of human immunodeficiency virus (HIV) or known active 
infection with hepatitis B virus (HBV) or hepatitis C virus (HCV)   
20. Patients with any other serious/active/uncontrolled infection, any infection requiring 
parenteral antibiotics, or unexplained fever > 38ºC within 2 weeks  prior to first study 
drug administration  
21. Patients with any other serious, life -threatening, or unstable pre -existing medical 
condition (aside from the underlying malignancy), including significant organ system 
dysfunction, or CS  laboratory abnormality(ies) , which, in the opinion of the Investigator, 
would either compromise the patient’s safety or interfere with  obtaining informed 
consent, compliance with study procedures, or  evaluation of the safety of the study drug  
22. Patients with a psychiatric disorder or altered mental status that would preclude understanding of the informed consent process and/or completion of the necessary study-related evaluations    
23. Patients with the inability  or with foreseeable incapacity , in the opinion of the 
Investigator, to comply with the protocol requirements  
4.3.2 Drugs and Other Treatments to be Excluded  
1. Other inhibitors of TIM -3 (e.g., mAbs)  
2. Any antineoplastic agent  for the primary malignancy (standard or investigational) without 
delayed toxicity within 4 weeks  or 5 plasma half -lives, whichever is shortest, prior to first 
administration of study drug and during study, except for :  
• Nitrosoureas and mitomycin C  within 6 weeks  prior to first study drug 
administration and during study 
Note:  Patients may have received and failed prior therapy with a PD -1/PD -L1 inhibitor and may still be 
considered eligible for this trial.  
3. Any other investigational treatments  within 4 weeks  prior to and during study. This 
includes participation in any medical device or other therapeutic intervention clinical trials.    
4. Radiotherapy:  
• For target lesions  within 4 weeks  prior to first administration of study drug unless 
disease progression has been documented in the lesion following treatment, and during study 
Symphogen Clinical Trial Protocol 
Trial ID: Sym023- 01 Version 5.0  
 
Confidential   Page 51 of 173 
 
 • For non- target lesions within 1 week  prior to first administration  of study drug  
Note:  Palliative (limited -field) radiotherapy for management of pain asso ciated with bone 
metastases present at baseline is permitted  during study .  Patients  with suspected  new bone 
lesions requiring pain management should be treated and evaluated for potential disease 
progression.  
5. Use of live vaccines against infectious diseases (e.g. , varicella) 4 weeks  prior to first 
study drug administration and during study  
6. Immunosuppressive or s ystemic hormonal therapy (> 10 mg daily prednisone equivalent) 
within 2 weeks  prior to first study drug administration and during study. The following 
therapies are allowed:  
• Hormonal therapy for appetite stimulation  (e.g., Megace)  
• Nasal, ophthalmic, inhaled, and topical glucocorticoid preparations  
• Hormone replacement therapy at standard doses for end- organ failure  
• Stable hormonal therapy for prostate carcinoma*  
• Stable hormonal therapy for ovarian suppression, hormonal contraceptive therapy, 
or post -menopausal HRT * 
• Neuroendocrine tumor patients: stable hormonal therapy with a somatostatin analog  (SSA) ** 
• Steroid therapy for contrast reaction prophylaxis  
• Intra -articular steroid injections  
• Low-dose maintenance steroid therapy for other conditions  (e.g., asthma 
exacerbation, stable steroid therapy [excluding tapering dose of steroids] for brain 
edema/metastases/radiation ) 
• Higher dose steroid therapy for treatment of an acute intercurrent illness (e .g., 
immune -related AEs or other adverse conditions) in patients with stable disease or 
an ongoing response.  In such situations , study drug treatment should be 
interrupted for the duration of immunosuppressive therapy.  
*Prior or concomitant therapies are permitted;  however, patient s must have been on a stable dose for 
at least 6 months  prior to study start , and if continuing must remain on the stable dose while receiving 
study treatment (i.e. , such treatment will not be considered as systemic hormonal therapy  for the 
purpose of study eligibility).  
** Patients with metastatic low -grade neuroendocrine tumors ( carcinoid tumors) are permitted to 
remain on concomitant SSA therapy ; however, patients must have been on a stable dose for at least 2 
months ( 8 weeks)  prior to study start and progressed on that dose, and if continuing,  must remain on 
the stable dose whil e receiving study treatment (i.e. , such treatment will not be considered as systemic 
hormonal therapy for the purpose of study eligibility).  
7. Prophylactic use of hematopoietic growth factors within 1 week  prior to first study drug 
administration and during Cycle 1 of study; thereafter prophylactic use of growth factor s 
is allowed as clinically indicated    
Note: Interventional/therapeutic use of growth factors is allowed at any time during study, including 
during Cycle 1, if deemed necessary by the Investigator.  Growth factor use must be consistent 
with product package insert instructions.  Transfusions are permitted as needed.  
 
Symphogen Clinical Trial Protocol 
Trial ID: Sym023- 01 Version 5.0  
 
Confidential   Page 52 of 173 
 
 Questions regarding patient eligibility must  be addressed and resolved by the Investigator in 
consultation with the Sponsor's Medical Monitor (s) prior to enrollment. 
Symphogen Clinical Trial Protocol 
Trial ID: Sym023- 01 Version 5.0  
 
Confidential   Page 54 of 173 
 
 5.4 Labeling of IMP  
Vials of study drug will be open- label; label text will be in accordance with applicable local 
regulatory requirements . Each vial will be uniquely numbered for allocation, dispensing, and 
traceability purpose s.    
5.5 Packaging of IMP  
Study drug will be packed in cartons containing multiple  vials. The vial number range in each 
carton will be detailed on the carton label.   
5.6 Administration of IMP  
Study drug will be administered by IV infusion via an indwelling catheter . An appropriate dose, 
based on the patient’s cohort assignment, diluted to the total volume specified  with 0.9% sodium 
chloride (NaCl)  for IV infusion  will be administered initially over :  
• Approximately 30 minutes  (+10 minutes)  for infusion volumes ≤  250 mL  
• Approximately 60 minutes  (+10 minutes) for infusion volumes of 500 mL   
Dosing will be once  every 2 week s (Q2W; 4 weeks [2 8 days] equals 1 dosing cycle).   
5.7 Dose Calculation  
The Investigator (or designee) will be responsible for calculating the amount of study drug and 
the appropriate dose to dispense to the patient as determined by the patient’s dose cohort assignment.   
The dose level  will be multiplied by the patient's weig ht in kilograms  to arrive at t he total dose to 
be delivered. In situations w here this calculation results in a value with an unwieldy number of 
decimal places, it is permissible to round the value to the nearest " tenth ". As a convention, values 
> 5 should be " rounded"  to the next higher number.  
Dose adjustments should be made in the event of noted weight change (± 10%; less at the site’s 
discretion or if required by institution procedures) at visits that require weight measurement. 
Adjustments may be made more frequently at the site's discretion.  
5.8 Dose Preparation   
The designated dose of study drug must be prepared by the study pharmacist (or designee) and 
should be administered by the study staff as soon as possible following preparation, within 8 
hours , and considering:   
• The total volume of study drug to be delivered will be withdrawn from the study drug 
vial(s) and added to a prefilled IV bag containing 0.9% NaCl  for IV infusion ( prior to 
adding the study drug and an appropriate volume of NaCl solution is removed , such that 
the final volume to be infused equals :   
o 50 mL for doses < 1 mg/kg  
o 100 mL for doses ≥ 1 mg/kg to ≤ 3 mg/kg  
o 100 mL for doses of > 3 mg/kg to ≤  10 mg/kg for patients with body weight ≤ 80 
kg 
Symphogen Clinical Trial Protocol 
Trial ID: Sym023- 01 Version 5.0  
 
Confidential   Page 55 of 173 
 
 o 250 mL for doses of > 3 mg/kg to ≤  10 mg/kg for patients with body weight > 80 
kg 
o 250 mL for doses > 10 mg/kg for patients with body weight ≤ 100 kg 
o 500 mL for doses > 10 mg/ kg for patients with body weight > 100 kg  
Note:  In a case where the amount of IMP is ≥ 40% of the total infusion volume, a larger IV solution 
bag should be used.    
• The IV bag containing the diluted study drug solution to be administered should be gently 
inverted  to ensure that the material is well mixed.   
• Infusion sets must contain  a 0.22 micron in -line filter .   
5.9 Accountability  
The Investigator acknowledges that study drug supplies are investigational and, as such, must be 
used strictly in accordance with the protocol and only under the supervision of the Principal 
Investigator. No study drug will be sent to the site until all re quired regulatory documents, 
including Institutional Review Board (IRB) or Ethics Committee (EC) approval, are received by the Sponsor  or its designee.  
The Investigator and site staff are responsible for maintaining an accurate inventory and accounting of study drug.  Receipt , use, and destruction of study drug will be recorded on the 
dispensing log in use .   
5.10 Disposition of Used IMP  
Once study drug is prepared for delivery and administered, the health care professional will  
maintain an inventory of all open/ used vials of study drug. S uch residual supplies may be 
destroyed in an appropriate manner according to institutional policy.   
Note: No other use of study drug intended for use in this trial is authorized by the Sponsor.  The Investigator 
(or designee) will be responsible for the appropriate handling and disposition of residual study drug in 
partially used vials.   
 
5.11 Unused IMP  
Unused study materials MUST be returned to the Sponsor (or designee)  upon expiry or at the 
conclu sion of the site’s participation in the trial, unless otherwise authorized in writing. 
5.12 Destruction of IMP  
No unused IMP  may be destroyed or discarded at the site without the written authorization of the 
Sponsor (or designee). The destruction of study drug materials must be carefully documented per 
instructions outlined in the IMP Manual . Disposition records must be available for review by a 
representative of the Sponsor . 
Symphogen Clinical Trial Protocol 
Trial ID: Sym023- 01 Version 5.0  
 
Confidential   Page 56 of 173 
 
 6 EXPERIMENTAL PLAN  
6.1 Design Element s 
• Open-label, uncontrolled, non- randomized  
• Escalating doses of study drug in sequential patient cohorts  
• Enrollment staggered between first and second  patient in each new higher 3 -patient dose 
cohort to allow for initial safety observations  
6.2 Projected Recruitment Period and Duration of  this Trial  
It is anticipated that enrollment to this study will be completed in approximately 12 months .  
• Anticipated date of enrollment of first patient: Q2 2018 
• Anticipated date of enrollment of last patient: Q3 2019 
• End of Trial  (i.e., data cut -off for primary analysis):  W ill be reached 1 month (30 +  7 
days) after all  patient s have discontinued trial treatment, or 6  months after the last patient 
has started trial treatment, whichever occurs earlier , at which point the trial objectives 
will be considered to have been met .     
• Patients still in treatment will be given the opportunity to continue receiving study drug.  
In such an event, w hile the Sponsor still needs to collect certain safety -related data to 
meet its regulatory obligations (AEs, SA Es, study drug dosing, reason for 
discontinuation, etc.), the Sponsor may elect to reduce non- safety -related protocol -
stipulated assessments , and/or transition  patients to an extension/rollover protocol  
6.3 Cohort Management  
For the purposes of this study, "enrollment" is defined as patient registration to participate in 
this trial; at that time , the patient's study identification code and dose cohort will be assigned.  
6.3.1 Patient Screening and Dose Cohort Assignment  
Once a patient has given written informed consent , screening assessments will be conducted, and  
if the patient is identified as meeting the study eligibility criteria , the Investigator (or designee) 
will contact the Sponsor’s re presentative to  authoriz e enroll ment of the patient into the trial.  
Patients will be enrolled into the study in the order of confirmation of their eligibility, and assigned to a cohort on a “first -come -first-served” basis.   
6.3.1.1 Screening of Potential Patients  
All screening activities must be performed within 14 days prior to the first day of dosing (C1/D1), unless otherwise specified.   
The Sponsor (or designee) will be made aware of potential patients for enrollment to  track such 
study- related activities.    
Patients who  sign informed consent and are ultimately deemed to be screen failures will be 
followed for the occurrence of SAEs/AEs during the screening process until such time that it is 
determined that they will not be participating in this trial.  
Symphogen Clinical Trial Protocol 
Trial ID: Sym023- 01 Version 5.0  
 
Confidential   Page 57 of 173 
 
 6.3.1.2 Submission of Patient Enrollment Documentation 
Once eligibility has been confirmed in accordance with the protocol -stipulated inclusion and 
exclusion criteria, p atient enrollment information must be submitted to the Sponsor (or designee)  
via a Patient Screening and Allocation Form  signed by the Principal Investigator  (or designee). 
This information will serve to confirm patient eligibility and in itiate the enrollment process. The 
following information must be provided by the site :   
• Patient gender   
• Date of birth  (or age), as allowed by local regulatory requirements  
• Date written informed consent was obtained  
• Underlying diagnosis  
• Confirmation of compliance with all inclusion/exclusion criteria.  
The following information may be requested  of the site : 
• Patient weight (for dose calculation)  
• Date of screening  
• Stage of disease and current PS  
• Sites of metastases (if applicable)  
• Brief description of the prior therapy for the primary diagnosis, including dates of 
initiation and discontinuation as well as best response  
• Planned date of first dosing 
The Sponsor (or designee) will review the information provided and by signing the form will 
authorize eligible patients for start of treatment. A copy of the fully executed Patient Screening 
and Allocation Form  will be returned to the trial site for archiv ing. This form will document the 
allocated dose of study drug, and will serve to assign patients to a dose cohort at the time of enrollment.   
6.3.1.3 Patient Identification Code Assignment  
Each patient who completes the study screening assessments and is enrolled  for study 
participation will be assigned a unique  identification code by the Sponsor  (or designee) . 
Identification codes will be assigned in chronological order , and will be concatenated to indicate 
relevant study information, including at minimum: the participating trial site  and the patient’ s 
order of enrollment to the trial . 
6.3.1.4 Screen Failures  
A patient found not eligible for the trial after giving informed consent will be considered a screen 
failure.  A list of patients failing screenin g and the reason for ineligibility will be maintained by 
the site on a Patient Screening Log or other similar document.   
Symphogen Clinical Trial Protocol 
Trial ID: Sym023- 01 Version 5.0  
 
Confidential   Page 58 of 173 
 
 Re-screening of a patient is  allowed  using the specified criteria and timing , if felt to be justified 
by the Investigator . 
6.3.2 Cohort Clos ure 
The Sponsor (or designee) will be in communication with the site s when the target total 
enrollment for a cohort has been attained . Once recruitment to a cohort is completed, accrual to 
the cohort will be closed, and sites w ill be so notified in writing . Cohorts will remain closed to 
further accrual , unless a decision is later made by the Sponsor (or designee) to further expand 
that cohort, based on protocol -defined criteria.  
6.4 Requirements for Patient Observation  
Patients will be treated on an outpatient basis, and will be evaluated and discharged from the 
clinic on days of scheduled study visits*, unless hospitalization is required for other reasons or to ensure patient safety.   
Study drug must be administered under close supervision of a physician, or other study personnel experienced in administration of IV agents, and in an environment where full resuscitation facilities are immediately available.  IV infusions will be carefully monitored to assess safety and 
tolerability by qualified sit e medical personnel. Such personnel must be available to  evaluate and 
treat any AE s, as well as to evaluate whether continued participation of the patient in the study is 
warranted or advisable.  
• Patients will be carefully observed for a minimum of 2 hours  following completion of the 
first administration of study drug ( C1/D1) for evidence of any treatment -related AE (s), 
and a minimum of 1 hour  following completion of subsequent infusions  (C1/D15 and 
onward) .   
• At the end of each infusion, the IV line must remain in place during the observation period to allow for administration of IV drugs, if necessary.   
Patients will be followed on an outpatient basis during the interval between each scheduled study visit.   
*Clinical and laboratory ass essments will occur at the frequencies indicated ( Sectio n 7).  In the event of an AE, 
assessment frequencies may  be increased, as clinically indicated.  
6.5 Drug Treatment Regimen  
6.5.1 Study Start Day   
All patients will receive the initial dose of study drug on Day 1  of Cycle 1  (C1/D1).   
On the day of the first scheduled study drug infusion, and prior to the start of infusion (SOI), the 
Investigator must assess whether any changes have occurred in the clinical state of the patient 
since Screening which would exclude the patient from the trial. 
6.5.2 Patient Availability   
The site should calculate study assessment days as well as sample collecti on dates and times in 
advance of scheduling a patient’s first day of study drug administration in order  to plan 
Symphogen Clinical Trial Protocol 
Trial ID: Sym023- 01 Version 5.0  
 
Confidential   Page 59 of 173 
 
 accordingly to avoid assessment or collection requirements during non- routine clinic times such 
as weekends, holidays, etc.   
Given the schedule  of study drug administration outlined herein, and the PK sampling schedule  
(Section  7.6),  patients must be available : 
• Cycle 1: Days 1, 2, 3 ( ± 1 day) ; Days 8, 15, and 22 (each ± 2 days) ; therefore, 
consideration should be given to scheduling Day 1  on a Monday, Tuesday , or 
Wednesday *   
• Cycles thereafter: Day 1 and Day 15 ( ± 2 days)  
• Patients must also be available at the end of cycles to determine whether continuation to 
the next cycle is feasible based on tolerability, and at the end of even -numbered cycles to 
evaluate disease status.  
*unless the study site has weekend hours of operation  
6.5.3 Therapy with Study Drug  
Based on their cohort assignment , patients will receive the assigned dose  of study drug by the 
route and schedule  as described below : 
6.5.3.1 Dose s to be Administered  
6.5.3.1.1 Doses to be Evaluated  
Dose cohorts will be numbered sequentially (i .e., Cohort 1, Cohort 2, etc.). The number of 
cohorts evaluated will depend upon toxicities experienced during Cycle 1 .   
Anticipated dose levels include : 
• Dose Level 1:  0.03 mg/kg 
• Dose Level 2:  0.1 mg/kg  
• Dose Level 3:  0.3 mg/kg  
• Dose Level 4:  1.0 mg/kg  
• Dose Level 5:  3.0 mg/kg  
• Dose Level 6:  10 mg/kg 
• Dose Level 7: 20 mg/kg  
6.5.3.1.2 Changes in Dose to be Administered  
Once assigned to a dose cohort , patient s will continue to be treated with study drug at that same 
dose level throughout the duration of their time on study.  There will be no intrapatient dose -
escalation.  
Dose adjustments should be made in the event of noted weight change ( ± 10% ; less at the site’s 
discretion or if required by institution procedures) at visits that require weight measurement. Adjustments may be made more frequently at the site's discretion.    
Symphogen Clinical Trial Protocol 
Trial ID: Sym023- 01 Version 5.0  
 
Confidential   Page 60 of 173 
 
 6.5.3.2 Route  of Administration  
Study drug will be administered by the IV route, via indwelling venous access catheter , utilizing 
a controlled infusion device . Infusion sets must contain a 0.22 micron in -line filter . 
The catheter may be placed into a peripheral vein (if accessible); administration via central 
venous catheter or port ( if in place) is allow ed. 
In those instances when study drug administration is associated with PK sampling, and administration is via peripheral IV catheter, infusions will be delivered into the arm contralateral to that from which blood samples for PK anal ysis are being obtained.  
6.5.3.3 Diluent and Delivery  
Commercially available sterile 0.9% NaCl for IV infusion is to be used as the diluent.  Once diluted for IV administration, study drug should be administered within 8 hours. 
6.5.3.4 Volume of Infusion  
Infusions will be delivered in a final volume of :  
• 50 mL for doses < 1 mg/kg 
• 100 mL for doses ≥ 1 mg/kg to ≤ 3 mg/kg  
• 100 mL for doses of > 3 mg/kg t o ≤ 10 mg/kg for patients with body weight ≤ 80 kg 
• 250 mL for doses of > 3 mg/kg to ≤  10 mg/kg for patients with body weight > 80 kg 
• 250 mL for doses > 10 mg/kg for patients with body weight ≤ 100 kg 
• 500 mL for doses > 10 mg/kg for patients with body weight > 100 kg  
Note:  In a case where the amount of IMP is ≥ 40% of the total infusion volume, a larger IV solution bag should 
be used.  
6.5.3.5 Duration of Infusion  
Study drug will be administered over : 
• Approximately 30 minutes  (+10 minutes)  for infusion volumes ≤  250 mL  
• Approximately 60 mi nutes (+10 minutes) for infusion volumes of 500 mL  
Administration should be at a constant rate using a programmable volumetric infusion pump to  
ensure accuracy of delivery (as well as integrity of PK sampling). Start and stop times of each infusion, and any interruptions in infusion will be recorded on the appropriate page of the patient’s CRF.  
Note: In the event of a  Grade 2 IRR,  see Section 8.5.1 , Appendix 9 for further instructions . 
Study drug will be administered over a longer period for all patients entered to the trial in the following situations:  
Symphogen Clinical Trial Protocol 
Trial ID: Sym023- 01 Version 5.0  
 
Confidential   Page 61 of 173 
 
 • In the event of a Grade 2 IRR in ≥ two thirds of the patients entered to a cohort, the 
duration of infusion for subsequent patients entered to the trial wi ll be extended by 30 
minutes  (or longer, if indicated).  
• In the event of a Grade 3 or greater IRR in any patient within a cohort, the duration of infusion for subsequent patients entered to the trial will be extended by 30 minutes  (or 
longer, if indicated). Such a case will also be considered to have met the protocol criteria for a DLT, thus requiring expansion of the cohort . 
These same criteria will be applied in the event IRRs occur on the extended infusion schedule.  In such a case, the duration of infusi on for subsequent patients entered to the trial will be further 
extended by 30 minutes  (or longer, if indicated).  
6.5.3.6 Schedule  
Study drug is to be administered once  Q2W on Day 1 and Day 15 of each cycle ( 4 weeks [ 28 
days] equals 1 dosing cycle) .    
EOC1 assessments are to be performed on C1 /D28 (± 2 days ). Subsequent cycles may be 
administered Q 2W (± 2 days) , unless further delay is required to allow for amelioration of 
toxicities  (or in the event of scheduling difficulties associated with weekends, holidays, etc.) .   
6.5.4 Premedication  
Since the mechanism of action of the study drug is to stimulate the immune system, 
premedication with agents such as glucocorticoids which are immunosuppressive is to be avoided. As a result, n o premedication is required t o be administered prior to patient s receiving 
the first dose of study drug.  
In patients with a history of IRR s to mAbs or similar products , it is recommended that 
premedication be administered . In such cases, patients should be premedicated with a regimen 
that includes acetaminophen  as well as an H1 (e.g. , diphenhydramine/hydroxyzine) and possibly 
an H2 -antagonist  (e.g., ranitidine/famotidine).   
Should a patient experience an IRR while on study , guidelines for instituting premedication prior 
to subsequent infusions are provided ( Section  8.4.3). Guidelines for the grading and 
management of IRRs  of all severities are also provided ( Appendix 9).  
6.6 Cycle 1  
A minimum of 1 cycle of study drug will be administered, if tolerated.  Any delays  in dosing and 
the reasons for such delays  must be documented. If an AE is the cause for dosing delay , it must 
be detailed on the Adverse Events  page of the CRF.   
Determinations regarding cohort escalation  and MTD will be based on the toxicities observed 
during this 4- week period (Cycle 1) of treatment , and the occurrence of DLTs* thought to be 
related  (i.e., possibly- related, probably- related, or related) to study drug.  
Symphogen Clinical Trial Protocol 
Trial ID: Sym023- 01 Version 5.0  
 
Confidential   Page 62 of 173 
 
 • Patients completing Cycle 1, and receiving their full planned doses of study drug in the 
absence of a DLT, will be considered to have tolerated the dose level they were assigned to receive.   
• Patients will be replaced  if they have  received < 2 full dose s of study drug plus follow -up 
through EOC1 ( C1/D28 ± 2 days ) for any reason other than a DLT, to  ensure MTD 
determination rules can be followed with an adequate number of evaluable patients in any dose cohort .   
• All treated  patients will be considered in the assessment of safety and tolerability.  
*See Section 6.8.3 and Section 6.9 
6.6.1 Rules for Dose -Escalation and Cohort Expansion   
Initially , a modified, accelerated -titration, dose -escalation design will be used with entry of 
single patient cohorts for up to 2 dose levels, based on tolerability. 
Thereafter, a standard 3+3 dose -escalation design will be used , with a target toxicity le vel of 
33.3% or less as determined by DLTs.   
Dose cohort s will be filled sequentially. Up to 6 patients may be treated at each dose level until 
the MTD and/or RP2D is determined. The  decision rules for dose -escalation and cohort 
expansion are as follows:  
1. A minimum of 1 patient will be entered into dose Cohort s 1 and 2 ONLY . 
• If during the initial 2 weeks of Cycle 1 no >  Grade 2 toxicity considered possibly-
, probably- , or related to study drug is encountered in the patient, dose -escalation 
may continue to the next level when the patient has been followed for safety until C1/D15 
• If at any time during Cycle 1, a patient experiences a >  Grade 2 toxicity 
considered possibl y-, probably- , or related to study drug, the cohort will be 
expanded to 3 patients  
• If during Cycle 1, a patient experiences a DLT considered possibly- , probably- , or 
related to study drug, the cohort will be expanded to 6 patients  
2. Beginning with Cohort 3, or earlier if required by observed toxicity, a m inimum of 3 
patients  will be entered to each cohort .  
• If during Cycle 1 no DLTs are encountered in any of the first 3 patients, dose -
escalation may continue to the next level when all patients have completed Cycle 
1. 
• If during Cycle 1, any 1 patient experiences a DLT considered possibly- , 
probably- , or related to  study drug, the cohort will be expanded to 6 patients . If no 
DLTs are encountered in the additional 3 patients, dose -escalation may continue 
to the next level when all patients have completed and tolerated Cycle 1.  
Symphogen Clinical Trial Protocol 
Trial ID: Sym023- 01 Version 5.0  
 
Confidential   Page 63 of 173 
 
 • If during Cycle 1, >1 patient experiences a DLT, dose -escalation will STOP .  This 
will indicate that the MTD has been exceeded.  
3. If it is determined that a dose level is not tolerated : 
• The previous lower dose cohort will be expanded to 6 patients (if this has not 
already been accomplished)  as a total of 6 patients must be treated before 
establishing a dose as the M TD. 
• There is also the potential to evaluate and expand a previously unplanned 
intermediate dose level between 2 established dose levels to 6 patients to more fully characterize tolerability.  
4. The MTD will be the highest dose level of study drug at which no more than 1 of 6 
evaluable patients has had a DLT.  
5. Once the MTD (or maximum dose to be studied) is achieved and/or  the RP2D is 
identified , that cohort may  be expanded up to 12 patients  to more fully evaluate safety 
and tolerability at that dose level at the Sponsor’s discretion. Should the DLT rate  equal 
or exceed 33.3% in an expanded cohort, it will be determined t hat the dose is not 
tolerated. If this occurs, the previous lower dose cohort  or an intermediate dose level  may  
be expanded as above.  Therefore:  
• There is potential for expansion of a lower dose cohort(s) if an initially identified MTD and/or RP2D is subsequently determined not to be tolerated (either with single or repeat cycles of therapy), and  
• There is potential to evaluate and expand a previousl y unplanned intermediate 
dose level(s) between 2 established dose levels to more fully characterize tolerability.  
Note: Such action would be taken by the Sponsor (or designee)  in the event of an unacceptably 
high frequency of toxicities observed in patient s treated at one dose level  considered to be 
in marked contrast to the tolerability noted in the immediately preceding dose cohort , or if 
after review of study data,  a more gradual dose -escalation appears warranted.  
The RP2D may be equal to or lower than t he MTD  or the MAD . The RP2D will be selected based 
on safety data, as well as available PK , pharmacodynamic/biomarker , and other data , as applicable.  
6.6.2 Rules for Duration of Exposure Prior to Start of Next Patient  and Next Cohort   
Single patient cohorts : Dos e-escalation and accrual to the next cohort will occur only after the 
patient has completed and tolerated the first dose of Cycle 1  including follow -up until C1/D15 to 
allow for review of clinical and laboratory assessments, and consultation with the Study Safety 
Team .  The DLT evaluation period for single patient cohorts will continue through to the 
EOC1 .  
The following rules apply to single patient cohorts  throughout the Cycle 1 DLT evaluation 
period (Cohort 1 and 2 only, receiving treatment at the lowest doses of 0.03 and 0.1 mg/kg, 
respectively) : 
Symphogen Clinical Trial Protocol 
Trial ID: Sym023- 01 Version 5.0  
 
Confidential   Page 64 of 173 
 
 • Should a patient experience an AE of concern  in the latter half of Cycle 1 that would, 
per protocol, result in cohort e xpansion, protocol rules as outlined herein will be 
followed ( Section 6.6.1) .  For example, in the event of a ≥ Grade 2 toxicity, the 
cohort (and a ll cohorts thereafter) will be expanded to 3 patients; in the event of a 
DLT the cohort will be expanded to 6 patients .   
• Additional patients entered to an expanded single patient cohort will follow rules as 
outlined below for 3+3 patient cohorts .  Enrollm ent will be staggered by at minimum 
2 weeks between the first and second patient, Thereafter, patients within a cohort may be added concurrently.  
• If in the meantime , if a patient has been entered to receive the next higher dose level, 
that patient will be allowed to continue  provided adequate tolerability is being 
demonstrated ; however, further enrollment to the higher dose level cohort will be 
halted until the lower dose level cohort has been fully expanded and evaluated. 
3+3 patient cohorts :  Enrollmen t will be staggered by 2 week s between the first and second 
patient  in each new higher 3+3 dose level cohort . The first patient within a cohort must complete 
and tolerate the first dose of Cycle 1  including follow -up until C1/ D15 to  allow for review of 
clinical and laboratory assessments . Thereafter , patients within a cohort may be added 
concurrently. 
All cohorts :  Dose -escalation and accrual to the next cohort will occur only after the minimum 
number of patients required for tolerability assessment in the current cohort have completed until 
C1/D15 in a single patient cohort, or completed Cycle 1  in a 3+3 patient cohort , and only after 
acceptable tolerance has been demonstrated in at least 1 of 1, 3 of 3, or  5 of 6 patients treated in 
the current cohort (depending on cohort size), and after consultation with the Study Safety Team . 
For all patients, EOC1 assessments are to  be performed no sooner than C1/ D28 (± 2 days) . 
6.6.3 Rules for Establishing the M TD and/or RP2D 
The MTD will be the highest dose level of study drug at which no more than 1 of 6 evaluable 
patients has had a DLT.   
The MAD, MTD , or a dose lower than the MAD or MTD , will be identified as  the RP2D, 
provided a minimum of 6 patients have been treated at that dose, and provided acceptable tolerance has been demonstrated in at least 5 of 6 patients treated. The RP2D choice will be 
based on the MTD evaluation as well as other toxicities observed in the study, including 
observations in later cycles of administration of study drug, as well as on PK , 
pharmacodynamic s/biomarkers, and/or other data.  
6.6.4  Rules for Stop ping the Study  
The study will be stopped if the MTD is exceeded at the lowest dose level.  
6.7 Continued Treatment  After Cycle 1  
Upon completion of Cycle 1, in the absence of unacceptable toxicity or documented PD , patients 
may continue to receive additional cy cles of study drug, unless further delay is required to allow 
for amelioration of ongoing AEs .   
Symphogen Clinical Trial Protocol 
Trial ID: Sym023- 01 Version 5.0  
 
Confidential   Page 65 of 173 
 
 Administration of subsequent dosing cycles is allowable at the discretion of the Investigator, 
provided the patient meets the retreatment criteria listed below . Additional cycles should be 
initiated as soon as possible, but not longer than 2 weeks  after  the completion of the previous 
cycle, if feasible.  
6.7.1 Retreatment Guidelines  
Clinical judgment will be used when determining whether it is advisable to continue a patient on 
to the next cycle(s) of dosing. To  start any new cycle, a patient must meet the following criteria:  
• ANC ≥  1,000 per mm3 
• Platelets ≥  75,000 per mm3 
• Any ongoing study drug- related  AE should NOT meet the criteria for DLT  
• Any ongoing study drug- related  AE should have either ameliorated to ≤ Grade 1 severity, 
returned to baseline status, or resolved, with the exceptions  of: 
o Grade 2 alopecia,  
o Grade 2 clinical events  that are being adequately controlled with best supportive 
care (e.g., fatigue, nausea, vomiting, diarrhea) , and  
o Grade 2 asymptomatic laboratory abnormalities that are considered clinically insignificant , clinically uncomplicated , and/ or that are resolving  spontaneously or 
with conventional medical interventions . 
• Dosing must be delayed in patients with evidence of Grade 2 immune -mediated 
toxicities, including  (Appendix 10 ):  
o Pneumonitis, myocarditis, adrenal insufficiency, encephalitis, nephritis /renal 
dysfunction (serum creatinine elevation), episcleritis /uveitis /iritis 
o Colitis, hypophysitis, hyperglycemia, inflammatory arthritis, myositis, rash  
o Hepatitis (transaminitis, total bilirubin elevation)  
Note:  Patients may receive standard doses of replacement hormonal therapy for adrenal insufficiency, 
hypothyroidism, or other endocrine end -organ failure, and may resume study drug once considered by 
the Investigator to be stable on such therapy provided a DLT criterion has not been met.  
Should above criteri a not be met, dosing must  be delayed  until further evaluation is completed 
and it is determine d that the patient is eligible for continued treatment .  
6.7.2 Doses and Regimens  
For a given patient, subsequent cycles of therapy with study drug will be administered at the same dose level* and infusion duration established for the patient, and on the same Q2W schedule.  
* Unless a dose adjustment is necessary due to ± 10% fluctuation in patient weight ( less at the site’s discretion or if 
required by institution procedures )  
Symphogen Clinical Trial Protocol 
Trial ID: Sym023- 01 Version 5.0  
 
Confidential   Page 66 of 173 
 
 6.7.3 Evaluation Schedules  
The same evaluations required during Cycle 1 of the study will be conducted during subsequent 
cycles, at the frequencies indicated ( Section  7). 
6.7.4 Duration of Treatment  
Additional cycles of study drug may continue to be administered if tolerate d and in the absence 
of documented PD , at the Investigator’s discretion, provided retreatment  criteria have been met 
(Section 6.7.1) .   
Such extended therapy will continue for a period of up to 12 months  after achieving the “best 
response,” at which time the Medical Monitor (s) and Investigator will discuss the advisability of 
continued therapy based upon the patient’s ongoing response stat us and the degree of 
demonstrated tolerability.  Patients who stop therapy with an ongoing OR or prolonged SD may 
be retreated in the event of relapse, if the trial is still open  (Section 6.7.6).  
6.7.5 Continued Treatment after Radiologic Disease Progression  
Immunotherapeutic agents may produce antitumor effects that can manifest as response after 
initial evidence of PD, a phenomenon referred to as “pseudopr ogression”  (PSPD) . 
Patients will be permitted to continue treatment beyond initial RECIST v1.1 (or RECIL  2017) 
defined PD while waiting for confirmation of PD, provided they are clinically stable as defined by the following criteria (per i RECIST ): 
• Investig ator-assessed clinical benefit and absence of rapid disease progression  
• Tolerating study drug  
• Stable PS  
• Absence of progressive tumor at critical anatomical sites (e.g. , cord compression) 
requiring urgent alternative medical intervention. 
6.7.6 Retreatment Following an Objective Response  
Treatment with study drug may be restarted in a patient who previously achieved a documented 
OR or prolonged SD (>  16 weeks) on this study, st opped  treatment,  and subsequently progresses . 
Such action may be taken at the Investigator’s discretion, following discussion with the Medical 
Monitor (s), provided retreatment criteria are met , no anti -cancer treatment was administered 
since the last dose of study drug, and the trial is still open .   
This option for retreatment does not  apply to patients who previously experienced a DLT  that 
required permanent discontinuation from study drug ( Section 6.8.3, Section 9.1).  
Retreatment with study drug may be initiated at the same dose and infusion duration established for that patient during their previous course of treatment, and on the same schedule.  
The same evaluations required during previous treatment will be conducted during subsequent 
cycles, at the frequencies indicated.  
Retreatment cycles of study drug may continue to be administered if tolerated and in the absence of further PD , at the Investigator’ s discretion, as long as retreatment criteria continue to be met.  
Symphogen Clinical Trial Protocol 
Trial ID: Sym023- 01 Version 5.0  
 
Confidential   Page 67 of 173 
 
 6.8 Adverse Events and Dose -Limiting Toxicit ies 
6.8.1 Adverse Event  Grading  
For reported AE s, the CTCAE v5.0* will be used to grade the severity or the AE . 
*See <  https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm  > 
6.8.2 Management of D ose-Limiting Toxicitie s and Other Toxicities  
If a significant toxicity thought to be related to study drug is experienced at any point during the 
patient’s partic ipation in the study, the Investigator will determine:   
• Whether that toxicity is dose -limiting ( Section 6.8.3 ), thus requiring discontinuation from  
study treatment, without exception .   
• Whether the toxicity does not meet the protocol definition of DLT, but nevertheless 
warrants dose modification, in which case the Investigator may elect to temporarily delay  
dosing with study drug to  allow for amelioration of the toxicity .   
For additional information on toxicity management and dose modification, see Section 8.  
6.8.3 Definiti on of D ose-Limiting T oxicity 
Any of the following toxicities  occurring during Cycle 1, if judged to be related to  study drug 
(i.e., possibly- related, probably- related, or related), will be considered a DLT for the purposes of 
tolerability assessment during  this trial.  
1. ≥ Grade 3  evidence of any of the following immune -mediated toxicities:  
• Pneumonitis  
• Myocarditis  
• Adrenal insufficiency  
• Encephalitis  
• Nephritis, renal dysfunction (serum creatinine elevation)  
• Episcleritis, uveitis, or iritis  
2. ≥ Grade 3  evidence of any of the following immune -mediated toxicities:  
• Colitis  
• Hypophysitis, hyperglycemia  
• Inflammatory arthritis  
• Myositis  
• Rash  
3. ≥ Grade 2:  
• Uveitis, eye pain or blurred vision that does not resolve with topical therapy within 2 weeks  
• AEs that are pr olonged excessively based upon the medical judgment of the 
investigator, and/or lead to permanent discontinuation of the study drug due to poor tolerance  
Symphogen Clinical Trial Protocol 
Trial ID: Sym023- 01 Version 5.0  
 
Confidential   Page 68 of 173 
 
 • Immune -mediated toxicity that requires use of glucocorticoids at a dose of ≥ 1 
mg/kg/day of prednisone  equivalents for treatment of the toxicity  
4. Any confirmed reduction in visual acuity, regardless of grade or duration  
Note:   Noted changes in visual acuity must be reevaluated by an ophthalmologist and confirmed within 48 
hours (if feasible, based on weekends  or holidays)  of the initial observation; study drug will be held 
pending evaluation by the ophthalmologist .   
Changes in visual acuity assessment , if associated with either an immune -related AE, including but 
not limited to iritis, episcleritis, uveitis , or any other condition  that may be considered to be related 
to therapy with study drug  will be considered to be a DLT .   
Patients in whom a minor fluctuation in visual acuity is due to another known or recently diagnosed 
underlying condition may contin ue to be treated  once visual acuity fluctuation returns to baseline 
status , but must be re evaluated  by an ophthalmologist prior to each cycle and upon the occurrence 
of any subsequent  ophthalmologic sign or symptom , including but not limited to  recurrent  changes 
in visual acuity  measurement , in order to reassess for DLT status .  
5. Hepat ic-related findings consistent with Hy’s Law criteria : 
• AST and/or ALT elevation > 3 × ULN (or > 3 × baseline if elevated at study entry 
due to hepatic involvement by tumor ), with  
• Total bilirubin ≥  2 × ULN without initial findings of cholestasis (i.e. , serum 
alkaline phosphatase [ALP]  < 2 × ULN ), and  
• No explanation for the above findings such as viral hepatic injury, preexisting or 
acute liver disease, or another drug or condition capable of causing the observed liver injury  
6. Any other ≥  Grade 3  non-hematologic toxicity regardless of duration, with the exception s 
of:  
• Grade 3 fatigue  
• Grade 3 nausea, vomiting, or diarrhea lasting ≤  2 days  with best supportive care   
• Grade 3  asymptomatic electrolyte abnormalities lasting ≤  3 days  that are not 
clinically complicated, and resolve spontaneously or respond to conventional medical interventions  
• Other Grade 3 asymptomatic laboratory abnormalities that are clinical ly non-
significant in the investigator’s opinion, and that resolve sponta neously or with 
conventional medical interventions  
7. Any Grade 4 non- hematologic laboratory toxicity  regardless of duration  
8. Neutropenia that is:  
Symphogen Clinical Trial Protocol 
Trial ID: Sym023- 01 Version 5.0  
 
Confidential   Page 69 of 173 
 
 • Grade 3  meeting the CTCA E v5.0 criteria for febrile neutropenia ( ANC < 1000 
per mm3 and a single temperature > 38.3ºC  [101ºF] or sustained temperature >  
38ºC [100.4ºF] for > 1 hour ) 
• Grade 4  
9. Thrombocytopenia  that is :  
• Grade 3 with CS hemorrhage  or requirement for transfusion  
• Grade 4  (platelets < 25,000 per mm3)  
10. Anemia that is Grade 4 and not explained by underlying disease  
11. Any other Grade 4 hematologic toxicity (other than those specifically excluded) lasting > 
5 days  
12. Any death where a relationship to study drug cannot be ruled out  
13. Inability to complete Cycle 1  at the assigned dose  (i.e., receipt of < 2 full planned dose s 
of study drug plus 2 weeks  of follow -up) due to any toxicity  
14. Treatment delays > 2 weeks  from the scheduled next dose during Cycle 1  due to any  
toxicity  
Other toxicities may be considered a DLT as determined by the Investigator in conjunction with the Study Safety Team . 
The above criteria will be used to make individual patient determinations regarding dose delays  
or discontinuation throughout the course of the trial ; however, only those DLTs occurring 
during Cycle 1  will be used to make decisions  regarding cohort dose -escalation and 
tolerability.   
Events occurring after Cycle 1 will also be evaluated by the Study Safety Team  and taken into 
consideration when deciding upon further doses to be assessed as well as to establish the RP2D.  
6.9 Definition of Maximum Tolerated Dose  
MTD will be defined as the dose below that which produces, during Cycle 1 of treatment, any of 
the indicated DLTs either in > 1 patient in a 3 to 6 patient cohort, or in ≥  33.3% of patients in the 
event of an expanded 7 to 12 patient cohort .  
The MTD will not be established until all patients in the cohort under evaluation have either completed Cycle 1  or discontinued further participation in the trial  due to the occurrence of a 
DLT.   
Previously established tolerability of a dose level will be reevaluated if DLTs thought to be 
possibl y-, probably- , or related to study drug are observed in later cycles  or in the event of 
expansion of a cohort to > 6 patients . 
6.10 Review of Safety Data During Study  
Clinical and laboratory safety data will be reviewed on an ongoing basis throughout the study by 
the Investigator s and Sponsor’s Representative(s) so that  decisions regarding the advisability of 
Symphogen Clinical Trial Protocol 
Trial ID: Sym023- 01 Version 5.0  
 
Confidential   Page 70 of 173 
 
 continuing accrual to a dose cohort, and/or escalating the dose and allowing accrual to a higher 
dose cohort  may b e made . In addition, patients will be carefully evaluated for evidence of 
potential cumulative and/or delayed toxicities throughout the duration of their time on study.   
To do so, SAEs, immune -related AEs of significance,  AEs resulting in permanent 
discontinuation from study ( regardless of seriousness or relationship to study drug), DLTs , IRRs , 
and dosing delays  will be promptly reported to the Sponsor (or designee) . 
A Study Safety Team  will be established and will be comprised of the Investigator(s) and the 
Sponsor’s Medical Representative(s). Biwe ekly Study S afety Team  Teleconferences will be held 
to discuss ongoing patient status and any emerging safety concerns ; frequency of teleconferences 
may fluctuate based on accrual and study activity, as indi cated  (Section 12.1) .  
6.11 Duration of Study Follow -Up 
Upon discontinuation of a patient from further treatment with study drug, every effort will be 
made to conduct follow -up assessments as detailed below.    
For patients continuing to another therapy, the expectation is that Investigators will show due 
diligence in obtaining adequate follow -up for this study, as indicated. In the event of ongoing 
toxici ties, Investigators will do their best to continue patient follow -up, based on both patient 
availability and Investigator ability to determine the etiology of noted toxicities within the context of initiation of  any new therapy  (i.e., whether the finding is due to study drug or due to 
the other therapy) .   
• End of Treatment  (EOT) evaluations will be conducted within approximately 10 days  
following treatment discontinuation , or before initiation of a new treatment, whichever 
occur s first .   
• 1-Month Follow -up (1M FUP ) evaluations will be conducted approximately 30 days  (+7 
days) following the last dose of study drug.  
Note: The 1M FUP evaluation should be conducted ≥  30 days  following the last dose of study drug a s all 
patients are to be followed for a minimum of 30 days after study drug discontinuation to  monitor 
for the occurrence of suspected AEs that are both serious and unexpected .      
• Long- Term Follow -up (FUP) for Safety :  If an observed toxicity (non- immune -media ted) 
thought to be related to study drug has not resolved by the 1M FUP  evaluation, an 
additional FUP  AE assessment will be conducted  approximately 2 months  (may be 
repeated at 4 months  if needed) following the last dose of study drug, if feasible,  to 
confirm that the event has either resolved, returned to baseline status, or been adequately 
explained  and assessed by the Investigator as chronic and/or stable , and that no long- term 
deleterious effects have become evident *      
Since late -occurring immune -mediated toxicities have been reported to occur several 
weeks to months after treatment with other immune checkpoint inhibitors, long- term 
surveillance for such toxicities will be conducted in this study. Patients will be followed at approximately 2- month intervals following the last dose of study drug for up to 6 
months  to assess for the onset of any post -therapy immune -mediated event thought to be 
related to study drug.*  
Symphogen Clinical Trial Protocol 
Trial ID: Sym023- 01 Version 5.0  
 
Confidential   Page 71 of 173 
 
 Any patient who develops an immune -mediated toxicity during study, or during the 6-
month post -therapy FUP period, will be followed at approximately 2- month intervals 
following the last dose of study drug for up to 2 years  to assess the course of the 
condition and evaluate potential reversibility of the finding.* 
*Investigator discretion may be used with respect to the method of contact for this AE assessment; clinical 
events may be followed in writing or by telephone ; an in-person visit will not be required.  
• Long- Term FUP for Response : In the event  of an  ongoing OR  or SD  at the EOT , 
response assessment -based  imaging studies (as indicated by disease type) will continue to 
be performed every 2 months  following the last dose of study drug, until confirmed PD  or 
another therapeutic intervention is initiated,  so that data may be collected on the duration 
of SD  or OR , as well as disease progression *   
*To continue at the intervals specified until disease progression or another therapeutic intervention is 
initiated , or until the end of trial ; documentation may be submitted in writing or by e -mail, an in- person 
visit will not be required.  
6.12 Concurrent Treatments and Supportive Care  
Therapy for other ongoing medical conditions, as well as palliative and supportive care for the 
underlying malignancy will be provided prior to and during this trial, as clinically indicated, and 
in accordance with the standard practices of the institution, except as stipulated by study eligibility  criteria ( Section 4.3.2).  
Other therapies allowed during the conduct of this trial include:  
1. Prophylaxis for IRRs and Study Drug- Related Toxicities : Patients with a history of IRRs 
to mAbs  or similar products , and patients who experience IRRs while on study, should 
receive premedication with standard therapies as defined herein prior to each dose of 
study drug to  reduce the risk of such eve nts. Patients experiencing other study drug-
related reactions  may be premedicated with standard therapies to  reduce the potential for 
such reactions in the future  (Section 8.4). 
 
2. Treatment of Study Drug -Related AEs  or Concurrent Diseases : Clinical judgment should 
be used in the treatment of any treatment- related AEs or concurrent disease s that occurs 
during the study and follow -up period.   
 
3. Blood Products and Growth Factors : Prophylactic hematopoietic growth factors should 
not be administered during Cycle 1 of study; thereafter prophylactic use of growth factors is allowed as clinically indicated. Interventional/therapeutic use of growth fact ors is 
allowed during study, including Cycle 1, if deemed necessary by the Investigator.  Growth factor use must be consistent with product package insert instructions. 
 
4. Radiotherapy: Radiotherapy for pain control against non- target lesions, provided it do es 
not influence BM  function.  Such treatment should be discussed with the Sponsor’s 
Medical Monitor(s).  
Symphogen Clinical Trial Protocol 
Trial ID: Sym023- 01 Version 5.0  
 
Confidential   Page 72 of 173 
 
 5. Bisphosphonates and denosumab : Bisphosphonates and denosumab for bone metastases 
and other skeletal conditions  are allowed , provided the patient is on a stable dose for at 
least 2 months prior to study start and remains  on the stable dose while receiving study 
treatment.  
 
6. Immunosuppressive or systemic hormonal therapy not exceeding  10 mg daily prednisone 
equivalent, as well as:  
• Hormonal therapy for appetite stimulation (e.g., Megace)  
• Nasal, ophthalmic, inhaled, and topical glucocorticoid preparations  
• Hormone replacement therapy at standard doses for end- organ failure  
• Stable hormonal therapy for prostate carcinoma*  
• Stable hormonal therapy for ovarian suppression, hormonal contraceptive therapy, 
or post -menopausal HRT* 
• Steroid therapy for contrast reaction prophylaxis  
• Intra -articular steroid injections  
• Low-dose maintenance ster oid therapy for other conditions (e.g., asthma 
exacerbation, stable steroid therapy [excluding tapering dose of steroids] for brain edema/metastases/radiation)  
• Higher dose steroid therapy for treatment of an acute intercurrent illness (e .g., 
immune -related  AEs or other adverse conditions) in patients with SD  or an 
ongoing response. In such situations study drug treatment should be interrupted for the duration of immunosuppressive therapy.  
*Concomitant therapies are permitted;  however, patients must have bee n on a stable dose for at least 6 
months  prior to study start, and if continuing must remain on the stable dose while receiving study 
treatment (i.e. , such treatment will not be considered as systemic hormonal therapy for the purpose of study 
eligibility).  
Information on all concomitant therapies administered, as well as other interventions or 
procedures occurring during the trial period, must be recorded on the appropriate page of the patient’s CRF.
 
Symphogen Clinical Trial Protocol 
Trial ID: Sym023- 01 Version 5.0  
 
Confidential   Page 73 of 173 
 
 7 STUDY ASSESSMENTS    
All patients will be assessed by sche duled clinical, laboratory, and other diagnostic assessments 
throughout the study. All efforts should be made to perform assessments as close as possible to 
the scheduled timepoints. The projection of visit days within each cycle should be made from Day 1 of the respective cycle. Visit windows are provided below. Study assessments are to be performed as follows:  
• Screening  evaluations  are to be performed within 14 days  prior to first study drug dose , 
unless otherwise specified ( for exceptions see Section  7.2.7.6, Section  7.3, Section  7.4).   
• The day of first administration  of study drug will be considered Day 1  of study.   
• C1/D3  evaluations may be conducted +1 day.  
• On-study evaluations  (including laboratory assessments) are to be performed  on or about 
the indicated study day ( i.e., ± 2 working days)  (a slightly longer allowance for routine 
assessments is permissible in the event of scheduling difficulties associated with weekends, holidays, etc .).   
• End of Cycle  assessments may be conducted at any time during the week prior to Day 1 
of the next cycle, including on Day 1 of the next cycle , prior to dosing. 
• EOT * evaluation s are to be performed within approximately 10 days  following treatment  
discontinuation, or before initiation of a new treatment, whichever occurs  first.   
• 1M FUP * evaluations  are to be performed  approximately  30 days  (+7 days) following the 
last dose of study drug ( i.e., as all patients are to be followed for a minimum of 30 days 
after study drug discontinuation to  monitor for the occurrence of AEs ). 
Note:  When a patient discontinues treatment with study drug , for any reason, every effort will be made 
to collect routine EOT  evaluations as well as subsequent 1M FUP evaluations, per protocol, until 
all protocol -specified assessments have been conducted .   
If during the study, significant changes from baseline ar e noted, additional monitoring or on-
study assessments may be undertaken by the Investigator, or requested by the Sponsor (or designee), to  determine both the relevance of the finding(s) and the duration of the event(s).  
Refer to Appendix 11 and Appendix 12 for the maximum total blood collection volumes and the schedule of assessments, respectively.  
7.1 Consent and Medical History  
7.1.1 Signing of Informed Consent /Assessment of Eligibility  
• Screening
 
Note:  All patients must sign an IRB /EC-approved informed consent form  (ICF) prior to enrollment and prior 
to submitting to any protocol -related procedure, unless such testing was performed previously as part 
of the routine clinical management of the patient.  Disease evaluations ( e.g., computed tomography 
[CT] scan, magnetic resonance imaging [ MRI] ) performed as part of standard of care and obtained 
prior to patient consent for this trial may be allowed as screening evaluations if conducted within 28 
Symphogen Clinical Trial Protocol 
Trial ID: Sym023- 01 Version 5.0  
 
Confidential   Page 74 of 173 
 
 days (+2) prior to the first study drug dose.  A copy of the fully executed  ICF will be given to the 
patient.    
7.1.2 Demography  
(To include date of birth, sex, race, and ethnicity)  
• Screening  
7.1.3 Past Medical History  
(To include prior and ongoing medical illnesses and conditions, prior surgical procedures 
[not related to the primary diagnosis])  
• Screening  
• C1/D1 (prior to dosing) *  
* Need not be assessed prior to Cycle 1 if ≤ 7 days since screening  
7.1.4 History of the Primary Malignancy  
(To include details of the primary malignancy, including:  diagnosis and histological/  
cytological classification;  date of initial diagnosis; date metastatic disease is identified;  
stage of disease at entry; current sites of metastases; prior surgical procedures for the malignancy  and dates ; prior antineoplastic t herapy ; prior radiation therapy ; dates of 
treatments, numbers of cycles, and best response to each  therapy ; and date of most recent 
disease progression)  
• Screening  
7.2 Safety Assessments (1)  
(To be performed within 14 days  prior to first dose of study drug unless otherwise specified)  
7.2.1 Medication and Procedure Surve ys  
(To include all medications taken other than study drug and all procedures performed during 
trial. For medications: Include name, indication for use, route of administration, start and 
stop dates or if ongoing at 1M FUP Visit. For procedures: Include date and reason for 
procedure. C orresponding illness or condition must appear  on the Medical History  or 
Adverse Event  pages of the CRF , as appropriate ) 
• Prior Medication /Procedure Surveys  
o Screening (to assess eligibility)  
o For 14 days  prior to first study drug dose   
• Concomitant Medication /Procedure  Survey s  
o Throughout the study 
o For 30 days  following last study drug dose  
7.2.2 Adverse Event  Reporting  
• Starting from signing of i nformed c onsent *  
Symphogen Clinical Trial Protocol 
Trial ID: Sym023- 01 Version 5.0  
 
Confidential   Page 75 of 173 
 
 • Throughout the study 
• For 30 days  following last study drug dose   
• Long- Term FUP  for Safety  
o For AEs (non -immune -mediated) ongoing at the 1M FUP  
 For 2 to 4 months following last study drug dose, if events related to study drug 
persist**#   
o For immune -mediated toxicity surveillance following 1M FUP  
 For up to 6 months (at 2- month intervals) following the last study drug dose, to 
assess for delayed onset of immune -related toxicity***# 
o For immune -mediated toxicity ongoing at the 1M FUP, and for delayed onset 
immune -mediated toxicity noted in the initial 6 -month FUP period  
 For up to 2 years (at 2 -month intervals) following the last study drug dose***#   
• As clinically indicated  
*To detail any symptoms that may be present prior to first study drug dose .  Patients who sign informed 
consent and are subsequently deemed to be screen failures will be followed for the occurrence of SAEs/AEs 
until it is determined that they will not be participating in the trial.  
**To confirm that events have resolved, returned to baseline status, or been adequately explained.   
*** Patients will be followed to assess for the onset of any post -therapy immune -mediated even t thought to be 
related to study drug. Any patient who develops an immune -mediated toxicity during study, or during the 6-
month post -therapy FUP period,  will be followed to assess the course of the disease and evaluate potential 
reversibility of the findin g.     
#Investigator discretion may be used with respect to the method of contact  for this AE assessment ; clinical 
events may be followed in writing or by telep hone; an in -person visit will not be required.  
7.2.3 Dose-Limiting T oxicity Assessment  
(To include details about AEs meeting DLT criteria; Section 6.8.3)  
• Starting from first dose of study drug (C1/ D1) 
• Through EOC1 (C1/ D28 ± 2 days)  
7.2.4 Performance Status Evaluation  
(To be assessed by ECOG  score ; Appendix 1)  
• Screening  
• Cycle 1  
o Day 1 (within ≤ 7 working days prior to dosing)*  
• Each cycle thereafter  
o Day 1 (prior to dosing)  
• EOT   
• 1M FUP  
• As clinically indicated  
*Need not be assessed prior to the first dose of Cycle 1 if ≤ 7 days since screening  
Symphogen Clinical Trial Protocol 
Trial ID: Sym023- 01 Version 5.0  
 
Confidential   Page 76 of 173 
 
 7.2.5 Vital Signs   
(Vital signs  [VS]  to include temperature, pulse, respiratory rate, blood pressure  [BP] , and 
oxygen saturation by pulse oximetry ) 
• Screening  
• Cycle 1  
o Day 1  
 Prior to SOI 
 End of infusion ( EOI) (± 10 min)  
 2, 4 hours after EOI ( ± 30 min)  
 8 hours * after EOI ( ± 90 min )  
o Day 2  (24 hours after EOI) (± 6 hours)  
o Day 3 (48 hours after EOI) (-  12 to + 24 hours)  
o Day 15  
 Prior to SOI 
 EOI ( ± 10 min)  
• Each cycle thereafter  
o Day 1 (prior to dosing)  
• EOT  
• 1M FUP  
• As clinically indicated  
*Comprehensive assessment of VS  is critical to the conduct of this study. In situations where an assessment at 8  
hours after EOI is logistically difficult due to clinic staff availability, the observation period may be shortened, 
and an "end of day" assessment may be obtaine d at the latest practical time .  Such an option (if to be routinely 
employed) is available only after discussion with and approval by the Sponsor . 
Note:  C1/D1 through C1/D3 window allowances align wi th PK timepoints windows  
7.2.6 Physical Examination  
(Complete at screening  including height, weight, general appearance, skin, head, eyes, ears, 
nose, throat, neck/thyroid, chest  [includes pulmonary assessment, breasts] , cardiovascular 
[includes heart,  peripher al pulses]  abdomen, musculoskeletal system, lymph nodes, 
neurologic and mental status ; directed thereafter , must include weight** and pulmonary and 
cardiac assessment s*** at each physical exam ) 
• Screening  
• Cycle 1  
o Day 1 (within ≤ 7 working days prior to  dosing)*  
• Each cycle thereafter  
o Day 1 (prior to dosing)  
• EOT   
• 1M FUP  
• As clinically indicated  
Symphogen Clinical Trial Protocol 
Trial ID: Sym023- 01 Version 5.0  
 
Confidential   Page 77 of 173 
 
 * Need not be assessed prior to the first dose of Cycle 1 if ≤ 7 days since screening  
** Dose adjustments may be made in the event of noted weight change ( ± 10% [less at the site’s discretion or if 
required by institution procedures] ).   
*** Pulmonary and cardiac findings will be evaluated in detail at each visit by the Principal Investigator (or 
physician designee); evaluation to include review of pulmonary symptoms including but not limited to: cough, 
sputum production, hemoptysis, wheezing, dyspnea, dyspnea  on exertion, chest pain, and/or chest pain 
associated with respirations , as well as review of cardiac symptoms including but not limited to chest pain, 
orthopnea, nocturia, edema, and palpitations  
7.2.7 Laboratory Assessments and Pregnancy Test  
All routine laboratory analyses will be performed at a laboratory facility local to the trial site.  
Sponsor (or designee)  must be provided with trial site laboratory normal ranges for all 
required parameters prior to screening of the first patient at the site. Likewise, any change in 
laboratory normal ranges during the trial should be forwarded to the Sponsor (or designee)  
promptly during the trial. 
Blood samples will be taken at the scheduled visits and analyzed for the following 
parameters as clinically indicated  (Table 2, Appendix 12) . Results must be available and 
assessed prior to dosing of study drug, w hen sampling is scheduled on days of dosing. 
Table 2:  Schedule of Safety Blood and Urine Sampling  
Sample Analysis  Screening  Cycle 1  Cycles 
Thereafter  EOT  1M 
FUP  
D1 D3 
D8 D15 D22 D1 D15   
Hematology Panel  X X1 X X X X X X X 
Biochemistry Panel  X X1 X X X X X X X 
Coagulation Panel  X X1  X  X  X X 
Thyroid Function Tests  X X1    X  X X 
Urinalysis  X X1  X  X  X X 
Pregnancy Test  X X      X  
Abbreviations (in alphabetical order): D, day; EOT, end of treatment; 1M FUP, 1-month follow -up 
1) Does not need to be performed prior to C1/D1, if performed during screening ≤7 days from C1/D1  
7.2.7.1 Hematology Panel   
(To include complete blood count [CBC] with hemoglobin, hematocrit, differential, ANC,  
and platelet count)  
• Screening  
• Cycle 1  
o Day 1 ( within ≤ 7 working days prior to  dosing)*  
o Day 3 (+1 day)  
o Day 8  
o Day 15 (prior to dosing)  
o Day 22  
• Each cycle thereafter  
Symphogen Clinical Trial Protocol 
Trial ID: Sym023- 01 Version 5.0  
 
Confidential   Page 78 of 173 
 
 o Day 1 (prior to dosing)  
o Day 15 (prior to dosing)  
• EOT   
• 1M FUP  
• As clinically indicated**   
*Need not be performed prior to the first dose of Cycle 1 if ≤ 7 days since screening  
**In the event of hematologic toxicity, the evaluation frequency should be increased to include additional 
evaluations between the scheduled assessments, as clinically indicated.  
7.2.7.2 Bioc hemistry Panel   
(Fasting not required; t o include sodium [ Na], potassium [ K], chloride [ Cl], bicarbonate  
or carbon dioxide , blood urea nitrogen [ BUN ], creatinine, glucose, bilirubin [total and 
direct], AST, ALT, ALP, calcium [ Ca], magnesium [ Mg], phosphorus , albumin, total 
protein, uric acid, amylase, lipase, and creatine kinase [CK] ***)  
• Screening  
• Cycle 1  
o Day 1 (within ≤ 7 working days prior to  dosing)*  
o Day 3 (+ 1 day)  
o Day 8  
o Day 15 (prior to dosing)  
o Day 22  
• Each cycle thereafter  
o Day 1 (prior to dosing)  
o Day 15 (prior to dosing)  
• EOT   
• 1M FUP  
• As clinically indicated **   
*Need not be performed prior to the first dose of Cycle 1 if ≤ 7 days since screening  
**In the event of significant serum chemistry abnormalities, the evaluation frequency should be increased to include additional evaluations between the scheduled assessments, as clinically indicated.   CS 
electrolyte abnormalities should be corrected prior to dosing.  
***In the event of CK abnormalities while on study , please perform isoenzyme analysis  (to include at 
minimum CK -MB); in the event of ECG abnormalities while on study, please perform isoenzyme analysis 
(to include at minimum CK -MB), serial troponins, and measurement of brain natriuretic peptide (BNP)  
7.2.7.3 Coagulation Pa nel 
(To include PTT  [or aPTT] , PT and/or INR)  
• Screening  
• Cycle 1  
o Day 1 (within ≤ 7 working days prior to  dosing)*  
Symphogen Clinical Trial Protocol 
Trial ID: Sym023- 01 Version 5.0  
 
Confidential   Page 79 of 173 
 
 o Day 15 (prior to dosing)  
• Each cycle thereafter  
o Day 1 (prior to dosing)  
• EOT   
• 1M FUP   
• As clinically indicated   
*Need not be performed prior to the first dose of Cycle 1 if ≤ 7 days since screening  
7.2.7.4 Thyroid Function Tests  
(To include measurement of thyroid stimulating hormone [TSH], free triiodothyronine 
[fT3], and free thyroxine  [fT4]) 
• Screening  
• Cycle 1  
o Day 1 (within ≤ 7 working days prior to  dosing)*  
• Each cycle thereafter  
o Day 1 (prior to dosing)  
• EOT  
• 1M FUP  
• As clinically indicated   
*Need not be performed prior to the first dose of Cycle 1 if ≤ 7 days since screening  
7.2.7.5 Urinalys is   
(Multi- panel chemical test strips are acceptable and should include assessment of 
specific gravity, pH, protein, glucose, ketones, leukocytes,  nitrite, bilirubin, urobilinogen, 
and blood. M icroscopic examination of sediment , if clinically indicated,  to include 
assessment of cells [white blood cells {WBC } per high power field {HPF } and red blood 
cells { RBC } per HPF ] and casts ) 
• Screening  
• Cycle 1  
o Day 1 (within ≤ 7 working days prior to  dosing)*  
o Day 15 (prior to dosing)  
• Each cycle thereafter  
o Day 1 (prior to dosing)  
• EOT   
• 1M FUP   
• As clinically indicated   
*Need not be performed prior to the first dose of Cycle 1 if ≤ 7 days since screening  
Symphogen Clinical Trial Protocol 
Trial ID: Sym023- 01 Version 5.0  
 
Confidential   Page 80 of 173 
 
 7.2.7.6 Pregnancy Testing  
(Beta-human chorionic gonadotropin [β -hCG] in WOCBP; serum at screening, serum or 
urine thereafter; negative test must be confirmed within 2 working days  prior to first dose 
of study drug)  
• Screening  
• Cycle 1  
o Day 1 (within ≤ 2 working days prior to  dosing)  
• EOT  
• As clinically indicated  
7.2.8 Electrocardiogram   
(To include standard 12- lead ECG with measurement of PR interval, QRS duration, QT 
interval, and QTc interval [msec], as well as HR [ beats per minute {BPM }]) 
(To be e valuated locally; t o be performed after patient has been supine or semi -recumbent 
for ≥ 10 minutes ) (Repeat subsequent timepoints in triplicate separated by 5 minutes for 4 
cycles in patients with a  Cycle 1  QTc  interval that is either: a)  >500 msec ; b) increased  by 
60 msec  over baseline *; or c) decreased by 20 msec below baseline *) (If abnormal ities 
suggest new evidence of myocardial ischemia, perform isoenzyme analysis [to include at 
minimum CK -MB], serial troponins, and measurement of BNP ) 
• Screening  
• Cycle 1   
o Day 1  
 Prior to SOI  
 EOI (+ 15 min)  
• Cycle 2  
o Day 1  
 Prior to SOI 
 EOI (+ 1 5 min)  
• Subsequent 4 cycles , if QTc interval abnormalities are observed during Cycle 1 or 2   
o Day 1  
 Prior to SOI  (in triplicate)  
 EOI (+ 15 min)  (in triplicate)  
• EOT  
• As clinically indicated ** 
*When evaluati ng QTc interval, baseline should be considered the ECG immediate preceding the start of  study 
drug infusion on the day of assessment.   
**In the event of significant electrolyte abnormalities, the evaluation frequency should be increased to include 
additional evaluations between the scheduled assessments, as c linically indicated.   
Symphogen Clinical Trial Protocol 
Trial ID: Sym023- 01 Version 5.0  
 
Confidential   Page 81 of 173 
 
 7.3 Safety Assessments (2)  
(Results from assessments previously performed  as standard of  care within 28 days  [+2 days] 
prior to first dose of study drug may be utilized , provided no antineoplastic therapy has been 
delivered between assessment and first dose of study drug; otherwise within 14 days of first  
dose) 
7.3.1 Multi-Gated Acquisition  Scan or Echocardiogram  
(For measurement of LVEF; to be performed ONLY in patients with a history of CHF; 
individual patients should be followed with the same testing procedure throughout the study)    
• Screening  
• EOT  
• As clinically indicated  
7.3.2 Ophthalmology Examination  
(To include funduscopic and slit lamp evaluation s for assessment of retinal and corneal 
integrity , visual acuity  as assessed by standardized chart or other appropriate measurement 
tool, and any other noted ocular abnormality ) 
• Screening  
• EOC1 (visual acuity only; by Snellen chart or similar measurement tool)*  
• EOC2  and every even -numbered cycle thereafter *, ** 
• EOT**  
• As clinically indicated  
*End of Cycle assessments may be conducted at any time during the week prior to Day 1 of the next cycle , 
including on Day 1 of the next cycle, prior to dosing.   Due to inherent variability of Snellen chart assessment s 
(21), if changes in visual acuity are noted, a thorough ophthalmologic evaluation should be performed w ithin 
48 hours (if feasible, based on weekend s or holidays) of the initial observation in order to confirm  the finding 
and determine if there is evidence of an immune -mediated AE,  or other event that would preclude further 
treatment with study drug.   No patient with any documented decrease in visual acuity will receive further 
therapy with Sym023 unless the event is considered unrelated to study drug and unless cleared for retreatment 
by an ophthalmologist . 
**May be combined if patient discontinues treatment at the end of an even -numbered cycle 
7.3.3 Pulmonary Function Test s 
(To include spirometry and diffusing capacity  of carbon monoxide  [DL CO] to assess for 
evidence of pulmonary fibrosis . Spirometry assessments to include at minimum: forced vital 
capacity [FVC], forced expiratory volume in 1 second [ FEV1], functional residual capacity 
[FRC], residual volume [RV ], and total lung capacity [TLC] ) 
• Screening  
• EOT  
• As clinically indicated * 
Symphogen Clinical Trial Protocol 
Trial ID: Sym023- 01 Version 5.0  
 
Confidential   Page 82 of 173 
 
 *To be repeated if evidence of interstitial pneumonitis, pulmonary fibrosis or other potential evidence of drug-
related p ulmonary toxicity is documented on imaging studies or if pulmonary symptomatology indicates  
7.4 Disease Assessment s  
(Screening disease assessments to be performed within 28 days  [+2 days ] prior to first dose of 
study drug)   
Standard response criteria will be applied for disease assessments and response evaluations 
(RECIST v1.1, Appendix 5; iRECIST,  Appendix 6; and RECIL  2017, Appendix 7) .  
Assessments should be performed at the intervals specified and in the event of suspected PD.  
If PD  and/or initiation of another therapeutic intervention is documented at any time , no further 
disease assessments will be required. Patients with confirmed PD will be discontinued from further treatment with study drug so that alternative management of their malignancy may be considered.  
Duration of OR to be measured from date initial response is observed to date PD is confirmed . 
 
To be assigned a status of partial response (PR) or complete response (CR), changes in disease 
status must be confirmed by repeat studies performed 4 weeks  (+7 days) after the criteria for 
response are first met. In the case of SD, follow -up measurements must have met the SD criteria 
at least twice after study entry for a minimum duration in general not less than 16 weeks .   
In the event of an ongoing OR or SD at the EOT, data will continue to be collected on the 
duration of OR or SD, as well as on disease progression . 
7.4.1 Tumor Marker Measurement   
(As indicated by  tumor type)  
• Screening  
• EOC 2 and every even -number ed cycle thereafter * 
• At least 4 weeks  following doc umentation of an OR  
• EOT  (if > 6 weeks since previous assessment)  
• 1M FUP (if PD was not confirmed before or at EOT)  
• Long- Term FUP for Response ** (in the event of an ongoing OR  or SD  at EOT)  
o Every 2 months  
7.4.2 Diagnostic Imaging for Assessment of Disease (and Pulmonary Status)   
The same method(s) of disease evaluation and the same technique should be used throughout the study.  
All patients : To include diagnostic imaging by CT or MRI of the chest with each evaluation 
(for disease evaluation where indicated, and to assess for evidence of pulmonary fibrosis) plus abdomen and pelvis, and other sites as indicated based on tumor type and clinical 
judgment to  assess the status of the underlying malignancy. Use of contrast is  preferred but 
is at the discretion of the Investigator, as medically indicated.  
Symphogen Clinical Trial Protocol 
Trial ID: Sym023- 01 Version 5.0  
 
Confidential   Page 83 of 173 
 
 Lymphoma patients : In addition to above, patients will be followed as indicated and per 
Investigator discretion  by: fluorodeoxyglucos e-positron emission tomography ( FDG -PET), 
X-ray, ultrasound (U/S), and/or BM aspiration/biopsy  (Bx) . 
For all imaging timepoints, the following will be recorded as per RECIST v1.1 (or other 
response criteria, as indicated) : target lesions including size, location, and type (nodal/non-
nodal); sum of diameters of target lesions; any new lesions noted during trial, including size, 
location, and type (nodal/non- nodal ). 
• Screening  
• EOC 2 and every even -number ed cycle thereafter * 
• At least 4 weeks  following documentation of an OR  
• EOT  (if > 6 weeks since previous assessment)  
• 1M FUP (if PD was not confirmed before or at EOT)  
• Long- Term FUP for Response ** (in the event of an ongoing OR  or SD  at EOT)  
o Every 2 months  
Imaging data (imaging studies and derived assessments) will be stored acco rding to usual 
practice by the sites and will be available upon request for potential review by the Sponsor or an independent radiology reviewer. 
 
7.4.3 Response Assessment  
(To be assessed by the Investigator  or qualified designee  as per RECIST v1.1 [or other 
response criteria, as indicated]; to be noted at each evaluation point as CR, PR, SD, PD, or Not Evaluable [NE])  
• EOC 2 and every even -numbered cycle thereafter*  
• At least 4 weeks  following documentation of an OR  
• EOT  (if > 6 weeks since previous assessm ent) 
• 1M FUP (if PD was not confirmed before or at EOT)  
• Long- Term FUP for Response ** (in the event of an ongoing OR or SD at EOT ) 
o Every 2 months  
*End of Cycle assessments may be conducted at any time during the week prior to Day 1 of the next cycle , including 
on Day 1 of the next cycle,  prior to dosing.  
** To continue at the intervals specified until disease progression or another therapeutic intervention is initiated, or 
until the end of trial; documentation may be submitted in writing, an in- person visit will not be required . 
7.5 Immunogenicity  Assessment  
To assess formation of ADA. All samples must be taken prior to the study drug infusion of that visit. Analysis of ADA and residual serum levels of study drug will be performed at a central 
laboratory (Specialty Lab) . A detailed laboratory manual specifying sample collection, 
handling, storage, and shipment will be provided to the trial sites ; retention time for specimens 
will be specified therein . If a collected serum sample is inadequate or insufficie nt for ADA 
analysis, the analysis of ADA can be done using a PK serum sample from the same timepoint, if 
available.  
Symphogen Clinical Trial Protocol 
Trial ID: Sym023- 01 Version 5.0  
 
Confidential   Page 84 of 173 
 
 7.5.1 Peripheral Blood for Immunogenicity Assessment (Specialty Lab)  
(To assess the potential immunogenicity of study drug; serum  to be isolated)  
ADA samples will be taken according to the schedule shown ( Table 3;  Appendix 12).  
Note: Whole blood (~ 5 mL) to be collected in serum acquisition tubes at each of the indicated timepoints.   
7.6 Pharmacokinetic Assessment s  
Every effort will be made to collect PK samples at the timepoints specified.  Sampling times may 
be adjusted according to early trial results to  optimize evaluation. No additional samples will be 
collected without form al amendment to this protocol. Analysis will be perf ormed at a central 
laboratory (Specia lty Lab). A detailed laboratory manual specifying sample collection, 
handling, storage, and shipment will be provided to the trial sites ; retention time for specimens 
will be specified therein .  If a collected serum sample is inadequate or insufficient for  PK 
analysis, the analysis of PK can be done using an ADA serum sample from the same timepoint, 
if available.  
7.6.1 Peripheral Blood for Pharmacokinetic Assessment  (Specialty  Lab)  
(To allow for assessment of parameters such as maximum concentration [ Cmax], trough 
concentration [ Tmax], area under the concentration- time curve [ AUC ], etc.; serum  to be 
isolated)  
PK samples will be taken according to the schedule shown ( Table 3;  Appendix 12).  
Note: Whole blood (~ 5 mL) to be collected in serum  acquisition tubes at each of the i ndicated timepoints .  
Table 3:  ADA and PK Sampling Timepoints  
Sample  Sampling 
Time3 Window  Cycle 1  Cycle 2  Cycle 3 
onward  EOT  1M 
FUP  Long -
Term  
FUP  
if OR/ SD at 
EOT  
(or ongoing 
critical AE); 
following PD  As 
Clinically 
Indicated  D1
-
D3 D8 D15 D22 D 1 D15 D 1 D15 
ADA Prior to 
SOI - 4h X  X  X  Odd # 
cycles   X X X2 X 
PK Prior to 
SOI - 4h X  X1  X1 X1 X1 X1     
EOI + 10 min  X  X1  X1 X1 X1 X1     
EOI + 2h  ±30 min  X            
EOI + 4h  ±30 min  X            
EOI + 8h4 ±90 min  X            
EOI + 
24h ±6h X            
EOI + 
48h -12h to          
+ 24h  X            
During 
Visit  NA  X  X     X X X2  
Abbreviations (in alphabetical order): 1M FUP, 1-month follow -up; ADA, anti-drug antibody; AE, adverse event; D, day ; EOI, end of i nfusion ; 
EOT, end of treatment; FUP, follow -up; h, hour; min, minutes; NA, not applicable ; OR, objective response; PD, progressive disease; PK, 
pharmacokinetic; SOI, start of i nfusion  
1) If study drug  administration is delayed to another day , only one PK sample should be taken during the visit  
Symphogen Clinical Trial Protocol 
Trial ID: Sym023- 01 Version 5.0  
 
Confidential   Page 85 of 173 
 
 2) Collection of samples during Long -Term FUP to continue at 2 -month intervals for 6 months  (for patients who are available for blood 
collection)   
3) Actual collection times to be recorded i n the patient’s CRF and/or sampling log 
4) Comprehensive collection of clinical samples is critical to the conduct of  this study. In situations where collection of the EOI + 8h 
sample is logistically difficult due to clinic staff availability, the observation period may be shortened, and an "end of day" samp le 
may be obtained at the latest practical time. Such an option (if to be routinely employed) is available only after discussion with and 
approval by the Sponsor.  
7.7 Pharmacodynamic and Other Biomarker Assessments (Specialty Lab)  
To assess potential pharmacodynamic and other biomarkers; e very effort will be made to collec t 
samples as  specified. Analys es will be perf ormed at a central laboratory  (Specialty Lab) . A 
detailed laboratory manual specifying sample collection, handling, storage, and shipment will be 
provided to the trial sites ; retention time for specimens will be specified therein .   
All analyses will be related to and used only in connection with the data collected in the present 
trial or other Sym 023-related trials, and the identity of the pat ient will remain confidential. The 
analyses will not have any medical consequences for the patient or their relatives .  
7.7.1 Pharmacodynamic Assessments 
(To include peripheral blood collection for evaluation of receptor occupancy)  
• Cycle 1  
o Day 1 (prior to dosing)  
o Day 1 (24 hours after dosing ±  6 hours , i.e., Day 2)  
o Day 15 (prior to dosing)  
• Cycle 2  
o Day 1  (prior to dosing)  
o Day 15 (after dosing + 0 to 7 days)  (at the time of biopsy if performed)  
• EOC 2* (combined with EOT if patient discontinues treatment prior to or at EOC2)  
• End of every 4th cycle thereafter * (i.e., EOC6, EOC10, etc .; may be combined with EOT 
if patient discontinues treatment)  
• EOT  
• 1M FUP  
Note: Whole blood (~ 10 mL) to be collected at each of the indicated timepoints; handling instructions will 
be provided.  
*End of Cycle assessments may be conducted at any time during the week prior to Day 1 of the next cycle, 
including on Day 1 of the next cycle, prior to dosing.  
7.7.2 Biomarker Assessments  
The purpose of biomarker assessments is to develop an approach for the identification and 
validation of genes or proteins that may predict which patients are likely to respond to Sym023, and that may change with the possible development of acquired resistance.  
Analys es may include genes and/or proteins that are unknown or have not been included in the 
scientific hypotheses of this trial, but that, during the collection of data from this trial, may emerge as new candid ate genes and markers related to Sym023 safety, efficacy, or mechanism of 
action.  
Symphogen Clinical Trial Protocol 
Trial ID: Sym023- 01 Version 5.0  
 
Confidential   Page 86 of 173 
 
 All analyses will be related to and used in connection with the data collected in the present trial 
and the ongoing and future development of Sym023 as a single drug and in combination.  The identity of the patient will remain confidential. The analyses will not have any medical consequences for the patient or their relatives.  
Residuals from samples collected will be stored for up to 15 years after completion of the trial, where after all samples will be destroyed.  
7.7.2.1 Blood Samples for Biomarker Assessments  
(To include peripheral blood collection for evaluation of  potential biomarkers , including but 
not limited to ctDNA, RNA, relevant proteins/cytokines , and cell ular biomarkers)  
• Screening (after confirmation of eligibility and study enrollment ; may be collected C1 /D1 
prior to dosing)  
• Cycle 2  
o Day 15 (after dosing + 0 to 7 days) ( at the time of biopsy if performed)  
• EOT   
Note: Whole blood (~ 30 mL) to be collected at each of the indicated timepoints; handling instructions will 
be provided. For those timepoints where both a blood sample and a tumor biopsy are to be obtained,  
the blood sample is to be collected first.   
7.7.2.2 Tumor Sampl e for Biomarker Assessment ( Biopsies Optional)  
(To include tumor tissu e collection for evaluation of potential biomarkers, including but not 
limited to DNA, RNA, protein, and cellular biomarkers ) 
• Screening (after confirmation of eligibility and study enrollment ; may be collected C1 /D1 
prior to dosing)  
• Cycle 2  
o Day 15 (after dosing + 0 to 7 days) ( with paired pharmacodynamic and biomarker 
peripheral blood)  
• EOT  at the time of PD for patients with a previous OR or prolonged SD (> 16 weeks)   
Note: Tumor tissue for formalin -fixed paraffin -embedd ing (FFPE) to be collected at each of the indicated 
timepoints; handling instructions will be provided.  For those timepoints where both a blood sample 
and a tumor biopsy are to be obtained,  the blood sample is to be collected first.  
Tumor biopsies to include core samples of a locally recurrent or metastatic lesion; to be 
performed with minimal morbidity to the patient by a percutaneous core needle biopsy either 
with or without the aid of an imaging modality chosen at the discretion of  the physician 
performing the biopsy.  
 
 
Symphogen Clinical Trial Protocol 
Trial ID: Sym023- 01 Version 5.0  
 
Confidential   Page 87 of 173 
 
 8 MANAGEMENT OF TOXICITY 
Comprehensive assessments of any toxicity experienced by the patient will be performed 
throughout the course of this study.  Anticipated toxicities that may be experienced with study 
drug are detailed in this protocol ( Section 2.4, Section 11), as well as in the IB.     
Grades of toxicity (CTCAE  v5.0*), as well as clinical judgment, will be used to determine 
appropriate management of the patient experiencing any AE  while participating in this study.  
*See <  https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm  > 
8.1 Grading and Recording of Toxicity 
Any clinical AE , whether observed by the Investigator, or observed or experienced by the 
patient, will be reported.  Any CS  change from baselin e in a laboratory assessment will be 
recorded as an AE.  All clinical and laboratory AEs must be carefully evaluated for:  
• Severity (Grades 1 -5; or mild , moderate, severe, life- threatening, fatal) ( Appendix 3)*  
• Duration 
• Relationship to study drug ( not-related , unlikely, possible, probable, related) ( Appendix 
4)   
*In those cases where further definition of an event is provided by the CTCAE  v5.0, please refer to  those 
criteria  for grading and severity information.  
This information will be documente d on the appropriate page of the CRF.  
8.2 Evaluation and Treatment of Toxicity  
The Principal Investigator, Sub- Investigator, or designated health professional must be available 
throughout the course of the study to  evaluate and treat any AE (s), as well as to e valuate whether 
continued participation in the trial is warranted or advisable.  
If, at any point during the study, significant changes occur in either the patient’s clinical status or laboratory assessments , such changes will be followed until the abnormality  either resolves, 
returns to baseline status, or is adequately explained. 
8.3 Determination of DLT versus Non -DLT  
Patients will be evaluated throughout the course of the trial for evidence of acute as well as 
delayed and/or cumulative toxicities.   
If a significant toxicity thought to be related to study drug is experienced at any point during the 
patient’s participation in the study, the Investigator will determine whether that toxicity meets the protocol criteria for DLT ( Section 6.8.3).  
If the protocol definition of DLT is met , the patient will be discontinued from study treatment , 
without exception.   
Alternatively, the Investigator may determine that the toxicity does not meet the protocol 
definition for DLT , but nevertheless warrants dose modification, because it is:  
• Not controlled by optimal supportive care, or  
Symphogen Clinical Trial Protocol 
Trial ID: Sym023- 01 Version 5.0  
 
Confidential   Page 88 of 173 
 
 • Not tolerated due to symptomatology or interference with normal daily activities  
For toxicity that does not me et the protocol definition of DLT, the Investigator may, as described 
below, elect to prolong the infusion duration (for IRRs), or temporarily delay dosing with study 
drug, to allow for amelioration of the toxicity. 
8.4 Premedication  
8.4.1 Infusion -Related Reaction s 
There is an inherent risk for IRRs with the administration of mAbs. An IRR is defined as an AE 
occurring during the study drug infusion and up to 24 hours after the EOI, which is assessed by 
the Investigator to be related to the infusion. Signs  and sympt oms of IRRs may include but are 
not limited to :   
• facial flushing and swelling 
• rash including urticaria  
• headache  
• fever  
• chills, rigors  
• diaphoresis  
• tachycardia  
• hypotension 
• nausea  
• dry mouth  
• chest/back/abdominal pain/discomfort  
• chest and throat tightness  
• shortness of breath 
• cough, wheeze, stridor  
• hypoxia  
• bronchospasm  
• laryngeal edema  
• angioedema  
• shock  
The risk of an IRR is highest for the first administration of a mAb and diminishes with subsequent infusions. If an IRR occurs, it should be classified according to the CTCAE v5.0. Guidelines for the grading and management of IRRs  of all severities are provided ( Appendix 9) .  
8.4.2 Premedication  for IRRs (Prior to the First Dose)  
Since the mechanism of action of the study drug is to stimulate the immune system premedication with agents such as glucocorticoids which are immunosuppressive is to be avoided. As a result, no premedication is required to be administered prior to patients receiving 
the first dose of study drug. In pa tients with a history of IRR s to mAbs  or similar products , it is  
recommended that premedication be administered . In such cases, patients should be 
Symphogen Clinical Trial Protocol 
Trial ID: Sym023- 01 Version 5.0  
 
Confidential   Page 89 of 173 
 
 premedicated with a regimen that includes acetaminophen  as well as an H1 (e.g., 
diphenhydramine/hydroxyzine) an d an H2- antagonist  (e.g., ranitidine/famotidine) .   
8.4.3 Premedication for IRRs (Following an IRR)  
For IRRs while on study, the following premedication instructions are provided:  
• For Grade 1 or Grade 2 reactions , premedication prior to subsequent infusions should be 
considered. Thereafter, if a patient is without recurrence of an IRR, the Investigator may 
choose to withdraw premedication to  determine whether such continued therapy is 
necessary for that patient. Where practical, it is recommended that withdrawal of 
premedication be done in a gradual fashion (e.g., by reduction in dose, frequency, or 
number of agents administered, at the Investigator’s discretion). For those patients who 
experience recurrent signs/ symptoms suggestive of an IRR, premedication should be re-
instituted for at minimum 2 additional doses  before any future attempt to withdraw.  
• For Grade 3 reactions , not applicable as this is considered a DLT ; therefore , no further 
treatment with study drug is allowed .  
• For Grade 4 reactions , not applicable as no further treatment with study drug is allowed. 
If premedication is to be administered, institutional standards may be followed ; however, a 
recommended regimen includes administration of the following approximately 30 minutes prior 
to the start of infusion ( Table 4) .   
Table 4:  Recommended Premedication Regimen  
 Medication  
 Dose and Route  
 Alternative 
Medication  Dose and Route  
 
1 acetaminophen  1000 mg IV (or PO)    
2 diphenhydramine  50 mg, IV hydroxyzine  25 mg, PO 
3 ranitidine  50 mg, IV famotidine  20 mg, IV 
Abbreviations (in alphabetical order): IV, intravenous; mg, milligrams; PO, per os (orally, by mouth)  
Note:  Doses may be adjusted based on s tandard institutional practice.  In the event of a Grade 2 IRR, glucocorticoid therapy 
equivalent to a minimum of 25 mg IV hydrocortisone approximately 0.5 to 2 hours prior to the start of the next infusion 
may be considered . 
 
8.4.4 Premedication for o ther Study Drug -Related Toxicities  
Followin g the first dose, should a patient experience symptoms suggestive of other mild -to-
moderate study drug- related reactions (e.g. , nausea, vomiting, diarrhea , etc. ), the patient may be 
premedicated with standard therapies to  reduce the potential for such reac tions in the future.   
Based on ongoing review of patient safety data, the Sponsor may implement m andatory 
premedication for all patients treated in this study should a  pattern  begin to emerge of  other mild -
to-moderate study drug- related reactions that are amenable to prophylaxis with standard agents. 
Such action will occur following discussions between the Investigator(s) and the Sponsor's 
Medical Representative(s). 
Any medications administered for either prophylaxis or therapy of signs/ symptoms conside red to 
be related to  study drug will be documented on the appropriate page of the CRF.   
Symphogen Clinical Trial Protocol 
Trial ID: Sym023- 01 Version 5.0  
 
Confidential   Page 90 of 173 
 
 8.5 Dose Modification Options  
8.5.1 Prolongation of Infusion Duration  
All IRRs that result in infusion prolongation must be reported promptly to the Sponsor (or 
designee).  
8.5.1.1 Instr uctions for Infusion Prolongation  for IRRs  
For IRRs , the following infusion prolongation instructions are provided:    
• For Grade 1 reactions , the infusion may  be slowed to 50%  of the prior rate such that the 
remaining dose to be delivered is administered in 2 × longer than the amount of time that 
was initially scheduled .     
• For Grade 2 reactions , the infusion should be interrupted for a minimum of 30 minutes , 
and at least until there is either amelioration to ≤  Grade 1 severity  or return to ba seline 
status. Supportive care should be provided. The infusion should then be restarted and slowed to 50% of the prior rate , as described.  Subsequent infusions should be 
administered at the prolonged rate.  
• For Grade 3 reactions , the infusion will be STOPP ED and s upportive care will be 
provided. The occurrence will be considered a DLT and the patient will be discontinued from treatment.  
• For Grade 4 reactions , the infusion will be STOPPED and supportive care will be 
provided.  The occurrence will be consider ed a DLT and the patient will be discontinued 
from treatment.  
In all cases , the Investigator should use best clinical judgme nt in managing such reactions. All 
infusion interruptions and subsequent prolongations, including modified infusion times, as well 
as the toxicity that necessitated them, will be clearly documented on the appropriate page of the 
patient’s CRF.  
Note: Any assessments to be performed or sa mples to be collected (e.g. , vital signs, PK ) at the end of or 
following the EOI will still be performed or collected  beginning at the delayed EOI timepoint. In situations 
where collection of late day samples, particular ly the 8 hours after EOI sample, is logistically difficult due 
to clinic staff availability, an "end of day" sample may be obtained at the latest practical time on the day of 
the reaction.  
Guidelines for the grading and management of IRRs  of all severities are provided ( Appendix 9).  
8.5.1.2 Treatment Following Infusion Prolongation  
To enhance patient safety following an infusion prolongation, subsequent infusions will be 
admi nistered at t he prolonged rate. For Grade 1 and Grade 2 IRRs, r echallenge with a shorter 
duration of infusion (no less than the duration designated by the patient’s dose assignment and 
weight ) may be attempted at the Investigator's discretion, after a minimum of 2 doses  with no 
evidence of infu sion- related toxicity  at the prolonged rate .  
8.5.2 Dose Reduction  
There is no provision for dose reduction in this study. 
Symphogen Clinical Trial Protocol 
Trial ID: Sym023- 01 Version 5.0  
 
Confidential   Page 91 of 173 
 
 8.5.3 Dose Delay  
All delays of study drug must be reported promptly to the Sponsor (or designee) .  
Toxicities may be managed by delay  in dosing provided they do not meet the criteria for study 
discontinuation ( Section  9.1).   
If indicated , the period between any 2 scheduled doses may be extended to allow for 
amelioration of the toxicity.  However, if any observed Grade 3 or Grade 4 toxicity thought to be 
possibly- , probably- , or related to  study drug results in delay of dosing beyond 2 weeks  of the 
next scheduled dose, the event will be considered a DLT.   
For toxicities that are to be managed by dose delay , dosing may be restarted at the same dose;  
however , administration of study drug may only be restarted upon amelioration to ≤  Grade 1, 
return to baseline status, or resolution of the observed toxicity.  
8.5.4 Schedule Alterations  
Altered schedules of study drug (i.e., reduced number of treatment days , longer interval between 
treatment days ) may be explored, only after discussion with the Sponsor (or designee) , and only 
during subsequent cycles of treatment (Cycle 2 and beyond).   
Patients requiring such schedule alterations during Cycle 1  of the study will be considered to 
have met the criteria for DLT due to the inability to complete Cycle 1 of study drug treatment.    
Note: Any modification of study drug administration, and the reason for such action, must be clearly noted in the 
patient’s CRF. If such a modification impacts a PK sampling interval, the details of such action must also  
be documented on the appropriate page of the CRF (to aid in the interpretation of PK findings).  
Symphogen Clinical Trial Protocol 
Trial ID: Sym023- 01 Version 5.0  
 
Confidential   Page 92 of 173 
 
 9 DISCONTINUING PATIENTS FROM STUDY TREATMENT  
Every reasonable effort will be made to keep patient s in the study; however, if  a patient is 
discontinued from stud y treatment , every effort will be made by the Investigator to complete and 
report the reasons for treatment discontinuation as thoroughly as possible. This includes  EOT  
observations, as required by the protocol at the time of treatment discontinuation , or before 
initiation of a new treatment, whichever comes first , as well as 1M FUP  evaluations  to follow  
(Section  7). The reason for treatment discontinuation must be clearly documented on the 
appropriate page of the CRF. A CRF must be completed for any patient who receives any 
amount of study drug.  
9.1 Criteria for Treatment Discontinuation  
Patients will be discontinued from further treatment with study drug in the event of any of the 
following:  
1. Adverse Event s, including:  
• Any AE or SAE that meets the study DLT criteria  at any time during the study    
• Another AE  or SAE considered by the Investigator to require treatment 
discontinuation 
Note: AEs resulting in a patient’s permanent discontinuation from study treatment , regardless of 
seriousness or relationship to study drug, MUST be reported promptly  to the Sponsor (or 
designee) . 
2. Progressive Disease:  Confirmed radiographically  
Note: An exception may be made in the case of suspected PSPD.   Patients will be permitted to continue 
treatment beyond initial RECIST v1.1 (or RECIL  2017) defined PD while wait ing for confirmation of 
PD, provided they are clinically stable (per i RECIST ).  
3. Clinical Progression : Treatment failure not meeting the criteria for PD , but considered by 
the Investigator to require treatment discontinuation  
4. Physician Decision , including:  
• Use of or requirement for a non- permitted concomitant medication  
• Requirement for a significant surgical procedure   
Note: Patients requiring a minor surgical procedure (e.g. , port placement, skin abscess drainage) 
may continue at the Investigator’s discretion following discussion with the Sponsor's Medical 
Monitor (s). A brief interruption in therapy may be considered.  
• Intercurrent illness which  would prevent completi on of study- related evaluations  
• Any other reason in the opinion of the Investiga tor that would justify treatment 
discontinuation  
5. Withdrawal by Patient:  Withdrawal of consent and election to discont inue treatment 
(patients may leave the study at any time for any reason if they wish to do so, without 
consequence)  
Symphogen Clinical Trial Protocol 
Trial ID: Sym023- 01 Version 5.0  
 
Confidential   Page 93 of 173 
 
 6. Protocol Deviation:  Significant deviation/violation  from the protocol or eligibility criteria 
(discontinuation considered only following discussion with the Medical Monitor(s))  
7. Noncompliance with study procedures  
8. Pregnancy  
9. Lost to Follow -up 
10. Death  
11. Study Terminated by the Sponsor  
12. Site Terminat ed by the Sponsor  
9.2 Replacements  
Should a patient discontinue treatment with study drug for reasons other than the occurrence of a 
DLT  prior to completing Cycle 1, a replacement patient will be obtained using the original 
eligibility criteria. Patients discontinued due to DLTs  will not be replaced.  
Note:  Patients must receive their full planned dose s of study drug during Cycle 1  to be considered evaluable for 
tolerability, unless dose delay  or discontinuation is the result of a DLT. Patients receiving < 2 full planned 
study drug dose s plus 2 weeks of follow -up during Cycle 1 for reasons other than toxicity will be replaced.  
Symphogen Clinical Trial Protocol 
Trial ID: Sym023- 01 Version 5.0  
 
Confidential   Page 94 of 173 
 
 10 ADVERSE EVENTS  
10.1 Definitions  of Adverse Events  
10.1.1 Adverse Event  
An AE is any untoward medical occurrence in a patient or a clinical investigation subject 
administered a pharmaceutical product and which does not necessarily have a causal relationship 
with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of an IMP , 
whether or not considered related to the IMP. 
Causality for an AE will be assessed as  related, possibly -related, probably -related, unlikely -
related, or not -related to IMP. Any AE, regardless of causality, that also meets the seriousness 
criteria, will be reported as an SAE.  
10.1.2 Events Not to be Considered as Adverse Events  
A pre-existing condition (i.e. , a disorder  that is  present before the AE recording period starts and 
is noted on the medical history/physical examination form) should not be recorded as an AE unless the condition worsens or episodes increase in frequency during the AE recording period.  
PD will not be capt ured as an AE  as this will be recorded as part of the patient’s efficacy 
evaluation.  PD should be reported as an AE if the nature of the PD is different than expected (i.e., signs/symptoms are not typical of PD).   
Note:  PD may be reported as an AE  in the case of patient death, with death being the outcome of the event.  
An abnormal  laboratory value  or an abnormal physiological test  finding ( e.g., ECG) need not be 
reported as an AE unless one of the following applies:  
• The Investigator considers the abnorma lity CS   
• The event meets the definition of an SAE  
• The event requires an intervention  
• The event results in an action taken with study drug ( e.g., dose -delay  and/or 
discontinuation)  
Diagnostic and therapeutic non- invasive and invasive procedures , such as surgery, should not be 
recorded as AEs. A medical condition for which an unscheduled procedure was performed, 
should however be recorded if it meets the definition of an AE. For example, acute appendicitis should be recorded as the AE and not the  appendectomy. 
Procedures to support the treatment regimens , such as insertion of central venous catheters , etc. , 
should not be recorded as AEs, unless the procedures result in complications. 
10.1.3 Adverse Events of Medical Interest  
Not applicable  
Symphogen Clinical Trial Protocol 
Trial ID: Sym023- 01 Version 5.0  
 
Confidential   Page 95 of 173 
 
 10.1.4 Serious Adverse Events  
An S AE is an AE that meets one or more of the following regulatory outcome criteria:      
• Results in d eath    
In the case of deaths, the event(s) leading to the death should be recorded and reported as 
SAE(s) with the outcome “Fatal”. The death itself will not be reported as an SAE, unless the cause of the death is unknown (e.g., in case of unexplained or s udden death)   
• Is life -threatening     
The term "life -threatening" refers to an event in which the patient is at immediate risk of 
death at the time of the event; it does not refer to an event which hypothetically might cause death if it was more severe  
• Requires i npatient hospitalization or prolongation of existing hospitalization  
• Results in persistent or significant disability/incapacity    
A disability is defined as any substantial disruption of a person’s ability to conduct normal life functions.   
• Is a congenital anomaly/birth defect  
• Is medically important  
Medical and scientific judgment must be exercised in deciding whether an AE is believed 
to be “medically important”. Medically important events may not be immediately life -
threatening or result in dea th or hospitalization but may jeopardize the patient or may 
require intervention to prevent one of the other outcomes listed in this  definition .  
10.1.5 Events T hat Do Not Meet the Definition of Serious Adverse Events  
PD will not be captured as an SAE  unless the nature of the PD is different than expected (i.e., 
signs/symptoms that are not typical of PD).   
Note:  PD may be reported as an SAE  in the case of patient death, with death being the outcome of the event.  
Elective surgery or other scheduled hospitalization periods  that were planned before the patient 
was included in this trial are not to be recorded as SAEs, unless an outcome of the 
surgery/hospitalization was considered serious.  
Hospitalization for observation or convenience  prior to or following study drug  infusions without 
an SAE occurring should not be recorded as an SAE, e.g., if a patient is hospitalized merely for observation, or if a patient begins or finalizes the infusion at a time of day requiring a convenience overnight stay in the hospital.  
Procedures to support the treatment regimen that require hospitalization  should not be recorded 
as SAEs ; however, in cases where a procedure results in complications requiring/prolonging 
hospitalization , this must be recorded and reported as an SAE.  
    
Symphogen Clinical Trial Protocol 
Trial ID: Sym023- 01 Version 5.0  
 
Confidential   Page 96 of 173 
 
 10.2 Adverse Event  Recording and Reporting   
All AE s will be  recorded from signing of informed consent  for participation in the trial.  The 
recording period ends 30 days after receiving the final dose of study drug ( at the time of the 1M 
FUP Visit), unless extended FUP is  indicated , per the clinical trial protocol .   
Note:  Patients who sign informed consent and are subsequently deemed to be screen failures will be followed for 
the occurrence of SAEs/AEs until it is determined that they will not be participating in th e trial. 
10.2.1 Information to be Provided for each AE  
The Investigator must record all directly observed AEs and all AEs spontaneously reported by 
the patient.  Information regarding the occurrence of AEs should be elicited through open- ended 
questioning of the patient, review of physical examination findings, and review of laboratory results  or other safety information, e.g., ECGs .  
All AEs that occur in patients during the AE recording period must be recorded/entered to the 
AE section of the CRF, whether or not the event is assessed as related to study drug.  If the AE is 
serious, the SAE report forms must also be completed and submi tted. The following information 
will be provided for each AE  term reported:  
• Diagnosis  
A diagnosis should be recorded, if possible. If no diagnosis is available, signs and symptoms should be recorded instead. For fatal AEs, death is  an outcome of the AE. The 
cause of death (rather than the term “death”) should be recorded.   
• Severity  
The Investigator will use the CTCAE version 5.0* to describe the severity of an AE.  If 
the severity of an AE is not specifically graded by the CTCAE guidance document, the 
Investigator should use the general definitions of Grades 1 to 5 as per the following, and 
use his/her best medical judgment to describe the severity of the AE (Appendix 3) : 
o Grade 1: Mild  
o Grade 2: Moderate  
o Grade 3: Severe  
o Grade 4: Life- threatening or disabling 
o Grade 5: Death caused by the event  
Changes in severity of AEs will be recorded.  
Generally, an AE of CTCAE Grade 4 or 5 qualifies for SAE reporting to the Sponsor (or designee) . However , a laboratory abnormality of Grade 4 does not  need to be reported as 
an SAE, unless it meets one of the SAE  criteria.  
*See < https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm  > 
• Relationship to IMP/ Causality  
The Investigator will attempt to assess causal relationship of the event to the study drug.  Relatedness must be assessed and recorded within the initial report (CRF and SAE report form).   
Symphogen Clinical Trial Protocol 
Trial ID: Sym023- 01 Version 5.0  
 
Confidential   Page 97 of 173 
 
 The causal relationship is an assessment of whether the event is r elated to the use of the 
IMP.  It is not an evaluation of whether the event could hypothetically occur in the 
investigational patient population. 
The causal relationship of an AE to the IMP will be rated  using a 5 -point  causality scale 
(Appendix 4):  
o Not-related  
o Unlikely -related  
o Possibly- related  
o Probably- related  
o Related    
• Outcome 
The outcome of the AE must be assessed by the Investigator utilizing one of the 
following options:  
o Recovered /resolved   
o Recovered /resolved  with sequelae  
o Recovering /resolving  
o Ongoing  
o Fatal  
o Unknown  
Instructions for reporting changes in an ongoing AE during a patient's participation in the trial 
will be provided. 
10.2.2 Required Follow -up for AEs  
Appropriate consultation and follow -up evaluations should be carried out until the event either 
resolves, returns to baseline status, or has been adequately explained and assessed by the 
Investigator as chronic and/or stable, and that no long- term deleterious effects have become 
evident.   
This follow -up may extend beyond the 1M FUP Visit, to up to 4 months  after the end of 
treatment  if indicated, if the event has not resolved or been adequately explained.   
Any patient who develops an immune -mediated event during study or after the end of treatment 
will be followed for up to 2 years  to assess the course of the condition and evaluate potential 
reversibility of the finding. 
Note:  Patients who sign informed consent and are subsequently deemed to be screen failures will be followed for 
the occurrence of SAEs/AEs until it is determined that they will not be participating in the trial.  
10.3 Serious Adverse Event Recording and Reporting  
10.3.1 Timeframes  for Reporting to the Sponsor  
All SAE s occurring at any time from signing of informed consent  for participation in the trial 
and until  30 days after receiving the final dose of study drug ( at the time of the 1M FUP  Visit) 
must be recorded on the SAE R eport F orm and recorded as an SAE in the CRF. 
Symphogen Clinical Trial Protocol 
Trial ID: Sym023- 01 Version 5.0  
 
Confidential   Page 98 of 173 
 
 Note:  Patients who sign informed consent and are subsequently deemed to be screen failures will be followed for 
the occurrence of SAEs/AEs until it is determined that they will not be participating in the trial.  
In case of an SAE, the Investigator must, within 24 hours  of awareness  of the event , report the 
SAE  to the Sponsor (or designee) by telefax or e -mail transmission . Fax number(s) and e -mail 
address(es) will be stated on the SAE R eport F orm and the SAE R eport F orm Completion 
Instructions . SAE follow -up information must also be reported to the Sponsor (or designee) 
within 24 hours of awareness . SAEs , still ongoing after the 1M FUP Visit, should be followed on 
a regular basis according to the Investigator’s clinical judgment, until the event resolve s or until 
the Investigator assesses it as chronic or stable. The Sponsor (or designee)  will pursue suff icient 
information and will return to the trial sites for such information as deemed required.  
If the Investigator becomes aware of an SAE that occurred after the 1M FUP Visit and finds it to 
be related to the IMP ( possibly- , probably- , or related to the study drug)  or trial conduct, it must 
be recorded and reported to the Sponsor (or designee)  as an SAE.  
The Investigator should be aware of local reporting regulations  to the  IRB/EC. The Sponsor (or 
designee) will either supply the Investigator with the reports, which should be forwarded to the IRB/EC, or report directly to the IRB /EC depending on loca l regulations.    
10.3.2 Safety Reporting to Health Authorities, Institutional Review Boards/Ethics 
Committees, and Investigators   
Reportability of an SAE as a “S uspected U nexpected S erious A dverse R eaction ” (SUSAR) will 
be determined solely by the Sponsor, based on seriousness, causality, and expectedness  criteria .   
In addition to SUSARs, the Sponsor or designee is responsible for reporting all relevant safety 
information regarding SUSARs, or other safety developments, to appropriate Health Authorities  
and centr al IRBs/ECs, as well as participating I nvestigators. Reporting of SUSARs to local 
IRBs/ECs will be handled either by the Sponsor or designee, or the Investigator depending on 
local regulations.  
The timeline for notification of SUSARs is within 7 calendar days  for fatal/life -threatening 
events and within 15 calendar days  for all other SUSARs.    
10.4 Pregnancy  
If any trial patient becomes pregnant during the trial, the patient must be discontinued from study drug immediately and the pregnancy must be reported to the Sponsor or designee according to the same timelines as an SAE.  While pregnancy is not considered an AE, all pregnancies are tracked as SAEs within the safety database to follow -up on exposure to the fetus/infant. 
Pregnancies reported in female partners of male trial patients must also be included in the safety database; therefore, a female partner of a male patient on the trial who becomes pregnant will be 
approached for consent to have the pregnancy followed until term and reported upon to the 
Sponsor (or designee).  
All pregnancies must be followed up every third month and 1- month post -delivery to determine 
outcome and status of mother and chi ld. Pregnancy complications and elective terminations for 
medical reasons must be reported as AEs or SAEs as appropriate. Elective terminations for non-
Symphogen Clinical Trial Protocol 
Trial ID: Sym023- 01 Version 5.0  
 
Confidential   Page 99 of 173 
 
 medical reasons should be reported as follow -up, but not as a separate AE/SAE unless 
complications meet AE/SAE criteria . Spontaneous abortion must be reported as an SAE.  
Any SAE occurring in association with a pregnancy brought to the Investigator’s attention after 
the patient has completed the trial and considered by the Investigator as possibly- , probably- , or 
related to the study drug, must be promptly reported to the Sponsor (or designee).  
All pregnancy information including follow -up information must be reported on a designated 
pregnancy form provided by the Sponsor (or designee).  
 
 
Symphogen Clinical Trial Protocol 
Trial ID: Sym023- 01 Version 5.0  
 
Confidential   Page 100 of 173 
 
 11 PRECAUTIONS WHEN DOSING WITH STUDY DRUG  
11.1 Precautions Regarding Procreation  
Studies have not been performed to determine whether this study drug affects reproductive 
function in males  or can cause fetal harm .  For this reason, men with partners of childbeari ng 
potential must use a highly effective method of contraception while receiving study drug. “A 
highly effective method of contraception” is defined as non -hormonal contraception 
equivalent to a double -barrier method ( includes a single -barrier method in co mbination 
with a spermicide)  or intrauterine device.  
There have been no studies in pregnant females ; therefore , it is not known whether study drug 
can cause fetal harm when administered to a pregnant woman, or whether it  can affect 
reproductive capacity. For this reason, WOCBP should only be administered study drug when highly effective contraceptive measures have been taken and when pregnancy tests  are negative.   
WOCBP includes any female who has experienced menarche and who has not undergone surgical sterilization (hysterectomy, bilateral tubal ligation, or bilateral oophorectomy), or is not postmenopausal. Post -menopause is defined as : 
• Amenorrhea  for ≥  12 months with no other cause  
• Irregular menstrual periods, on HRT, with documented FSH  level > 35 mIU/mL  
Note:  Women who are using oral contraceptives, other hormonal contraceptives (vaginal products, transdermal 
patches, or implanted or injectable products), or mechanical products such as an intrauterine device or 
barrier methods (diaphragm, condoms, spermicides) to prevent pregnancy, or are practicing abstinence, or 
where their partner is sterile (e.g. , vasectomy), should be considered of childbea ring potential.  
 
Women and men of childbearing potential will be informed as to the unknown risk to procreation 
while participating in this trial and will be advised that they must use highly effective 
contraception within 2 weeks  prior to the first dose and continuing until 6 months  after final 
administration of study drug. A pregnancy test will be performed on each premenopausal female 
of childbearing potential  within ≤  2 working days  prior to first study drug administration, and 
again at the end of the final treatment cycle.   
11.2 Additional Precautions  
There are no known contraindications to the administration of study drug, however the following additional precautions are provided:   
• Lactating women and children:  Use in lactating women or in children has not been 
evaluated. These patients will be excluded from study entry.   
• Drug interactions : No formal drug interaction studies have been performed, therefore no 
specific guidance can be provided about use of concomitant medications.   
• Overdose : There is no experience with clinical overdose. If severe reactions occur in 
patients , study drug should be discontinued, and all appropriate supportive medical care 
should be instituted to ameliorate these potential AEs. 
Symphogen Clinical Trial Protocol 
Trial ID: Sym023- 01 Version 5.0  
 
Confidential   Page 101 of 173 
 
 • Nonclinical toxicology studies : No adverse events have been observed at the highest dose 
level of Sym 023 tested, which was weekly administration of 100 mg/kg. The highest 
dose to be administered in this trial is 20 mg/kg administered Q2W.  
• Studies of other mAbs : IRR s have been observed, therefore safety in patients with a 
history of IRRs to mAbs or similar products  should be carefully evaluated prior to 
administration of study drug. It is recommended that p remedication to prevent infusion 
reactions be administered to  all patients  with a history of such reactions , and facilities and 
personnel to treat such reactions, if they occur, should be available. In the event of an 
IRR, the infusion should be slowed /interrupted  so that appropriate measures may be 
taken  (Section 8.5.1, Appendix 9) .  
• Studies of other anti -TIM-3 antibodies : For a listing of AEs observed with an other TIM -3 
antibody, see Section  2.3.1.2. 
• Studies of other antibodies to immune checkpoint s: For a listing of AEs observed with 
anti-PD-1/PDL1 antibodies , see Appendix 8 . For information on grading and 
managem ent of immune -mediated toxicities, see Appendix 10 . 
 
 
 
Symphogen Clinical Trial Protocol 
Trial ID: Sym023- 01 Version 5.0  
 
Confidential   Page 102 of 173 
 
 12 SAFETY SURVEILLANCE DURING STUDY 
12.1 Safety Review  
The Investigator(s) and Sponsor's Medical Repres entatives will comprise a Study Safety Team . 
The team will review clinical and laboratory safety data on an ongoing basis throughout the 
study and make decisions regarding the advisability of continuing accrual to a dose cohort, and/or escalating the dose and allowing accrual to a higher dose cohort. To  do so:   
• The following will be promptly reported to the Sponsor (or designee) : 
o SAEs within 24 hours  of Investigator awareness  
o Any immune -related AE of significance, even if not meeting the SAE or DLT 
definition  
o AEs resulting in permanent discontinuation from study, regardless of seriousness or relationship to study drug  
o DLTs  
o IRRs  
o Dose delays  
• AEs will be recorded i n the CRF in a timely manner following a patient completing (or 
being discontinued from) each dosing cycle. Each event will be assessed as to grade and causality.  
• The Investigator will make critical laboratory safety data available in a timely manner.    
• Patients will be carefully evaluated for evidence of all AEs, including potential cumulative and/or delayed toxicities, throughout the duration of their time on study.  
• Biweekly Safety Team Teleconferences will be held between the Investigat or(s) and the 
Sponsor’s Representative (s) to discuss ongoing patient status and any emerging safety 
concerns; frequency may fluctuate based on accrual and study activity, as indicated.  
Availability of these data also will enable the Sponsor (or designee) to act promptly in response to safety signals and ensure that governing Health A uthorities, as well as Investigators who may 
be participating at other sites or in other clinical trials of the study drug, are informed of events occurring during the trial.  
12.2 Other Safety Surveillance Activities  
At least one Medical  Monitor will be assigned to review and evaluate relevant clinical/safety 
information concerning the clinical trial. The responsibilities of the Medical Monitor include, but are not limited to: 
• Consultation with Investigator(s) regarding evaluation of pati ents to be enrolled to the 
study, treatment delays, restarts, and/or discontinuations   
• Ongoing safety monitoring of all patients being treated in the study  
• Evaluation of coding and trending of AEs in conjunction with the Drug Safety physician 
Symphogen Clinical Trial Protocol 
Trial ID: Sym023- 01 Version 5.0  
 
Confidential   Page 103 of 173 
 
 • Performing s urveillance on potential safety signals in conjunction with the Drug Safety 
physician 
• Evaluating abnormal laboratory values  and other relevant safety data, e.g., ECGs  
• Providing medical support to the Sponsor in answering questions related to the study 
protocol 
• Updating the Safety Team on trial status  
A Drug Safety physician will be assigned to review, assess, and approve all SAE cases and associated reports. This physician will also perform the following:  
• Assess for safety signals and trends in conjunction  with the Medical Monitor  
• Assist with questions regarding medical coding of SAEs  
• Discuss with the Sponsor’s Chief Medical Officer any cases which may present a concern regarding a signal or safety issue. 
Symphogen Clinical Trial Protocol 
Trial ID: Sym023- 01 Version 5.0  
 
Confidential   Page 104 of 173 
 
 13 REGULATORY AND ETHICAL CONSIDERATIONS  
13.1 Conditions of Testing  
In sponsoring this study, it is the intention of the Sponsor  to obtain patient safety data for 
submission to governing Health A uthorities. In agreeing to conduct this investigation, the 
investigative facility agrees to follow all requirements stipu lated in this protocol as well as 
regulations described in the U.S. CFR and /or by governing Health  Authorities concerning:  
• Responsibilities of Investigators ( in the U.S. Title 21  CFR Part 312)  
• Informed Consent of Human Subjects ( in the U.S. Title 21 CFR Part 50)  
• Institutional Review Boards ( in the U.S. Title 21 CFR Part 56)  
In addition, the Investigator agrees to perform the study in accordance with the principles of the 
Declaration of Helsinki, and ICH E6(R2) GCP . 
13.2 Institutional Review  
The Investigator will submit this protocol, any protocol modifications, and the patient ICF to be 
utilized in this study to the appropriate IRB/EC for review and approval. This committee must 
operate in accordance with ICH E6 (R2) GCP , the U.S. Title 21 CFR  Part 56 , and/ or governing 
Health  Authorities, as appropriate .  A letter confirming approval of the protocol and the ICF 
must be forwarded to the Sponsor (or designee)  prior to initiation of this study. The Investigator 
will not start the study, nor will s tudy drug be shipped to the investigational site, before 
providing the Sponsor (or designee)  with evidence of this approval.  
The Investigator is responsible for assuring continuing review and approval of the clinical study.  The Investigator must also promptly report all changes in the research activity and all 
unanticipated problems involving risk to the patients or others to the IRB/EC. The Investigator 
will not make any changes in the protocol without IRB /EC approval, except where necessary to 
eliminate  apparent immediate hazards to the patients. The Investigator will provide progress 
reports to the IRB /EC as required by the IRB /EC. If the study remains in progress for more than 
the IRB/EC -specified approval period, the Investigator must obtain renewal a nd re -approval 
from the IRB /EC where appropriate. Documentation of renewal must be submitted to the 
Sponsor (or designee) . The Investigator will provide notice to the IRB /EC of completion of 
participation in the study.  
13.3 Informed Consent  
The Investigator agrees to protect the rights, safety, and welfare of the patients entered into the 
study, including obtaining written  informed consent prior to performing any study- related 
procedures , and informing each patient that the study drug is  being used for investigational 
purposes.   
Prior to study start, the Sponsor will provide a sample ICF for modification, as appr opriate, by 
each Investigator. The sample ICF must include all elements required by ICH E6 (R2) GCP  and 
must adhere to the IRB/E C requirements and ethical principles that have their origin in the 
Declaration of Helsinki.   
Symphogen Clinical Trial Protocol 
Trial ID: Sym023- 01 Version 5.0  
 
Confidential   Page 105 of 173 
 
 The Investigator's revision to the Sponsor's sample ICF, along with any other written study 
information to be provided to the patient , must be reviewed and approved by the IRB /EC. A 
copy of the IRB /EC-approved ICF to be utilized during the study must be submitted to the 
Sponsor (or designee) prior to study initiation.  
Prior to each patient's entry to the study, the Investigator or his/her staff will explain the na ture 
of the study, its purpose and associated procedures, its expected duration, and the potential risks  
associated with participation.  All questions about the trial will be answered to the satisfaction of 
the patient or the patient’s legal representative.  The patient will be informed of the right to 
withdraw from the study at any time without consequence, and without having to provide a 
reason for this decisio n. Following the discussion, the patient will be asked if they are willing to 
personally sign and date the ICF. Only if the patient voluntarily agrees to sign the ICF  and has 
done so, may he/she enter the study.   
It is the responsibility of the Investigator to obtain written informed consent from each patient, 
thereby attesting that consent was given freely in accordance with ICH E6 (R2) GCP , the U.S. 
Title 21 CFR Part 50, or governing Health  Authorities, as appropriate. An Investigator listed on 
the Form FDA 1572 will then co- sign the ICF. A copy of the signed and dated ICF will be 
provided to the pati ent. The original executed version must remain in the Investigator's file, per 
local requirements, and must be available for verification by a representative of the Sponsor (or 
designee) . 
13.4 Conditions for Modifying or Terminating the Study  
13.4.1 Modification of th e Study Protocol  
The study is to be conducted as described in this protocol. Departures from either the protocol eligibility criteria or the experimental plan, as outlin ed herein, will not be allowed. No protocol 
waivers will be granted.   
If modifications  in the experimental design, dosages, assessments, patient selection, etc., of the 
protocol are indicated or required, such changes will only be instituted following consultation 
between the Sponsor (or designee)  and Investigator and will be accomplished through formal 
amendment(s) to this protocol and approval by the appropriate regulatory authorit y (as indicated) 
and review committees, except where necessary to immediately eliminate apparent hazards to patients.    
A modification to the protocol will not be made without the express written approval of the Sponsor (or designee) . Any amendment prepared by the Sponsor (or designee)  will be 
implemented according to the Sponsor ’s (or designee ’s) standard operating proc edures (SOPs) 
and will be reported to the appropriate regulatory authority, the appropriate IRB /EC, and made a 
formal component of the protocol document.  
Protocol changes to eliminate an apparent hazard to a trial patient may be implemented by the 
Investig ator immediately. The Investigator must then, without delay, inform the local IRB /EC, 
and the Sponsor (or designee) will immediately notify local governing Health Authorities.  
Symphogen Clinical Trial Protocol 
Trial ID: Sym023- 01 Version 5.0  
 
Confidential   Page 106 of 173 
 
 13.4.2 Modification of the Informed Consent Form  
If modifications to the experimental design, dosages, assessments, patient selection, etc. of the 
protocol are indicated or required, and if  such modifications substantially alter the study design 
or increase the potential risk to patients, the Sponsor (or designee)  will prepare a revision to  the 
existing sample ICF  for modification, as appropriate, by each Investigator.  Any revision to the 
sample ICF prepared by the Sponsor (or designee) will be implemented according to the 
Sponsor’s (or designee’s) SOPs .  Such a revision will be reviewed and approved by the 
appropriate regulatory authority (as indicated) and IRB /EC.  
In addition, all current patients , as well as subsequent study candidates, will be informed of the 
study design modification or increase in potential risk, and written informed consent for the modification/risk will be obtained as outlined ( Section  13.3).  
13.4.3 Conditions for Termination of the Study  or a Study Site  
The Sponsor reserves the right to terminate the study, or terminate a clinical trial site's participat ion in the study, at any time. Should the Sponsor , the Sponsor’s designee, and/or the 
Investigator(s) discover conditions that indicate the study or a study site  should be discontinued, 
an appropriate procedure for termination will be instituted. Reasons f or termination may include, 
but are not limited to, the following:  
• Termination of the Study 
o Safety concerns; incidence and/or severity of AEs in the study that indicate a 
potential health hazard or unexpected, serious, or unacceptable risk caused by the 
study treatment  
o Discovery of lack of efficacy  
o Unsatisfactory enrollment across the entirety  of the trial 
o Drug supply or manufacturing issues  
o The Sponsor’s decision to modify or discontinue development of the study drug 
o A request to discontinue the study by a  regulatory authority or H ealth A uthority  
• Termination of a Study Site  
o Investigator non- compliance with the protocol, ICH E6 (R2) GCP, or regulatory 
requirements  
o Unsatisfactory enrollment at the site with respect to quantity or quality  
o Incomplete data collection; inaccurate or knowingly false data submission 
If terminating the study, the Sponsor and Investigator(s) will ensure that adequate consideration is given to the protection of patients' interests. Further, the governing Health Authority and IRB/EC will be notified in writing and the reason for termination will be stated.  
13.5 Trial Registration  
The trial will be registered in one or more public trial registries (e.g., ClinicalTrials.gov) . The 
trial resu lts will be posted in the same clinical trial registries as the initial registration in 
Symphogen Clinical Trial Protocol 
Trial ID: Sym023- 01 Version 5.0  
 
Confidential   Page 107 of 173 
 
 accordance with the latest International Committee of Medical Journal Editors (ICMJE) 
recommendations (URL: www.icmje.org ). 
13.6 Insuran ce and Liability  
The Sponsor will obtain Human Clinical Trials Insurance for its legal liability in accordance with laws and regulations, and with limits customary or required by law in the territory in question. 
Symphogen Clinical Trial Protocol 
Trial ID: Sym023- 01 Version 5.0  
 
Confidential   Page 108 of 173 
 
 14 INVESTIGATOR RESPONSIBILITIES  
14.1 Medical Supervision  
An Investigator conducting a clinical study with an investigational agent is required to comply 
with regulations described in U.S. Title 21 CFR Part s 50, 56, and 312 and/or by governing 
Health Authorities, as well as  ICH E6 (R2) GCP . 
Medical supervis ion for the conduct of this protocol is the responsibility of the Principal 
Investigator. The Principal Investigator must name all Sub -Investigators and may delegate 
certain day -to-day activities to such Sub- Investigators, but retains overall responsibilit y for 
ensuring that the study is conducted properly and in accordance with the design and intent herein. A document outlining the specifics of the delegation will be maintained at the 
investigational site, in the study files, and will be updated as appropr iate.   
The Principal Investigator is responsible for ensuring that drugs and devices are available for 
treating  possible medical emergencies. The Principal Investigator is required to ensure 
compliance with respect to the study drug schedule, visit schedule , and procedures required by 
the protocol. The Principal Investigator is responsible for ensuring that the study is conducted 
according to sound medical practices.  
14.2 Confidentiality  
All goods, materials, information (oral or written) and unpublished documentation provided to the Investigator (or any company acting on their behalf), inclusive of this protocol, the patient 
CRFs,  and the IB , are the exclusive property of the Sponsor. Doc uments and information 
provided to the Investigator by the Sponsor may not be given or disclosed by the Investigator or 
by any person within his /her authority either in part or in totality to any unauthorized person 
without the prior written formal consent  of the Sponsor. 
The submission of this protocol and other necessary documentation to the IRB /EC is expressly 
permitted ; the IRB /EC members hav e the same obligation of confidentiality.  
The Investigator shall consider as confidential , and shall take all necessary measures to ensure 
that there is no breach of confidentiality, all information accumulated, acquired or deduced during the trial, other than that information to be disclosed to a third party mandated by applicable law.  
Note: Any language relating to these issues appearing in the clinical trial agreement will supersede that which is 
outlined in this section.  
14.3 Use of Information  
All unpublished information relating to this trial and the study drug is considered confidential by the Sponsor and shall remain the sole property of the Sponsor. The Investigator must accept that 
the Sponsor may use information from this trial relating to  the development of the study drug, 
and therefore, may disclose it as required to Investigators, government -licensing authorities, 
Health Authorities  of other governments, investors, and commercial partners as indicated.  
Symphogen Clinical Trial Protocol 
Trial ID: Sym023- 01 Version 5.0  
 
Confidential   Page 109 of 173 
 
 14.4 Publication s 
The Sponsor acknowledges the Investigators’ rights to publish the full results of the trial, 
regardless of the outcome, in ac cordance with the latest ICMJE recommendations. Publication of 
a summary of the results of the study is permissible according to the Sponsor and is not 
inconsistent with the preceding affirmation  regarding confidentiality . Scientific dissemination of 
the results of this s tudy is encouraged. Any formal publication of data collected from  the study 
will be considered a joint publication by the Investigator and the appropriate personnel of the Sponsor  or their designees. Authorship will be determined by agreement .   
The Sponsor retains the right to designate one of the authors or someone else involved to be 
named as the Coordinating Investigator . The Coordinating Investigator and the Sponsor will 
decide on the publication strategy. The Coordinating Investigator will have the right to publish 
and present the results and methods as first or last author of multicenter publications. Co-
authorship will be decided by the Sponsor and the Coordinating Investigator and will be limited to persons who have contributed subst antially to the trial. The Sponsor will have representation 
in the list of authors. 
Publication is subject to the following conditions:   
• No publication before the completion of the trial at all participating trial sites without 
preceding written approval from the Sponsor  
• Publications shall not disclose any Sponsor confidential information and property (not including the trial results)  
• The Sponsor reserves the right to review results communications prior to public release 
and can embargo communications rega rding trial results for a period that is less than or 
equal to 60 days. The Sponsor cannot require changes to the communication and cannot 
extend the embargo.  
Note:   Any language relating to these issues appearing in the C linical Trial Agreement will supersede that which 
is outlined in this section.  
14.5 Patient Screening Log  
A record listing all patients entered into the study, as well as those considered for entry into the 
study and subsequently excluded, must be maintained by the Investigator. Patients e xcluded from 
the study will have the reason for exclusion recorded on the Patient Screening Log (or similar 
document).  
14.6 Drug Dispensing Inventory  
Study site personnel will maintain adequate records of the receipt, dispensing, and disposition of all study drug that the Sponsor ships to the site. Records will be maintained either on a form to be provided by the Sponsor or another similar document  authorized for use by the Sponsor, and 
should include appropriate dates, quantities received, quantities dispensed, lot number (or kit 
number), disposition details, and the identification code of the patient who received the study drug. 
Symphogen Clinical Trial Protocol 
Trial ID: Sym023- 01 Version 5.0  
 
Confidential   Page 110 of 173 
 
 The Investigator agrees to administer study drug only to patients under his/her personal 
supervision.  The Investigator will not supply study drug to any person not authorized to receive 
it. 
14.7 Handling and Disposal of Study Drug  
Study drug should be stored in a secure location, under the indicated conditions ( Section  5.2).  
Information regarding the number of vials utilized for each patient, as well as the dose of study drug administered to the patient, will be recorded on the appropriate drug inventory form.  
Periodically throughout and at the conclusion of the study, vials of study drug will be inventoried 
by a representative of the Sponsor (or designee). At the completion of the study, all unused study 
materials MUST be returned to the Sponsor (or designee), unless otherwise authorized in writing.   
Information regarding the storage, handling, inventory, and disposition of study drug will be provided by the Sponsor  (or designee) .   
14.8 Recording of Data  
Clinical trial data for this study will be cap tured in an electronic format. Electronic data capture 
(EDC) services will be provided by a vendor to be determined by the Sponsor. The Investigator agrees to pro vide all information requested in the CRF in an accurate manner accor ding to 
instructions provided. CRFs are d esigned for computer processing and analysis. All data must be 
carefully entered to per mit meaningful interpretation. Corrections to entered data will be 
identified and tracked by audit trails within the EDC system. Data must be entered i nto CRFs in 
a timely fashion.  
A CRF is required to be submitted for every patient who receives any amount of study drug.  
This includes submission of retrievable data on patients who withdraw before completion of the study. Prior to submission, CRFs must be reviewed for  completeness and accuracy, and signed 
and dated where indicated, by either the Principal Investigator or a physician Sub- Investigator 
whose name is listed on the  Form FDA 1572 for this study.  
All collected data will be entered into a validated database.  
14.9 Source Document Requirements  
The Investigator will maintain adequate and accurate records for each patient treated with study drug. Source documents including but not limited to hospital, clinic or office charts, laboratory reports, radiology and pathology reports, pharmacy records, study worksheets, anonymized 
photographs aimed at documenting study- associated clinical findings, and signed ICFs , must 
completely reflect the nature and extent of the patient’s medical care, must be included in the 
Investigator’ s files along with patient study records, and must be available for source document 
verification against entries in the CRF.    
Each trial site will permit authorized representatives of the Sponsor and relevant Health 
Authorities direct access to (and when  required by applicable law, to copy) clinical records for 
the purposes of quality assurance reviews, audits , and evaluation of the trial safety and progress. 
The Sponsor (or designee) will check CRF entries against source documents according to the 
Symphogen Clinical Trial Protocol 
Trial ID: Sym023- 01 Version 5.0  
 
Confidential   Page 111 of 173 
 
 guidel ines of ICH E6 (R2) GCP . Data not requiring a separate written record, i.e. , data which 
may be recorded directly in the CRF, will be determined before trial start.  
The ICF will include a statement by which patients allow the Sponsor (or designee), as well a s 
authorized regulatory agencies, to have direct access to  source data that support data i n the CRF 
(e.g., patient medical files, appointment books, original laboratory records, etc.). The Sponsor (or 
designee), bound by confidentiality and privacy regulat ions, will not disclose patient identities or 
personal medical information. 
14.10 Laboratory Reports  
Prior to initiation of this study, the Investigator must supply the Sponsor (or designee)  with the 
normal laboratory values for the laboratories to be utilized; specifically, the normal laboratory 
values for analytes required to be measured, per protocol, are to be supplied .   
Laboratory safety evaluations must be performed at the intervals specified.  If unexplained laboratory abnormalities occur, corroborative t ests will be performed until the laboratory 
abnormality has  resolved, returned to baseline status , and/or adequate explanation of the 
abnormality has been provided. 
Copies of any additional records pertinent to the study (e.g., laboratory data, radiological reports, 
patient chart summaries, autopsy reports) must be made available to the Sponsor (or designee)  or 
governing Health A uthorities, if requested, with due precaution taken to ensure patient 
confidentiality.  
14.11 Record Retenti on 
Regulatory authorities require that the Investigator retain copies of all files pertaining to the 
study according to local requirements. In addition, the Investigator is responsible for archiving 
all relevant source documents so that trial data may be compared against source data after 
completion of the trial, e.g., in case of inspection from authorities. Study records must be stored 
in a safe and secure location permitting timely retrieval, if necessary. The Investigator must 
obtain written permission f rom the Sponsor prior to disposing of any records. 
If the Investigator relocates, retires, or withdraws for any reason from the study, trial records 
may be transferred to an acceptable designee, such as another Inves tigator within the institution.  
The Sponsor (or designee) , as well as the responsible IRB /EC, must be notified of the identity of 
the individual assuming responsibility for maintaining the study records and the location of their 
storage.   
14.12 Monitoring of the Study  
The Sponsor has responsibility t o governing Health Authorities  to take all reasonable steps to 
ensure the proper conduct of the study with respect to trial ethics, protocol adherence, and data integrity and validity. 
This study will be closely monitored by representatives of the Sponsor (and/or designee) 
throughout its duration. Monitoring will be in the form of periodic personal visits with the 
Investigator and his/her staff as well as any appropriate communications by telephone, telefax, 
mail, or e -mail transmission. The purpose of thes e contacts is to review study progress, 
Investigator and patient adherence to protocol requirements , and any emergent problems 
Symphogen Clinical Trial Protocol 
Trial ID: Sym023- 01 Version 5.0  
 
Confidential   Page 112 of 173 
 
 associated with the conduct of the study. The following usually will be assessed during 
monitoring visits at the site: 
• Required r egulatory documentation 
• Signed ICFs  
• Patient accrual and follow -up 
• Study drug inventory records  
• Investigator and patient compliance to the study protocol  
• Concomitant therapy us age 
• AE documentation  
• Data is accurate, complete, and verifiable when compared to source documents  
The Investigator and study staff are expected to cooperate with monitors during such visits and provide them with all relevant study documents. The Investigator must give the Sponsor ( and/or 
designee)  direct access to all relevant source documents to confirm con sistency with the CRF 
entries. It is important that the Investigator and relevant personnel are available during 
monitoring visits and possible audits and that sufficient time is devoted to the process . 
In addition, the study may be evaluated by Sponsor  auditors (and/or designees) and government 
inspectors who must be allowed access to CRFs, source documents , and other study files. 
Sponsor  reports will be kept confidential. The Investigator shoul d promptly notify the Sponsor of 
any audits scheduled by any regulatory authorities, and promptly forward copies of audit reports. 
As applicable, in accordance with the Health Insurance Portability and Accountability Act (HIPAA) and associated privacy regu lations, patient authorization to use personally identifiable 
health information may be required from each patient before research activities. This 
authorization document must clearly specify what parties will have access to a patient’s personal 
health inf ormation, for what purpose , and for how long. 
14.13 Patient Confidentiality  
Every effort will be made to maintain the anonymity and confidentiality of patients during this clinical study. Each participating site will maintain appropriate medical and research records for 
this trial, in compliance with ICH E6 (R2) GCP , regulatory, and institutional requirements for the 
protection of confidentiality of patients.   
Coded patient identifiers will be utilized always  (including in any publications) when referring to 
a patient. However, because of the experimental nature of this treatment, the Investigator agrees 
to allow representatives of the Sponsor  (and/ or designee ), as well as authorized representatives of 
the governing Health Authority , to inspect the facilities used  in this study and to inspect, for 
purposes of verification, the hospital or clinic records of all patients enrolled into this study. A 
statement to this effect should be included in the ICF. 
Symphogen Clinical Trial Protocol 
Trial ID: Sym023- 01 Version 5.0  
 
Confidential   Page 113 of 173 
 
 14.14   Financing and Insurance  
The study will be supported by the Sponsor . Specifics of the financing and insurance coverage 
will be addressed in the clinical study agreement between the Sponsor  and the Investigator or 
Institution.  
Symphogen Clinical Trial Protocol 
Trial ID: Sym023- 01 Version 5.0  
 
Confidential   Page 114 of 173 
 
 15 HANDLING AND PROCESSING OF DATA  
15.1 Data Handling  
Study data collection, processing, transfer, and reporting, as well as handling of study personnel 
information , will be in compliance with ICH E6(R2) GCP and all applicable data protection 
regulations , including Regulation (EU) 2016/679 of the European Parliament and of the Council 
of 27 April 2016 on the protection of natural persons with regard to the processing of personal 
data and on the free movement of such data (General Data Protection Regulation) . 
15.2 Data Review During this Study  
Data obtained from  the study will be reviewed in a timely  manner throughout by the Sponsor (or 
designee) and Sponsor's Medical Representative(s) to  assess safety and the progress of the 
project.  
15.3 Data Processing 
A Data Management Plan (DMP) will be prepared for this trial. The Sponsor ( or designee ) will 
be responsible for data processing in accordance with applicable D ata M anagement SOPs  and 
the trial DMP .  
Once recorded within the electronic CRF, study data will pass through a set of pre -programmed 
data validation checks designed to identify inconsistencies and other data errors, and also will 
undergo an additional study- specific data review process, as stated above in Section 15.2.  Data 
issues will be queried via the EDC  system and query resolutions will be documented.  
Entry and processing of data other than those directly recorded on electronic CRFs by trial sites (e.g., imports of laboratory results) will follow vendor (s) SOPs. Transfer of such data from 
vendor (s) to Sponsor (or designee) will be handled according to vendor (s) data transfer SOPs and 
the Sponsor data transfer requirements with full compliance to applicable regulations. 
Database Lock will occur upon reaching the pre -defined data cut -off for primary a nalysis  and 
completion of Sponsor’s (or designee’s) quality control and quality assurance procedures . 
Portable Document Format (PDF) files of the electronic CRFs will be provided to the 
Investigator upon removal of access to the electronic CRF s. 
15.4 Clinical T rial Report  
Following study completion, a final integrated clinical/statistical Clinical Trial Report (CTR) will be prepared.  
15.5 Compliance with the General Data Protection Regulation  
The applicable data protection legislation requires that parties enter into a written contract if one party (data processor) processes personal data on behalf of the other party (data controller). This written contract must regulate the subject- matter and duration of the processing, the nature and 
purpose of the processing, the types of personal data and categories of data subjects, as well as the obligations and rights of the data controller. Accordingly, the parties must enter into a data processing agree ment. To the extent the processing of personal data involves transfers of 
personal data to third countries (e.g., jurisdictions outside of the European Economic Area [EEA]), the parties will enter into the European Commission's standard contractual clauses  
Symphogen Clinical Trial Protocol 
Trial ID: Sym023- 01 Version 5.0  
 
Confidential   Page 115 of 173 
 
 between the data controller, the data processor, and all sub -processors, if any. The European 
Commission's standard contractual clauses ensure an adequate level of protection in relation to 
transfers of personal data to third countries. 
 
Symphogen Clinical Trial Protocol 
Trial ID: Sym023- 01 Version 5.0  
 
Confidential   Page 116 of 173 
 
 16 STATISTICAL ANALYSIS   
16.1 Statistical Considerations  
A Statistical Analysis Plan (SAP) that includes a more technical and detailed description 
(including templates for Tables, Listings, and Figures) of the planned statistical summaries 
analyses will be prepared and finalized p rior to database lock.  
Further data- driven and exploratory analyses may be defined and performed and presented in the 
CTR  as appropriate.    
16.2 Sample Size Considerations  
Approximately 20- 48 male and female patients will be enrolled and treated , based on a modified 
accelerated titration Phase 1 design (more specifically, up to 2 single patient cohort s, followed by 
a standard 3+3 design) , to allow determination of the MTD and /or RP2D. It is assumed that 
approximately 7 cohorts may be required during the dose -escalation. However, the protocol 
allows for enrollment of > 7 cohorts, should this be necessary to identify the MTD and/or RP2D . 
Expansion of the MTD/MAD cohort to treat up to 12 patients may be considered for further evaluation of tolerability.   
16.3 Analysi s Populations  
Two analysis sets will be defined in accordance with the consolidated guidelines, ICH E9 
Statistical Principles for Clinical Trials.  
The Full Analysis Set (FAS) will comprise all enrolled patients who have received at least a 
fraction of one  dose of study drug. The FAS will be used for evaluation of all endpoints except 
evaluation of DLTs. The patients in the FAS will contribute to the analyses as allocated to treatment.  For the evaluation of PK endpoints, patients, full profiles, or single m easurements can 
be excluded from the analyses. The decision of excluding patients, full profiles, or part of 
profiles will be described in the CTR . 
The DLT Analysis Set will comprise all patients in the FAS enrolled in the dose -escalation , 
except patients who did not complete Cycle 1 for reasons other than drug toxicity. The DLT Analysis Set will be used for evaluation of DLTs.   
16.4 Trial Endpoint s 
16.4.1 Primary Endpoints  
DLTs to establish MTD as defined in Section 6.9, and/or  the RP2D as defined in Section 6.6.3, 
will be the pr imary study endpoint .  RP2D will be determined by:  
• Incidence, severity, and relationship of treatment emergent AEs measured from 
administration of the first dose of study drug or worsening after taking study drug, to the last dose of study drug plus 30 days  
• AEs leading to dose interruption, dose delays, dose reduction, and permanent treatment 
cessation  
• Changes in safety laboratory values from baseline to end of safety follow up 
 
Symphogen Clinical Trial Protocol 
Trial ID: Sym023- 01 Version 5.0  
 
Confidential   Page 117 of 173 
 
 16.4.2 Secondary Endpoints  
• Additional safety  endpoints , including:  
o Exposure to study medication, including duration, dose reduction and/or delay 
o Changes in vital signs, body weight, and physical examination findings from 
baseline to end of trial participation  
o ECG Findings  
• Occurrence of ADA measured in serum at selected timepoints from baseline to end of trial participation  
• Antineoplastic Activity, measured by tumor response to study treatment and tumor 
shrinkage, time to progression (TTP) based on radiological evident as per RECIST v1.1 
and relevant lymphomas assessment criteria.  
• PK profile of study drug, derived based on the concentration- time curves after the first 
infusion 
16.5 Statistical Analysis  
16.5.1 General Specifications  
Statistical analyses will be carried out using Statistical Analysis System (SAS
®) Version 9.4 or 
higher. 
All data summaries and statistical analyses will be performed based on the FAS population, 
unless otherwise specified. 
In general, continuous variables, including baseline characteristics, will be summarized using 
descriptive statistics by reporting the number of observations, mean, standard deviation, median, 
minimum, and maximum. Categorical/discrete variables will be summarized using frequency 
distributions showing the number and percentage of patients within a cate gory.  Time -to-event 
data will be summarized using the Kaplan -Meier method, as appropriate.  
Unless indicated otherwise, summary statistics will be presented using observed data onl y. 
Missing data will not be imputed. If a baseline value is missing, no change fr om baseline will be 
calculated.  Baseline is defined as the last available observation prior to the first administration of 
study drug on C1/D1. 
16.5.2 Patient Disposition, Baseline and Treatment Characteristics  
Patient disposition, including withdrawals of patients from study drug and reason, will be 
summarized using frequency distributions.  
Patient demographics, baseline and disease characteristics such as age, sex, race, cancer type, 
prior anti -cancer therapies, and ECOG PS, will be presented using descriptive statistics or 
Frequency distributions, as appropriate.  
Symphogen Clinical Trial Protocol 
Trial ID: Sym023- 01 Version 5.0  
 
Confidential   Page 118 of 173 
 
 16.5.3 Study Treatment  
Exposure to study drug and the administration profile will be summarized descriptively for each 
cohort with respect to number of cycles taken, the cumulative dose, the dose intensity, the relative dose intensity, and dose modifications. 
16.5.4 Maximum Tolerated Dose  
All DLT events will be listed by dose cohort and patient. A summary table of DLTs across dose 
cohorts by System Organ Class (SOC) and preferred term will be presented, i f applicable. The 
summaries will include number of DLTs, and number and percentages of patients experiencing a 
DLT.  
A table will be presented showing the MTD, if identified, as well as a summary of the dose -
escalation.  
16.5.5 Adverse Events  
AEs will be coded by S OC and preferred term using the most current version of MedDRA.   AEs 
including SAEs  will be recorded starting at signing of informed consent * through 30 days 
following the last dose of study drug (1M FUP Visit) , and will be tabulated by maximum 
severity according to the CTCAE v5.0.   
*Patients who sign informed consent and are subsequently deemed to be screen failures will be followed for the 
occurrence of SAEs/AEs until it is determined that they will not be participating in the trial  
AEs will b e regarded as TEAEs  if they occur after first treatment. Non -treatment emergent AEs 
(non- TEAEs) are defined as AEs collected before administration of the first dose . If non- TEAEs 
increase in frequency or severity after treatment , these will be considered T EAEs. TEAEs will be 
presented by SOC and preferred term unless stated otherwise. The frequencies of TEAEs will be 
presented including number and percentages of patients having experienced an event and the 
total number of events.  
The calculation of AE incid ence will be based on the number of patients per AE category. For 
each patient who has multiple AEs classified to the same category, that patient will be tabulated 
under the highest  toxicity  grade for that AE category. Summary tables will be presented by:  
1. AEs, in total and sorted by frequency  
2. AEs by relationship 
3. AEs by grade and maximum grade  
4. SAEs, in total, and by relationship 
5. AEs leading to dose interruption, dose delays, dose reduction, and permanent treatment cessation  
6. AEs leading to trial drug delay  
7. Fatal AEs  
During dose -escalation , first-cycle DLTs, AEs leading to death or to discontinuation of study 
treatment, and SAEs will be evaluated with special attention.  
Symphogen Clinical Trial Protocol 
Trial ID: Sym023- 01 Version 5.0  
 
Confidential   Page 119 of 173 
 
 16.5.6 Laboratory Determinations  
Biochemistry, hematology, and coagulation parameters will be presented using box plots , if 
appropriate .  In addition, individual patient biochemistry, hematology, and coagulation 
parameters during the trial will be presented graphically using longitudinal plots. U rinalysis 
parameters will be summarized using descrip tive statistics.    
Laboratory measurements will be graded according to CTCAE  v5.0, when applicable. T he 
frequencies of the highest  CTCAE  v5.0 grade observed will be displayed for each AE and for 
each starting dose level.   
Laboratory values outside normal range will be flagged and laboratory values will be listed 
including grading of abnormal values. Laboratory determinations categorized as in or out of normal range may be summarized in some cases using worst -case shift tables. CS or not 
clinically signific ant (NCS) criteria may be applied for out -of-range values.  
16.5.7 Vital Signs, Body Weight, Physical Exam Findings  
Actual values and change- from -baseline values for VS , body weights, PS, as well as physical 
examination findings, will be summarized descriptively. Normal and abnormal findings in physical examination will be presented in shift tables by visit, if appropriate . 
16.5.8 ECG Findings  
Descriptive statistics of ECG observa tions will be presented. The frequency and percentage of 
ECG results will be summarized for the following ECG measurements:  HR , PR interval, QRS 
duration, QT interval , and QTc interval. The QTc  interval , indicating repolarization time, will be 
calculated . T-wave and ST -segment ECG abnormalities will be graded based on definitions in 
the Common Toxicity Criteria (CTC).   
Normal and abnormal findings will be presented in shift tables by visit. Additional details regarding the ECG analyses will be provided in the SAP. 
16.5.9 Other Safety Data  
Concomitant medications and findings in ophthalmology examinations, PFTs , thyroid function 
tests, and ADA analyses  will be summarized in text as  recorded in the CRF , and as made 
available from an independent central assay laboratory, in the ca se of ADA data.  
16.5.10 Antineoplastic Activity  
All antineoplastic activity analyses will be descriptive and exploratory in nature. Disease status 
will be summarized by cycle and dose group, including changes from baseline. As a secondary 
objective, OR , duration of OR , SD, and TTP  will be assessed and calculated, wherever possible, 
according to standard response criteria.    
Response Calculations  
In the event of an OR (CR or PR) the duration of the OR  will be determined from the day the 
initial response is observed (using screening/baseline images for comparison) to the day that 
progression is observed. Number and percentages of patients with documented OR will be 
presented.  
Symphogen Clinical Trial Protocol 
Trial ID: Sym023- 01 Version 5.0  
 
Confidential   Page 120 of 173 
 
 Duration of SD (minimum duration of not less than 16 weeks) will also be assessed  using the 
time from the first dose of study drug to the day that PD is confirmed  based on radiological 
evidence or censored at the last on -study tumor assessment without PD . The number and 
percentages  of patients with SD for more than 16 weeks will be presented.  
Best overall response will be summarized by cohort using frequency distribution. 
Waterfall plots will be presented  for patients with measurable disease.  
TTP calculated as from the first dose of  study drug to the day that PD is confirmed based on 
radiological evidence or censored at the last on -study tumor assessment without PD will be 
presented in a Kaplan -Meier plot , as appropriate .   
Other Antineoplastic Assessments  
Tumor markers will be listed and summarized, as appropriate . 
16.5.11 Pharmacokinetic Analysi s 
PK analyses will be performed in dose -escalation c ohorts on patients who receive any amount of 
their assigned dose of study drug and have an adequate number of concentration determinations 
to allow for PK calculation . 
The PK profile of study drug will be derived based on the concentration- time cu rves after the 
first infusion. C max, CEOI, Ctrough and T max will be derived from observed data while AUC inf, 
AUC τ, AUC norm, τ , CL, V d, and T ½ will be estimated using non -compartmental methods and 
actual timepoints.   For repeated dosing, C EOI and C trough (equivalent to the concentration at EOI 
and SOI, respectively) will be assessed.  
Individual curves of serum concentration of total study drug versus time after the first infusion will be presented on log-  and linear scale for all patients in the PK population. Furthermore, 
maximum and trough serum concentrations for the period from first dose to EOT will be 
presented on linear scale individual pl ots. In addition, mean concentration- time curves will be 
presented on linear scale using nominal timepoint by cohort and trial part. All PK endpoints will 
be listed and summarized by trial part and cohort  (Table 5) .  
 
  
Symphogen Clinical Trial Protocol 
Trial ID: Sym023- 01 Version 5.0  
 
Confidential   Page 121 of 173 
 
 Table  5:  PK Endpoint, Definitions, and Derivations  
Symbol  Definition and Derivation  
Ctrough Trough concentration (i.e. , concentration of study drug  measured pre -infusion)  
AUC inf Area under the concentration -time curve from start of infusion to infinity  
AUC τ Area under the concentration -time curve from start of infusion up to 336 hours.  
AUC norm,  τ 
 Dose -normalized area under the concentration -time curve in a dosing interval, calculated as AUC  τ divided by the 
dose infused  
Cmax Maximum concentration  
Tmax Time to maximum concentration  
CEOI Concentration at  the end of infusion  
λz Terminal rate constant (negative of the slope of an ln -linear regression of the un -weighted data considering the 
terminal phase of the concentration -time curve ≥ limit of quantification). λ z is not an endpoint, but is used for 
derivation of endpoints  
T½ Terminal elimination half -life, calculated as ln(2)/ λ z 
CL  Clearance after first dose, calculated as Dose/AUC inf for C1/D1, where AUC inf will be calculated as the sum of 
the area from time zero to time of last quantifiable concentration, t z, and the area from t z to infinity. The second 
area will be estimated using the observed concentration at t z and the terminal ra te constant  
Vd Volume of distribution during the terminal phase after first dose (CL S/ λz) 
 
16.6 Additional Endpoints and Analyses  
16.6.1 Pharmacodynamic and other Biomarker Analyses  
Pharmacodynamic and other biomarker assessments , to include collection of peripheral blood, 
will be conducted in all patients . Tumor biopsies are optional and biomarker analysis of biopsied 
tumors may be performed on material collected.    
Exploratory analysis may  be performed.  Endpoints may include genes and/or proteins that are 
unknown or have not been included in the scientific hypotheses at the time of the trial, but that, 
during the collection of data from this trial, may evolve as new candidate genes and markers related to safety, efficacy, or mech anism of action of the study drug.  
Pharmacodynamic and other biomarker  analyses will be performed according to standard 
methodologies and will examine relationships between the pharmacodynamic /biomarker  
assessments and clinical toxicities observed during t he study.  
16.7 Modeling of Pharmacokinetic and P harmacodynamic /Biomarker Data  
PK samples will be analyzed on an on -going basis during the trial. All data collected in this trial 
may be used for modeling of PK , pharmacodynamic  and other biomarker  assessment  to support 
the planning and dose setting within the current trial as well as for future trials. Preliminary data generated during the trial may be used for exploratory modelling. The final data  (i.e., after 
Database Lock) will be used for the final model and potentially for cross -trial modelling. These 
modelling activities will be reported separately from the current trial.  
16.8 Deviations from the Statistical Plan  
Any deviation(s) from the original analysis plan will be descri bed in a protocol amendment 
and/or in the SAP  and/or in the final CTR , as appropriate.  
Symphogen Clinical Trial Protocol 
Trial ID: Sym023- 01 Version 5.0  
 
Confidential   Page 122 of 173 
 
 16.9 Interim Analysis  
Safety evaluation will be performed prior to each dose -escalation. No other interim analyses are 
planned.  
All relevant safety, PK , and toxicity data wil l be reviewed on an ongoing basis throughout the 
trial.  Based on an overall evaluation of data collected, the RP2D will be chosen. 
Symphogen Clinical Trial Protocol 
Trial ID: Sym023- 01 Version 5.0  
 
Confidential   Page 123 of 173 
 
 17 REFERENCES 
1. WHO World Cancer Report 2014. Edited by Bernard W. Stewart and Christopher P. Wild.  
2. Le Mercier I, Lines JL, Noel le RJ. Beyond CTLA -4 and PD -1, the g eneration Z of  
negative c heckpoint r egulators. Front Immunol. 2015; 6: 418. 
 
3. Anderson AC, Joller N, Kuchroo VK. Lag- 3, Tim -3, and TIGIT: Co- inhibitory 
receptors with s pecialized f unctions in i mmune r egulation. Immunity 2016; 44(5): 989- 1004.  
 
4. Du W, Yang M, Turner A, et al. TIM -3 as a t arget for c ancer i mmunotherapy and 
mechanisms of a ction. Int. J. Mol. Sci. 2017; 18(645): 1- 12. 
 
5. Ngiow SF, von Scheidt B, Akiba H, et al. Anti -TIM3 antibody promotes T c ell IFN -γ–
mediated a ntitumor i mmunity and s uppresses e stablished t umors. Cancer Res 2011; 71 (10): 
3540–3551.  
6. Sakuishi K, Apetoh L, Sullivan JM, et al. Targeting Tim -3 and PD -1 pathways to reverse T 
cell exhaustion and restore anti -tumor immunity. J. Exp. Med. 2010; 207(10) : 2187–2194. 
 7. Weiss GJ, Luke JJ, Falchook G, et al. Abstract O13: A phase 1 study of TSR -022, an anti -
TIM-3 monoclonal antibody, in patients (pts) with advanced solid tumors. J Immunother. 
Cancer 2017, 5 (Suppl 2); 86: 7. 
 8. Weiss GJ, Luke JJ, Falchook G , et al. A phase 1 study of TSR -022, an anti -TIM-3 
monoclonal antibody, in patients with advanced solid tumors. Presented a t Society of 
Immunotherapy of Cancer Annual Meeting, November 8- 12, 2017.  
 
9. Opdivo (nivolumab) [package insert]. Princeton, NJ: Bristol -Myers Squibb Company; 2017. 
 10. Keytruda (pembrolizumab) [package inset]. Whitehouse Station, NJ: Merck & Co., Inc; 2017. 
 11. Tecentriq (atezolizumab) [package insert]. South San Francisco, CA: Genent ech, Inc.; 2017.  
 12. Bavencio (avelumab) [package insert]. Rockland, MA; EMD Serono, Inc.; 2017. 
 13. Imfinzi (durvalumab) [package insert]. Wilmington, DE : AstraZeneca Pharmaceuticals LP; 
2017. 
 14. Postow M and Wolchok J. Toxicities associated with checkpoint inhibitor immunotherapy. UpToDate 2017; 13.57: 1- 21. 
 15. Adbel -Wahab N, Sha M, and Suarez -Almazor ME. Adverse events associated with immune 
checkpoint blockade in patient s with cancer: a systematic review of case reports.  PLoS ONE 
2016; 11(7):  e0160221.  
 
Symphogen Clinical Trial Protocol 
Trial ID: Sym023- 01 Version 5.0  
 
Confidential   Page 124 of 173 
 
 16. Heinzerling L and Goldinger SM. A review of serious adverse effects under treatment with 
checkpoint inhibitors. Current Opinion- Oncol. 2017; 29:  1-9. 
 17. Kumar V, Chaudhary N, Garg M, et al. Current diagnosis and management of immune related adverse events (irAEs) induced by immune checkpoint inhibitor therapy. Frontiers in Pharmacol. 2017; 8: 1- 14. 
 18. Seymour L, Bogaerts J, Perrone A, et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol. 2017; 18:  e143-e152. 
 19. Litiè re S, Collette S, de Vries EGE, et al. RECIST -learning from the past to build the future. 
Nature Reviews -Clinical Oncol. 2017; 14:  187- 192. 
 20. Bumbaca D,  Xiang H, Boswell CA, et al. Maximizing tumour exposure to anti -neuropilin- 1 
antibody requires saturation of non- tumour tissue antigenic sinks in mice. Br J Pharmacol. 
2012; 166(1): 368- 377. 
 21. Kaiser PK. Prospective evaluation of visual acuity assessment: a comparison of Snellen versus ETDRS charts in clinical practice (an AOS thesis). Tran s Am Ophthalmol Soc. 2009; 
107:311- 324. 
 
 
Symphogen Clinical Trial Protocol 
Trial ID: Sym023- 01 Version 5.0  
 
Confidential   Page 125 of 173 
 
 18 APPENDICES  
Appendix 1  Performance Status Evaluation  
 
 
Measures of Performance Status  
 
 
Percent   
KARNOFSKY  
Performance Status Description1 
   
Level   
Eastern Cooperative Oncology Group 
(ECOG )  
Performance Status Description2 
 
 
100  
Normal; no complaints, no evidence of  
disease  
  
0 
 
  
Normal activity  
 
90  
Able to carry on normal activity; minor signs or 
symptoms of disease  
 
 
80  
Normal activity with effort; some signs or 
symptoms of disease  
  
1 
 
  
Symptoms but ambulatory  
 
70  
Cares for self; unable to carry on normal activity or 
do active work  
 
 
60  
Requires occasional assistance but is able to care 
for most needs  
  
2 
 
  
In bed < 50% of time  
 
50  
Requires considerable assistance and frequent 
medical care  
 
 
40  
Disabled; requires special care and assistance  
  
3 
 
  
In bed > 50 % of time  
 
30  
Severely disabled; hospitalization is indicated 
although death is not imminent  
 
 
20  
Very sick; hospitalization is necessary  
 
  
4 
 
  
100 % bedridden  
 
10  
Moribund; fatal processes progressing rapidly 
 
 
0  
Death  
 
  
5  
Death  
 
1Karnofsky DA, Abelman WH, Craver LF, Burchenal JH. The use of nitrogen mustards in the palliative treatment of carcinoma.  Cancer . 
1948 ;1:634 -656. 
2Oken M, Creech RH, Tormey DC, Horton J, Davis TE, McFadden E, Carbone PP. Toxicity and response criteria of the eastern coope rative 
oncology group.  Am J Clin Oncol . (CCT) 1982 ; 5:649 -655. 
  
Symphogen Clinical Trial Protocol 
Trial ID: Sym023- 01 Version 5.0  
 
Confidential   Page 126 of 173 
 
 Appendix 2  New York Heart Association Functional Criteria  
 
 
New York Heart Association Functional Criteria  
 
 
Class I   
No limitation of physical activity.  Ordinary physical activity does not cause undue fatigue, 
palpitation, dyspnea, or anginal pain.  
 
 
Class II   
Slight limitation of physical activity.  Comfortable at rest, but ordinary physical activity results in 
fatigue, palpitation, dyspnea, or anginal pain.  
 
 
Class III   
Marked limitation of physical activity.  Comfortable at rest, but less than ordinary physical activity 
results in fatigue, palpitation, dyspnea, or anginal pain.  
 
 
Class IV  
  
Unable to carry on any physical activity without discomfort.  Symptoms of cardiac insufficiency or anginal syndrome may be present even at rest.  If any physical act ivity is undertaken discomfort 
increases.  
 
 
The Criteria Committee of the New York Heart Association. Nomenclature and Criteria for Diagnosis of Diseases of the Heart and Great 
Vessels. 9th ed. Boston, Mass: Little, Brown & Co; 1994:253 -256 
 
Symphogen Clinical Trial Protocol 
Trial ID: Sym023- 01 Version 5.0  
 
Confidential   Page 127 of 173 
 
 Appendix 3  Clinical Adverse Event s: Grading Scale  
 
Severity  CTCAE*  
Grade  Definition  
Mild  1 Awareness of symptom, but easily tolerated.  Event is usually transient requiring 
no special treatment; does not interfere with usual status or activities  
 
Moderate  2 Event may be ameliorated by simple therapeutic measures; may interfere with usual activities  
 
Severe 3 Event results in temporary disability or incapacity; inability to perform usual activities; requires intervention  
 
Life-threatening  4 Event requires immediate intervention; need for emergency treatment; patient is at 
risk of death at the time of the event  
 
Fatal  5 Event resulting in the subsequent death of the patient  
 
 
Note:  In those cases where further definition of an event is provided by the Common Terminology Criteria for Adverse Events 
(CTCAE v 5.0), please refer to that document for grading and severity information.  
*< https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm  > 
Symphogen Clinical Trial Protocol 
Trial ID: Sym023- 01 Version 5.0  
 
Confidential   Page 128 of 173 
 
 Appendix 4  Clinical Adverse Events: Determining Relationship to Study Drug  
 
NOT-RELATED  
This category applies to those AEs which, after careful medical consideration, are clearly felt to be due to extraneous causes 
(disease, environment, etc. ) that are not-related  to the administration of study drug.  
UNLIKELY -RELATED  (must have first 2)  
This category applies to those AEs which, after careful medical consideration, are felt unlikely to be related to the administration 
of the study drug.  The relationship of an AE  to the study drug can be considered unlikely  if: 
• It does not follow a reasona ble temporal sequence from administration of the drug.  
• It could readily have been a result of the patient’s clinical state, environmental or toxic factors, or other modes of 
therapy administered to the patient.  
• It does not follow a known response pattern t o the suspected drug.  
• It does not reappear or worsen when the drug is re -administered.  
 
POSSIBLY -RELATE D (must have first 2)  
This category applies to those AEs which, after careful medical consideration, are felt unlikely to be related to the administration 
of the study drug, but the possibility cannot be ruled out with certainty.  The relationship of an AE  to the study drug can be 
considered possible  if: 
• It follows a reasonable temporal sequence from administration of the drug.  
• It could readily have been a result of the patient’s clinical state, environmental or toxic factors, or other modes of 
therapy administered to the patient.  
• It follows a known response pattern to the suspected drug.  
 
PROBABLY -RELATED  (must have first 3)  
This category applies to those AEs which, after careful medical consideration, are felt with a high degree of certainty to be 
related to the administration of the study drug.  The relationship of an AE  to the study drug can be considered probable  if: 
• It follows a reasonable temporal sequence from administration of the drug.  
• It could not be reasonably explained by the known characteristics of the patient’s clinical state, environmental or toxic 
factors , or other modes of therapy administered to the patient.  
• It disappears or decreases upon cessation of drug or reduction in dose  (if applicable) .* 
• It follows a known response pattern to the suspected drug.  
 
RELATED  (must have first 3)  
This category applies to those AEs, which, after careful medical consideration, are felt to be related to the administration of the 
study drug.  The relationship of an AE  to the study drug can be considered related  if: 
• It follows a reasonable temporal sequence from administration of the d rug or drug levels have been established in body 
fluids or tissues.  
• It could not be reasonably explained by the known characteristics of the patient’s clinical state, environmental or toxic factors , or other modes of therapy administered to the patient.  
• It disappears or decreases upon cessation of drug or reduction on dose (if applicable) and appears upon rechallenge.*  
• It follows a known response pattern to the suspected drug.  
 
Adapted from:  Karch FE and Lasagna L. Adverse drug reactions: a critical review. JAMA . 1975 Dec 22;  234 (12):1236 -1241.  
 
*There are exceptions when an AE  does not disappear upon discontinuation of the drug, yet drug-relatedness clearly exists, e.g. , 
1) tardive dyskinesia, 2) fixed drug eruptions.  
 
 
Symphogen Clinical Trial Protocol 
Trial ID: Sym023- 01 Version 5.0  
 
Confidential   Page 129 of 173 
 
 Appendix 5  Response Evaluation Criteria in Solid Tumors ( RECIST  v1.1)  
 
Summary of RECIST v1.1 Guidelines  
 
For the purposes of this study, patients should be re -evaluated for response every 8 weeks .  In addition to a baseline scan, 
confirmatory scans should also be obtained >  4 weeks  following initial documentation of objective response  (OR).  
 
Response and progression will be evaluated in this study using the new international criteria proposed by t he revised 
Response Evaluation Criteria in Solid Tumors (RECIST) guideline (version 1.1) [ Eur J Ca  45:228 -247, 2009].  Changes in 
the largest diameter (unidimensional measurement) of the tumor lesions and the shortest diameter in the case of malignant lymp h nodes are used in the RECIST v1.1 criteria.  
 
A. DEFINITIONS  
 
Evaluable for Toxicity:   All patients will be evaluable for toxicity from the time of their first treatment with study drug.   
 
Evaluable for Objective Response:  Only those patients who have measurable disease present at baseline, have received at 
least one cycle of therapy, and have had their disease re-evaluated will be considered evaluable for response.  These patients will have their response classified accor ding to the definitions stated below.   
 
Note:        Patients who exhibit objective disease progression prior to the end of cycle 1 will also be considered evaluable.  
 
Evaluable Non -Target Disease Response :  Patients who have lesions present at baseline t hat are evaluable but do not meet 
the definitions of measurable disease, have received at least one cycle of therapy, and have had their disease re-evaluated will be considered evaluable for non-target disease.  The response assessment is based on the pres ence, absence, or 
unequivocal progression of the lesions.  
 
B. DISEASE PARAMETERS  
 
Measurable Disease:  Measurable lesions are defined as those that can be accurately measured in at least one dimension 
(longest diameter to be recorded) as ≥  20 mm by chest x -ray, as ≥ 10 mm with CT scan, or as ≥10 mm with calipers by 
clinical exam.  All tumor measurements mu st be recorded in millimeters  (or decimal fractions of centimeters).  
 
Note:  Tumor lesions that are situated in a previously irradiated area might or might not be considered measurable.   
If the investigator thinks it appropriate to include them, the conditions under which such lesions should be considered must be 
defined in the pr otocol . 
 
Malignant Lymph Nodes :  To be considered pathologically enlarged and measurable, a lymph node must be ≥  15 mm in 
short axis when assessed by CT scan (CT scan slice thickness recommended to be no greater than 5 mm) .  At baseline and at  
follow -up, only the short axis will be measured and followed.  
 
Non-Measurable Disease:  All other lesions (or sites of disea se), including small lesions (longest diameter < 10 mm or 
pathological lymph nodes with ≥ 10 to < 15 mm short axis), are considered non-measurable disease.  Bone lesions, 
leptomeningeal disease, ascites, pleural/pericardial effusions, lymphangitis cutis/pu lmonitis, inflammatory breast disease, 
and abdominal masses (not followed by CT or MRI) are considered as non-measurable.  
 
Note:  Cystic lesions that meet the criteria for radiographically defined simple cysts should not be considered as malignant lesions  
(neither measurable nor non -measurable) since they are, by definition, simple cysts.  
 
Cystic lesions  thought to represent cystic metastases can be considered as measurable lesions, if they meet the definition of 
measurability described above.  However, if non -cystic lesions are present in the same patient, these are preferred for selection as 
target lesi ons. 
 
Target Lesions :  All measurable lesions up to a maximum of 2 lesions per organ and 5 lesions in total, representative of all 
involved organs, should be identified as target lesions  and recorded and measured at baseline.  Target lesions should be 
selected based on their size (lesions with the longest diameter), be representative of all involved organs, but in addition 
should be those that lend themselves to reproducible repeated measurements.  It may be the case that, on occasion, the 
largest lesion do es not lend itself to reproducible measurement in which circumstance the next largest lesion which can be 
Symphogen Clinical Trial Protocol 
Trial ID: Sym023- 01 Version 5.0  
 
Confidential   Page 130 of 173 
 
 measured reproducibly should be selected.  A sum of the diameters (longest for non -nodal lesions, short axis for nodal 
lesions) for all target lesions  will be calculated and reported as the baseline sum diameters.  If lymph nodes are to be 
included in the sum, then only the short axis is added into the sum.  The baseline sum diameters will be used as reference to 
further characterize any objective tumor  regression in the measurable dimension of the disease.  
 
Non-Target Lesions :  All other lesions (or sites of disease) including any measurable lesions over and above the 5 target 
lesions should be identified as non -target lesions and should also be recorde d at baseline.  Measurements of these lesions 
are not required, but the presence, absence, or in rare cases unequivocal progression of each should be noted throughout follow -up. 
 
C. METHODS FOR EVALUATION OF MEASURABLE DISEASE  
 
All measurements should be taken and recorded in metric notation using a ruler or calipers.  All baseline evaluations should be performed as closely as possible to the beginning of treatment and never more than 4 weeks  before the beginning of the 
treatment . 
 
Note:  The same method of assessment and the same technique should be used to characterize each identified and reported lesion at 
baseline and during follow -up.  Imaging -based evaluation is preferred to evaluation by clinical examination unless the lesion(s) 
being followed cannot be imaged but are assessable by clinical exam.  
 
Clinical Lesions :  Clinical lesions will only be considered measurable when they are sup erficial (e.g. , skin nodules and 
palpable lymph nodes) and ≥  10 mm diameter as assessed using calipers (e.g. , skin nodules).  In the case of skin lesions, 
documentation by color photography, including a ruler to estimate the size of the lesion, is recommen ded.  
 
Chest X-ray :  Lesions on chest x -ray are acceptable as measurable lesions when they are clearly defined and surrounded by 
aerated lung.  However, CT is preferable.  
 
Conventional CT and MRI :  This guideline define s measurability of lesions on CT scan based on the assu mption that CT 
slice thickness is 5 mm or less.  If CT scans have slice thickness greater than 5 mm, the minimum size for a measurable 
lesion should be twice the slice thickness.  MRI is also acceptable in certain situations (e.g. , for body scans).   
 
Use of MRI remains a complex issue.  MRI has excellent contrast, spatial, and temporal resolution; however, there are many 
image acquisition variables involved in MRI, which greatly impact image quality, lesion conspicuity, and measurement.  
Furthermore, the availability of MRI is variable globally.  As with CT, if an MRI is performed, the technical specifications 
of the scanning sequences used should be optimized for the evaluation of the type and site of disease.  Furthermore, as with 
CT, the modality used at  follow -up should be the same as was used at baseline and the lesions should be measured/assessed 
on the same pulse sequence.  It is beyond the scope of the RECIST v1.1 guidelines to prescribe specific MRI pulse sequence 
parameters for all scanners, body p arts, and diseases.  Ideally, the same type of scanner should be used and the image 
acquisition protocol should be followed as closely as possible to prior scans.  Body scans should be performed with breath-hold scanning techniques, if possible.  
 
PET-CT :  At present, the low dose or attenuation correction CT portion of a combined PET -CT is not always of optimal 
diagnostic CT quality for use with RECIST v1.1 measurements.  However, if the site can document that the CT performed 
as part of a PET -CT i s of identical diagnostic quality to a diagnostic CT (with IV and oral contrast), then the CT portion of 
the PET -CT can be used for RECIST v1.1 measurements and can be used interchangeably with conventional CT in 
accurately measuring cancer lesions over ti me.  Note, however, that the PET portion of the CT introduces additional data 
which may bias an Investigator if it is not routinely or serially performed.   
Ultrasound :  Ultrasound is not useful in assessment of lesion size and should not be used as a meth od of measurement.  
Ultrasound examinations cannot be reproduced in their entirety for independent review later,  and, because they are operator 
dependent, it cannot be guaranteed that the same technique and measurements will be taken from one assessment to  the next.  
If new lesions are identified by ultrasound during the study, confirmation by CT or MRI is advised.  If there is concern about 
radiation exposure using CT, MRI may be used instead of CT in selected instances.  
 
Endoscopy, Laparoscopy:  The utilization of these techniques for objective tumor evaluation is not advised.  However, 
such techniques may be useful to confirm complete pathological response when biopsies are obtained or to determine relapse in trials where recurrence following complete response (CR) or surgical resection is an endpoint.  
 
Symphogen Clinical Trial Protocol 
Trial ID: Sym023- 01 Version 5.0  
 
Confidential   Page 131 of 173 
 
 Tumor Markers :  Tumor markers alone cannot be used to assess response.  If markers are initially above the upper normal 
limit, they must normalize for a patient to be considered in complete clini cal response.  Specific guidelines for both CA -125 
response (in recurrent ovarian cancer) and prostate specific antigen ( PSA) response (in recurrent prostate cancer) have been 
published [ JNCI 96:487 -488, 2004; J Clin Oncol  17, 3461- 3467, 1999; J Clin Oncol  26:1148 -1159, 2008].  In addition, the 
Gynecologic Cancer Intergroup has developed CA -125 progression criteria which are to be integrated with objective tumor 
assessment for use in first -line trials in ovarian cancer [ JNCI 92:1534 -1535, 2000].  
 
Cytology, Histology:  These techniques can be used to differentiate between partial responses (PR) and complete responses 
(CR) in rare cases (e.g. , residual lesions in tumor types, such as germ cell tumors, where known residual benign tumors can 
remain).  
 
The cytolo gical confirmation of the neoplastic origin of any effusion that appears or worsens during treatment when the 
measurable tumor has met criteria for response or stable disease is mandatory to differentiate between response or stable 
disease (an effusion may  be a side effect of the treatment) and progressive disease.  
 
FDG -PET:  While FDG -PET response assessments need additional study, it is sometimes reasonable to incorporate the use 
of FDG -PET scanning to complement CT scanning in assessment of progression (particularly possible 'new' disease).  New 
lesions based on  FDG -PET ima ging can be identified according to the following algorithm:  
a. Negative FDG -PET at baseline, with a positive FDG -PET at follow -up is a sign of PD based on a new lesion.  
b. No FDG-PET at baseline and a positive FDG -PET at follow -up:   
• If the positive FDG -PET at follow -up corresponds to a new site of disease confirmed by CT, this is PD.   
• If the positive FDG -PET at follow -up is not confirmed as a new site of disease on CT, additional follow -up 
CT scans are needed to determine if there is truly progression occurri ng at that site (if so, the date of PD will 
be the date of the initial abnormal FDG -PET scan).   
• If the positive FDG -PET at follow -up corresponds to a pre -existing site of disease on CT that is not 
progressing based on the anatomic images, this is not PD.  
c. FDG-PET may be used to upgrade a response to a CR in a manner similar to a biopsy in cases where a residual 
radiographic abnormality is thought to represent fibrosis or scarring.  The use of FDG -PET in this circumstance 
should be prospectively described in the protocol and supported by disease -specific medical literature for the 
indication.  However, it must be acknowledged that both approaches may lead to false positive CR due to limitations 
of FDG-PET and biopsy resolution/sensitivity.  
 
Note:  A ‘positive’  FDG- PET scan lesion means one which is FDG avid with an uptake greater than twice that of the surrounding 
tissue on the attenuation corrected image.  
D. RESPONSE CRITERIA  
 
1. Evaluation of Target Lesions  
 
 Complete Response (CR) :  Disappearance of all target lesions.  Any pathological lymph nodes (whether target or non-
target) must have reduction in short axis to <  10 mm.  
 
 Partial Response (PR) :  At least a 30% decrease in the sum of the diameters of target lesions, taking as ref erence the 
baseline sum diameters.  
 
 Progressive Disease (PD) :  At least a 20% increase in the sum of the diameters of target lesions, taking as reference 
the smallest sum on study (this includes the baseline sum if that is the smallest on study).  In addi tion to the relative 
increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.   
 
Note:       The appearance of one or more new lesions is also considered progressions . 
 
 Stable Disease (SD) :  Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as 
reference the smallest sum diameters while on study.  
 
2.  Evaluation of Non -Target Lesions  
 
Complete Response (CR) :  Disappearance of all non -target lesions and normalization of tumor marker level.  All 
lymph nodes must be non -pathological in size (< 10 mm short axis).  
Symphogen Clinical Trial Protocol 
Trial ID: Sym023- 01 Version 5.0  
 
Confidential   Page 132 of 173 
 
  
Note:   If tumor markers are initially above the upper normal limit, they must normalize for a patient to be considered in complete 
clinical response.  
 
Non-CR/Non -PD:  Persistence of one or more non -target lesion(s) and/or maintenance of tumor marker level above 
the normal limits.  
 
Progressive Disease (PD) :  Appearance of one or more new lesions and/or unequivocal progression of existing non-
target lesions.  Unequivocal progression should not normally trump target lesion status.  It must be representative of 
overall disease status change, not a single lesion increase.     
 
Although a clear progression of “non -target” lesions only is exceptional, the opinion of the treating physician should 
prevail in such circumstances, and the progression status should be confirmed later  by the review panel (or Principal 
Investigator).  
 
3.  Evaluation of Best Overall Response  
 
The best overall response is the best response recorded from the start of the treatment until disease 
progression/recurrence (taking as reference for progressive disease the smallest measurements recorded since the 
treatment started).  The patient's best response assignment will depend on the achievement of both measurement and 
confirmation criteria.  
 
For Patients with Measurable Disease (i.e. , Target Disease)  
Target 
Lesions  Non-Target Lesions  New 
Lesions  Overall 
Response  Best Overall Response when 
Confirmation is Required*  
CR CR No CR ≥ 4 wks. Confirmation**  
CR Non-CR/Non -PD No PR  
≥ 4 wks. Confirmation**  CR Not evaluated  No PR 
PR Non-CR/Non -PD/Not evaluated  No PR 
SD Non-CR/Non -PD/Not evaluated  No SD Documented at least once  
≥ 4 wks. from baseline**  
PD Any Yes or No  PD  
no prior SD, PR or CR  Any PD***  Yes or No  PD 
Any Any Yes PD 
*      See RECIST v1.1 manuscript for further details on what is evidence of a new lesion.  
**    Only for non -randomized trials with response as primary endpoint.  
***  In exceptional circumstances, unequivocal progression in non -target lesions may be accepted as disease 
progression.  
 
Note:    Patients with a global deterioration of he alth status requiring discontinuation of treatment without objective 
evidence of disease progression at that time should be reported as “symptomatic deterioration.”   Every effort 
should be made to document the objective progression even after discontinuati on of treatment.  
 
Abbreviations (in alphabetical order):  CR, complete response; PD, progressive disease; PR, partial response; SD, stable dise ase 
 
For Patients with Non -Measurable Disease (i.e. , Non-Target Disease)  
Non-Target Lesions  New Lesions  Overall Response  
CR No CR 
Non-CR/non -PD No Non-CR/Non -PD* 
Not all evaluated  No Not evaluated  
Unequivocal PD  Yes or No  PD 
Any Yes PD 
*   Non -CR/non -PD is preferred over ‘stable disease’ for non -target disease since SD is increasingly used as an 
endpoint for assessment of efficacy in some trials , so to assign this category when no lesions can be measured is not 
advised.  
 
Abbreviations (in alphabetical order):  CR, complete response; PD, progressive disease; PR, partial response; SD, stable disease  
 
  
Symphogen Clinical Trial Protocol 
Trial ID: Sym023- 01 Version 5.0  
 
Confidential   Page 133 of 173 
 
 E. DURATION OF RESPONSE  
 
Duration of Overall Response:  The duration of overall response is measured from the time measurement criteria are met 
for CR or PR (whichever is first recorded) until the first date that recurrent or progressive disease is objectively document ed 
(taking as reference for progressive disease the smallest measurements r ecorded since the treatment started).  
 
The duration of overall CR  is measured from the time measurement criteria are first met for CR until the first date that 
progressive disease is objectively documented.   
 
Duration of Stable Disease :  Stable disease is measured from the start of the treatment until the criteria for progression are 
met, taking as reference the smallest measurements recorded since the treatment started, including the baseline 
measurements.  
 
F. PROGRESSION  FREE SURVIVA L 
 
Progression Free Survival  is defined as the duration of time from start of treatment to time of progression or death, 
whichever occurs first.  
 
Adapted from:  Eisenhauer EA, Therasse P, Bogaerts J, et. al.  New response evaluation criteria in solid tumours: revised 
RECIST guideline (version 1.1). Eur. J. Cancer.  2009; 45:229-247.  
  <http://www.eortc.be/recist/documents/RECISTGuidelines.pdf >  
 
 
Symphogen Clinical Trial Protocol 
Trial ID: Sym023- 01 Version 5.0  
 
Confidential   Page 134 of 173 
 
 Appendix 6  Immunotherapeutics RECIST ( iRECIST )  
 
1. DEFINITIONS  
 
1.1 Evaluable for adverse events .  All patients will be evaluable for adverse event evaluation for the time of their 
first treatment.   
 
1.2 Evaluable for response .  All patients who have received at least one cycle of therapy and have their disease re-
evaluated will be considered evaluable for response (exceptions will be those who exhibit objective disease 
progression prior to the end of cycle 1 who will also be considered evaluable).  Patients on therapy for at least 
this period and who meet the other listed criteria will have their respon se classified according to the definitions 
set out below.  
 Response and progression will be evaluated in this study using the revised international criteria proposed by the 
Response Evaluation Criteria in Solid Tumors  (Version 1.1 ) (RECIST v1.1) committee as well as the modified 
iRECIST guidelines.  Investigators should note the different requirements for confirmatory scans as well as 
follow -up for the two criteria.  
 
See below  for criteria for continuing treatment past RECIST v 1.1 di sease progression.  
 
2 RECIST v1.1 RESPONSE AND EVALUATION ENDPOINTS  
 
2.1 Measurable  Disease .  Measurable tumor lesions (nodal, subcutaneous, lung parenchyma, solid organ 
metastases) are defined as those that can be accurately measured in at least one dimension ( longest diameter to 
be recorded) as ≥ 20 mm with chest x- ray and as ≥ 10 mm with CT scan or clinical examination.  Bone lesions 
are considered measurable only if assessed by CT scan and have an identifiable soft tissue component that 
meets these requiremen ts (soft tissue component ≥ 10 mm by CT scan).  Malignant lymph nodes  must be ≥ 15 
mm in the short axis to be considered measurable; only the short axis will be measured and followed.  All tumor 
measurements must be recorded in millimeters (or decimal fractions of centimeters).  Previously irradiated 
lesions are not conside red measurable unless progression has been documented in the lesion.  
 
2.2 Non-measurable Disease .  All other lesions (or sites of disease), including small lesions are considered non -
measurable disease.  Bone lesions without a measurable soft tissue component,  leptomeningeal disease, ascites, 
pleural/pericardial effusions, lymphangitis cutis/pulmonis, inflammatory breast disease, lymphangitic involvement of lung or skin and abdominal masses followed by clinical examination are all non- measurable.  
Lesions in pr eviously irradiated areas are non -measurable, unless progression has been demonstrated.   
 
2.3 Target Lesions .  When more than one measurable tumor lesion is present at baseline , all lesions up to a 
maximum of 5 lesions total (and a maximum of 2 lesions per or gan) representative of all involved organs should 
be identified as target lesions and will be recorded and measured at baseline.  Target lesions should be selected 
based on their size (lesions with the longest diameter), be representative of all involved o rgans, and should be 
those that lend themselves to reproducible repeated measurements.  Note that pathological nodes must meet the 
criterion of a short axis of ≥ 15 mm by CT scan and only the short axis of these nodes will contribute to the 
baseline sum.  All other pathological nodes (those with short axis ≥ 10 mm but < 15 mm) should be considered 
non-target lesions.  Nodes that have a short axis < 10 mm are considered non -pathological and should not be 
recorded or followed.  At baseline, the sum of the tar get lesions (longest diameter of tumor lesions plus short 
axis of lymph nodes: overall maximum of 5) is to be recorded.   
 
After baseline, a value should be provided on the CRF for all identified target lesions for each assessment, even 
if very small.  If extremely small and faint lesions cannot be accurately measured but are deemed to be present, 
Symphogen Clinical Trial Protocol 
Trial ID: Sym023- 01 Version 5.0  
 
Confidential   Page 135 of 173 
 
 a default value of 5 mm may be used.  If lesions are too small to measure and indeed are believed to be absent, a 
default value of 0 mm may be used.   
 
2.4 Non-target  Lesions .  All non -measurable lesions (or sites of disease) plus any measurable lesions over and 
above those listed as target lesions are considered non- target lesions.  Measurements are not required but these 
lesions should be noted at baseline and should be followed as “present” or “absent”.  
 
2.5 Response .  All patients will have their BEST RESPONSE from the start of study treatment until the end of 
treatment classified as outlined below:  
 
Complete Response  (CR):  disappearance of target and non -target lesions and normalization of tumor markers.  
Pathological lymph nodes must have short axis measures < 10 mm (Note:  continue to record the measurement 
even if < 10 mm and considered CR).  Residual lesions (other than nodes < 10 mm) thought to be non-
malignant should be further investigated by cytology specialized imaging or other techniques as appropriate for 
individual cases before CR can be accepted.  Confirmation of response is only required in non- randomized 
studies.  
 
Partial Response  (PR):  at least a 30% decrease in the sum of measures (longest diameter for tumor lesions and 
short axis measure for nodes) of target lesions, taking as reference the baseline sum of diameter.  Non -target 
lesions must be non- PD.  Confirmation of response is only required in non- randomized studies.   
 
Stable Disease (SD):  Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD , 
taking as reference the smallest sum of diameters on study.   
 
Progre ssive Disease  (PD): at least 20% increase in the sum of diameters of measured lesions taking as reference 
the smallest sum of diameters recorded on study (including baseline) AND an absolute increase of ≥ 5 mm.  Appearance of new lesions will also constitute progressive disease (including lesions in previously unassessed 
areas).  In exceptional circumstances, unequivocal progression of non- target disease may be accepted as 
evidence of disease progression, where the overall tumor burden has increased by at l east 73% in volume.  
Modest increases in the size of one or more non -target lesions are NOT considered unequivocal progression.  If 
the evidence of PD is equivocal (target or non -target), treatment may continue until the next assessment, but if 
confirmed, the earlier date must be used.   
 
  
Symphogen Clinical Trial Protocol 
Trial ID: Sym023- 01 Version 5.0  
 
Confidential   Page 136 of 173 
 
 Integration of Target, Non -Target and New Lesions into Response Assessment  
Target Lesions  Non-Target Lesions  New  
Lesio ns Overall  
Response  Best Response for this Category Also  Requires  
Target lesions +  non- target lesions  
CR CR No CR Normalization of tumor markers, tumor nodes < 10 mm  
CR Non-CR/Non -PD No PR  
CR Not all evaluated  No PR  
PR Non-PD/not all evaluated  No PR  
SD Non-PD/not all evaluated  No SD Documented at least once ≥ 4 weeks from baseline  
Not all evaluated  Non-PD No NE  
PD Any Any PD  
Any PD Any PD  
Any Any Yes PD  
Non-target lesions ONLY  
No Target  CR No CR Normalization of tumor markers, tumor nodes < 10 mm  
No Target  Non-CR/non -PD No Non-CR/non -PD  
No Target  Not all evaluated  No NE  
No Target  Unequivocal PD  Any PD  
No Target  Any Yes*  PD  
Note:  Patients with a global deterioration of health status requiring discontinuation of treatment without objective evidenc e of disease 
progression at that time should be reported as “symptomatic deterioration”.  This is a reason for stopping therapy, bu t is NOT objective PD.  
Every effort should be made to document the objective progression even after discontinuation of treatment.   
*Investigators should record all new lesions; if the new lesion is felt to be equivocal, treatment may be continued pending  further 
assessments.  
Abbreviations (in alphabetical order):  CR, complete response; NE, not evaluable; PD, progressive disease; SD, stable disease  
 
3 iRECIST RESPONSE ASSESSMENT  
Overall response will also be assessed using iRECIST.  Immunotherapeutics may result in infiltration of 
immune cells leading to transient increase in the size in malignant lesions, or undetectable lesions becoming detectable for instance where an increase in tumor burden, or the appearance of new lesions, does not reflect 
true tumor progression.  
 Key differences are described below.  All responses defined using iRECIST criteria are designated with a prefix  
“i”.  iRECIST time -point and best overall response s will be recorded separately.   
 
3.1 Confirming Progression  
Unlike RECIST v 1.1, iRECIST requires the confirmation of progression and uses the terms iUPD (unconfirmed 
progression) and iCPD (confirmed progression).  Confirmatory scans should be performed at lea st 4 weeks , but 
no longer than 8 weeks , after iUPD.  
 
iCPD is confirmed if further increase in tumor burden, compared to the last assessment, is  evidenced by one or 
more of the following:  
• Continued increase in tumor burden (from iUPD) where RECIST v 1.1 definitions of progression had 
been met (from nadir) in target, non- target disease or new lesions.  
o Progression in target disease worsens  with an increase of at least 5 mm in the absolute val ue 
of the sum  
o Continued unequivocal progression in non- target disease with an increase in tumor burden  
Symphogen Clinical Trial Protocol 
Trial ID: Sym023- 01 Version 5.0  
 
Confidential   Page 137 of 173 
 
 o Increase in size of previously identified new lesion(s) (an increase of at least 5 mm in the 
absolute value of the sum of those considered to be target n ew lesions) or additional new 
lesions.  
• RECIST v1.1 criteria are met in lesion types (target or non -target or new lesions) where progression was 
not previously identified, including the appearance of additional new lesion.  
 
If iUPD is not confirmed at the  next assessment, then the appropriate response will be assigned (iUPD if the 
criteria are still met, but no worsening, or iSD, iPR, or iCR if those criteria are met compared to baseline).  As 
can be seen in  the table below , the prior documentation of iUPD  does not preclude assigning iCR, iPR, or iSD 
in subsequent time -point assessments or as best overall response providing that iCPD is not documented at the 
next assessment after iUPD.  
 
3.2 New Lesions  
New lesions should be assessed and measured as they appear using RECIST v 1.1 criteria (maximum of 5 
lesions, no more than 2 per site, at least 10 mm in long axis [or 15 mm in short axis for nodal lesions]), and 
recorded as New Lesion -Target (NLT) and New Lesion -Non-Target (NLNT) to allow clear differentiation from  
baseline target and non -target lesions.   
 New lesions may either meet the criteria of NLT or NLNT to drive iUPD (or iCPD).  However, the 
measurements of target lesions should NOT be included in the sum of measures of original lesions identified at 
baseli ne.  Rather, these measurements will be collected on a separate table in the CRF .    
 
PD is confirmed in the New Lesion category if the next imaging assessment, conducted at least 4 weeks (but not 
more than 8 weeks) after iUPD confirms further progression from iUPD with either an increase of at least 5 mm 
in the absolute value of the sum of NLT or an increase (but not necessarily unequivocal increase) in the size of 
NLNT lesions or  the appearance of additional new lesions.  
 
  
Symphogen Clinical Trial Protocol 
Trial ID: Sym023- 01 Version 5.0  
 
Confidential   Page 138 of 173 
 
 iRECIST Timepoint Response  
Target 
Lesions*  Non-Target 
Lesions*  New 
Lesions*  Time point Response  
No 
Prior 
iUPD**  Prior iUPD**, ***  
iCR iCR No iCR iCR 
iCR Non-iCR/Non -
iUPD No iPR iPR 
iPR Non-iCR/Non -
iUPD  No iPR iPR 
iSD Non-iCR/Non -
iUPD No iSD iSD 
iUPD with no 
change or 
decrease from 
last TP  iUPD with no 
change or 
decrease from last TP  Yes NA NLs confirms iCPD if NLs were previously identified and increase in 
size (≥ 5 mm in SOM for NLT or any increase for NLNT) or number.  
If no change in NLs (size  or number) from last TP, remains iUPD  
iSD iUPD  No iUPD  Remains iUPD unless iCPD confirmed based on further increase in size 
of NT  lesion  (need not meet RECIST v 1.1 criteria for unequivocal PD)  
iUPD  Non-iCR/Non -
iUPD No iUPD  Remains iUPD unless iCPD confirmed based on:  
• Further increase in SOM of at least 5 mm, otherwise remains iUPD  
iUPD  iUPD  No iUPD  Remains iUPD unless iCPD confirmed based on further increase in:  
• Previously identified T lesion iUPD SOM ≥ 5 mm and/or  
• NT lesion iUPD (prior assessment –  need not be unequivocal PD)  
iUPD  iUPD  Yes iUPD  Remains iUPD unless iCPD confirmed based on further increase in:  
• Previously identified T lesion iUPD ≥ 5 mm and/or  
• Previously identified NT lesion iUPD (need not be unequivocal) 
and/or  
• Size or number of NLs previously identified  
Non-iUPD/PD  Non-iUPD/PD  Yes iUPD  Remains iUPD unless iCPD confirmed based on  
• Increase in size or number of NLs previously identified  
*Using RECIST v 1.1 principles.  If no PSPD occurs, RECIST v 1.1 and iRECIST categories for CR, PR, and SD would be the same  
**in any lesion category 
***previously identified in assessment immediately prior to this TP  
Abbreviations (in alphabetical order):  CPD, confirmed progressive disease; CR, complete response; NE, not evaluable; NL, new  lesion;  
NLNT, new lesion -non-target; NLT, new lesion -target;  NT, non -target; PD, progressive disease; PR, partial response; PSPD, 
pseudoprogression; SD, stable disease; SOM, sum of measure ment s; T, target; TP, timepoint; UPD, unconfirmed progressive disease  
 
Symphogen Clinical Trial Protocol 
Trial ID: Sym023- 01 Version 5.0  
 
Confidential   Page 139 of 173 
 
 All patients will have their iRECIST best overall response (i BOR)  from the start of study treatment until the end 
of treatment classified as outline d below.  
 
iRECIST Best Overall Response  
TPR1  TPR2  TPR3  TPR4  TPR5  iBOR  
iCR iCR, iPR, iUPD, NE  iCR, iPR, iUPD, NE  iUPD  iCPD  iCR 
iUPD  iPR, iSD, NE  iCR iCR, iPR, iSD, iUPD, NE  iCR, iPR, iSD, iUPD, iCPD, NE  iCR 
iUPD  iPR iPR, iSD, iUPD, NE  iPR, iSD, iUPD, NE, iCPD  iPR, iSD, iUPD, iCPD, NE  iPR 
iUPD  iSD, NE  PR iPR, iSD, iUPD, NE  iPR, iSD, iUPD, iCPD, NE  iPR 
iUPD  iSD iSD, iUPD, NE  iSD, iUPD, iCPD, NE  iSD, iUPD, iCPD, NE  iSD 
iUPD  iCPD  Anything  Anything  Anything  iCPD  
iUPD  iUPD  iCPD  Anything  Anything  iCPD  
iUPD  NE NE NE NE iUPD  
• Table assumes a randomized study where confirmation of CR or PR is not required  
• NE=not evaluable that cycle 
• Designation “i” for BOR can be used to indicate prior iUPD to aid in data interpretation  
• For patients with non -target disease only at baseline, only CR or non -CR/non -PD can be assigned at each TPR but is not shown in 
the table for ease of presentation.  
Abbreviations (in alphabetical order):  BOR, best overall response; CPD, confirmed progressive disease; CR, complete response ; NE, not 
evaluable; NL, new lesion; PD, progressive disease; PR, partial response; PSPD, pseu doprogression; SD, stable disease; SOM, sum of 
measurement s; TP, timepoint; TPR, timepoint response; UPD, unconfirmed progressive disease  
 
 
4 RESPONSE AND STABLE DISEASE DURATION (RECIST v 1.1 AND iRECIST)  
Response duration will be measured from the time measurement criteria for CR/PR or iCR/iPR (whichever is 
first recorded) are first met until the first date that recurrent or progressive disease is objectively documented, 
taking as reference the smallest measurements recorded on study (including baseline) . 
 
Stable disease duration will be measured from the time of start of treatment until the criteria for progression are 
met, taking as reference the smallest sum on study (including baseline).  
 
5 METHODS OF MEASUREMENT  
The same method of assessment and the same technique should be used to characterize each identified and 
reported lesion at baseline and during follow -up.  Assessments should be identified on a calendar schedule and 
should not be affected by delays in therapy.  While on study, all lesions recorde d at baseline should have their 
actual measurements recorded at each subsequent evaluation, even when very small (e.g. , 2 mm).  If it is the 
opinion of the radiologist that the lesion has likely disappeared, the measurement should be recorded as 0 mm.  
If the lesion is believed to be present and is faintly seen but too small to measure, a default value of 5 mm 
should be assigned.  For lesions which fragment/split , add together the longest diameters of the fragmented 
portions; for lesions which coalesce, measure the maximal longest diameter for the “merged lesion”.  
 
5.1 Clinical Lesions .  Clinical lesions will only be considered measurable when they are superficial and ≥ 10 mm as 
assessed using calipers (e.g. , skin nodules).  For the case of skin lesions, documentation by color photography 
including a ruler to estimate the size of the lesion is recommended.  If feasible, imaging is preferred.   
 
5.2 Chest X -Ray.  Chest CT is preferred over chest X -ray, particularly when progression is an important endpoint, 
since CT i s more sensitive than X -ray, particularly in identifying new lesions.  However, lesions ≥ 20 mm on 
chest X -ray may be considered measurable if they are clearly defined and surrounded by aerated lung.  
 
5.3 CT, MRI .  CT is the best currently available and reprod ucible method to measure lesions selected for response 
assessment.  This guideline has defined measurability of lesions on CT scan based on the assumption that CT 
Symphogen Clinical Trial Protocol 
Trial ID: Sym023- 01 Version 5.0  
 
Confidential   Page 140 of 173 
 
 slice thickness is 5 mm or less.  If CT scans have slice thickness greater than 5 mm, the min imum size for a 
measurable lesion should be twice the slice thickness.  MRI is also acceptable in certain situations (e.g. , for 
body scans).  Other specialized imaging or other techniques may also be appropriate for individual cases.  For 
example, while PE T scans are not considered adequate to measure lesions, PET -CT scans may be used 
providing that the measures are obtained from the CT scan and the CT scan is of identical diagnostic quality to a diagnostic CT (with IV and oral contrast).    
 
5.4 Ultrasound.   Ultrasound is not useful in assessment of lesion size and should not be used as a method of 
measurement.  If new lesions are identified by ultrasound during the study, confirmation by CT is advised.  
 
5.5 Endoscopy, Laparoscopy .  The utilization of these techniques for objective tumor evaluation is not advised.  
However, they can be useful to confirm complete pathological response when biopsies are obtained or to 
determine relapse in trials where recurrence following complete response or surgical resection is an  endpoint.   
 
5.6 Tumor Markers .  Tumor markers alone  cannot be used to assess objective tumor response.  If markers are 
initially above the upper normal limit, however, they must normalize for a patient to be considered in complete response.   
 
5.7 Cytology, Histology .  These techniques can be used to differentiate between PR and CR in rare cases if required 
by protocol (for example, residual lesions in tumor types such as germ cell tumors, where known residual 
benign tumors can remain).  When effusions are known to be a potential adverse effect of treatment (e.g. , with 
certain taxane compounds or angiogenesis inhibitors), the cytological confirmation of the neoplastic origin of 
any effusion that appears or worsens during treatment when the measurable tumor has met criteria for response or stable disease is advised to differentiate between response or stable disease and progressive disease.   
 
Adapted from : Seymour L, Bogaerts J, Perrrone A, et. al.  iRECIST: guidelines for response criteria for use in trials 
testing immunotherapeutics. Lancet . 2017; 18:143 -152. (supplemental materials)  
     <http://www.eortc.org/recist/irecist/>  
Symphogen Clinical Trial Protocol 
Trial ID: Sym023- 01 Version 5.0  
 
Confidential   Page 141 of 173 
 
 Appendix 7  Response Evaluation Criteria in Lymphoma ( RECIL  2017)  
 
Response Evaluation Criteria in Lymphoma  
International Working Group: Response Criteria Based on Assessment of Target 
Lesions  
Response  % Change from Baseline  FDG -PET Bone Marrow 
Involvement  New 
Lesions  
CR Complete disappearance of all target  lesions and 
all nodes with long axis < 10 mm  
 
≥ 30% decrease in the sum of longest diameter 
of target lesions (PR) with normalization of 
FDG -PET Normalization of FDG -
PET (Deauville score 1 -3)* Not involved  No 
PR ≥ 30% decrease in the sum of longest diameters 
of target lesions but not a CR  Positive  
(Deauville score 4 -5)* Any No 
MRa ≥ 10% decrease in the sum of longest diameters 
of target lesions but not a PR (< 30%)  Any Any No 
SD < 10% decrease or  ≤ increase in the sum of 
longest diameters of target lesions  Any Any No 
PD 20% increase in the sum of longest diameters of 
target lesions  
 For small lymph nodes measuring < 15 mm post therapy, a minimum absolute increase of 5 mm 
and the long diameter should exceed 15 mm  
 
Appearance of a new lesion  Any Any Yes or No  
a A provisional category  
 
*Deauville Scoring  (for FDG avidity in Hodgkin’s or Non -Hodgkin’s Lymphoma ) (as seen by FDG -PET)  
Score 1:  No uptake above the background  
Score 2:  Uptake ≤ mediastinum  
Score 3:  Uptake > mediastinum but ≤ liver  
Score 4:  Uptake moderately increase compared to the liver at any site  
Score 5:  Uptake markedly increased compared to the liver at any site  
Score X:  New areas of update unlikely to be relate d to lymphoma  
 
Abbreviations (in alphabetical order):   CR, complete response ; FDG, fluorodeoxyglucose ; mm, millimeter; MR, minor response; PD, progressive 
disease; PET, positron emission tomography; PR, partial response ; SD, stable disease  
 
Adapted from:  Younes A, Hilden P, Coiffier B , et. al.  International Working Group consensus response evaluation criteria in 
lymphoma  (RECIL 2017). Annals  Oncol . 201 7 Apr 3. doi: 10.1093/annonc/mdx097.  
Barrrington  SF, Qian W, Somer EJ,  et al., Concordance between four European centres of PET reporting criteria 
designed for use in multicentre trials in Hodgkin lymphoma. Eur J Nucl Med Mol Imaging. 2010 . 37: 1824- 1833.  
 Fellows  GA, Ardeshna KM, Barrington ST,  et al. Guidelines for the first line m anagement of classical Hodgkin 
lymphoma.  British J Haemotology, 2014 . 166: 34-49. 
Symphogen Clinical Trial Protocol 
Trial ID: Sym023- 01 Version 5.0  
 
Confidential   Page 142 of 173 
 
 Appendix 8  Adverse Events Observed with Antibodies to PD -1 and PD -L1 
 
Although the mechanism of action is distinct, inhibitors of TIM -3 have many similarities to 
blockers of immune checkpoint pathways. Because of these similarities, data on the potential AEs seen after treatment with antibodies to PD -1 and PD -L1 are being in cluded in this CTP.  
Immune -mediated and non- immune -mediated AEs  reported in the literature and/or prescribing 
information for  PD-1 and PD -L1 pathway inhibitors are listed below, organized by System 
Organ Class.  These data have been collated from the pres cribing information of approved 
products as well as applicable literature and are listed below . 
 
Adverse Events Observed with Antibodies to PD-1 and PD -L1 
Blood and lymphatic 
system disorders  
 Anaemia  
Lymphopenia  
Haemolytic anaemia  
Neutropenia  
Thrombocytopenia  
Pure red cell aplasia 
Pancytopenia  
Eosinophilia  
Acquired haemophilia A  
Cryoglobulinemia  
Disseminated intravascular coagulopathy  
Cardiac disorders  Myocarditis  
Ventricular arrhythmias  
Hypotension  
Cardiomyopathy  
Pericarditis  
Ear and labyrinth 
disorders  Autoimmune inner ear disease (listed below under Immunologic Disorders)  
Endocrine disorders  Autoimmune inflammation of pituitary, thyroid, adrenal glands  
Hypophysitis, hypopituitarism, panypopituitarism  
Autoimmune thyroid disease (thyr oiditis, hypothyroidism, hyperthyroidism)  
Thyroid disorders  
Adrenal insufficiency (central or primary)  
Diabetes mellitus (type 1)  
Syndrom e of inappr opriate antidiuretic hormone secretion  
Eye disorders (Intraocular 
inflammation is rare ~1% in 
patients treated)  Uveitis  
Iridocylitis  
Retinal detachment  
Decreased visual acuity  
Ocular inflammatory toxicity  
Iritis  
Episcleritis  
Conjunctivitis  
Orbital inflammation (symptoms include photophobia, dryness of the eye, pain, 
blurred vision)  
Gastrointestinal disorders  Diarrheal colitis (common, presents ~ 6 -8 weeks into treatment; G rade 3-4 in 1 -2%) 
Diarrhea 
Colitis, enterocolitis, gastroenteritis  
Nausea  
Vomiting  
Abdominal pain (abdominal discomfort, upper and lower abdominal pain)  
Decreased appetite  
Intestinal perforation  
Intestinal obstruction  
Symphogen Clinical Trial Protocol 
Trial ID: Sym023- 01 Version 5.0  
 
Confidential   Page 143 of 173 
 
 Adverse Events Observed with Antibodies to PD-1 and PD -L1 
Constipation  
Pancreatitis (increased amylase and lipase)  
Stomatitis  
Dysphagia  
Hypogeusia  
Ulcer haemorrhage  
General disorders and 
administration site 
conditions  Fatigue -includes asthenia and fatigue, decreased activity, malaise  
Pyrexia  
IRR (Mild up to 25%, Severe < 2%; composite term includes chills, fever, back pain, 
flushing, dyspnea, hypotension)  
Oedema (includes periorbital, face oedema, generalized oedema, localized oedema, 
gravitational oedema, peripheral oedema, pulmonary oedema, and lymph 
oedema 
Weight loss (also listed under investigations)  
Cachexia secondary to dysphagia  
Hepatobiliary disorders  Hepatitis  
Immune system disorders 
(See also endocrine and 
other classes)  Pneumonitis  
Inflammatory myositis  
Myositis  
Myocarditis  
Colitis  
Hepatitis  
Autoimmune inflammation of pituitary, thyroid, adrenal glands  
Pancreatitis  
Myasthenia gravis and other autoimmune neurologic disorders  
Inflammatory arthritis  
Bullous pemphigoid  
Complications after allogeneic HSCT (veno -occlusive disease, graft versus host 
disease)  
Vasculitis  
Arthritis  
Psoriasis 
Histiocytic necrotizing lymphadeni tis 
Systemic inflammatory response  
Polymyositis  
Pericarditis  
Dry eye (sicca syndrome)  
 Defined systemic disease  
Sarcoidosis (cutaneous, pulmonary, muscle, neurological)  
Polymyalgia rheumatica-giant cell arteritis  
Celiac disease  
Lupus nephritis  
Dermatomyositis  
Autoimmune inflammatory myopathy  
Psoriasis 
Polymyositis  
Myasthenia gravis  
Sjogren’s syndrome  
Bullous skin diseases (pemphigoid, bullous pemphigus)  
Autoimmune endocrinopathies (pituitary, thyroid, adrenals)  
Autoimmune hepatitis  
Autoimmune pancreatitis  
Autoimmune haemolytic anaemia Pure red cell aplasia 
Cryoglobulinemia  
Acquired Haemophilia A  
Autoimmune hepatitis  
Symphogen Clinical Trial Protocol 
Trial ID: Sym023- 01 Version 5.0  
 
Confidential   Page 144 of 173 
 
 Adverse Events Observed with Antibodies to PD-1 and PD -L1 
Systemic inflammatory response syndrome  
Autoimmune colitis  
Autoimmune pneumonitis  
Infections and infestations  Upper respiratory tract infection (rhinitis, viral rhinitis, pharyngitis, nasopharyngitis)  
Respiratory tract infection  
Pneumonia/bronchopneumonia (bacterial, mycoplasma, Pneumocystis jiroveccii  
pneumonia)  
Nasal congestion  
Urinary tract infecti on (bacterial, fungal)  
Severe infections including sepsis, herpes encephalitis, mycobacterial infection 
leading to retroperitoneal haemorrhage  
Sepsis  
Investigations  Increased ALT  
Increased AST  
Increased bilirubin  
Increased alkaline phosphate  
Increased GGT  
Increased creatinine 
Hyponatremia 
Hyperkalaemia Hypocalcemia 
Hypercalcemia  
Hypomagnesemia  
Hypermagnes emia 
Hypophosphatemia  
Decreased bicarbonate 
Increased amylase  
Increased lipase Increased thyroid stimulating hormone ( TSH ) 
Decreased weight  
Anaemia  
Lymphopenia  
Leukopenia  
Thrombocytopenia  
Increased triglycerides  
Increased cholesterol  
Hyperglycaemia  
Hypoalbuminemia  
Glomerular filtration rate decreased  
Musculoskeletal and 
connective tissue 
disorders  Arthralgia  
Sjogren’s syndrome  
Spondyloarthropathy 
Myositis  
Myopathy 
Rhabdomyolysis  
Musculoskeletal pain (includes back pain, bone pain, musculoskeletal chest pain, 
musculoskeletal discomfort, myalgia, pain in jaw, pain in extremities, neck pain, 
and spinal pain)  
Inflammatory arthritis -polyarthritis  
Myalgia  
Sarcoidosis  
Dry eye (sicca syndrome)  
Nervous system disorders 
(neurologic syndromes in 
~1-3% of patients)  Guillain -Barre syndrome  
Myasthenia gravis  
Non-infectious meningitis  
Transverse myelitis  
Symphogen Clinical Trial Protocol 
Trial ID: Sym023- 01 Version 5.0  
 
Confidential   Page 145 of 173 
 
 Adverse Events Observed with Antibodies to PD-1 and PD -L1 
Peripheral neuropathy and sensory neuropathy (hyperesthesia, hypoesthesia, 
paraesthesia, dysesthesia, peripheral motor neuropathy, peripheral sensory 
neuropathy, polyneuropathy); motor and sensory neuropathy  
Autoimmune encephalitis  
Encephalitis  
Dizziness  
Peroneal ner ve palsy  
Neuritis  
Headache/migraine headache 
Partial seizures associated with focal inflammatory foci in brain  
Dizziness  
Dysgeusia  
Confusional state  
Meningitis/encephalitis  
Demyelination  
Encephalopathy  
Paralysis  
Polymyositis  
Insomnia  
Hypersomnia  
Recurrent seizures -bradykinesia (Parkinsonism)  
Polyradiculopathy  
Necrotizing myelopathy  
Symmetrical multifocal neuropathy  
Phrenic nerve palsy  
Meningoradiculoneuritis  
Posterior reversible encephalopathy syndrome (PRES)  
Aseptic Meningitis -Immune related meningitis  
Enteric neuropathy  
Autoimmune inner ear disease 
Multiple sclerosis  
Pregnancy, puerperium 
and perinatal conditions  Embryo -foetal toxicity  
 
Psychiatric disorders  Insomnia  
Renal and urinary 
disorders  Nephritis and renal dysfunction  
Renal failure  
Acute kidney injury (rare ~ 1- 2% of any grade; G rade 3-4 < 1%; Onset median 91 
days; range 21 -245 days)  
Glomerular filtration rate decreased  
Hematuria   
Urinary obstruction  
Tubulointerstitial nephritis -acute granulomatous int erstitial nephritis  
Acute tubular necrosis  
Immune complex glomerulonephritis  
Thrombotic microangiopathy  
Creatinine elevation  
Reproductive system and 
breast disorders  Lymphocytic vasculitis of the uterus  
 
Respiratory, thoracic, and 
mediastinal disorders  Pneumonitis (uncommon~3%, but potentially severe or life -threatening; median 
onset 2.8 months)  
Cough, productive cough  
Dyspnea, exertional dyspnea  
Pleural effusion  
Respiratory failure  
Respiratory distress  
Pneumonia  
Pulmonary embolism  
Pneumothorax  
Symphogen Clinical Trial Protocol 
Trial ID: Sym023- 01 Version 5.0  
 
Confidential   Page 146 of 173 
 
 Adverse Events Observed with Antibodies to PD-1 and PD -L1 
Hypoxia  
Acute respiratory distress syndrome  
Radiation recall pneumonitis  
Skin and subcutaneous 
tissue disorders -
Dermatologic (Overall 30 -
40%; average onset 3.6 
weeks  Rash (includes maculopapular rash, erythematous rash, macular rash,  popular rash, 
reticular rash, pustular rash, vesicular rash, acneiform rash, follicular rash, 
pruritic rash, drug eruption, generalized rash, seborrheic keratosis, lichenoid 
keratosis, genital rash)  
Palmar plantar erythrodyses thesia  
Erythema 
Vitiligo  
Pruritus  
Exfoliative dermatitis  
Erythema multiforme 
Pemphigoid  
Bullous dermatitis  
Erythema multiforme 
Toxic epidermal necrolysis  
Stevens -Johnson syndrome  
Alopecia Dermatitis  
Sweet syndrome (neutrophil infiltration of skin)  
Oral mucositis  
Xerostomia  
Vascular disorders  Venous thromboembolism  
Hypertension/hypertensive crisis  
Angiopathy  
Adapted from:   Opdivo (nivolumab) [package insert]. Princeton, NJ: Bristol -Myers Squibb Company; 2017.  
 Keytruda (pembrolizumab) [package inset]. Whitehouse Station, NJ: Merck & Co., Inc; 2017.  
 Tecentriq (atezolizumab) [package insert]. South San Francisco, CA: Genentech, Inc.; 2017.  
 Bavencio (avelumab) [package insert]. Rockland, MA; EMD Serono, Inc.; 2017.  
 Imfinzi (durvalumab) [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2017.  
 
 
Symphogen Clinical Trial Protocol 
Trial ID: Sym023- 01 Version 5.0  
 
Confidential   Page 147 of 173 
 
 Appendix 9  Grading and Management of Infusion -Related  Reactions  
 
Grading of Infusion -Related  Reactions  
The CTCAE v 5.0* definition of IRRs  (General Disorders and Administration Site Conditions) is shown below. 
Symptoms occurring during or following infusion of investigational therapy may also be defined according to AE 
categories such as allergic reaction, anaphylaxis, or cytokine release sy ndrome.  In the setting of symptoms occurring 
during or following infusion of investigational therapy, investigators are encouraged to use the AE term “Infusion -
Related Reaction” and any additional terms (including those not listed here) that best describe the event. Those 
described should be graded as follows:  
 
Grading of Infusion- Related  Reactions  
Adverse 
Event  Grade 1  Grade 2  Grade 3  Grade 4  Grade 5  
Infusion -
related 
reaction  Mild transient 
reaction;  infusion 
interruption not  
indicated; 
intervention not  
indicated  Therapy or infusion  
interruption indicated but  
responds promptly to 
symptomatic treatment 
(e.g.,  antihistamines, 
NSAIDS,  narcotics, IV 
fluids);  prophylactic 
medications  indicated for 
≤ 24 hours Prolonged (e.g. , not rapidly  
respon sive to symptomatic  
medication and/or brief  
interruption of infusion);  
recurrence of symptoms  
following initial 
improvement;  hospitalization 
indicated for  clinical sequelae  Life-threatening  
consequences; urgent  intervention 
indicated  Death  
Definition: A disorder characterized by adverse reaction to the infusion of pharmacological or biological substances.  
Allergic 
reaction  Systemic  
intervention not 
indicated  Oral intervention indicated  Bronchospasm; 
hospitalization indicated for clinical se quelae; intravenous 
intervention indicated  Life-threatening  
consequences; urgent  intervention 
indicated  Death  
Definition: A disorder characterized by an adverse local or general response from exposure to an allergen.  
Anaphylaxis  - - Symptomatic bronchospasm,  
with or without urticaria; parenteral intervention  
indicated; allergy -related  
edema/angioedema;  
hypotension  Life-threatening  
consequences; urgent  intervention 
indicated  Death  
Definition: A disorder characterized by an acute inflammatory reaction resulting from the release of histamine and histamine -like substances 
from mast cells, causing a hypersensitivity immune response. Clinically, it presents with breathing difficulty, dizziness, hy potension, cyanosis 
and loss of conscio usness and may lead to death.  
Cytokine 
release syndrome  Fever with or 
without constitutional 
symptoms  Hypotension  responding 
to fluids; hypoxia responding to < 40% O2  Hypotension managed with 
one pressor; hypoxia requiring ≥ 40% O2  Life-threatening  
consequences; urgent intervention  
indicated  Death  
Definition: A disorder characterized by fever, tachypnea, headache, tachycardia, hypotension, rash, and /or hypoxia  caused by the release of 
cytokines.  
*See < https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm  > 
 
Symphogen Clinical Trial Protocol 
Trial ID: Sym023- 01 Version 5.0  
 
Confidential   Page 148 of 173 
 
 Guidelines for Management of Infusion -Related  Reactions  
Consistent with usual medical practice, selected parenteral medications may be utilized for Grade >  2 
allergic/hypersensitivity reactions. The Sponsor should be contacted immediately if questions arise concerning the 
grade of the reaction. The following ar e recommended management guidelines for IRRs  associated with study drug 
administration . In all cases the Investigator should use best clinical judgment in managing such reactions.  
Management of Infusion -Related Reactions  
Grade 1  • Consider slowing the infusion to 50% of the prior rate  
• Monitor the patient for worsening condition  
• If the infusion is extended, a dminister subsequent infusions at the prolonged rate  
• Consider premedication or adjustment to premedications for subsequent infusions  
Grade 2  
 • Interrupt  the infusion for a minimum of 30 minutes  
• Administer additional pharmacologic therapy (e.g. , diphenhydramine, acetaminophen) and appropriate 
supportive care (e.g. , oxygen), as medically indicated  
• Resume the infusion at 50% of the prior rate once the infusion-related  reaction has resolved or decreased to 
Grade 1  
• Monitor the patient for worsening condition  
• Administer subsequent infusions at the prolonged rate  
• Consider premedication or adjustment to premedicatio ns for subsequent infusions  
≥ Grade 3  
 • Stop the infusion  
• Administer additional pharmacologic therapy (diphenhydramine, dexamethasone) and appropriate 
supportive care (e.g. , oxygen), as medically indicated  
• Administer epinephrine or bronchodilators as medically indicated  
• Hospital admission for observation may be indicated  
• Do not resume infusion after a ≥  Grade 3  reaction  
• Patients who have a Grade 3  infusion -related  reaction will be considered to have had a DLT and will be 
discontinued from treatment . 
• Patients who have a > Grade 3  infusion- related reaction will be considered to have had a DLT and will be 
discontinued from treatment  
 
In the Event of Infusion Prolonga tion 
Any assessments to be performed or samples to be collected (e.g. , VS, PK) at the end of or following EOI  will still 
be performed or collected beginning at the delayed EOI timepoint. In situations where collection of late day 
samples, particular ly the 8 hours after EOI sample, is logistically difficult due to clinic staff availability, an "end of 
day" sample may be obtained at the latest practical time on the day of the reaction.  
 
For Grade 1 and Grade 2 reactions, r echallenge with a shorter  duration of infusion (no le ss than the duration 
designated by the patient’s dose assignment and weight ) may be attempted at the Investigator's discretion, after a 
minimum of 2 doses  with no evidence of infusion- related toxicity  at the prolonged rate .   
 All infusion interruptions and subsequent prolongations, including modified infusion times, as well as the toxicity 
that necessitated them, will be clearly documented on the appropriate page of the patient’s CRF.  
 
Modification of Infusion Duration for the Trial  
The dur ation of infusion will be prolonged for all subsequent patients entered to the trial in the following situations:  
• In the event of a Grade 2 IRR in ≥ two thirds of the patients entered to a cohort, the duration of infusion for 
subsequent patients entered to the trial will be extended by 30 minutes  (or longer, if indicated).  
• In the event of a Grade 3 or greater IRR in any patient within a cohort, the duration of infusion for 
subsequent patients entered to the trial will be extended by 30 minutes  (or longer, i f indicated). Such a case 
will also be considered to have met the protocol criteria for a DLT, thus requiring expansion of the cohort . 
 
Symphogen Clinical Trial Protocol 
Trial ID: Sym023- 01 Version 5.0  
 
Confidential   Page 149 of 173 
 
 These same criteria will be applied in the event IRRs occur on the extended 1 -hour infusion schedule. In such a case, 
the duration of infusion for subsequent patients entered to the trial will be further extended by 30 minutes  (or longer, 
if indicated).  See Section 6.5.3.5 .  
Symphogen Clinical Trial Protocol 
Trial ID: Sym023- 01 Version 5.0  
 
Confidential   Page 150 of 173 
 
 Appendix 10  Management of Immune -Mediated Toxicities  
 
Instructions for management of immune -mediated toxicities are provided below and are to be implemented as 
detailed  EXCEPT where AEs meet  the protocol -specified DLT criteria ( Section 6.8.3). AEs that meet the protocol 
definition of DLT will require discontinuation from study treatment, without exception (Section 6.8.2); this 
instruction supersede s those provided below.    
Adverse Reaction  Severity*  Dose Modification  
Pneumonitis  Grade 2 pneumonitis  Withhold dose^  
Grade 3 or 4 pneumonitis  Permanently discontinue  
Myocarditis** Grade 2 myocarditis  Withhold dose^  
Grade 3 or 4 myocarditis  Permanently discontinue  
Adrenal 
Insufficiency  Grade 2 adrenal insufficiency  Withhold dose^  
Grade 3 or 4 adrenal insufficiency  Permanently discontinue  
Encephalitis  New -onset moderate or severe neurologic signs or symptoms  Withhold dose^  
Immune -mediated encephalitis  Permanently discontinue  
Nephritis and 
Renal Dysfunction  Serum creatinine more than 1.5 and up to 6 × ULN  Withhold dose^  
Serum creatinine more than 6 times the ULN  Permanently discontinue  
Episcleritis, 
Uveitis, or Iritis**  Grade 2  episcleritis, uveitis, or iritis     Withhold dose^  
Grade 3 or 4 episcleritis, uveitis, or iritis  Permanently discontinue  
Colitis/Diarrhea  Grade 2 or 3 diarrhea or colitis  Withhold dose^  
Grade 4 diarrhea or colitis  Permanently discontinue  
Hypophysitis  Grade 2 or 3 hypophysitis  Withhold dose^  
Grade 4 hypophysitis  Permanently discontinue  
Type 1 Diabetes 
Mellitus  Grade 2 or 3 hyperglycemia  Withhold dose^  
Grade 4 hyperglycemia  Permanently discontinue  
Inflammatory arthritis  Grade 2 arthritis  Withhold dose^  
Grade 3 arthritis  Permanently discontinue  
Myositis**  Grade 2 myositis  Withhold dose^  
Grade 3 myositis  Permanently discontinue  
Rash  Grade 2 or 3 rash  Withhold dose^  
Grade 4 rash  Permanently discontinue  
Hepatitis  AST or ALT > 3 - 5 × ULN or  
total bilirubin > 1.5 - 3 × ULN (Grade 2)  Withhold dose^  
AST or ALT > 5 × ULN or  
total bilirubin > 3 × ULN (≥ Grade 3)  Permanently discontinue  
Other  Other Grade 3 adverse reaction:    
 First occurrence  
 Recurrence of same event  Withhold dose^  
Permanently discontinue  
Life-threatening or Grade 4 adverse reaction  Permanently discontinue  
Requirement for 10 mg per day or greater prednisone or 
equivalent for more than 12 weeks  Permanently discontinue  
Persistent Grade 2 or 3 adverse reactions lasting ≥ 12 weeks  Permanently discontinue  
Abbreviations (in alphabetical order):  ALT, alanine aminotransferase; AST, aspartate aminotransferase; mg, milligram; ULN, u pper limit of 
normal  
* Toxicity graded per Common Terminology Criteria for Adverse Events (Version 5.0) (CTCAE v 5.0) 
**Adapted from product package inserts to include these reactions; there are no recommended dose modifications for hypothyroi dism or 
hyperthyroidism.  
^ May resume treatment when adverse reaction returns to Grade 0 or Grade 1 and glucocorticoid therapy for reaction is discont inued  
Symphogen Clinical Trial Protocol 
Trial ID: Sym023- 01 Version 5.0  
 
Confidential   Page 151 of 173 
 
 Appendix 11  Maximum Total Blood Collection Volumes  
 
Maximum Total Blood Collection Volumes  
STUDY 
ASSESSMENTS  Vol./ 
sample 
(mL) Screening  Cycle 1  Cycle 2  EOT  1M FUP  
TOTAL 
VOLUME  # Vol.  
(mL)  # Vol.   
(mL)  # Vol.  
(mL)  # Vol.  
(mL)  # Vol.   
(mL)  
Hematology Panel  5 1 5 5 25 2 10 1 5 1 5 50 
Biochemistr y Panel  10 1 10 5 50 2 20 1 10 1 10 100 
Coagulation Panel  5 1 5 2 10 1 5 1 5 1 5 30 
Thyroid Function 
Tests  5 1 5 1 5 1 5 1 5 1 5 25 
Pregnancy Test  5 1 5 1 5   1 5   15 
Tumor Markers  5 1 5   1 5 1 5 1 5 20 
ADA Testing  5   2 10 1 5 1 5 1* 5 25 
PK Studies  5   11 55 4 20 1 5 1* 5 85 
Pharmacodynamic 
Studies ( Receptor 
Occupancy ) 10   3 30 3 30 1 10 1 10 80 
Biomarker Studies  30 1 30   1 30 1 30   90 
Total Volume   65  190  130  85  50 520 
Abbreviations (in alphabetical order): #, number of samples; 1M FUP, 1-month follow -up; ADA, anti -drug antibody; EOT, end of treatment; mL, 
milliliter; PK, pharmacokinetic; Vol, volume  
 
*additional samples to be obtained at 2, 4, and 6 months after EOT if patient is available for blood collection  
 
 
Along with Screening, days with maximum blood volume requirements:  
• C1/D1:  100 mL  
• Cx/D1: 40 mL (+ 5 mL for odd number cycles)  
• EOT:  85 mL 
• 1M FUP:   50 mL 
 
Blood volumes for each additional cycle:    
• Additional odd number cycles:  ~70 mL  
• Additional even number cycles: ~ 70 mL  
If sites can perform hematology, serum chemistry, and coagulation studies with smaller volumes of blood per sample, they are encouraged to do 
so.  Required PK, ADA, and PD/biomarker volumes are fixed and should not be reduced.   
To estimat e a patient’s tot al blood collection volume during study participation, maximum estimates are used. During a patient’s study 
participation, the maximum amounts of venous blood that will be collected are listed above.  Study duration is based on 8 weeks  estimated 
average pa tient participation, i.e. , an average of Cycle 1 (4 weeks) plus Cycle 2 (4 weeks).   
An indwelling venous access device is required for PK blood sample collections on Day 1 of Cycle 1.  When an indwelling catheter (or 
equivalent venous access)  is utilized,  a blood flush discard of up to 3  mL is to be done before drawing the first blood tube collected on the 
scheduled day/time for routine laboratory tests and PK samples. Blood flush discard volumes ARE NOT included in volume calculations in 
table above and s hould be considered when summarizing actual blood collection volumes.  
Symphogen Clinical Trial Protocol 
Trial ID: Sym023- 01 Version 5.0 
 
Confidential   Page 152 of 173 
 
 Appendix 12  Schedule of Assessments  
 
STUDY ASSESSMENTS  Screening  CYCLE 1  CYCLE 2  SUBSEQUENT CYCLES  
EOT     
within 10d after  
treatment  
discontinuation  1M FUP* 
30d (+7) 
after last 
dose Long -Term 
FUP *              
if OR/ SD at 
EOT , 
for new -onset 
or ongoing 
immune -
mediated AEs    As 
Clinically 
Indicated  D1 D2 D3 
(+1) D8 
(±2) D15 
(±2) D22 
(±2) D1 
(±2) D15 
(±2) End of 
Cycle 2 
(final 
week)  D1 
(±2) D15 
(±2) End of 
Even 
Number ed 
Cycles 
(final week)  
CONSENT AND MEDICAL HISTORY  
Informed Consent1/ Eligibility 
Assessment  x                 
Demography  x                 
Past Medical History2 x xa                
History of Primary Malignancy3 x                 
SAFETY ASSESSMENTS (screening assessments within 14 days prior to first dose of study drug unless otherwise specified)  
Medication/Procedure Survey4 from 14 days prior to 1st dose through 30 days after last dose    
AE Reporting5 from signing of informed consent through 30 days after last dose; through 2 month s (or 4 months to 2 years) FUP if related critical AEs persist  Q2Md x 
DLT Assessment6   C1/D1 through C1 /D28 (+/ - 2 days)          x 
ECOG PS Evaluation  x xa      x   x   x x  x 
Vital Signs7  x SOI; 
EOI;  
2h, 4 h, 8h 
after EOI  x x  SOI,  
EOI  x   x   x x  x 
Physical Exam  (to include weight, 
pulmonary and cardiac 
assessments )8 x xa      x   x   x x  x 
Hematology Panel9 x xa  x x x x x x  x x  x x  x 
Biochemistry Panel10 x xa  x x x x x x  x x  x x  x 
Coagulation Panel11 x xa    x  x   x   x x  x 
Thyroid Function Tests12 x xa      x   x   x x  x 
Urinalysis13 x xa    x  x   x   x x  x 
Pregnancy Testing14 x x            x   x 
ECG (12 -lead)15 x SOI,  
EOI           
+15 min          SOI, 
EOI   
+15 
min      x   x 
SAFETY ASSESSMENTS (results from assessments previously performed as standard of  care within 28 days [+2d] prior to 1st dose may be utilized provided no antineoplastic therapy has been delivered between assessment and 1st dose; 
otherwise within 14 days of 1st dose) 
MUGA Scan or ECHO16 x             x   x 
Ophthalmology Exam17 x       EOC1 
visual 
acuity 
only  xb   xb x   x 
Pulmonary Function Tests18 x             x   x 
DISEASE ASSESSMENTS (screening assessments within 28 days [+2d] prior to first dose of study drug)  
Tumor Marker Measurement19 x         xb   xb xc If no  
prior PD  Q2Me  
Symphogen Clinical Trial Protocol 
Trial ID: Sym023- 01 Version 5.0 
 
Confidential   Page 153 of 173 
 
 STUDY ASSESSMENTS  Screening  CYCLE 1  CYCLE 2  SUBSEQUENT CYCLES  
EOT     
within 10d after  
treatment  
discontinuation  1M FUP* 
30d (+7) 
after last 
dose Long -Term 
FUP *              
if OR/ SD at 
EOT , 
for new -onset 
or ongoing 
immune -
mediated AEs    As 
Clinically 
Indicated  D1 D2 D3 
(+1) D8 
(±2) D15 
(±2) D22 
(±2) D1 
(±2) D15 
(±2) End of 
Cycle 2 
(final 
week)  D1 
(±2) D15 
(±2) End of 
Even 
Number ed 
Cycles 
(final week)  
Imaging for Disease (and 
Pulmonary Status)20 x         xb   xb xc If no  
prior PD  Q2Me  
Lymphoma patients :  FDG -PET, X -
ray, U/S, BM aspiration/Bx  As 
indicated          As 
indicatedb   As 
indicatedb As indicated  As 
 indicated  Q2Me  
Response Assessment (in event of 
OR or SD)21          xb   xb xc If no  
prior PD  Q2Me  
ADDITIONAL ASSESSMENTS  
ADAAssessment22  x    x  x   Odd 
# Cs   x x Q2M for 6 
monthsf x 
PK Assessment23  SOI; EOI;  
2h, 4h, 8h 
after EOI  24h 
after 
EOI -12h 
to 
+24h  x SOI, 
EOI x SOI, 
EOI SOI, 
EOI  SOI, 
EOI SOI, 
EOI  x x Q2M for 6 
monthsf  
Peripheral Blood for 
Pharmacodynamic Studies ( receptor 
occupancy )24  x 24h   x  x D15   
(+ 0-7) EOC2 or 
C3/D1b   Q4C (C6, 
C10, etc.)b x x   
Peripheral Blood for Biomarker 
Studies25 upon 
eligibility         D15   
(+ 0-7)     x    
Tumor Biopsy for Biomarker 
Studies  (optional)26 upon 
eligibility         D15   
(+ 0-7)     Upon PD i f 
prior OR or 
SD > 16wks     
TRIAL TREATMENT  
Premedication Administration (if 
indicated)   x    x  x x  x x      
Study Drug Infusion (30 minutes ) 
(+10 min )  x    x  x x  x x      
Post-Infusion Monitoring   2h    1h  1h 1h  1h 1h      
Abbreviations (in alphabetical order): 1M FUP, 1-month follow -up; ADA, anti -drug antibody; AE, adverse event; BM, bone marrow; Bx, biopsy; C, cycle: D /d, day; DLT, dose -limiting toxicity; h, hour; ECG, 
electrocardiogram; ECHO, echocardiogram; ECOG, Eastern Cooperative Oncology Group; EOC, end of cycle; EOI, end of infusion; EOT , end of treatment; FDG, fluorodeoxyglucose ; FUP, follow -up; MUGA, 
multi -gated acquisition; OR, objective response; PET, positron emission tomography ; PK, pharmacokinetic; PS, performance status; Q2M, every 2 months; Q4C, every 4 cycles; SD, stable disease; SOI, start of 
infusion ; U/S, ultrasound  
 
a Need not be assessed prior to Cycle 1 if ≤ 7 days since screening  
b End of Cycle assessments may be conducted at any time during the week prior to Day 1 of the next cycle, including on Day 1 of  the next cycle, prior to dosing  
c Conduct only if > 6 weeks since the previous assessment  
d To be conducted to assess for delayed onset of any post -therapy immune-mediated AE (up to 6 months following last dose), and in the event of an immune -mediated toxicity 
ongoing at the 1M FUP or noted during the 6-month post -therapy FUP period (up to 2 years). Clinical events may be followed in writing or by telephone; an in- person visit will 
not be required.  
Symphogen Clinical Trial Protocol 
Trial ID: Sym023- 01 Version 5.0 
 
Confidential   Page 154 of 173 
 
 e To be conducted in the event of ongoing OR or SD at the end of treatment; continue until confirmed PD or another the rapeutic intervention is initiated , or until the end of trial.  
Documentation may be submitted in writing  or by e -mail ; an in -person visit will not be required.   
f Samples to be obtained if patient is available for blood collection  
 
1. Informed Consent : To be signed prior to enrollment and prior to performing any protocol -related procedure, unless such testing was performed previously as part of the routine 
clinical management of the patient.   
2. Past Medical History : To include history of prior/on going diseases or conditions as well as prior surgical procedures not related to the underlying malignancy . 
3. History of Primary Malignancy : To include details of the primary malignancy, including:  diagnosis and histological/cytological classification; date  of initial diagnosis; stage of 
disease at diagnosis and at entry; current sites of metastases; prior surgical procedures for the malignancy and dates; prior  antineoplastic therapy, prior radiation therapy, as well as 
dates of treatments, numbers of cycles , and best response to each therapy; date of most recent disease progression.   
4. Medication/Procedure Survey :  To include period within 14 days  prior to first study drug dose and throughout study for a period of 30 days following last study drug dose.  
5. AE Reporting:  To detail symptoms that may be present prior to/at the time of first administration.  AEs to be assessed from signing of informed consent, throughout study,  and for 
the 1-month period (30 days) following last study drug dose; AEs to continue to be assessed for 2 months  (and if necessary 4 month s) following last study drug dose if events 
associated with study drug persist (to confirm that events have resolved, returned to baseline status,  or been adequately explained. Investigator discretion may be used with respect 
to the method of contact for this AE assessment; clinical events may be followed in writing or by telephone, an in- person visit will not be required). Any patient who develops an 
immune-related toxicity (e.g ., pulmonary fibrosis, myocarditis, ocular toxicity, drug-induced hepatotoxicity, etc.) will be followed at approximately 2-month intervals for up to 2 
years to assess the course of the condition and evaluate potential reversibility of the finding.  
6. DLT Assessment : Beginning on C1/ D1 and ending at EOC1 (C1/ D28 ± 2 days).  To include evaluation for the occurrence of events meeting the trial DLT criteria.  Only DLTs 
occurring during Cycle 1 will be used to make decisions regarding dose -escalation and tolerabil ity. Events occurring after Cycle 1 will also be evaluated and taken into 
consideration when deciding upon further doses to be assessed as well as establishment of the RP2D.  
7. Vital Signs :  To include temperature, pulse, respiratory rate, blood pressure, an d pulse oximetry .  C1/D1 through C1/D3 window allowances align with PK timepoints windows  
8. Physical Examination : Complete at screening including height, weight, general appearance, skin, head, eyes, ears, nose, throat, neck/thyroid, chest  [includes pulmonar y assessment, 
breasts], cardiovascular [includes heart, peripheral pulses] abdomen, musculoskeletal system, lymph nodes, neurologic and men tal status; directed thereafter, must include weight as 
well as pulmonary and cardiac assessments . Dose adjustments s hould be made in the event of noted weight change (± 10% [less at the site’s discretion or if required by institution 
procedures]).  Pulmonary findings will be evaluated in detail at each visit by the Investigator (or physician designee). Evaluation to inc lude review of pulmonary symptoms 
including but not limited to: cough, sputum production, hemoptysis, wheezing, dyspnea, dyspnea on exertion, chest pain, and/or chest pain associated with respirations, as well as 
review of cardiac symptoms including but not limited to chest pain, orthopnea, nocturia, edema, and palpitations.  
9. Hematology Panel :  To include CBC with hemoglobin, hematocrit, differential, ANC, and platelet count. Evaluation frequency should be increased in the event of hematologic 
toxicity.  
10. Biochemistry Panel  (fasting not required): To include Na, K, Cl, bicarbonate or carbon dioxide, BUN or equivalent, creatinine, glucose, bilirubi n [total and direct], AST, ALT, ALP, 
Ca, Mg, phosphorous, albumin, total protein, uric acid, amylase, lipase, and CK (if abnormal , perform isoenzyme analysis to include at minimum CK -MB ), serial trop onins, and 
measurement of BNP. Evaluation frequency should be increased in the event of significant serum chemistry abnormalities. Clinically significant el ectrolyte abn ormalities should be 
corrected prior to dosing.  
11. Coagulation Panel : To include PTT (or aPTT), PT  and/or INR. 
12. Thyroid Function T ests: To include measurement of TSH, fT3, and fT4 . 
13. Urinalysis : Multi- panel chemical test strips are acceptable and should include assessment of specific gravity, pH, protein, glucose, ketones, leukocyte s, nitrite, bilirubin, 
urobilinogen, and blood. Microscopic examination of sediment, if clinically indicated, to include assessment of cells (WBC and RBC per HPF, and casts ).   
14. Pregnancy Testing :  β-hCG in WOCBP; serum at Screening, serum or urine thereafter; negative test must be confirmed within 2 working days prior to f irst dose of study drug.  
15. ECG (12 -Lead) : To include measurement of PR interval, QRS duration, QT interval, an d QTc interval (msec), as well as HR  (BPM ); to be performed after patient has been supine  
Symphogen Clinical Trial Protocol 
Trial ID: Sym023- 01 Version 5.0 
 
Confidential   Page 155 of 173 
 
 or semi -recumbent  for ≥ 10 minutes; repeat subsequent timepoints in triplicate separated by 5 minutes for 4 cycles (Day 1, SOI and EOI) in pati ents with a Cycle 1 or Cycle 2 QTc 
that is either:  a)  > 500 msec; b), increased by 60 msec over baseline; or c) decreased by 20 m sec below baseline. If abnormit ies suggest new evidence of myocardial ischemia, 
perform isoenzyme analysis (to include at minimum CK -MB ), serial troponins, and measurement of BNP.  
16. MUGA Scan or ECHO: For measurement of LVEF; to be performed ONLY in patients  with a history of CHF, individual patients should be followed with the same testing 
procedure throughout the study.  
17. Ophthalmology Examination:  To include funduscopic and slit lamp evaluation s for assessment of retinal and corneal integrity , visual acuity as assessed by standardized chart or 
other appropriate measurement tool (e.g. , Snellen chart) , and any other noted ocular abnormality . If changes in visual acuity are noted, a thorough ophthalmologic evaluation should 
be performed within 48 hours (i f feasible, based on weekend s or holidays) of the initial observation in order to confirm the finding and determine if there is evidence of an immune -
mediated AE, or other event that would preclude further treatment with study drug.  
18. Pulmonary Function Test s: To include spirometry and diffusing capacity of carbon monoxide [DL CO] to assess for evidence of pulmonary fibrosis.  Spirometry assessments to 
include at minimum:  FVC, FEV1, FRC, RV, and TLC.  To be repeated if evidence of interstitial pneumonitis, pulmonary fibrosis or other potential evidence of drug-related 
pulmonary toxicity is documented on imaging studies or if pulmonary symptomatology indicates . 
19. Tumor Marker Measurement : As indicated by tumor type.  
20. Imaging for Assessment of Diseas e (and Pulmonary Status) : To include diagnostic imaging by CT or MRI of the chest with each evaluation  (for disease evaluation where indicated, 
and to assess for evidence of pulmonary fibrosis) plus abdomen and pelvis, and other sites as indicated based on tumor type and clinical judgment to  assess the status of the 
underlying malignancy. Use of contrast is preferred but is at the discretion of the Investigator, as medically indicated .  The same method(s) of disease evaluation and the same 
technique should be used throughout the study. For all imaging timepoints, the following will be recorded as per RECIST v1.1 (or other response criteria, as indicated): tar get 
lesions including size, location, and type (nodal/non- nodal); sum of diameters of target lesions;  any new lesions noted during trial, including size, location, and type (nodal/non-
nodal).  
21. Response Assessment : To be assessed by the Investigator or qualified designee as per RECIST v1.1 ( or other response criteria, as indicated ). 
22. ADA (Specialty Lab): To assess immunogenicity; whole blood (~5 mL at each timepoint) will be collected for serum acquisition.  If sampling is on a  dosing day, collect prior to 
infusion.  If a collected serum sample is inadequate or insufficient for ADA analysis, the analysis of  ADA can be done using a PK serum sample from the same timepoint, if available. 
A detailed laboratory manual specifying sample collection, handling, storage, and shipment will be provided to the trial site s.   
23. PK Sampling  (Specialty Lab): See Section 7.6.1  for window allowances. Whole blood (~5 mL at each timepoint) will be collected for serum acquisition. If a collected serum sample 
is inadequate or insufficient for PK analysis, the analysis of PK can be done using an ADA serum sample from the same timepoint,  if available.  A detailed laboratory manual 
specifying sample collection, handling, storage, and shipment will be provided to the trial sites.  PK sampling times may be adjusted  according to early trial results to  optimize 
evaluation.   
24. Peripheral Blood for Pharmacodynamic Studies ( Receptor Occupancy ) (Specialty Lab):  Whole blood (~ 10 mL at each timepoint) will be collected for assessment of receptor 
occupancy .  C2D15 (+ 0 to 7 days) after dosing; to be collected on the day of tumor biopsy, if performed. End of Cycle sampling may be combined with EOT if patient discontinues 
treatment. A detailed laboratory manual specifying sample collection, handling, storage, and shipment will be provided to the trial sites.    
25. Peripheral Blood for Biomarker Studies  (Specialty Lab):  To be obtained only after eligibility has been confirmed .  (May be coll ected C1 /D1 prior to dosing.)   Whole blood (~30 
mL at each timepoint) to be collected.  C2D15 (+ 0 to 7 days) after dosing; to be collected on the day of tumor biopsy, if performed. For those timepoints where both a blood sample 
and a tumor biopsy are to be obtained,  the blood sample must  be collected first. A detailed laboratory manual specifying sample collection, handling, storage, and shipment will be 
provided to the trial sites.  
26. Tumor Biopsy for Biomarker Studies  (optional) ( Specialty Lab ): To be obt ained only after eligibility has been confirmed.  (May be collected C1/ D1 prior to dosing.)   Tissue for 
FFPE to be collected . C2D15 (+ 0 to 7 days) after dosing; to be collected with paired periphera l blood for biomarker studies.  For those timepoints where both a blood sample and a 
tumor biopsy are to be obtained,  the blood sample must be collected first.  EOT sample upon PD only in patients with a prior OR  or prolonged SD (> 16 weeks). A detailed 
laboratory manual specifying sample collecti on, handling, storage, and shipment will be provided to the trial sites   
Symphogen Clinical Trial Protocol 
Trial ID: Sym023- 01 Version 5.0 
 
Confidential   Page 156 of 173 
 
 19 SUMMARY OF CHANGES  
19.1 Protocol Amendment 1 dated 04- Apr-2018  
• All DLTs will require discontinuation from study treatment, without exception. 
• Any treatment delay >2 weeks during Cycle 1 du e to toxicity will be considered a DLT, regardless of severity of the event.  
• Failure to complete Cycle 1 due to any AE will be considered a DLT, regardless of severity of the event. 
• Clarified that immune -mediated toxicity that requires use of glucocorticoids at a dose of ≥ 1 mg/kg/day of prednisone 
equivalents for treatment of the toxicity will be considered a DLT.  
• Any reduction in visual acuity will be considered a DLT , regardless of  grade or duration.  
• All Grade 4 non- hematologic laboratory changes will be considered a DLT , regardless of rapidity of resolution. 
• Any Grade 4 hematologic toxicity (other than those specifically covered which include neutropenia, thrombocytopenia, and 
anem ia) lasting >5 days will be considered a DLT.  
• Patients with a history of organ transplantation (e.g., stem cell or solid organ transplant) have been added as an exclusion 
criterion.  
• Added a notation to the retreatment guidelines to indicate that patients m ay receive standard doses of replacement hormonal 
therapy for adrenal insufficiency, hypothyroidism, or other endocrine end -organ failure, and may resume study drug once 
considered by the Investigator to be stable on such therapy. This was added to be cons istent with eligibility criteria.  
• Tables have been updated based on changes described, including correction to the recommended premedication dose of famotidine from 30mg to 20mg (Table 4).  
• Formatting adjustments, outline modifications, cross -reference links and link corrections, and other minor typographical 
corrections and slight wording changes are included. 
Refer to Table 6  for the  changes in Protocol Amendment 1. 
 
  
Symphogen Clinical Trial Protocol 
Trial ID: Sym023- 01 Version 5.0 
 
Confidential   Page 157 of 173 
 
 Table 6:  Protocol Amendment 1  
SECTION  ORIGINAL TEXT  NEW TEXT  
1 Synopsis: Patient 
Selection: Eligibility  
 
4.3.1 Patients to be 
Excluded  Patients to be Excluded  
8. Patients with a clinically significant (CS) cardiovascular disease or 
condition, including:…  
• History of acute coronary syndromes (including myocardial 
infarction [MI] and unstable angina), coronary angioplasty, or stenting within 6 months prior to first study drug administration  
 Not applicable (new exclusion criterion added, shifting list)  Patients to be Excluded  
8. Patients with a clinically significant (CS) cardiovascular disease or 
condition, including:…  
• History of acute coronary syndromes (including myocardial 
infarction [MI] and unstable angina), coronary angioplasty, stenting, or 
bypass within 6 months prior to first study drug administration  
 12. Patients with a history of organ transplantation (e.g. stem cell or 
solid organ transplant)  
1 Synopsis: IMP 
Administration: Doses to be Administered  
 5.7 Dose Calculation  
 
6.5.3.1.2 Changes in Dose to be 
Administered  Changes in Dose to be Administered  
Dose adjustments should be made in the event of noted weight change (± 10%; less at the site’s discretion or if required by institution procedures) at visits that require weight measurement. Adjustments may 
be made in the event of lesser incremental changes in weight and more 
frequently at the site's discretion.   Changes in Dose to be Administered  
Dose adjustments should be made in the event of noted weight change 
(± 10%; less at the site’s discretion or if required by institution procedures) at visits that require weight measurement. Adjustments may 
be made more frequently at the site's discretion.   
 
(Text was add ed to section 5.7)  
1 Synopsis: IMP 
Administration: 
Premedication  Premedication for Infusion -Related Reactions  
In the event of an IRR during study:  
• For Grade 3 reactions, premedication prior to subsequent infusions 
is required. Patients experiencing a Grade 3 reaction after having received premedication will be discontinued from treatment.  Premedication for Infusion -Related Reactions  
In the event of an IRR during study:  
• For Grade 3 reactions, not applicable as this is considered a DLT; 
therefore, no further treatment with study drug is allowed.  
1 Synopsis: 
Continued Treatment:  
Retreatment Following an 
Objective Response  This option for retreatment does not apply to patients who previously 
experienced an immune-mediated toxicity that re quired permanent 
discontinuation from study drug ( see Treatment Discontinuation 
Criteria ). This option for retreatment does not apply to patients who previously 
experienced a DLT that required permanent discontinuation from study drug ( see DLT and Treatmen t Discontinuation Criteria ). 
1 Synopsis: AEs and 
DLTs: Management of DLTs and Other Toxicities  Management of Dose -Limiting Toxicities  
AEs that meet the protocol definition of DLT will be managed by either discontinuing the patient from further participati on in the study, or the 
patient may continue if there is evidence of response or other clinical 
benefit, but dosing must be delayed, and the patient may not  be retreated 
until retreatment criteria are met.   Management of Dose -Limiting Toxicities  
AEs that meet the protocol definition of DLT will require 
discontinuation from study treatment, without exception.   
Symphogen Clinical Trial Protocol 
Trial ID: Sym023- 01 Version 5.0 
 
Confidential   Page 158 of 173 
 
 Table 6:  Protocol Amendment 1  
SECTION  ORIGINAL TEXT  NEW TEXT  
Patients experiencing certain immune -mediated toxicities may not  be 
retreated and will be discontinued from further participation ( see 
Treatment Discontinuation Criteria ). 
1 Synopsis: AEs and 
DLTs: Dose -Limiting 
Toxicities Definition  
 
6.8.3 Definition of Dose -Limiting 
Toxicity  Any of the following toxicities occurring during Cycle 1, if judged to be 
related to study drug (i.e. possibly -related, probably-related, or related), 
will be considered a DLT for the purposes of this trial.  
 
1. ≥ Grade 3 evidence of any of the following immune -mediated 
toxicities (patient must be permanently discontinued)…  
2. ≥ Grade 3 evidence of any of the following immune -mediated 
toxicities (if > Grade 3, patient must be permanently 
discontinued)…  
3. ≥ Grade 2…  
Not applicable (new bullet point added)  
 
 Not applicable (new toxicity added, shifting list)  
4. Hepatic-related find ings consistent with Hy’s Law criteria…  
5. Any other ≥ Grade 3 or 4 non- hematologic toxicity regardless of 
duration with the exceptions of…  
• ≥ Grade 3 asymptomatic electrolyte abnormalities lasting ≤ 3 
days that are not clinically complicated, and resolv e 
spontaneously or respond to conventional medical interventions  
Not applicable (new toxicity added, shifting list)  
 
6. Neutropenia that is…  
7. Thrombocytopenia that is…  
8. Anemia that is Grade 4 and not explained by underlying disease  
Not applicable (new  toxicity added, shifting list)  
 
9. Any death where a relationship to study drug cannot be ruled out  
10. Inability to complete Cycle 1 at the assigned dose (i.e. receipt of < 
2 full planned doses of study drug plus 2 weeks of follow -up) due to ≥ 
Grade 3 to xicity  Any of the following toxicities occurring during Cycle 1, if judged to be 
related to study drug (i.e. possibly -related, probably-related, or related ), 
will be considered a DLT for the purposes of tolerability assessment during this trial.  
1. ≥ Grade 3 evidence of any of the following immune -mediated 
toxicities…  
2. ≥ Grade 3 evidence of any of the following immune -mediated 
toxicities…  
3. ≥ Grade 2…  
• Immune-mediated toxicity that requires use of glucocorticoids at a dose of ≥ 1 mg/kg/day of prednisone equivalents for 
treatment of the toxicity  
4. Any reduction in visual acuity, regardless of grade or duration  
5. Hepatic-related findings consistent with Hy’s Law criteria…  
6. Any other ≥ Grade 3 or 4 non- hematologic toxicity regardless of 
duration with the exceptions of...  
• Grade 3 asymptomatic electrolyte abnormalities lasting ≤ 3 
days that are not clinically complicated, and resolve 
spontaneously or res pond to conventional medical interventions  
7. Any Grade 4 non- hematologic laboratory toxicity regardless of 
duration  
8. Neutropenia that is…  
9. Thrombocytopenia that is…  
10. Anemia that is Grade 4 and not explained by underlying disease  
11. Any other Grade 4 hematologic toxicity (other than those specifically excluded) lasting > 5 days  
12. Any death where a relationship to study drug cannot be ruled out  
13. Inability to complete Cycle 1 at the assigned dose (i.e. receipt of < 
2 full planned doses of study drug plus 2 weeks of follow -up) due to any 
toxicity  
14. Treatment delays > 2 weeks from the scheduled next dose during 
Cycle 1 due to any toxicity  
Symphogen Clinical Trial Protocol 
Trial ID: Sym023- 01 Version 5.0 
 
Confidential   Page 159 of 173 
 
 Table 6:  Protocol Amendment 1  
SECTION  ORIGINAL TEXT  NEW TEXT  
11. Treatment delays > 2 weeks from the scheduled next dose during 
Cycle 1 due to ≥ Grade 3 toxicity  
1 Synopsis: Toxicity 
Safety Management 
and Safety Monitoring: IRR 
Management  
 
8.5.1.1 Instructions 
for Infusion Prolongation for IRRs  • For Grade 3 reactions , the infusion will be STOPPED and 
supportive care will be provided.  The occurrence will be considered a DLT and the patient will be either discontinued from treatment, or must receive subsequent doses at a prolonged infusion rate (slowed to 50% of 
the prior rate, or longer).  
 In all cases the Investigator should use best clinical judgment in managing such reactions. For Grade 1 and 2 IRRs, rechallenge with a shorter duration of infusion (no less than 30 minutes) may be attempted at the Investigator’s discretion, after a minimum of 2 doses with no 
evidence of infusion-related toxicity at the prolonged rate. For Grade 3 
IRRs, continue administration at the prolonged rate.  • For Grade 3 re actions , the infusion will be STOPPED and 
supportive care will be provided.  The occurrence will be considered a DLT and the patient will be discontinued from treatment.  
 
 
 In all cases the Investigator should use best clinical judgment in 
managing such re actions. For Grade 1 and 2 IRRs, rechallenge with a 
shorter duration of infusion (no less than 30 minutes) may be attempted 
at the Investigator’s discretion, after a minimum of 2 doses with no 
evidence of infusion-related toxicity at the prolonged rate.  
1 Synopsis: 
Discontinuation and Follow -Up: Key 
Treatment 
Discontinuation 
Criteria  
 
9.1 Criteria for 
Treatment 
Discontinuation  1. Adverse Events, including:  
• ≥ Grade 3  evidence of any of the following immune -mediated 
toxicities: 
o Pneumonitis  
o Myocarditis  
o Adrenal insufficiency  
o Encephalitis  
o Nephritis, renal dysfunction (serum creatinine elevation)  
o Episcleritis, uveitis, or iritis  
• > Grade 3  evidence of any of the following immune -mediated 
toxicities: 
o Colitis  
o Hypophysitis, hyperglycemia  
o Inflammatory arthritis  
o Myositis  
o Rash  
• Hepatotoxicity characterized by:  
o AST and/or ALT elevation > 3 × ULN (or > 3 × baseline if elevated at stud y entry due to hepatic involvement by 
tumor), with  
o total bilirubin ≥ 2 × ULN without initial findings of 
cholestasis (i.e. serum ALP < 2 × ULN), and  1. Adverse Events, including:  
• Any AE or SAE that meets the study DLT criteria at any time 
during the study  
• Another AE or SAE considered by the Investigator to require 
treatment discontinuation  
 (All other AEs listed in the original text were removed)  
Symphogen Clinical Trial Protocol 
Trial ID: Sym023- 01 Version 5.0 
 
Confidential   Page 160 of 173 
 
 Table 6:  Protocol Amendment 1  
SECTION  ORIGINAL TEXT  NEW TEXT  
o No explanation for the above findings, such as viral 
hepatic injury, preexisting or acute liver disease, another 
drug or condition capable of causing the observed liver injury   
• > Grade 3  IRR; Grade 3 IRR in a patient who has received 
premedication  
• Any DLT considered by the Investigator to require treatment 
discontinuation  
• Another AE or SAE consider ed by the Investigator to require 
treatment discontinuation  
3.2 Trial Design 
Summary  Study Assessments  
…Patients will be evaluated for evidence of immune-mediated toxicities, evidence of certain specified conditions will result in 
immediate discontinuation from treatment with study drug. Patients will also be evaluated for evidence of antibody formation to study drug. Patients experiencing a DLT regarded as possibly-, probably-, or related to study drug at any point during treatment will either be discontinued 
from treatment with study drug, or may continue if there is evidence of 
an OR, SD, or other clinica l benefit, but may do so ONLY following 
discussion with the Sponsor’s Medical Monitor(s). Patients may not be 
retreated following the occurrence of a DLT until there is amelioration to ≤ Grade 1 severity, return to baseline status, or resolution of the 
toxicity. Only DLTs occurring during Cycle 1 will be used to make 
determinations regarding dose -escalation and tolerability. Exceptions to 
continuing on-study include evidence of certain immune-mediated 
toxicities, as detailed in Section 9.1; in such instance s patients must be 
permanently discontinued from treatment with study drug.   Study Assessments  
…Patients will be evaluated for evidence of immune-mediated 
toxicities. Patients will also be evaluated for evidence of antibody 
formation to study drug. Patients experiencing a DLT regarded as possibly-, probably-, or related to study drug at any point during treatment will be discontinued from study treatment, without exception. Patients may not be retreated following the occurrence of a DLT. Only 
DLTs occurrin g during Cycle 1 will be used to make determinations 
regarding dose -escalation and tolerability.   
6.5.3.5 Duration of 
Infusion  Note:   In the event of a Grade 2 IRR, the Investigator may prolong the infusion 
duration to extend longer than the initially as signed duration  (for further 
instructions see Section 8.5.1, Appendix 9).  
 
Study drug will be administered over a longer period for all patients 
entered to the trial in the following situations:  
• In the event of a Grade 2 IRR in ≥ two thirds of the patients entered 
to a cohort, the duration of infusion for subsequent patients entered to 
the trial will be extended to 1 hour (or longer, if indicated).  Note:   In the event of a Grade 2 IRR, see Sectio n 8.5.1, Appendix 9 for further 
instructions.  
 
 
Study drug will be administered over a longer period for all patients 
entered to the trial in the following situations:  
• In the event of a Grade 2 IRR in ≥ two thirds of the patients entered 
to a cohort, the  duration of infusion for subsequent patients entered to 
the trial will be extended by 30 minutes (or longer, if indicated).  
Symphogen Clinical Trial Protocol 
Trial ID: Sym023- 01 Version 5.0 
 
Confidential   Page 161 of 173 
 
 Table 6:  Protocol Amendment 1  
SECTION  ORIGINAL TEXT  NEW TEXT  
• In the event of a Grade 3 or greater IRR in any patient within a 
cohort, the duration of infusion fo r subsequent patients entered to the 
trial will be extended to 1 hour (or longer, if indicated). Such a case will 
also be considered to have met the protocol criteria for a DLT, thus requiring expansion of the cohort.  
These same criteria will be applied in  the event IRRs occur on the 
extended 1 -hour infusion schedule.  In such a case, the duration of 
infusion for subsequent patients entered to the trial will be extended to 1.5 hours (or longer, if indicated).  • In the event of a Grade 3 or greater IRR in any patient within a 
cohort, the duration of infusion for subsequent patients entered to the 
trial will be extended by 30 minutes (or longer, if indicated). Such a case will also be considered to have met the protocol criteria for a DLT, thus requiring expansion of the cohort.  
These same criteria will be applied in the event IRRs occur on the extended infusion schedule.  In such a case, the duration of infusion for 
subsequent patients entered to the trial will be further extended by 30 
minutes (or longer, if indicated).
 
6.7.1 Retreatment 
Guidelines  Not applicable (new text added)  Note:  Pa tients may receive standard doses of replacement hormonal therapy for 
adrenal insufficiency, hypothyroidism, or other endocrine end -organ failure, and 
may resume study drug once considered by the Investigator to be stable on such 
therapy provided a DLT cri terion has not been met.  
6.7.6 Retreatment 
Following an 
Objective Response This option for retreatment does not  apply to patients who previously 
experienced an unacceptable toxicity that required permanent discontinuation of study drug (Section 9.1).  This option for retreatment does not  apply to patients who previously 
experienced a DLT that required permanent discontinuation from study drug (Section 6.8.3, Section 9.1).  
6.8.2 Management of 
Dose -Limiting 
Toxicities and Other Toxicities  If a significant toxicity thought to be related to study drug is experienced 
at any point during the patient’s participation in the  study, the 
Investigator will determine:   
• Whether that toxicity is dose -limiting (Section 6.8.3), thus 
requiring either discontinuation  from study, or the patient may continue 
if there is evidence of response or other clinical benefit, but dosing must be delayed and the patient may not  be retreated until retreatment criteria 
are met.   
Patients experiencing certain immune-mediated toxicities may not  be 
retreated and will be discontinued from further participation (Section 9.1) 
• Whether the toxicity does  not meet the protocol definition of DLT, 
but nevertheless warrants dose modification, in which case the Investigator may elect to temporarily delay  dosing with study drug to 
allow for amelioration of the toxicity.   If a significant toxicity thought to be  related to study drug is 
experienced at any point during the patient’s participation in the study, the Investigator will determine:   
• Whether that toxicity is dose -limiting (Section 6.8.3), thus 
requiring discontinuation  from study treatment, without ex ception.   
• Whether the toxicity does not meet the protocol definition of DLT, 
but nevertheless warrants dose modification, in which case the Investigator may elect to temporarily delay  dosing with study drug to 
allow for amelioration of the toxicity.   
7.1.3 Past Medical 
History  • Screening  
• C1/D1 (prior to dosing)  
 • Screening  
• C1/D1 (prior to dosing)*  
* Need not be assessed prior to Cycle 1 if ≤ 7 days since screening  
Symphogen Clinical Trial Protocol 
Trial ID: Sym023- 01 Version 5.0 
 
Confidential   Page 162 of 173 
 
 Table 6:  Protocol Amendment 1  
SECTION  ORIGINAL TEXT  NEW TEXT  
7.2.8 
Electrocardiogram  (To be evaluated locally; to be performed after patient has been supine 
for ≥ 10 minutes)  (To be evaluated locally; to be performed after patient has been supine 
or semi -recumbent for ≥ 10 minutes)  
7.3.2 Ophthalmology 
Examination  (To include funduscopic and slit lamp evaluations for assessment of 
retinal and corneal integrity, visual acuity, and any other noted ocular 
abnormality)  
• Screening  
• EOC2 and every even-numbered cycle thereafter*, **  
• EOT**  
• As clinically indicated  (To include funduscopic and slit lamp evaluations for assessment of 
retinal and corneal integrity, visual acuity as assessed by standardized chart or other appropriate measurement tool, and any other noted 
ocular abnormality)  
• Screening  
• EOC1 (visual acuity only; by Snellen chart or similar measurement tool)*  
• EOC2 and every even-numbered cycle thereafter*, **  
• EOT**  
• As clinically indicated  
7.7.1 
Pharmacodynamic 
Assessments • Cycle 2  
o Day 1  
o Day 15 (after dosing + 7 days) (at the time of biopsy if 
performed)  • Cycle 2  
o Day 1 (prior to dosing)  
o Day 15 (after dosing + 7 days) (at the time of biopsy if 
performed)  
8.3 Determination of 
DLT versus Non -
DLT  If the protocol definition of DLT is met , the patient will be either 
discontinued from further treatment, or may continue if there is evidence 
of an OR, SD, or other clinical benefit, but may do so ONLY following 
discussion with the Sponsor’s Medical Monitor(s). Patients may not  be 
retreated fol lowing the occurrence of a DLT until there is amelioration 
to ≤ Grade 1 severity, return to baseline status, or resolution of the 
toxicity.   
Exceptions to continuing on study include evidence of certain immune -
mediated toxicities as detailed in Section 9. 1. In such instances patients 
must be permanently discontinued from treatment with study drug.   If the protocol definition of DLT is met , the patient will be discontinued 
from study treatment, without exception.   
8.4.3 Premedication 
for IRRs (Following an IRR) • For Grade 3 reactions,  premedication prior to subsequent infusions 
will be required (if the patient is to be retreated). Patients experiencing a Grade 3 reaction after having received premedication will be 
discontinued from treatment.  • For Grade  3 reactions , not applicable as this is considered a DLT; 
therefore, no further treatment with study drug is allowed.  
8.5.1.2 Treatment 
Following Infusion 
Prolongation  For Grade 3 IRRs, continue administration at the prolonged rate.  Text removed  
Symphogen Clinical Trial Protocol 
Trial ID: Sym023- 01 Version 5.0 
 
Confidential   Page 163 of 173 
 
 Table 6:  Protocol Amendment 1  
SECTION  ORIGINAL TEXT  NEW TEXT  
10.1.2 E vents Not to 
be Considered as 
Adverse Events  PD may be reported as an AE/SAE  in the case of patient death, with 
death being the outcome of the event.  Note: PD may be reported as an AE  in the case of patient death, with death being 
the outcome of the event.  
10.1.5 Events That 
Do Not Meet the Definition of Serious Adverse Events  PD may be reported as an SAE  in the case of patient death, with death 
being the outcome of the event.  Note: PD may be reported as an SAE  in the case of patient death, with death 
being the outcome of the event.  
10.3.1 Timeframes 
for Reporting to the Sponsor  In case of an SAE, the Investigator must, within 24 hours of awareness 
of the event, report the SAE to the Sponsor (or designee) by te lefax or e -
mail transmission. Fax number(s) and e-mail address(es) will be stated on the SAE Report Form  and the SAE Report Form Completion 
Instructions . 
 
Timelines for reporting of SAEs and SAE follow -up information are 
shown (Table 5).  In case of an SAE,  the Investigator must, within 24 hours of awareness 
of the event , report the SAE to the Sponsor (or designee) by telefax or e -
mail transmission. Fax number(s) and e-mail address(es) will be stated 
on the SAE Report Form  and the SAE Report Form Completion 
Instructions .  SAE follow -up information must also be reported to the 
Sponsor (or designee) within 24 hours of awareness . 
 
Removed Table 5: Timelines for Submission of SAEs and SAE Follow -
up 
10.4 Pregnancy  Elective terminations for non -medical reasons sho uld not be reported as 
AEs.  Elective terminations for non -medical reasons should be reported as 
follow -up, but not as a separate AE/SAE unless complications meet 
AE/SAE criteria.  
11.1 Precautions 
Regarding Procreation  Studies have not been performed to determine whether this study drug 
affects reproductive function in males. For this reason, men with partners with childbearing potential must use a highly effective method 
of contraception while receiving study drug.  Studies have not been perf ormed to determine whether this study drug 
affects reproductive function in males or can cause fetal harm. For this 
reason, men with partners of childbearing potential must use a highly 
effective method of contraception while receiving study drug.  
13.4.2 Modification 
of the Informed 
Consent Form  If modifications… the Investigator will prepare a revision to the existing 
ICF.  Such a revision will be reviewed and approved by the appropriate regulatory authority (as indicated) and IRB/EC, and documentation of  
this approval will be forwarded to the Sponsor (or designee) for submission to the appropriate regulatory body.  If modifications… the Sponsor (or designee) will prepare a revision to 
the existing sample ICF for modification, as appropriate, by each Invest igator.  Any revision to the sample ICF prepared by the Sponsor 
(or designee) will be implemented according to the Sponsor’s (or designee’s) SOPs. Such a revision will be reviewed and approved by the 
appropriate regulatory authority (as indicated) and IRB/ EC. 
14.1 Medical 
Supervision  An Investigator conducting a clinical study with an investigational agent 
is required to comply with regulations described in U.S. Title 21 CFR 
Part 312 and ICH E6(R2) GCP.  An Investigator conducting a clinical study with an i nvestigational agent 
is required to comply with regulations described in U.S. Title 21 CFR Parts 50, 56, and 312 and/or by governing Health Authorities, as well as 
ICH E6(R2) GCP.  
14.8 Recording of 
Data  All data must be carefully entered to permit meaning ful interpretation. 
Corrections to entered data will be tracked within the EDC system. Data must be entered into CRFs in a timely fashion.  CRFs are designed for computer processing and analysis. All data must 
be carefully entered to permit meaningful inter pretation. Corrections to 
Symphogen Clinical Trial Protocol 
Trial ID: Sym023- 01 Version 5.0 
 
Confidential   Page 164 of 173 
 
 Table 6:  Protocol Amendment 1  
SECTION  ORIGINAL TEXT  NEW TEXT  
entered data will be identified and tracked by audit trails within the EDC 
system. Data must be entered into CRFs in a timely fashion.  
15.1 Data Handling  Data will be handled according to good data management practices, all 
applicable data protection regulations, and will comply with ICH 
E6(R2) GCP.  Study data collection, processing, transfer, and reporting as well as 
handling of study personnel information will be in compliance with ICH E6(R2) GCP and all applicable data pro tection regulations.  
15.3 Data Processing  A Data Management Plan will be prepared for this trial. The Sponsor (or 
designee) will be responsible for data processing in accordance with applicable Data Management SOPs.  
 Database Lock will occur once quality control procedures and quality assurance p rocedures (if applicable) have been completed upon reaching 
the data cut -off for primary analysis.  
 Portable Document Format (PDF) files of the CRFs will be provided to the Investigator before access to the CRF system is revoked.  A Data Management Plan (DM P) will be prepared for this trial. The 
Sponsor (or designee) will be responsible for data processing in accordance with applicable Data Management SOPs and the trial DMP.  
 Database Lock will occur upon reaching the pre -defined data cut -off for 
primary an alysis and completion of Sponsor’s (or designee’s) quality 
control and quality assurance procedures.  
 Portable Document Format (PDF) files of the electronic CRFs will be provided to the Investigator upon removal of access to the electronic 
CRFs.  
Appendix 9: Grading 
and Management of 
Infusion-Related Reactions  In the Event of Infusion Prolongation  
For Grade 3 reactions, subsequent infusions must be administered at the prolonged rate.  
 Modification of Infusion Duration for the Trial  
• In the event of a Grade 2 IRR in ≥ two thirds of the patients entered 
to a cohort, the duration of infusion for subsequent patients entered to the trial will be extended to 1 hour (or longer, if indicated).  
• In the event of a Grade 3 or greater IRR in any patient within a 
cohort, the duration of infusion for subsequent patients entered to the 
trial will be extended to 1 hour (or longer, if indicated). Such a case will 
also be considered to have met the protocol criteria for a DLT, thus 
requiring expansion of the cohort.  
 
These same criteria will be applied in the event IRRs occur on the 
extended 1 -hour infusion schedule. In such a case, the duration of 
infusion for subsequent patients entered to the trial will be extended to 1.5 hours (or longer, if indicated). See Section 6.5.3.5.  In the Event of Infusion Prolongation  
Text removed  
  Modification of Infusion Duration for the Trial  
• In the event of a Grade 2 IRR in ≥ two thirds of the patients entered 
to a cohort, the duration of infusion for subsequent patients entered to the trial will be extended by 30 minutes (or longer, if indicated).  
• In the event of a Grade 3 or greater IRR in any patient within a 
cohort, the duration of infusion for subsequent patients entered to the 
trial will be extended by 30 minutes (or longer, if  indicated). Such a case 
will also be considered to have met the protocol criteria for a DLT, thus 
requiring expansion of the cohort.  
 
These same criteria will be applied in the event IRRs occur on the extended 1 -hour infusion schedule. In such a case, the  duration of 
infusion for subsequent patients entered to the trial will be further extended by 30 minutes (or longer, if indicated). See Section 6.5.3.5.  
Symphogen Clinical Trial Protocol 
Trial ID: Sym023- 01 Version 5.0 
 
Confidential   Page 165 of 173 
 
 Table 6:  Protocol Amendment 1  
SECTION  ORIGINAL TEXT  NEW TEXT  
Appendix 10: 
Management of 
Immune-Mediated 
Toxicities  Not applicable (new text added)  Instructions for management of immune -mediated toxicities are 
provided below and are to be implemented as detailed EXCEPT where 
AEs meet the protocol -specified DLT criteria (Section 6.8.3). AEs that 
meet the protocol definition of DLT will require disconti nuation from 
study treatment, without exception (Section 6.8.2); this instruction 
supersedes those provided below.    
 
  
Symphogen Clinical Trial Protocol 
Trial ID: Sym023- 01 Version 5.0 
 
Confidential   Page 166 of 173 
 
 19.2 Protocol Amendment 2 dated 02- Aug-2018 
• Patient exclusion criterion 9 has been added to exclude patients with a significant ocular dise ase or condition. Patients with 
non-significant, non- inflammatory disorders (e.g., cataracts, glaucoma) will be allowed.   
• DLT criterion 4 has been modified to indicate that study drug- related changes in visual acuity will continue to be considered 
dose-limiting but changes must now be confirmed by subsequent ophthalmologic exam.  In addition, a footnote has been 
added providing further guidance.  
• The Study Safety Committee  has been renamed to the Study Safety Team to better align with scope.  
• Vital Sign s windows have been modified to correspond with PK sampling windows . 
• Instructions for ophthalmology reassessment in the event of changes in visual acuity are provided (i.e., within 48 hours, if 
feasible).  The notation also indicates that no patient with a documented decrease in visual acuity may be retreated unless the 
event is considered unrelated to study drug, and unless the patient is cleared for retreatment by an ophthalmologist.  
• Guidelines pertaining to the General Data Protection Regulation have been added.  
• Formatting adjustments, minor typographical corrections, outline modifications , and slight wording changes are included.  
• The synopsis and tables have been updated based on changes described, where applicable.  
Refer to Table 7 for the changes in Protocol Amendment 2. 
 
Table 7:  Protocol Amendment 2 
SECTION  ORIGINAL TEXT  NEW TEXT  
4.3.1  Patients to be 
Excluded  Not applicable  (new text added)  9. Patients with a significant ocular disease or condition, including 
history of an autoimmune or inflammatory disorder, e.g., episcleritis, 
uveitis, iritis  
Note:   Patients with a history of dry eye  for reasons other than an autoimmune 
disease or condition may be included if adequately treated. Patients with 
non-significant, non -inflammatory disorders (e.g., cataracts, glaucoma) 
will be allowed.   
6.8.3  Definition of 
Dose -Limiting 
Toxicity  
 4. Any reduction in visual acuity, regardless of grade or duration  4. Any confirmed reduction in visual acuity, regardless of grade or 
duration  
Note:  Noted changes in visual acuity must be reevaluated by an ophthalmologist 
and confirmed within 48 hours (if feasible, based on weekends or holidays)  
of the initial observation; study drug will be held pending evaluation by the ophthalmologist.   
Changes in visual acuity assessment, if associated with either an immune-
related AE, including but not limited to iriti s, episcleritis, uveitis, or any 
Symphogen Clinical Trial Protocol 
Trial ID: Sym023- 01 Version 5.0 
 
Confidential   Page 167 of 173 
 
 Table 7:  Protocol Amendment 2 
SECTION  ORIGINAL TEXT  NEW TEXT  
other condition that may be considered to be related to therapy with study 
drug will be considered to be a DLT.   
Patients in whom a minor fluctuation in visual acuity is due to another 
known or recently diagnosed underlyin g condition may continue to be 
treated once visual acuity fluctuation returns to baseline status, but must be reevaluated by an ophthalmologist prior to each cycle and upon the occurrence of any subsequent ophthalmologic sign or symptom, including but not limited to recurrent changes in visual acuity measurement, in order 
to reassess for DLT status.  
7.2.5  Vital Signs  
 (Vital signs [VS] to include temperature, pulse, respiratory rate, blood 
pressure [BP], and oxygen saturation by pulse oximetry)*  
• Screening  
• Cycle 1  
o Day 1  
 Prior to SOI  
 End of infusion (EOI) (± 5 min)  
 2, 4, 8 hours after EOI (± 15 min)  
o Day 2  
o Day 3 (+ 1 day)  
o Day 15  
 Prior to SOI  
 EOI (± 5 min)  
• Each cycle thereafter  
o Day 1 (prior to dosing)  
• EOT  
• 1M FUP  
• As clinically indicated  
*Comprehensive assessment of VS is critical to the conduct of this study. In situations where an assessment at 8 hours after EOI is logistically difficult due to 
clinic staff availability, the observation period may be shortened, and an "end of 
day" assessment may be obtained at the latest practical time.  Such an option (if 
to be routinely employed) is available only after discussion with and approval by 
the Sponsor.  (Vital signs [VS] to include temperature, pulse, resp iratory rate, blood 
pressure [BP], and oxygen saturation by pulse oximetry)*  
• Screening  
• Cycle 1  
o Day 1  
 Prior to SOI  
 End of infusion (EOI) (± 10 min)  
 2, 4 hours after EOI (± 30 min)  
 8 hours after EOI (± 90 min  
o Day 2 (24 hours after EOI) (± 6 hours)  
o Day 3 (48 hours after EOI) ( - 12 to + 24 hours)  
o Day 15  
 Prior to SOI  
 EOI (± 10 min)  
• Each cycle thereafter  
o Day 1 (prior to dosing)  
• EOT  
• 1M FUP  
• As clinically indicated  
*Comprehensive assessment of VS is critical to the conduct of this study. In 
situations where an assessment at 8 hours after EOI is logistically difficult due to clinic staff availability, the observation period may be shortened, and an "end of day" assessment may be obtained at the latest practical time.  Such an option (if 
to be routinely employed) is available only after discussion with and approval by the Sponsor.  
Note:  C1/D1 through C1/D3 window allowances align with PK timepoints 
windows  
Symphogen Clinical Trial Protocol 
Trial ID: Sym023- 01 Version 5.0 
 
Confidential   Page 168 of 173 
 
 Table 7:  Protocol Amendment 2 
SECTION  ORIGINAL TEXT  NEW TEXT  
7.3.2 Ophthalmology 
Examination  
 *End of Cycle assessments may be conducted at any time during the week prior 
to Day 1 of the next cycle, including on Day 1 of the next cycle, prior to dosing.   *End of Cycle assessments may be conducted at any time during the week prior 
to Day 1 of the n ext cycle, including on Day 1 of the next cycle, prior to dosing.  
Due to inherent variability of Snellen chart assessments, if changes in visual 
acuity are noted, a thorough ophthalmologic evaluation should be performed 
within 48 hours (if feasible, based  on weekends or holidays) of the initial 
observation in order to confirm the finding and determine if there is evidence of 
an immune -mediated AE, or other event that would preclude further treatment 
with study drug.  No patient with any documented decrease  in visual acuity will 
receive further therapy with Sym023 unless the event is considered unrelated to 
study drug and unless cleared for retreatment by an ophthalmologist.  
7.7.1  
Pharmacodynamic 
Assessments • Cycle 2  
o Day 1 (prior to dosing)  
o Day 15 (aft er dosing +  7 days) (at the time of biopsy if 
performed)  • Cycle 2  
o Day 1 (prior to dosing)  
o Day 15 (after dosing + 0 to 7 days) (at the time of biopsy if 
performed)  
7.7.2.1  Blood 
Samples for Biomarker Assessments • Cycle 2  
o Day 15 (after dosing +  7 days) (at the time of biopsy if 
performed)  • Cycle 2  
o Day 15 (after dosing + 0 to 7 days) (at the time of biopsy if 
performed)  
7.7.2.2  Tumor 
Sample for Biomarker Assessment (Biopsies 
Optional)  • Cycle 2  
o Day 15 (after dosing +  7 days) (with paired pharmacodynamic 
and biomarker peripheral blood)  • Cycle 2  
o Day 15 (after dosing + 0 to 7 days) (with paired 
pharmacodynamic and biomarker peripheral blood)  
15.1 Data Handling  
 Study data collection, processing, transfer, and reporting as well as 
handling of study personnel information will be in compliance with ICH E6(R2) GCP and all applicable data protection regulations . Study data collection, processing, transfer, and reporting, as well as 
handling of study personnel information, will be in compliance with ICH E6(R2) GCP and all applicable data protection regulations, including Regulation (EU) 2016/679 of the European Parliament and of the Council of 27 April 2016 on the protection of natural persons with 
regard to the processing of personal data and on the free movement of 
such data (General Data Protection Regulation).  
15.5 Compliance 
with the General Data Protection Regulation  
 Not applicable  (new section and text added)  The applicable data protection legislation requires that parties enter into 
a written contract if one party (data processor) processes personal data on behalf of the other party (data controller). This written contract must 
regulate the subject -matter and duration of the processing, the nature 
and purpose of the  processing, the types of personal data and categories 
of data subjects, as well as the obligations and rights of the data 
controller. Accordingly, the parties must enter into a data processing 
Symphogen Clinical Trial Protocol 
Trial ID: Sym023- 01 Version 5.0 
 
Confidential   Page 169 of 173 
 
 Table 7:  Protocol Amendment 2 
SECTION  ORIGINAL TEXT  NEW TEXT  
agreement. To the extent the processing of personal data invol ves 
transfers of personal data to third countries (e.g., jurisdictions outside of 
the European Economic Area [EEA]), the parties will enter into the European Commission's standard contractual clauses between the data controller, the data processor, and all  sub-processors, if any. The 
European Commission's standard contractual clauses ensure an adequate level of protection in relation to transfers of personal data to third 
countries.  
 
19.3 Protocol Amendment 3 dated 1 8-Mar- 2019  
• In order to apply more current adverse event grade descriptions and term definitions, the version of the Common 
Terminology Criteria for Adverse Events (CTCAE) used for this study has been updated from Version 4.03 to Version 5.0. All references to the CTCAE version throughout t his protocol have been updated accordingly.  
• Grading of infusion- related reactions specified in  Appendix 9 ha ve been updated to reflect the use of CTCAE Version 5.0.  
• Formatting adjustments, minor typographical corrections, and slight wording changes are i ncluded.  
• The synopsis and tables have been updated based on changes described, where applicable.  
Refer to Table 8 for the changes in Protocol Amendment 3. 
 
Table 8:  Protocol Amendment 3 
SECTION  ORIGINAL TEXT  NEW TEXT  
2.3.2 Clinical 
Experience with 
Sym023  No prior studies with Sym023 have been conducted.  The study described in this clinical trial protocol is ongoing.  Sym023 is 
also being studied in a Phase 1 study in combination with Sym021 (anti -
PD-1 monoclonal antibody; ClinicalTrials.gov number [STUDY_ID_REMOVED]).  
4.3.1  Patients to be 
Excluded  6. Patients with any of the following coagulation parameter 
abnormalities at baseline (unless on a stable dose of anticoagulant 
therapy for a prior thrombotic event, as determined by the Investigator):  
• Prothrombin time (PT) ( as assessed by  international normalized 
ratio [INR]) > 1.5 × ULN for the institution (> 3× ULN for the institution if anticoagulated) … 6. Patients with any of the following coagulation parameter 
abnormalities at baseline (unless on a stable dose of anticoagulant 
therapy for a prior thrombotic event, as determined by the Investigator):  
• Prothrombin time (PT) ( or international normalized ratio [INR]) > 
1.5 × ULN for the institution (> 3× ULN for the institution if 
anticoagulated) … 
Symphogen Clinical Trial Protocol 
Trial ID: Sym023- 01 Version 5.0 
 
Confidential   Page 170 of 173 
 
 Table 8:  Protocol Amendment 3 
SECTION  ORIGINAL TEXT  NEW TEXT  
6.8.3  Definition of 
Dose -Limiting 
Toxicity  6. Any other ≥ Grade 3 non -hematologic toxicity regardless of 
duration, with the exceptions of:  
• Grade 3 fatigue  
• Grade 3 nausea, vomiting, or diarrhea lasting ≤ 2 days with best 
supportive care  
• Grade 3 asymptomatic electrolyte abnormalities lasting ≤ 3 days 
that are not clinically complicated, and resolve spontaneously or respond to con ventional medical interventions  6. Any other ≥ Grade 3 non -hematologic toxicity regardless of 
duration, with the exceptions of:  
• Grade 3 fatigue  
• Grade 3 nausea, vomiting, or diarrhea lasting ≤ 2 days with best 
supportive care  • Grade 3 asymptomatic el ectrolyte abnormalities lasting ≤ 3 days 
that are not clinically complicated, and resolve spontaneously or respond to conventional medical interventions  
• Other Grade 3 asymptomatic laboratory abnormalities that are 
clinically non -significant in the inves tigator’s opinion, and that resolve 
spontaneously or with conventional medical interventions  
7.2.7.3 Coagulation 
Panel  (To include PTT [or aPTT], PT , INR)  (To include PTT [or aPTT], PT and/or INR)  
 
19.4 Protocol Amendment 4 dated 02- May-2019  
• Final infusion volumes have been revised and made more granular to accommodate higher doses of drug product as well as 
patients who have a higher body weight. Additionally, where the amount of IMP is ≥ 40% of the total infusion volume, a 
larger IV solution bag should be used to prevent the infusion from becoming hypotonic.  
• Infusion duration for Sym023 infusion volumes of 500 mL has been specified as 1 hour.  
• Formatting adjustments, typographical corrections, and slight wording changes are included.  
• The synopsis has been updated based on changes described, where applicable. 
Refer to Table 9 for the changes in Protocol Amendment 4. 
 
Table 9:  Protocol Amendment 4 
SECTION  ORIGINAL TEXT  NEW TEXT  
3.2 Trial Design 
Summary  • On Day 1 of study, patients will receive study drug administered by 
30-minute (+10 min) IV infusion in a fixed 50 mL volume for doses < 1 
mg/kg, or in a fixed 100 mL volume for doses ≥ 1 mg/kg to ≤ 10 mg/kg, 
or in a fixed 250 mL volume for doses > 10 mg/kg.  • On Day 1 of study, patients will receive study drug administered by 
30-minute (+10 min) or by 60-minute (+ 10 min) IV infusion (depend ing on dose and body weight) in a fixed 50 mL, 100 mL, 250 
mL, or 500 mL volume depending on dose and body weight.  
4.3.1  Patients to be 
Excluded  16. Patients with unresolved > Grade 1 toxicity* associated with any 
prior antineoplastic therapy except for persistent Grade 2 alopecia, 16. Patients with unresolved > Grade 1 toxicity* associated with any 
prior antine oplastic therapy except for persistent Grade 2 alopecia, 
Symphogen Clinical Trial Protocol 
Trial ID: Sym023- 01 Version 5.0 
 
Confidential   Page 171 of 173 
 
 Table 9:  Protocol Amendment 4 
SECTION  ORIGINAL TEXT  NEW TEXT  
peripheral neuropathy, decreased hemoglobin, hypomagnesemia, and/or 
end-organ failure being adequately managed by hormone replacement 
therapy  peripheral neuropathy, decreased hemoglobin, lymphopenia, 
hypomagnesemia, and/or end -organ failure being adequately managed 
by hormone replacement therapy  
5.6 Administration of 
IMP 
 Study drug will be administered by IV infusion via an indwelling 
catheter. An appropriate dose, based on the patient’s cohort assignment, 
diluted to the total volume specified with 0.9% sodium chloride (NaCl) 
for IV infusion will be administered initially over 30 minutes (+10 
minutes), once every 2 weeks (Q2W; 4 weeks [28 days] equals 1 dosing 
cycle).   Study drug will be administered by IV infusion via an indwelling 
catheter. An appropriate dose, based on the patient’s cohort assignment, 
diluted to the total volume specif ied with 0.9% sodium chloride (NaCl) 
for IV infusion will be administered initially over:  
• Approximately 30 minutes (+10 minutes) for infusion volumes ≤ 250 mL  
• Approximately 60 minutes (+10 minutes) for infusion volumes 
of 500 mL  
Dosing will be once e very 2 weeks (Q2W; 4 weeks [28 days] equals 1 
dosing cycle).   
5.8 Dose 
Preparation  • The total volume of study drug to be delivered will be withdrawn 
from the study drug vial(s) and added to a prefilled IV bag containing 0.9% NaCl for IV infusion (prior to adding the study drug and an 
appropriate volume of NaCl solution is removed, such that the final 
volume to be infused equals:   
o 50 mL for doses < 1 mg/kg  
o 100 mL for doses ≥ 1 mg/kg to ≤ 10 mg/kg  
o 250 mL for doses > 10 mg/kg.     • The total volume of study drug to be delivered will be withdrawn 
from the study drug vial(s) and added to a prefilled IV bag containing 
0.9% NaCl for IV infusion (prior to adding the study drug and an 
appropriate volume of NaCl solution is removed, such that the final 
volume to be infused equals:   
o 50 mL for doses < 1 mg/kg  
o 100 mL for doses ≥ 1 mg/kg to ≤ 3 mg/kg  
o 100 mL for doses of > 3 mg/kg to ≤ 10 mg/kg for patients with 
body weight ≤ 80 kg  
o 250 mL for doses of > 3 mg/kg to ≤ 10 mg/kg for patients with body weight > 80 kg  
o 250 mL for doses > 10 mg/kg for patients with body weight ≤ 100 kg 
o 500 mL for doses > 10 mg/kg for patients with body weight > 
100 kg  
Note:  In a case where the amount of IMP is ≥ 40% of the total infusion 
volume, a larger IV solution bag should be used.   
6.5.3.4  Volume of 
Infusion  
 Infusions will be delivered in a final volume of:  
• 50 mL for doses < 1 mg/kg  
• 100 mL for doses ≥ 1 mg/kg to ≤ 10 mg/kg  
• 250 mL for doses > 10 mg/kg  Infusions will be delivered in a final volume of:  
• 50 mL for doses < 1 mg/kg  
• 100 mL for doses ≥ 1 mg/kg to ≤ 3 mg/kg  
• 100 mL for doses of > 3 mg/kg to ≤ 10 mg/kg for patients with 
body weight ≤ 80 kg  
Symphogen Clinical Trial Protocol 
Trial ID: Sym023- 01 Version 5.0 
 
Confidential   Page 172 of 173 
 
 Table 9:  Protocol Amendment 4 
SECTION  ORIGINAL TEXT  NEW TEXT  
• 250 mL for doses of > 3 mg/kg to ≤ 10 mg/kg for patients with 
body weight > 80 kg  
• 250 mL for doses > 10 mg/kg for patients with body weight ≤ 
100 kg 
• 500 mL for doses > 10 mg/kg for patients with body weight > 
100 kg 
Note:  In a case where the amount of IMP is ≥ 40% of the total infusion 
volume, a larger IV solution bag should be used.  
6.5.3.5  Duration of 
Infusion  
 Study drug will be administered over 30 minutes (+10 minutes)  Study drug will be administered over:  
• Approximately 30 minutes (+10 minutes) for infusion volumes 
≤ 250 mL  
• Approximately 60 minutes (+10 minutes) for infusion volumes 
of 500 mL  
6.7.1  Retreatment 
Guidelines  • Any ongoing study drug -related AE should have either ameliorated 
to ≤ Grade 1 severity, returned to baseline status, or resolved, with the exceptions of: … 
o Asymptomatic laboratory abnormalities that are considered clinically insignificant, clinically uncomplicated, and/or that are resolving spontaneously or with conventional medical interventions.  • Any ongoing study drug -related AE should have either ameliorated 
to ≤ Grade 1 severity, returned to baseline status, or resolved, with the excep tions of: … 
o Grade 2 asymptomatic laboratory abnormalities that are considered clinically insignificant, clinically uncomplicated, and/or that are resolving spontaneously or with conventional 
medical interventions.  
8.5.1.2  Treatment 
Following Infusion Prolongation  
 To enhance patient safety following an infusion prolongation, 
subsequent infusions will be administered at the prolonged rate. For Grade 1 and 2 IRRs, rechallenge with a shorter duration of infusion (no less than 30 minutes) may be attempted at the Investigator's discretion, after a minimum of 2 doses with no evidence of infusion-related toxicity at the prolonged rate.  To enhance patient safety following an infusion prolongation, 
subsequent infusions will be administered at the prolonged rate. For Grade 1 and Grade 2 IRRs, rechallenge with a shorter duration of infusion (no less than the duration designated by the patient’s dose assignment and weight) may be attempted at the Investigator's discretion, after a minimum of 2 doses with no evidence of  infusion -
related toxicity at the prolonged rate.  
16.5.11  
Pharmacokinetic Analysis Individual curves of serum concentration of total study drug versus time 
after the first and fourth infusion will be presented on log-  and linear 
scale for all patients in the PK population.  Individual curves of serum concentration of total study drug versus time 
after the first infusion will be presented on log- and linear scale for all 
patients in the PK population.  
Appendix 9 : Grading 
and Management of Infusi on-Related 
Reactions  For Grade 1 and 2 reactions, rechallenge with a shorter duration of 
infusion (no less than 30 minutes) may be attempted at the Investigator's discretion, after a minimum of 2 doses with no evidence of infusion-related toxicity at the p rolonged rate.   For Grade 1 and Grade 2 reactions, rechallenge with a shorter duration 
of infusion (no less than the duration designated by the patient’s dose assignment and weight) may be attempted at the Investigator's discretion, after a minimum of 2 d oses with no evidence of infusion-
related toxicity at the prolonged rate.   
Symphogen Clinical Trial Protocol 
Trial ID: Sym023- 01 Version 5.0 
 
Confidential   Page 173 of 173 
 
  
 